

**HEALTH**

**PUBLIC HEALTH SERVICES BRANCH**

**Reportable Communicable Diseases, Infections, and Conditions; Reportable Zoonotic Diseases Occurring in Animals; Communicable Disease Reporting and Surveillance System; New Jersey Immunization Information System; Childhood Immunization; and Immunization of Collegians**

**Collection, Processing, Storage and Distribution of Blood**

**New Jersey Youth Camp Safety Standards**

**Tanning Facilities**

**Standards for Licensure of Assisted Living Residences, Comprehensive Personal Care Homes, and Assisted Living Programs**

**Standards for Licensure of Adult Family Care Caregivers and Sponsor Agencies**

**Standards for Licensure of Residential Substance Use Disorder Treatment Facilities**

**Standards for Licensure of Long-Term Care Facilities**

**Manual of Standards for Licensing of Ambulatory Care Facilities**

**Standards for Licensure of Pediatric Community Transitional Homes**

**Hospital Licensing Standards**

**Public Health Practice Standards of Performance for Local Boards of Health in New Jersey**

**Proposed Repeals and New Rules: N.J.A.C. 8:57-1.1, 4.5, 4.9, 4.10, 4.11, 4.12, 4.13, 8:57-5 Appendices A and B, and 6.1 through 6.15**

**Proposed New Rules: N.J.A.C. 8:57-1.8, 2.1, 2.5, 2.12, 2.13, 4.3, and 4.6, and 8:57 Appendices A through M, and P through U**

**Proposed Repeals: N.J.A.C. 8:57-1.2 and 1.12, 8:57-1 Appendices A and B, 3.2, 3.3, 3.17, 3.18, 3.21, 3.23, 8:57-3 Appendices A through J, 4.7, 4.8, 4.14 through 4.21, 4.23, 8:57-4 Appendix, 6.16, 6.18, 6.19, 6.20, 6.21, and 8:57-6 Appendix**

**Proposed Recodifications with Amendments: N.J.A.C. 8:57-1.15, 4.24, 1.14, 1.4 through 1.11, 1.13, and 4.6 as 8:57-1.14, 1.5, 1.7, 2.2 through 2.10, 2.11, and 4.4, Respectively**

**Proposed Amendments: N.J.A.C. 8:8-5.2; 8:25-1.4 and 5.5; 8:28-1.2; 8:36-18.4; 8:39-19.4 and 27.4; 8:43A-14.2; 8:43B-6.10; 8:43D-15.4; 8:43G-14.1 and 19.15; 8:52-3.3, 12.3, and 14.1 and 8:52 Appendix; 8:57-1.3, 3.1, 3.4 through 3.16, 3.19, 3.20, 3.22, 4.1, 4.2, 4.3, 4.4, 4.22, 5.1, 5.3 through 5.6, 5.8 through 5.12, 5.14, 5.16, and 6.17; and 8:111-9.1**

Authorized By: Jeffrey A. Brown, Acting Commissioner, Department of Health, and in consultation with the Public Health Council.

Authority: N.J.S.A. 4:19-15.14 et seq.; 17:23A-13.1; 17:48-6i and 6m; 17:48A-7h; 17:48E-35.6 and 35.10; 17B:26-2.1h; 17B:27-46.1h and 46.1i; 17B:27A-7; 18A:40-20, 21.1, 21.2, 26, and 42; 18A:61D-1 et seq., specifically 18A:61D-6; 18A:62-15, 15.1 and 15.2; 18A:75A-1 et seq., specifically 18A:75A-4, 5, and 13; 24:15-10; 26:1A-1 et seq., specifically 26:1A-7, 9, 9.1, and 15; 26:2-137.1 and 137.7; 26:2F-3, 13, and 13.2; 26:2H-1 et seq., specifically 26:2H-5 and 18.79; 26:2J-4.6 and 4.10; 26:2N-1 et seq., specifically 2N-2, 7.1, and 7.2; 26:2T-1 et seq., specifically 26:2T-4; 26:4-1 through 26:4-59; 26:4-60 through 72, specifically 26:4-70; 26:4-78 through 95; 26:4-96

through 26:4-100.13, specifically 26:4-100.3; 26:4-129 and 130; 26:4-131 through 138, specifically 26:4-134; 26:12-1 et seq., specifically 26:12-5 and 16; 26:13-1 et seq.; 30:5B-1 et seq., specifically 30:5B-5; 34:9A-12 and 13; 45:9-42 through 45:9-42.25, specifically 45:9-42.24; 45:9-42.26 through 42.49, specifically 45:9-42.34 and 42.35; and 47:1A-1 et seq.; and P.L. 2005, c. 222, § 35; Reorganization Plan No. 003-2005.

Calendar Reference: See Summary below for explanation of exception to calendar requirement.

Proposal Number: PRN 2025-122.

Submit written comments by November 14, 2025, electronically to <http://www.nj.gov/health/legal/ecomments.shtml>, or by regular mail postmarked by November 14, 2025, to:

Genevieve Raganelli, Regulatory Officer  
Office of Legal and Regulatory Compliance  
Office of the Commissioner  
New Jersey Department of Health  
PO Box 360  
Trenton, NJ 08625-0360

The agency proposal follows:

### **Summary**

N.J.A.C. 8:57, Communicable Diseases, establishes standards for the reporting, investigation, and other activities attendant to the identification of cases of, at Subchapter 1, communicable diseases, infections, or conditions, pursuant to N.J.S.A. 26:4-1 et seq., and reportable zoonotic diseases occurring in animals pursuant to

N.J.S.A. 4:19-15.14 et seq., and 26:4-78 et seq., and, at Subchapter 5, tuberculosis pursuant to N.J.S.A. 26:4-70. The chapter establishes, at Subchapter 3, standards for an automated and electronic immunization registry, known as the New Jersey Immunization Information System, pursuant to N.J.S.A. 26:4-131 et seq., the Statewide Immunization Registry Act. The chapter establishes standards addressing, at Subchapter 4, childhood immunization pursuant to N.J.S.A. 26:1A-7 and 26:2-137.1, and, at Subchapter 6, immunization of collegians entering and attending institutions of higher education pursuant to N.J.S.A. 18A:61D-1 et seq., and 18A:62-15.1 and 15.2.

Reorganization Plan No. 003-2005 (Reorganization Plan) transferred the functions, powers, and duties of the Public Health Council, other than its advisory and consultative functions, to the Department of Health (Department), to be allocated within the Department by the Commissioner of the Department (Commissioner).

N.J.A.C. 8:57 was scheduled to expire on March 10, 2016. On February 8, 2016, the Department readopted the chapter without change, thereby extending the chapter expiration date seven years to February 8, 2023. 48 N.J.R. 420(a). On June 16, 2022, the Department recodified N.J.A.C. 8:57-2, Reporting of Acquired Immunodeficiency Syndrome (AIDS) and Infection with Human Immunodeficiency Virus (HIV), as new N.J.A.C. 8:65, HIV Infection Reporting, with amendments, repeals, and new rules. 53 N.J.R. 1440(a); 54 N.J.R. 1408(a).

In 2023, the Department undertook extensive efforts to obtain stakeholder feedback on this chapter. The Department prepared and distributed a presentation identifying the more significant changes to the chapter that the Department was considering, and a survey. The survey asked for comments on all topics that the

presentation addressed, or any other aspects of the existing rules. The Department distributed the presentation directly to 34 identified stakeholders, including State agencies, hospital associations, and local health professional associations and interest groups, among others. The Department also distributed the presentation through the New Jersey Local Information Network and Communications System (LINCS) to LINCS agencies (see N.J.S.A. 26:13-2), which include local health officers and public and private health organizations. The Department received over 650 responses to this survey commenting on all subchapters of N.J.A.C. 8:57 and capturing a variety of health concerns. The Department circulated the comments to appropriate program staff members, based on their respective areas of expertise and took these comments and staff feedback thereon into consideration in drafting the proposed revisions to N.J.A.C. 8:57.

The expiration date of N.J.A.C. 8:57 was extended by Gubernatorial Order from February 8, 2023, to February 8, 2024. 55 N.J.R. 390(a).

On January 3, 2024, the Department readopted N.J.A.C. 8:57-1, 3, 4, 5, and 6, without change, thereby extending the chapter expiration date for those subchapters seven years to January 3, 2031, and permitted Subchapter 8, Childhood Immunization Insurance Coverage, to expire on February 8, 2024. 56 N.J.R. 213(a).

On February 5, 2024, the Department proposed to readopt and recodify N.J.A.C. 8:57-7, Student Health Insurance Coverage, as new N.J.A.C. 8:92, Higher Education Student Health Insurance Coverage, with amendments and a new rule, thereby extending that subchapter expiration date to August 6, 2024. 56 N.J.R. 174(a). On May 17, 2024, the Department adopted that notice of proposal, thereby extending that

expiration date by seven years from the date of filing with the Office of Administrative Law OAL). 56 N.J.R. 1094(a).

As the Department is providing a 60-day comment period for this notice of proposal, this notice is excepted from the rulemaking calendar requirement.

The Department proposes to rename N.J.A.C. 8:57, Communicable Diseases, to Reportable Communicable Diseases, Infections, and Conditions; Reportable Zoonotic Diseases Occurring in Animals; Communicable Disease Reporting and Surveillance System; New Jersey Immunization Information System; Childhood Immunization; and Immunization of Collegians.

The Department proposes non-substantial amendments throughout the chapter, to correct spelling and grammar, improve readability, replace descriptive text with acronyms and cross-references to terms that statutes and/or other rules establish, correct formatting of scientific terms, correct or update communication information and internet website links, and eliminate redundancy. The Department is proposing amendments in other chapters of Title 8 to correct cross-references to N.J.A.C. 8:57 and the chapter name, and the name of the Department, specifically at N.J.A.C. 8:8, 8:25, 8:28, 8:36, 8:39, 8:43A, 8:43D, 8:43G, 8:52, and 8:111. The Department proposes to amend N.J.A.C. 8:25, New Jersey Youth Camp Safety Standards, Subchapter 5, Health, at N.J.A.C. 8:25-5.5, Health records, to add a cross-reference to N.J.S.A. 26:12-16, which establishes the immunization exemption available to a youth camper on religious grounds.

The Department proposes to amend existing N.J.A.C. 8:39-27.4, Mandatory postmortem policies and procedures, to add cross-references to N.J.S.A. 26:6-8.2 and

8.3, which establish notification requirements with respect to the transportation of the dead human body of a person who had a communicable disease, and N.J.A.C. 8:9, Preparation, Handling, Transportation, Burial and Disinterment of Dead Human Bodies, which, at N.J.A.C. 8:9-1.3, identifies the obligations of persons involved in the handling of a dead body to adhere to isolation precautions and, at N.J.A.C. 8:9-1.6, to transport in a sealed casket the remains of a person who dies of one or more listed diseases and to obtain a license for the transportation of the remains from the Department.

The Department proposes to correct references appearing throughout N.J.A.C. 8:52 Appendix to standards addressing reportable occupational and environmental diseases, injuries, and poisonings, which formerly existed at N.J.A.C. 8:57-3, and which the Department recodified as new N.J.A.C. 8:58 in 2009. 40 N.J.R. 1962(a); 41 N.J.R. 1419(a).

## **Subchapter 1**

Existing Subchapter 1, Reportable Communicable Diseases, establishes standards addressing reportable communicable diseases, infections, and conditions. The Department proposes to amend the subchapter heading to “General Provisions.” The Department proposes to repeal existing N.J.A.C. 8:57-1.1, Purpose and scope, and replace it with new N.J.A.C. 8:57-1.1, Purpose, to rearticulate the purpose of the chapter as establishing standards: (1) for reporting communicable diseases, infections, and conditions and reportable zoonotic diseases occurring in animals; (2) governing the Communicable Disease Reporting and Surveillance System known as CDRSS; (3) governing the automated and electronic immunization registry known as the “New Jersey Immunization Information System”; and (4) addressing immunizations upon

which administrators are to condition admission of minors to schools and child care centers, and collegians to institutions of higher education.

The Department proposes to repeal existing N.J.A.C. 8:57-1.2, Incorporated documents. As described more fully below, proposed new N.J.A.C. 8:57-1.4 would replace the substance of this section.

Existing N.J.A.C. 8:57-1.3, Definitions, establishes definitions of words and terms used in the chapter. The Department proposes amendments throughout the chapter to delete or repeal subchapter-specific sections including definitions and consolidate these definitions into this section. The Department proposes to amend the section to add definitions of the following terms, some of which are to be relocated from the subchapter-specific definitions sections: “AAP Red Book,” “academic degree,” “academic term,” “ACIP recommendations,” “Adult Immunization Recommendations,” “‘Advisory Committee on Immunization Practices’ or ‘ACIP,’” “animal rescue organization,” “billing vendor,” “biological,” “bioterrorism,” “birthing facility,” “carbapenemase gene,” “‘carbapenemase-producing organism’ or ‘CPO,’” “case,” “Catch-up Schedule,” “CDC Laboratory Recommendations for Syphilis Testing,” “‘Centers for Disease Control and Prevention’ or ‘CDC,’” “Child and Adolescent Immunization Recommendations,” “Class B1 or B2 referral,” “collegian,” “‘Communicable Disease Reporting and Surveillance System’ or ‘CDRSS,’” “‘Communicable Disease Service’ or ‘CDS,’” “condition,” “contact,” “contraindication,” “cosmetic establishment,” “‘Council of State and Territorial Epidemiologists’ or ‘CSTE,’” “designated agent,” “Directory of Local Health Departments in New Jersey,” “Division of HIV, STD, and TB Services,” “Division of Local Public Health,” “DNA,” “drug



establishment," "EBC," "electronic case reporting," "electronic health record vendor" or  
 'EHR vendor,'" "endemic level," "farm or migrant labor camp," "FDA Food Code," "food  
 employee," "food establishment," "full-time collegian," "health benefits plan,"  
 "'Healthcare Effectiveness Data And Information Set®' or 'HEDIS®,'" "healthcare  
 personnel," "healthcare professional," "Health History and Appraisal form," "health  
 information exchange" or 'HIE' or 'health information network' or 'HIN,'" "health  
 information organization" or "HIO," "HL7 Implementation Guide," "hospital,"  
 "immunization," "infection," "institution," "institution of higher education" or 'IHE,'"  
 "insurer," "invalid dose," "line list," "local health agency," "'Local Information Network and  
 Communications System' or 'LINCS,'" "'Logical Observation Identifiers Names and  
 Codes' or 'LOINC,'" "manager," "'Maternal and Child Health Consortium' or 'MCHC,'"  
 "minor," "'Morbidity and Mortality Weekly Report' or 'MMWR,'" "'MRSA laboratory  
 identification event' or 'MRSA LabID event,'" "newborn," "'New Jersey Immunization  
 Information System' or 'NJiIS,'" "NJ ELR Implementation Guide," "NJiIS access level,"  
 "NJiIS Personal Immunization Record," "NJiIS site," "NJiIS site administrator," "NJiIS  
 user," "NJiIS webpage," "NJ Medicaid Program," "Notifiable Condition List," "nucleic  
 acid amplification test" or 'NAAT,'" "nursing home" or 'nursing facility,'" "Official State of  
 New Jersey School Immunization Record," "pan-non-susceptible organism," "parent,"  
 "part-time collegian," "pharmacist," "point-of-care test" or 'POC test,'" "polymerase  
 chain reaction" or 'PCR,'" "practice management vendor," "precaution," "PSAST,"  
 "'Public Health and Environmental Laboratories' or 'PHEL,'" "pupil," "rabies post-  
 exposure prophylaxis administration" or 'rabies PEP administration,'" "referral  
 laboratory," "registrant," "religious-affiliated facility," "RNA," "SARS," "satellite

emergency department,” “serologic test,” “site administrator,” “SNOMED,” “surveillance case definition,” “suspected outbreak,” “‘United States of America’ or ‘USA,’” “vaccine,” “valid dose,” “‘Vaccine-Preventable Disease Program’ or ‘VPDP,’” “veterinary diagnostic laboratory,” “veterinary diagnostic laboratory director,” and “‘virtual private network’ or ‘VPN.’”

The Department proposes to delete the definitions of the following terms, which the chapter would not use: “kennel,” “local health department,” “‘multidrug-resistant organisms’ or ‘MDROs,’” “nosocomial infection,” “overlap agent or toxin,” “pet shop,” “pound,” “shelter,” and “‘Vancomycin-intermediate *Staphylococcus aureus*’ or ‘VISA.’”

The Department proposes amendments to the existing definition of the term “administrator.” The Department proposes to amend the definition to reflect that the term means the person who controls or supervises a State psychiatric hospital; a facility within the jurisdiction of the Departments of Children and Families (DCF), Corrections (DOC), or Human Services (DHS); and/or a residential health care facility not located with, and operated by, a licensed health care facility, within the jurisdiction of the Department of Community Affairs (DCA).

P.L. 1995, c. 284 (approved December 15, 1995), codified at N.J.S.A. 52:17B-169 et seq., established the Juvenile Justice Commission in, but not of, the Department of Law and Public Safety, and transferred to that Commission jurisdiction over juvenile correctional facilities and related custodial facilities, such as pretrial detention facilities and various transitional program facilities, which were formerly within the jurisdiction of the DOC. N.J.S.A. 52:17B-176. P.L. 2025, c. 35 (approved March 17, 2025) renamed the Juvenile Justice Commission the Youth Justice Commission (YJC). The

Department proposes to amend the definition of the term “administrator,” to add a facility within the YJC’s jurisdiction, to reflect the reallocation of control over those facilities from the DOC to the YJC.

In a previous rulemaking, the Department established a definition of the term “health care facility” to mean facilities that the Department licenses pursuant to N.J.S.A. 26:2H-1 et seq. 40 N.J.R. 1962(a); 41 N.J.R. 1419(a). This had the unintended effect of removing the existing applicability of the chapter to custodial and/or residential facilities within the DHS’ jurisdiction that provide health-related services. Therefore, the Department proposes to amend the definition of the term “administrator” to refer to facilities operating within the jurisdiction of the DHS, to reflect the longstanding applicability of the chapter to facilities that provide health-related services at State institutions; see N.J.S.A. 26:4-19.

The Department proposes to amend the definition of the term “administrator” to add a reference to a farm or migrant labor camp and, thereby, reflect the communicable disease reporting obligations of a person in charge of this type of facility pursuant to N.J.S.A. 34:9A-12 and 13.

The Department proposes to amend the definition of the term “administrator” to add a reference to an insurer, as N.J.S.A. 17:23A-13.1 et seq., and 17B:17-1 et seq., use that term, to reflect the obligation that State law imposes on insurers, if they require applicants for insurance “to submit to medical testing as a condition of issuing, extending or renewing” that insurance, to “promptly provide the Department of Health ... a copy of the results of the test,” if “in the course of the testing the insurer determines that the applicant has a reportable communicable disease.” N.J.S.A. 17:23A-13.1.

The Department proposes to delete the reference to a person in charge of a “preschool” from the definition of the term “administrator” because the chapter does not use the term “preschool” to refer to a separate type of facility, independent of its inclusion within the meaning of the defined term “child care center” as proposed for amendment.

The Department proposes to amend the existing definition of the term “certified animal control officer” to define that term by reference to its statutory definition at N.J.S.A. 4:19-15.1.

The Department proposes to amend the existing definition of the term “child care center” to refer to the statutory definitions at N.J.S.A. 30:5B-1 et seq., specifically at 30:5B-3, and include an “early childhood program” as N.J.A.C. 3A:52-1.4, 6A:14-1.3, and 10:122-1.3 define that term and a public or private preschool program as being within the meaning of the term.

The Department proposes technical amendments to the existing definitions of the terms “Commissioner” and “Department” to reflect the renaming of the Department pursuant to N.J.S.A. 26:1A-2.1.

The Department proposes to replace the existing definition of the term “communicable disease” by referencing the statutory definition of that term.

The Department proposes to amend the existing definition of the term “electronic laboratory reporting” or “ELR” to mean laboratory test result reporting in accordance with the format specified in, at the option of the reporter, either the national HL7 or the Department’s implementation guide. The Department’s implementation guide is a lesser-included subset of the data fields that the HL7 implementation guide requires.

This is to accommodate laboratories that engage in multistate reporting, which might require more data than that which the Department requires.

The Department proposes to amend the existing definition of the term “influenza virus, novel strain” to be “influenza A virus, novel” and correspond to the CSTE surveillance case definition of the term “novel influenza A virus infection.”

The Department proposes to amend the existing definition of the term “neonatal” to mean occurring in a newborn.

The Department proposes to amend the definition of the term “outbreak” to delete internal definitions of terms that the chapter as proposed for amendment would separately define.

The Department proposes to amend the definition of the term “veterinarian” by adding a cross-reference to N.J.S.A. 45:16-1 et seq.

As discussed more fully below, the Department proposes to recodify, with amendments, existing N.J.A.C. 8:57-1.4 through 1.11, 1.13, and 1.15, to be part of proposed new Subchapter 2. N.J.A.C. 8:57-1.4 through 1.11 and 1.13 are proposed for recodification with amendments into proposed new Subchapter 2, as described below. The Department proposes to repeal existing N.J.A.C. 8:57-1.12, Medical examination and specimen submission.

The Department proposes to recodify existing N.J.A.C. 8:57-1.15, Enforcement, which addresses enforcement of the subchapter, as N.J.A.C. 8:57-1.4, Enforcement. The Department proposed to amend subsection (a) to indicate that it applies to chapter-wide noncompliance by entities upon which the chapter imposes reporting and other compliance obligations. The Department proposes to amend paragraph (a)1 to indicate

that the Department might issue a warning notifying an entity of its noncompliance prior to initiating an enforcement action. The Department proposes to amend paragraph (a)<sup>2</sup> to indicate that the Department might notify an agency that has licensing or other credentialing jurisdiction over a noncompliant person or entity of the noncompliance, which might result in the agency's imposition of disciplinary and enforcement measures against the noncompliant entity. The Department proposes to delete subsections (b) through (h), which refer to specific credentialing or licensing bodies and their respective enforcement jurisdiction over the various entities upon which the chapter imposes compliance obligations.

Existing N.J.A.C. 8:57-4.24, Penalties, identifies the availability of penalties for violations of Subchapter 4. The Department proposes to recodify existing N.J.A.C. 8:57-4.24 as 1.5, State Sanitary Code, penalties, with amendments. Proposed new N.J.A.C. 8:57-1.5(a) would indicate that, pursuant to N.J.S.A. 26:1A-7, the chapter is part of the State Sanitary Code. The Department proposes to recodify the existing text of this section as newly codified (b), to amend the text to indicate that violations of any part of the chapter, not only Subchapter 4, are subject to the penalties and sanctions available at N.J.S.A. 26:1A-10, and refer to the availability of sanctions and penalties for violations of N.J.S.A. 26:4-129 and 137, and other applicable laws.

Existing N.J.A.C. 8:57-1.14, Confidentiality, addresses the confidentiality and authorized uses of records and information that the Department holds pursuant to existing Subchapter 1. The Department proposes to recodify existing N.J.A.C. 8:57-1.14 as 1.7, Confidentiality, and proposes to amend existing subsection (a) to indicate that the protections in the subsection apply to records and information that a local health

agency holds, in addition to the Department, pursuant to Chapter 57, and not only Subchapter 1, and that the Commissioner may designate other entities, in addition to those carrying out mandated duties, to have access to these materials, in accordance with applicable law. The Department proposes to delete existing N.J.A.C. 8:57-1.14(b), which repeats N.J.S.A. 26:13-3d.

The Department proposes new N.J.A.C. 8:57-1.7(b), which would identify the circumstances in which the Department may release personally identifiable information that it obtains pursuant to the chapter. These circumstances are for purposes of research, with written consent, to protect the health of individuals, to cooperate with a multijurisdictional public health investigation, and/or pursuant to the order of a court of competent jurisdiction.

The Department proposes new N.J.A.C. 8:57-1.7(c), which would exclude isolation and quarantine orders, material containing the health information of natural persons who participate in medical testing, treatment, vaccination, isolation, or quarantine pursuant to the chapter, and any correspondence, records, reports, and other material associated with medical testing, treatment, vaccination, isolation, or quarantine of natural persons, from the definition of a “government record” that is subject to public access and inspection within the meaning of N.J.S.A. 47:1A-1 et seq., and declare these materials to be exempt from disclosure pursuant to other executive orders and laws. The proposed amendment would be consistent with protections that the Emergency Health Powers Act, N.J.S.A. 26:13-1 et seq., affords this material upon the Governor’s declaration of a public health emergency pursuant to N.J.S.A. 26:13-3. See N.J.S.A. 26:13-14, 15, 17, and 26. The Department perceives no rationale to limit

the protection afforded this kind of individual health information only to circumstances warranting gubernatorial action declaring the existence of a public health emergency.

The Department proposes to recodify existing N.J.A.C. 8:57-1.14(d) as 1.7(d) with an amendment to make the provision applicable to information collected pursuant to the chapter. The Department proposes new N.J.A.C. 8:57-1.7(e), which would authorize the Department or a local health agency to withhold a record that it holds pursuant to the chapter that is otherwise subject to public access, regardless of whether individual identifiers have been removed or redacted from a record, if the agency has actual knowledge, or reason to believe, that the remaining unredacted information could be used, alone or in combination, with other publicly accessible information, to identify an individual who is the subject of the record or to link an individual to the information contained therein.

The Department proposes new N.J.A.C. 8:57-1.7(f), which would generally track the Emergency Health Powers Act at N.J.S.A. 26:13-17 in establishing the purposes for which certain entities could obtain access to isolation, quarantine, and other health information, absent the order of a court of competent jurisdiction finding the need to provide access to avert a clear danger to an individual's or the public's health. The Department proposes new N.J.A.C. 8:57-1.7(g), which would establish that the exemptions from public disclosure at subsections (a) through (f) would not apply to reports and records relating to diseases in animals made pursuant to N.J.A.C. 8:57-2.7, unless the record could be used alone, or in combination, with other information to identify health or other information about an individual as to which the individual may



have a reasonable expectation of privacy; and/or that the agency is required or authorized to protect from public access or disclosure.

The Department proposes new N.J.A.C. 8:57-1.7(h), which would establish the circumstances and conditions that would authorize the Department to release otherwise protected records to the employer of an individual who is the subject of the record and other entities, such as healthcare personnel, school health officials, and IHE institutional liaisons.

The Department proposes new N.J.A.C. 8:57-1.7(i), which would establish the conditions that the Commissioner must determine to exist that would authorize the Department to release otherwise protected records about an individual pursuant to proposed new N.J.A.C. 8:57-1.7(h).

N.J.S.A. 26:2-137.1 directs the Department to specify the vaccine-preventable disease immunization requirements upon which to condition admission to and attendance at child care centers and schools, guided by the ACIP recommendations. N.J.S.A. 18A:61D-1 likewise directs the Department to specify the immunization requirements applicable to IHE attendees. N.J.S.A. 26:1A-7, as modified by the Reorganization Plan, directs the Commissioner, in consultation with the Public Health Council, to establish rules within the State Sanitary Code, “as may be necessary properly to preserve and improve the public health in this State.” N.J.S.A. 17:48-6i and 6m, 17:48A-7h, 17:48E-35.6 and 35.10, 17B:26-2.1h, 17B:27-46.1h and 46.1l, 17B:27A-7 and 19, and 26:2J-4.6 establish coverage requirements for health promotion services applicable to various health benefits plan types, including Department-recommended adult and childhood immunizations. Pursuant to this authority, the Department

proposes new N.J.A.C. 8:57-1.8, Department procedure for the establishment of vaccine-preventable disease immunization recommendations and requirements, to indicate the procedure by which the Department may establish recommendations and requirements for vaccine-preventable disease immunizations.

## **New Subchapter 2**

Existing Subchapter 2 is reserved. The Department proposes to establish new Subchapter 2, Reportable Communicable Diseases, Infections, and Conditions, and as stated above, proposes to recodify existing sections of N.J.A.C. 8:57-1 within new Subchapter 2.

N.J.S.A. 26:4-1 states that the term “communicable disease” means “any infectious or contagious disease so declared or defined by law, or which has been or may hereafter be declared a ‘communicable disease’ by the [Department]. N.J.S.A. 26:4-2 states, in part, that “to prevent the spread of disease affecting humans, the Department ... shall have power to [declare] what diseases are communicable [and] when any communicable disease has become epidemic[; require] the reporting of communicable diseases[; maintain] and enforce proper and sufficient quarantine, wherever deemed necessary[; and remove] any person infected with a communicable disease to a suitable place, if ... necessary.”

N.J.S.A. 26:4-15 provides that “Every physician shall ... after [the physician’s] diagnosis that a person is ill or infected with a communicable disease or other disease required by any law of this State, the State Sanitary Code, or ordinance, to be reported, report such diagnosis and such related information as may be required by the ... Department.” N.J.S.A. 26:4-19 requires persons in control of public and private

institutions “in which any person ill or infected with any disease required by law or the State Sanitary Code to be reported [to] report the fact ... and such other information as may be required by regulation of the ... Department.”

N.J.S.A. 26:4-78 through 95 establish standards for reporting known and suspected cases of rabies in animals. When an animal is known or suspected of either having, or having been bitten by another animal that is known or suspected of having, rabies, N.J.S.A. 26:4-78 requires “the owner or person in charge of the animal or any person having knowledge thereof” to “notify the local board having jurisdiction of the place where the animal is located.”

N.J.S.A. 45:9-42.34 and 35 establish the Department’s obligation, in consultation with the Public Health Council, to establish standards governing clinical laboratory operation, and clinical laboratory reporting of laboratory test results, “for the protection of the public health,” as part of the State Sanitary Code.

Proposed new Subchapter 2 would implement these Department mandates by declaring the communicable diseases, infections, conditions, and laboratory testing information that are reportable, identifying entities that have reporting obligations, and establishing the manner and processes by which entities that have reporting responsibilities are to report.

The Department proposes new N.J.A.C. 8:57-2.1, Scope, to establish that the subchapter would apply to administrators, healthcare professionals, clinical laboratory directors, veterinarians, certified animal control officers, animal facility managers, veterinary diagnostic laboratory directors, health officers, and employers, and other

persons in charge, at food establishments, drug establishments, and cosmetic establishments.

Existing N.J.A.C. 8:57-1.4, Health care provider and administrator reporting of reportable communicable diseases, establishes the obligation of health care providers and administrators to report certain communicable diseases, infections, and conditions. The Department proposes to recodify this section as N.J.A.C. 8:57-2.2, Healthcare professional and administrator reporting and compliance obligations with respect to reportable communicable diseases, infections, and conditions. The Department proposes to amend existing subsection (a) to cross-refer to the reporting procedures at proposed new N.J.A.C. 8:57-2.4 and the disease-specific reporting deadlines at proposed new N.J.A.C. 8:57-2.3. The Department proposes to add new N.J.A.C. 8:57-2.2(a)1, which would require reporting of suspected or confirmed cases of the types listed at N.J.A.C. 8:57-2.3(a); paragraph (a)2, which would require reporting of confirmed cases of the types listed at N.J.A.C. 8:57-2.3(b) and (c); paragraph (a)3, which would require reporting of positive POC tests for the organisms listed at N.J.A.C. 8:57-2.6; and paragraph (a)4, which would require reporting of a confirmed case of a disease, condition, or illness not listed at N.J.A.C. 8:57-2.3, if it is on the infectious Notifiable Condition List for the year in which the case is identified. The Department proposes to amend existing subsection (b) to indicate that, while the section does not require duplicate reporting of cases, each entity with a reporting obligation remains responsible to ensure the submission of required reports, regardless of any arrangement into which entities with mutual reporting obligations for a case might enter to allocate responsibility for ministerial acts associated with reporting. The Department

proposes to delete existing subsection (c) because it would be redundant of the proposed amendment at subsection (b). Proposed new subsection (c) would require a healthcare professional and an administrator to comply with control measures that the Department or a health officer issues, in writing, with respect to individual named cases.

Existing N.J.A.C. 8:57-1.5, Reportable communicable diseases, establishes the lists of reportable communicable diseases and applicable reporting deadlines. The Department proposes to recodify this section as N.J.A.C. 8:57-2.3, Reportable communicable diseases, infections, and conditions. Existing subsection (a) provides a list of diseases, infections, or conditions that are immediately reportable, regardless of whether the case is suspected or confirmed, followed in parentheses by the causative organism, and existing subsection (b) establishes a list of communicable diseases, infections, or conditions that must be reported within 24 hours of confirmation of the case.

Many diseases, infections, or conditions that existing subsection (a) identifies as immediately reportable no longer pose the same public health threat, requiring immediate notification and response, as they may have in the past, whether this be due to advances in the field or because these diseases, infections, and conditions have become more routinely and readily treatable. Additionally, most modern disease reporting is accomplished through electronic means. This type of reporting is near instantaneous. Due to this, the Department can receive these reports faster than it did using the historical methods, allowing a much quicker response. In view of these changed circumstances, the Department reassessed which suspected or confirmed cases must be reported immediately and which could await case confirmation and be

reported with less urgency. Additionally, the Department is proposing to add novel conditions to these lists.

Existing N.J.A.C. 8:57-1.5(a), proposed for recodification as N.J.A.C. 8:57-2.3(a), establishes the list of immediately reportable, suspected, or confirmed cases of a communicable disease, infection, or condition, or an outbreak thereof, and an act of bioterrorism. The Department proposes to amend subsection (a) to: (1) add to the list of immediately reportable diseases the following: biological intoxications, novel coronavirus that causes severe acute respiratory syndrome, free-living amebic infection, melioidosis, mpox (formerly known as monkeypox), plague, poliomyelitis, and rubella; (2) delete brucellosis, pertussis, and tularemia, and SARS as a separate entry (as the latter would be encompassed within the proposed addition of novel coronavirus causing severe acute respiratory syndrome); (3) modify the existing immediate reportability of strains of influenza A virus to include novel and/or unsubtypeable forms of the virus; (4) identify additional types of foodborne intoxication and viral hemorrhagic fever; (5) modify hantavirus to delete the qualifier of pulmonary syndrome; and (6) relocate the reference to reporting of a suspected or confirmed outbreak or act of bioterrorism to proposed new subsection (f), while retaining the immediate reportability of such events in accordance with subsection (a), and simplifying the description by using the defined term “communicable disease, infection, or condition” and deleting redundant descriptions.

Existing N.J.A.C. 8:57-1.5(b), proposed for recodification as N.J.A.C. 8:57-2.3(b), establishes the list of cases that are reportable “within 24 hours of diagnosis.” The Department proposes to amend subsection (b) to require reporting by the close of the next business day following the date on which a healthcare professional confirms a

diagnosis or receives a positive laboratory or POC test result, or other confirmation of a diagnosis. This would establish a more objectively measurable and enforceable standard than the existing phrase “within 24 hours of diagnosis.” The Department proposes to amend the list of reportable cases in subsection (b) to: (1) add alpha-gal syndrome, anaplasmosis, bacterial tickborne disease, brucellosis, *Candida auris* infection or colonization, carbapenemase-producing organism infection or colonization, chikungunya virus, COVID-19 infection (SARS-CoV-2), invasive *Cronobacter* infection in minors up to one year old, dengue virus, eastern equine encephalitis, extrapulmonary nontuberculous *Mycobacterium* (NTM) infection, *Haemophilus ducreyi*, influenza, Jamestown Canyon virus, leptospirosis, pertussis, Powassan virus disease, rabies exposure and cases in which rabies PEP is administered, RSV-associated pediatric mortality, spotted fever group rickettsiosis, tularemia, West Nile virus, and Zika virus; (2) delete Rocky Mountain spotted fever (which would be addressed by the addition of spotted fever group rickettsiosis); (3) modify the description of arboviral disease to add examples of viral diseases in this category (Bourbon, Cache Valley fever, California serogroup, Heartland, Japanese encephalitis, La Crosse encephalitis, and St. Louis encephalitis) and relocate yellow fever to this group from its existing listing as a separate disease (accompanied, as described above, by the addition of the common arboviruses dengue, eastern equine encephalitis, Powassan, West Nile, and Zika); (4) modify the reportability of hepatitis B, in addition to newly diagnosed cases, to cases occurring in persons who while pregnant test positive for hepatitis B surface antigen or virus DNA, or hepatitis E antigen, regardless of prior diagnosis, cases that were originally diagnosed in a jurisdiction or geographic subdivision other than New Jersey,

and cases occurring in minors of up to 36 months of age born to persons who had hepatitis B during pregnancy with, and/or the birth of, the minor; (5) modify the reportability of hepatitis C, in addition to newly diagnosed cases, to cases occurring in persons who test positive for hepatitis C RNA and/or antigen while pregnant, regardless of prior diagnosis, cases that were originally diagnosed in a jurisdiction or geographic subdivision other than New Jersey, and cases occurring in minors of up to 36 months of age born to persons who had hepatitis C during pregnancy with, and/or the birth of, the minor; (6) limit the reportability of Streptococcal disease, invasive group B to cases in infants who are fewer than 90 days of age; (7) delete amoebiasis, neonatal Chlamydial conjunctivitis, Creutzfeldt-Jakob disease, diarrheal disease, post-diarrheal hemolytic uremic syndrome, lymphogranuloma venereum, and tuberculosis; (8) modify sexually transmitted chlamydial infection to be *Chlamydia trachomatis* and, with influenza and Lyme disease, to require only electronic case reporting of these conditions; (9) relocate congenital syphilis to appear within syphilis, all stages; and modify the reportability of animal bites to mean bite of a human, regardless of whether the bite is treated for rabies; and (10) modify the causative organism for trichinellosis to be *Trichinella* spp., modify the causative organism for varicella disease to be varicella-zoster virus, and modify vibriosis to be vibriosis non-cholerae and indicate *Vibrio* spp. as the causative organism.

The Department proposes to delete existing N.J.A.C. 8:57-1.5(c), which reiterates the existing obligation created by N.J.S.A. 26:13-4 that persons with reporting obligations are to report “[a]ny illness or health condition that is a potential cause of a



public health emergency” and add this obligation at proposed new subsection (f) as immediately reportable in accordance with subsection (a).

Recodified N.J.A.C. 8:57-2.3(c) establishes standards for reporting cases of hospital-onset MRSA and hospital patient MRSA surveillance statistics. The Department proposes to amend this subsection to delete the existing description of MRSA reporting requirements and add in place thereof reference to the existing obligation of a hospital administrator to report MRSA LabID events to the NHSN in accordance with existing N.J.A.C. 8:56, Health Care Facility Infection Reporting.

The Department proposes new N.J.A.C. 8:57-2.3(d), which would require reporting of cases of suspected or confirmed tuberculosis (*Mycobacterium tuberculosis*) in accordance with N.J.A.C. 8:57-5.

Existing N.J.A.C. 8:57-1.5(e), proposed for recodification as N.J.A.C. 8:57-2.3(e), establishes HIV case reporting standards. The Department proposes to amend subsection (e) to update the cross-reference to the applicable HIV case reporting standards at N.J.A.C. 8:65, HIV Infection Reporting.

Proposed new N.J.A.C. 8:57-2.3(f) would restate the reportability of suspected and confirmed outbreaks, bioterror events, and cases that may be a source of a public health emergency, while retaining these as immediately reportable in accordance with subsection (a). The Department proposes corresponding deletions of references to these events as reportable from existing subsection (a) and existing N.J.A.C. 8:57-1.6(e).

Existing N.J.A.C. 8:57-1.6, Method of reporting and content of report, establishes the method of reporting and the content of a required report. The Department proposes

to recodify this section as N.J.A.C. 8:57-2.4, Method of reporting and content of report. Existing subsection (a) establishes standards for reporting immediately reportable cases. The Department proposes to amend subsection (a) to cross-reference the list of immediately reportable conditions at proposed new N.J.A.C. 8:57-2.3(a), restate and reorganize the subsection through subcodification, simplify the description of the reporting process, identify the entities, by jurisdiction, to whom reports are to be made based on case location, identify procedures for alternative entities to whom reports are to be made if the primary recipient is unavailable, and delete redundant and superfluous text.

Existing N.J.A.C. 8:57-1.6(b), proposed for recodification as N.J.A.C. 8:57-2.4(b), establishes standards for reporting cases that are reportable “within 24 hours of diagnosis.” The Department proposes to amend subsection (b) to delete reference to this reporting period, add in place thereof a cross-reference to the list of conditions that would be reportable “by the close of the next business day following the date on which the diagnosis is confirmed” pursuant to proposed new N.J.A.C. 8:57-2.3(b), restate and reorganize the subsection through subcodification, including the addition of new subsection (c) to refer to the directory of local health departments in New Jersey, simplify the description of the reporting processes, identify the jurisdictions of entities to whom reports are to be made based on case location and/or reported conditions; and identify procedures for reporting to alternative entities if the primary recipient is unavailable.

Existing N.J.A.C. 8:57-1.6(c), proposed for recodification as N.J.A.C. 8:57-2.4(d), identifies the minimum content of a report that the subchapter requires. The

Department proposes to amend this subsection to delete the reference therein, and throughout the chapter, to the subject of a report as being “ill or infected,” and add instead reference to the subject using the defined term “case” to include those who are suspected of being ill or infected, in addition to persons in whom infection is confirmed.

Existing N.J.A.C. 8:57-1.6(d), proposed for recodification as N.J.A.C. 8:57-2.4(e), identifies the minimum content of an outbreak report. The Department proposes to amend the subsection to identify additional demographic, identifying, and clinical information to be reported about each case within an outbreak. The Department proposes to delete existing subsection N.J.A.C. 8:57-1.6(e), the content of which the Department proposes to add to the list of immediately reportable conditions at proposed new N.J.A.C. 8:57-2.3(a) and (f).

Proposed new N.J.A.C. 8:57-2.4(f) would require a hospital that maintains an internet-based mechanism by which the Department could obtain access to the hospital's health records regarding a case or an outbreak to notify the Department as to the procedure by which it might submit an access request.

The Department proposes new N.J.A.C. 8:57-2.5, Clinical laboratory reporting procedures and obligations with respect to laboratory results; establishment of electronic interface for ELR. This section would establish standards by which a clinical laboratory is to report the results of laboratory tests for the presence of the reportable organisms listed at recodified N.J.A.C. 8:57-2.6 and, with respect to ELR, establishes an electronic interface with the Department. The Department proposes corresponding amendments to delete potentially redundant or conflicting reporting procedures and

obligations at recodified N.J.A.C. 8:57-2.4, specifically at paragraphs(a)1, 2, and 3 and subsections (b), (d), and (e).

Proposed new N.J.A.C. 8:57-2.5(a) would establish that a clinical laboratory is to report by means of ELR or electronic reporting unless otherwise specified at new N.J.A.C. 8:57-2.6. Proposed new subsection (b) would require a clinical laboratory, in establishing an ELR interface with the Department, to adhere to the ELR On-Boarding Manual, Version 1.5 (May 6, 2019), at N.J.A.C. 8:57 Appendix S.

Proposed new N.J.A.C. 8:57-2.5(c) would require a clinical laboratory reporting by means of ELR to use the LOINC and SNOMED terminology standards and, as a maximum standard, at proposed new paragraph (c)1, in accordance with the HL7 Implementation Guide, which the chapter incorporates by reference, as amended and supplemented, at proposed new N.J.A.C. 8:57-1.2(b). The LOINC is a coding vocabulary of terminology used to describe laboratory test results, specifically observations and findings, whereas the SNOMED is a coding vocabulary for medical terms. The HL7 Implementation Guide establishes specifications for reporting laboratory results to health agencies of the USA, including messaging content and dynamics related to the transmission of reportable laboratory result messages. Each USA jurisdiction that requires clinical laboratories to report laboratory results specifies the findings that are reportable and the minimum content of those reports. Some clinical laboratories that report to the Department are multijurisdictional reporters and may elect to report the plenary content of the HL7 Implementation Guide to ensure compliance with differences in ELR requirements among health authorities and jurisdictions. Others may participate in Federal incentive programs designed to

encourage “meaningful use” of electronic health records. Federal standards for these incentive programs may condition eligibility on a clinical laboratory being able to demonstrate reporting ability in accordance with the HL7 Implementation Guide. The Department accepts reports containing all the content that HL7 Implementation Guide requires, but retains only those data elements that it needs. The Department’s information needs with respect to the content of laboratory result reports are less than the plenary content that the HL7 Implementation Guide requires, and the content the Department requires can increase or decrease as the State’s need for epidemiological data changes. For example, if cases of a particular disease start to occur in greater numbers than expected, suggesting an outbreak, the Department’s epidemiologists temporarily may need laboratories to report additional demographic or disease progression data on specimens to facilitate investigation and inform appropriate response measures, until the outbreak subsides.

As an alternative, less burdensome, standard than reporting in compliance with the HL7 Implementation Guide, and to accommodate clinical laboratories that are not multijurisdictional reporters, or that customize their reports by jurisdiction, proposed new N.J.A.C. 8:57-2.5(c)2 would authorize a clinical laboratory to elect to report in accordance with the NJ ELR Implementation Guide, which is a subset of the content that the HL7 Implementation Guide requires. The Department proposes to make the NJ ELR Implementation Guide available online, to allow revision as the State’s epidemiological data needs might change, as described above. However, the NJ ELR Implementation Guide’s compliance requirements would never exceed those of the HL7 Implementation Guide.

Proposed new N.J.A.C. 8:57-2.5(d) would establish the continuing obligation of a clinical laboratory director to ensure the reporting and/or submission of, respectively, laboratory results as to which proposed new N.J.A.C. 8:57-2.6 would require reporting, and culture isolates as to which proposed new N.J.A.C. 8:57-2.6 would require submission.

Existing N.J.A.C. 8:57-1.7, Reporting of positive laboratory results denoting diseases, establishes a list of communicable disease-causing organisms, the presence of which in laboratory findings a clinical laboratory is to report, and the applicable reporting deadlines. The Department proposes to recodify this section as N.J.A.C. 8:57-2.6, Reportable laboratory results for certain organisms; reporting procedures; submission of culture isolates and other test specimens, to indicate that laboratories report results indicative of the presence of organisms, and do not make diagnoses. See N.J.S.A. 45:9-42.34 at subsection e, which states that “[clinical laboratory] reports shall not be construed as constituting a diagnosis.” The Department proposes to amend existing subsection (a) to require a clinical laboratory director to report laboratory results indicative of the presence of the listed communicable disease, illness, or condition-causing organisms, and identify the manner in which, the deadlines by which, and the jurisdictions to which, a clinical laboratory director is to report, depending on the organism and the case location. The Department proposes to amend this subsection to identify organisms requiring, at proposed new paragraph (a)1, immediate reporting by telephone notice to the Communicable Disease Service; at proposed new paragraph (a)2, immediate electronic reporting and telephone notice to the local health agency with case jurisdiction; at proposed new paragraph (a)3, immediate electronic reporting,

including by a clinical laboratory that ordinarily reports by means of ELR; at proposed new (a)4 and (a)5, by ELR or electronic reporting by the close of the next business day following the receipt of results; and at proposed new (a)6, in accordance with N.J.A.C. 8:65, HIV Infection Reporting.

Proposed new N.J.A.C. 8:57-2.6(a)1 would require immediate telephone reporting to the Communicable Disease Service if a culture were suspected to contain *Bacillus anthracis*, *Brucella* spp., *Burkholderia mallei*, *Burkholderia pseudomallei*, *Francisella tularensis*, and *Yersinia pestis*. At new N.J.A.C. 8:57-2.6(a)2, the Department proposes to require immediate electronic reporting and telephone notice to the local health officer with case jurisdiction upon obtaining a laboratory result that indicates, or is positive (and, if indicated, negative) for, the presence of the following organism or antibodies: *Acanthamoeba* spp., *Bacillus anthracis*, *Balamuthia mandrillaris*, *Burkholderia pseudomallei*, unsubtypeable or novel influenza A virus, *Naegleria fowleri*, rubeola virus upon identification by specified serologic tests, variola virus, viruses that cause viral hemorrhagic fever (with corresponding proposed deletion of the existing separate references to the viruses the term comprises, that is, Ebola, Lassa, and Marburg), and *Yersinia pestis*. The Department proposes to delete from this category of reportable results, the existing references to *Bordetella pertussis*, foodborne intoxication, including, but not limited to, ciguatera, paralytic shellfish poisoning, scombroid, or mushroom poisoning; *Francisella tularensis*; *Haemophilus influenzae*; hepatitis A; and rubella virus.

Proposed new N.J.A.C. 8:57-2.6(a)3 would require immediate electronic reporting, even if the laboratory ordinarily reports by ELR, of results indicative of the

presence of (positive for) the following organisms, and, if specified, negative results: acid-fast bacilli, *Haemophilus influenzae* from particular specimen sites, hepatitis A virus from certain tests and the results of certain additional tests if performed on the same specimen collection that yields the hepatitis A result, positive and negative orthopoxvirus monkeypox, and rubella virus if identified by serology testing and the results of certain additional tests if performed on the same specimen collection that yields the positive serology result. The Department proposes to amend this list to delete reporting of antibiotic-resistant organisms by a hospital-based laboratory.

Proposed new N.J.A.C. 8:57-2.6(a)4 would require reporting of laboratory test results that are positive, and in certain cases, negative, for the presence of the listed organisms by the close of the next business day. The Department proposes to: (1) require reporting of positive results for the following organisms: Alpha-gal, *Anaplasma* spp., arbovirus, *Bordetella pertussis*, *Borrelia* spp., *Cronobacter* spp., invasive infection, in minors up to one year of age, *Cryptosporidium* spp., *Cyclospora* spp., eastern equine encephalitis, *Giardia lamblia*, *Haemophilus ducreyi*, Jamestown Canyon virus, *Listeria monocytogenes*, *Neisseria gonorrhoeae*, nontuberculous *Mycobacterium* (NTM), respiratory syncytial virus, *Staphylococcus aureus*, *Streptococcus agalactiae*, *pneumoniae*, and *pyogenes*, when isolated from cerebrospinal fluid, blood, or a normally sterile site, *Trichinella* spp., Varicella-zoster virus, and *Yersinia* spp.; (2) require reporting of positive and negative results for the following organisms: *Babesia* spp., non-culture *Brucella* spp., *Candida auris*, Carbapenemase-producing organism, chikungunya virus, *Chlamydia psittaci*, non-culture *Coxiella burnetii*, *Cronobacter* spp., invasive infection, in minors up to one year of age, *Cryptosporidium* spp., dengue virus,



*Ehrlichia* spp., *Escherichia coli*, non-culture *Francisella tularensis*, influenza virus, *Klebsiella granulomatis*, *Legionella* spp., *Leptospira* spp., *Plasmodium* spp., *Rickettsia* spp., *Salmonella* spp., *Salmonella enterica* serotype Typhi, SARS-CoV-2, *Shigella* spp., *Treponema pallidum*, *Vibrio* spp., West Nile virus, and Zika virus; (3) modify the reportability of hepatitis B, hepatitis C, and mumps upon obtaining certain serology results and add as reportable the results of certain other tests if performed on a specimen collection yielding results of reportable hepatitis B, hepatitis C, or mumps virus; and (4) modify the reportability of test types and results for *treponema pallidum*.

Proposed new N.J.A.C. 8:57-2.6(a)5 would require a laboratory to report by means of ELR or electronic reporting by the close of the business day next following the day on which it obtains a result that is positive for a communicable disease-causing organism not listed at proposed new N.J.A.C. 8:57-2.6(a)1, 2, 3, and 4, if the organism is a cause of an infectious condition that appears on the CDC infectious Notifiable Condition List applicable for the year in which the result is obtained.

Proposed new N.J.A.C. 8:57-2.6(a)6 would require laboratory reporting of HIV in accordance with N.J.A.C. 8:65, HIV Infection Reporting.

Proposed newly codified N.J.A.C. 8:57-2.6(b) would specify the required minimum content of a laboratory report that N.J.A.C. 8:57-2.6(a) requires. Proposed new paragraph (b)8 would require a laboratory to provide the initial reportable laboratory test reports upon request.

The Department proposes to delete existing N.J.A.C. 8:57-1.7(b) and recodify existing N.J.A.C. 8:57-1.7(c) as 2.6(b). The Department proposes to delete existing N.J.A.C. 8:57-1.7(d). The Department proposes to recodify existing N.J.A.C. 8:57-

1.7(e) as 2.6(c) and proposes to amend the subsection to modify the types of culture isolates and specimens that clinical laboratory directors are required to submit to the PHEL. Additions to this list would include *Candida auris*; carbapenemase-producing organisms (CPO); chikungunya serology specimens; nontuberculous mycobacteria (NTM) excluding *Mycobacterium leprae* and *Mycobacterium goodii*, when collected from sterile body sites, excluding lower respiratory specimens; influenza A virus, novel and/or unsubtypeable; influenza virus, severe and fatal pediatric; *Legionella* spp., pan-non susceptible organisms; severe and fatal pediatric respiratory syncytial virus; high-level vancomycin-resistant *Staphylococcus aureus* (VRSA) from any body site; *Vibrio* spp.; and all IgM-positive West Nile virus specimens. Proposed deletions from this list would include *Candida haemulonii* species complex (to be replaced with *Candida auris*) and multidrug-resistant organisms (MDROs) (to be replaced with pan non-susceptible organisms).

The Department proposes to recodify existing N.J.A.C. 8:57-1.7(f) as 2.6(d) and proposes to amend the subsection to delete a reference to tuberculosis reporting and require a laboratory director to submit any specimen or isolate, obtained from humans, food, or other sources, which is associated with an outbreak or public health investigation and for which the Department issues a written request.

The Department proposes to delete existing N.J.A.C. 8:57-1.7(g), which requires certain hospital-based clinical laboratories to submit data that the Department no longer needs, and existing subsection (h), as redundant.

The Department proposes new N.J.A.C. 8:57-2.6(e), which would require a clinical laboratory director to submit to PHEL certain respiratory specimens tested for influenza virus, depending on the time of year.

The Department proposes to recodify existing N.J.A.C. 8:57-1.8, Reporting of zoonotic diseases and any disease outbreaks in domestic companion animals by veterinarians, certified animal control officers, and animal facility management, which addresses the reporting of certain zoonotic diseases and disease outbreaks, as N.J.A.C. 8:57-2.7, Reporting obligations and procedures applicable to a veterinarian, a certified animal control officer, an animal facility manager, and a veterinary diagnostic laboratory.

Existing subsection (a) establishes the list of reportable zoonotic diseases, infections, and conditions and shows, in parentheses, the disease-causing organism. The Department proposes to amend this subsection to add a cross-reference to the case reporting procedure at N.J.A.C. 8:57-2.7(e) and add, to the list of reportable diseases in animals, canine brucellosis (*Brucella canis*), glanders (*Burkholderia mallei*), harmful algal bloom toxicity, melioidosis (*Burkholderia pseudomallei*), SARS-CoV-2, and tuberculosis.

Existing subsection (b) provides a cross-reference to the existing obligation to report confirmed and suspected cases of rabies in any animal in accordance with the reporting procedure at N.J.A.C. 8:23-1.2. The Department proposes to amend the subsection to identify the applicability of the subsection to animal facility managers and animal rescue organization managers. The Department proposes to amend existing subsection (c) to indicate that the subsection establishes the obligation to report

confirmed and suspected outbreaks of any disease in domestic companion animals in accordance with the procedures at proposed new subsections (e) and (f).

The Department proposes to amend existing subsection (d) to track more closely the statutory obligation at N.J.S.A. 26:4-81 to report cases of persons being bitten by animals or exposed to rabies to the appropriate health officer with jurisdiction, to refer to the applicability of this reporting obligation to an animal rescue organization manager, and to add new paragraph (d)1 to reflect the statute's exemption from the reporting obligation when a person is treated by a healthcare professional.

The Department proposes to amend subsection (e) to indicate the manner by which one is to make the report that subsections (a) and (c) require, and to require the report to be submitted "by the close of the business day next following" the diagnosis or the outbreak identification by submission of either a completed Zoonotic Disease Incident Report form at proposed new N.J.A.C. 8:57 Appendix A (CDS-32), or a written report containing the information the form requires.

The Department proposes to amend existing subsection (f) to use the defined term "animal facility manager" and provide a cross-reference to the obligation of an animal facility to establish a program of disease control and health care within the supervision of a veterinarian at N.J.A.C. 8:23A-1.9.

The Department proposes to amend existing subsection (g) to indicate that, while duplicate reporting of the same case is unnecessary, entities having mutual reporting obligations with respect to a case remain obliged to ensure that the case is reported in accordance with the subchapter, regardless of any agreement to delegate ministerial tasks associated with reporting.

The Department proposes to amend existing subsection (h) to refer to a suspected or confirmed reportable zoonotic disease and outbreak of any disease affecting animals within the jurisdiction of the Departments of Agriculture or Environmental Protection.

The Department proposes new subsection (i), which would establish a list of organisms to be reported by a veterinary laboratory director to the Department within one business day following test completion, when identified in a domestic companion animal.

The Department proposes new subsection (j), which would identify procedures for reporting laboratory results pursuant to subsection (i).

The Department proposes to recodify existing N.J.A.C. 8:57-1.9, Reporting of diseases by health officers, which establishes the reporting obligations and procedures by which health officers are to report to the Department, and addresses jurisdictional issues, as N.J.A.C. 8:57-2.8, Health officer reporting obligations and procedures. The Department proposes to amend existing subsection (a), which establishes the procedure by which health officers are to immediately report reportable cases and laboratory findings to the Department. The proposed amendment would require immediate telephonic and electronic reporting to the Department, upon a health officer's receipt of a report pursuant to N.J.A.C. 8:57-2.3(a), except telephone notice is not required for the following: *Haemophilus influenzae*, hepatitis A, mpox, and rubella. Proposed new subsection (b) would require a health officer receiving a report pursuant to N.J.A.C. 8:57-2.3(b) to report the case by electronic reporting by the close of the next business day. Proposed new subsection (c) would require a health officer receiving a

report pursuant to N.J.A.C. 8:57-2.3(f) to immediately notify the Department by telephone. Proposed new subsection (d) would require a health officer receiving a report of a laboratory result that is reportable pursuant to N.J.A.C. 8:57-2.6(a)2 to immediately notify the Department by telephone and, if the reporting laboratory has not already done so, by electronic reporting. Recodified subsection (e) is amended to require a health officer receiving a report of a laboratory result that is reportable pursuant to N.J.A.C. 8:57-2.6(a)3 to report the result by electronic reporting within 12 hours of receipt, if the reporting laboratory has not already reported the result. Proposed new subsection (f) would require a health officer receiving a report of a laboratory result that is reportable pursuant to N.J.A.C. 8:57-2.6(a)4 to report the result by electronic reporting by the close of the next business day, if the reporting laboratory has not already reported the result. Proposed new subsection (g) would require a health officer receiving a Zoonotic Disease Incident Report (or the content therein) to submit the report to the CDS by telefacsimile or electronic mail by the close of the next business day.

The Department proposes to recodify existing paragraph (b)1 as subsection (h), which establishes the obligation of a health officer to investigate an incomplete report and submit additional information to the Department, and to amend the subsection to require health officers to report in accordance with the reporting procedures at subsections (a) through (g) and to change the phrase “working days” to the more commonly used term “business days.” The Department proposes to recodify existing paragraph (b)2 as subsection (i), which establishes a procedure by which health officers experiencing circumstances that impede electronic reporting to fulfill their reporting

obligations by other means. A proposed amendment would delete reference to mail reporting and establish that the Department would instruct a health officer as to an acceptable alternative means of reporting, which would depend on the nature of the case and the urgency of the response.

Existing subsection (c) addresses health officer communications with respect to reports implicating multiple jurisdictions. The Department proposes amendments to reorganize the subsection as new subsections (j), (k), and (l). Proposed newly codified subsections (j) and (k) would require a health officer to notify the health officer of another jurisdiction in which a case of a suspected or confirmed reportable communicable disease, infection, or condition, respectively, is known or believed to have been contracted, or resides. Proposed newly codified subsection (l) would require a health officer to notify the Department when subsections (j) or (k) would require issuance of a notice to a jurisdiction outside of New Jersey. The Department proposes to delete existing subsection (d) because it unnecessarily reiterates the reporting responsibility of health officers who delegate ministerial functions associated with reporting.

The Department proposes to recodify existing N.J.A.C. 8:57-1.10, Health officer investigations, which establishes standards for health officer investigations of communicable diseases and outbreaks, as N.J.A.C. 8:57-2.9, Health officer investigations. The Department proposes to amend subsection (a) to delete a reference to a guidance publication and indicate that a health officer is to investigate, in accordance with the section and the “Guidance for Prioritizing Communicable Disease Investigations,” at N.J.A.C. 8:57 Appendix T, each suspected and confirmed case of, at

new paragraph (a)1, a reportable disease, infection, and condition and, at new paragraph (a)2, an outbreak of any disease, infection, or condition. The Department proposes to delete existing subsection (b).

The Department proposes to amend recodified subsection (b) to restate the actions that a health officer is to undertake in performing an investigation. Proposed new paragraph (b)2 would add the obligation to determine the number of cases. The Department proposes to amend recodified paragraph (b)3 to replace the term “spread” with “mode of transmission.” Proposed new paragraph (b)5 would require a health officer to collaborate with the Department on public health notifications, including press releases and communications with constituents. Proposed new paragraph (b)6 would restate the existing obligation of a health officer to adhere to Department direction that the Department may issue, depending on the circumstances of a case or outbreak.

The Department proposes to delete existing subsection (d), which is redundant of the reporting procedures at existing N.J.A.C. 8:57-1.9, as proposed for recodification with amendment as N.J.A.C. 8:57-2.8. The Department proposes to recodify existing subsection (e), which addresses the factors implicating overlapping health officer jurisdiction with respect to an investigation, as subsection (c), and amend the subsection to indicate that a jurisdiction is implicated in an investigation if the case or outbreak is suspected or confirmed to have been transmitted there, if the case is employed, maintains an additional residence, conducts other activities, or is receiving care there, or if the Department determines the jurisdiction to have a geographic nexus to the investigation.



The Department proposes to recodify existing subsection (f), which addresses multijurisdictional case coordination, as subsection (d) and proposes to amend the subsection to use the defined term “local health agency” rather than “local health department” and to indicate that other State and Federal entities may be involved in an investigation.

Proposed new subsection (e) would indicate that, pursuant to N.J.S.A. 26:1A-7, 26:4-2, 26:4-4, and App. A:9-33 et seq., each health officer is to conduct communicable disease investigations within the health officer’s respective jurisdiction, including at a State-owned or affiliated building or facility. The Department proposes to recodify existing subsection (g) as (f) and amend the subsection to require a health officer to report to the Department, at least every 30 days, on the status of each investigation in progress until the completion thereof, and more frequently, depending on specified factors. This would ensure that the Department remains apprised of the status of ongoing investigations, rather than having to wait until an investigation is “completed” and would encourage the prompt completion, when possible, of an investigation that might otherwise languish due to inactivity. The Department proposes to reorganize existing (g), which establishes the required content of a status report, as subsections (f) and (g) and amend subsection (g) to add to the minimum content of a required monthly status report, case counts, line lists, and, upon Department request, inspection reports and preliminary findings associated with site visits to locations associated with the investigation.

The Department proposes to delete existing subsection (h), which cross-references the procedures for handling infected pet birds at N.J.A.C. 8:23-1.4, and

subsection (i), which cross-references the Commissioner's powers pursuant to the Emergency Health Powers Act. Proposed new subsection (h) would identify disease-specific worksheets that the Department makes available on its forms page for optional use by health officers in conducting investigations.

The Department proposes to recodify existing N.J.A.C. 8:57-1.11, Isolation and quarantine for communicable disease, which addresses isolation and quarantine for communicable disease, as N.J.A.C. 8:57-2.10, Isolation and quarantine for communicable disease, infection, or condition. The Department proposes to amend subsection (a) to indicate that isolation and quarantine measures might be appropriate and would be available for both a suspected or confirmed case of a communicable disease, infection, or condition and add cross-references to N.J.S.A. 26:4-1 et seq., and 26:13-1 et seq.

The Department proposes to recodify existing N.J.A.C. 8:57 Appendix B, the Model Rules for Local Boards of Health, as N.J.A.C. 8:57 Appendix R, the Model Ordinance for Quarantine and Isolation (model ordinance), with amendments. Proposed new N.J.A.C. 8:57-2.10(a)1 would state that a geographic subdivision of the State, such as a municipality or a county (health jurisdiction), might elect to enact the model ordinance. A health jurisdiction's adoption of the model ordinance, or a version thereof customized to local needs, would enable it to establish the preneed isolation and quarantine measures that it would use to prevent or control the spread of a quarantinable disease, infection, or condition, should a case or an outbreak occur within its jurisdiction. The Department proposes to amend the model ordinance to modify the definition of the term "quarantinable disease" as used therein, to indicate that the term is

not limited to communicable diseases, infections, and conditions that N.J.A.C. 8:57 identifies as reportable. This would facilitate the ability of a health jurisdiction to implement an appropriate public health response to emerging and novel diseases. The Department proposes nonsubstantial and technical amendments throughout the model ordinance to ensure that it remains consistent with other proposed changes at N.J.A.C. 8:57, to correct grammar, and to improve readability.

Proposed new N.J.A.C. 8:57-2.10(a)2 would state that, with the Department's consent, an order issued pursuant to the section would remain in force unless terminated. The Department proposes to amend recodified N.J.A.C. 8:57-2.10(a)3 to use the defined term "case." The Department proposes to delete existing paragraphs (a)2 and 3. The Department proposes to amend existing subsection (b) to indicate that the subsection would apply to a quarantined case.

The Department proposes to delete existing subsection (c) and recodify existing subsection (d) as (c). The Department proposes to add new subsection (d), which would cross-reference procedures for quarantine and other handling measures with respect to infected pet birds at N.J.A.C. 8:23-1.4. The Department proposes to add new subsection (e) to establish procedures for quarantining domestic companion animals if infected or exposed to reportable diseases set forth at N.J.A.C. 8:57-2.7 and proposes a corresponding amendment to delete, as redundant, a comparable provision at existing N.J.A.C. 8:57-1.10(h).

The Department proposes to repeal existing N.J.A.C. 8:57-1.12, Medical examination and specimen submission.

The Department proposes to recodify existing N.J.A.C. 8:57-1.13, Foodhandlers ill or infected with communicable diseases, as N.J.A.C. 8:57-2.11, Work restrictions associated with a food establishment, drug establishment, or cosmetic establishment, and other worksites at which food, drugs, or cosmetics are handled. The Department proposes new subsection (a), indicating that a person who works at a food establishment, drug establishment, or cosmetic establishment, or is a food employee who is confirmed as or suspected of being ill or infected with a communicable disease, infection, or condition shall comply with a directive of the Department or local health agency. The Department proposes to amend recodified subsection (b) to refer to N.J.S.A. 24:15-10, which requires an employer to prohibit a person from working with food, drugs, or cosmetics if the person is, or has been exposed to a person who is, confirmed to be or suspected of being ill with a communicable disease, infection, or condition that is transmissible through food, drugs, and/or cosmetics. The Department proposes to delete existing subsection (b). The Department proposes to amend existing subsection (c), indicating that the public health authority may condition the removal of a prohibition established pursuant to subsections (a) or (b) upon laboratory testing to determine if the person subject to the prohibition continues to be capable of disease transmission by working in a food establishment, drug establishment, or cosmetic establishment and qualifying the term “communicable disease” with the phrase “that is transmissible through food, drugs, or cosmetics.” Proposed new paragraph (c)<sup>1</sup> would prohibit removal of a prohibition if a person continued to be capable of transmission of a disease that is transmissible through food, drugs, or cosmetics. The Department proposes to amend existing subsection (d) and paragraph (d)<sup>1</sup> to indicate

the public health authority's ability to prohibit sale or distribution of food, drugs, or cosmetics that a person manufactured, processed, stored, prepared, or served, if the person is ill or infected with, or capable of transmission of a communicable disease, infection, or condition that is transmissible through food, drugs, or cosmetics. The Department proposes to amend existing paragraph (d)2 to delete the term "vehicle" and use the more accurate terms "vector" or "fomite." Proposed new subsection (e) would reiterate the obligation of an owner, operator, or another person in charge of a food establishment, drug establishment, or cosmetic establishment to comply with directives of the Department to exclude persons who are ill or infected with a communicable disease, infection, or condition that is transmissible through food, drugs, or cosmetics from working at a food establishment, drug establishment, or cosmetic establishment.

Proposed new N.J.A.C. 8:57-2.12, School data reporting, would establish data reporting requirements of schools. This section indicates that schools must report weekly data to the Department into CDRSS. This data includes: (1) student census; (2) number of absent students; (3) reason for each absence; and (4) whether an outbreak of communicable disease, infection, or condition is known or suspected to have occurred, or did occur and if an outbreak did occur, the communicable disease, infection, or condition that was known or suspected to have occurred as an outbreak. The proposed new section would establish, as a permanent requirement, the reporting obligation that Executive Directive No. 21-011, Protocols for COVID-19 Reporting for School Settings, established requiring schools to report this data. Thus, this is an existing reporting obligation.

Proposed new N.J.A.C. 8:57-2.13, Nursing home data reporting, would establish data reporting requirements applicable to nursing homes. Proposed new subsection (a) would require each nursing home administrator to ensure that the facility submits data twice weekly to the Department through REDCap, the CDRSS, or a designated successor vendor. This data includes: (1) number of residents and staff; (2) number of residents and staff who received a vaccine for COVID-19, influenza, and RSV as of each reporting date; (3) the number of new cases of a reportable communicable disease, infection, or condition among staff or residents; and (4) whether there was an outbreak of any disease, infection, or condition, known or suspected. Proposed new subsection (b) would state that the CDS would report a failure to meet these reporting requirements to the Office of Health Care Facility Survey and Field Operations of the Department. Proposed new subsection (c) would require the Department to issue written and electronic notice if the platform vendor were to change. Nursing homes began the reporting requirements described in the proposed new rule during the COVID-19 pandemic, and this new section would make the data reporting permanent.

### **Subchapter 3**

P.L. 2004, c. 138, the Statewide Immunization Registry Act, codified at N.J.S.A. 26:4-131 through 135, established a Statewide automated and electronic immunization registry. N.J.S.A. 26:4-134i directs the Commissioner to promulgate rules to implement the Statewide Immunization Registry Act. The Department establishes and maintains the New Jersey Immunization Information System (NJIIS) to serve as the Statewide automated and electronic immunization registry that the Statewide Immunization Registry Act requires.

Existing Subchapter 3, The New Jersey Immunization Information System (NJIIS), establishes standards governing the New Jersey Immunization Information System (NJIIS). Existing N.J.A.C. 8:57-3.1, Purpose and scope, establishes the purpose and scope of the chapter. The Department proposes to merge existing paragraph (a)1 into subsection (a). The Department proposes to delete existing paragraphs (a)2 and 3. The Department proposes to delete existing subsection (b). The Department proposes to amend recodified subsection (b) to indicate that the subchapter applies to applicants for NJIIS user and NJIIS site access, and persons serving as NJIIS coordinators, NJIIS sites, NJIIS site administrators, NJIIS users, and NJIIS registrants.

The Department proposes to repeal existing N.J.A.C. 8:57-3.2, Incorporated documents. This section identified, and incorporated by reference, forms and publications to which the subchapter referred.

The Department proposes to repeal existing N.J.A.C. 8:57-3.3, Definitions, which establishes definitions of terms the subchapter uses, as the proposed amendments at recodified N.J.A.C. 8:57-1.2 would establish new and/or relocate existing definitions of terms the subchapter uses.

The Department proposes to recodify and amend existing N.J.A.C. 8:57-3.4, Confidentiality, as 3.2. The Department proposes to amend existing subsection (a) to reflect that it addresses individually identifiable information in the NJISS. The Department proposes to amend existing paragraph (a)1 to correct a cross-reference and indicate that the Department would maintain registrant confidentiality and, if it disseminates reports using the data therein, it will not release information that can be

used to identify registrants. The Department proposes to delete paragraph (a)2. The Department proposes to amend recodified paragraphs (a)2 and 3 to indicate that information about withdrawn registrants would be available to civil and/or criminal law enforcement authorities and to update a cross-reference. The Department proposes to amend existing subsection (b) to indicate that all information in the NJIIS is confidential and to cross-reference N.J.S.A. 26:4-137 as a basis of sanctions for improper use of NJIIS information. The Department proposes to amend existing subsection (c) to authorize a health benefit plan to request information about a registrant who is an existing or prior member, customer, or beneficiary.

The Department proposes to recodify existing N.J.A.C. 8:57-3.5, Administration, which establishes NJIIS administrative standards, as N.J.A.C. 8:57-3.3. The Department proposes to delete existing paragraph (a)1. The Department proposes to amend existing subsection (b) to refer to the applicable jurisdiction of an MCHC as governing the NJIIS site it is to coordinate. The Department proposes to codify new paragraph (b)1 with amendments to delete the characterization of records in the NJIIS as “medical” records and add instead the more generic term “health” records and delete the requirement that an NJIIS coordinator conduct oversight activities under VPDP supervision, to indicate that, while an NJIIS coordinator may always consult with the VPDP, VPDP supervision is not required in the conduct of an NJIIS coordinator’s routine oversight activities. The Department proposes to amend existing subsection (c) to delete the requirement that a request for MCHC information be made by a mailed request. The Department proposes to amend existing subsection (d) to refer to the authority of an NJIIS coordinator, rather than the responsibilities of an MCHC office.



The Department proposes to reorganize existing paragraphs (d)1, 2, and 3 as paragraphs (d)1 through 7 and proposes amendments to restate the duties of an NJIIS coordinator. These would include identifying the authority of a coordinator to administer NJIIS enrollment, making enrollment eligibility determinations, ensuring as a precondition to granting access to the NJIIS that applicants for NJIIS enrollment execute the NJIIS User Confidentiality Agreement at N.J.A.C. 8:57 Appendix D, and undergo NJIIS training, specifying user permissions and access rights, providing NJIIS training, issuing credentials, and auditing compliance with the NJIIS User Confidentiality Agreement.

The Department proposes to recodify existing N.J.A.C. 8:57-3.6, Eligibility to become an authorized user and NJIIS site, as N.J.A.C. 8:57-3.4, Eligibility to become an NJIIS user and NJIIS site, and proposes amendments to reorganize existing paragraph (a)1 as new paragraphs (a)1 through 13, and restate the entities that are eligible to become NJIIS users and NJIIS sites using the defined terms “health care facility,” “health care professional,” “early childhood center,” “IHE,” “EHR vendor,” and “HIE, HIO, and HIN.” The Department proposes to delete existing subsection (b), which describes the Commissioner’s rulemaking authority.

The Department proposes to recodify existing N.J.A.C. 8:57-3.7, Authorized user enrollment requirements, as N.J.A.C. 8:57-3.5, NJIIS user enrollment eligibility requirements, and amend the section to delete paragraph (a)1. The Department proposes to recodify existing paragraphs (a)2 and 3 as paragraphs (a)1 and 2. The Department proposes new paragraph (a)3 to require an applicant to be associated with an approved NJIIS site. The section would require an applicant to submit Subchapter 3

Appendix C, User Confidentiality Agreement, which the Department proposes to recodify with amendments as N.J.A.C. 8:57 Appendix D, the NJIIS User Confidentiality Agreement form.

The Department proposes to recodify existing N.J.A.C. 8:57-3.8, Authorized user applicant enrollment process, as 3.6, NJIIS site and NJIIS user applicant enrollment process. The Department proposes to amend existing subsection (a) to delete references to application submission methods and identify the procedures to which an applicant for enrollment must adhere to become an NJIIS site. The section would require an applicant to execute and submit the NJIIS Enrollment Request for New NJIIS Site form, which is an existing form proposed for recodification from Subchapter 3 Appendix A as N.J.A.C. 8:57 Appendix B, and the Interface Enrollment Request Form, which the Department proposes as new N.J.A.C. 8:57 Appendix U.

The Department proposes to amend existing subsection (b), which establishes the procedure to which an NJIIS site administrator must adhere to enroll new NJIIS users at the NJIIS site. The Department proposes to delete existing paragraph (b)1. The Department proposes to amend recodified paragraph (b)1 to require the NJIIS site administrator to submit the NJIIS User Enrollment and Training Request form, which is an existing form at N.J.A.C. 8:57-3 Appendix B that the Department proposes to recodify with amendments as N.J.A.C. 8:57 Appendix C. The Department proposes to delete existing subparagraphs (b)2i through vi. The Department proposes to amend existing subsection (c) to delete existing paragraphs (c)1, 2, 3, and 4 and identify the procedure to which an NJIIS coordinator is to adhere in reviewing an application for NJIIS site enrollment and allocating the applicable NJIIS access level. Proposed new

subsection (d) would establish the procedure to which an NJIIS coordinator is to adhere in reviewing an application for NJIIS user enrollment and allocating the applicable NJIIS access level. The Department proposes to amend recodified subsection (e) to delete existing paragraph (d)<sup>1</sup> and restate the notice requirements following denial of an application for a requested NJIIS access level. The Department proposes to delete existing subsection (e).

The Department proposes to recodify existing Subchapter 3 Appendix D as N.J.A.C. 8:57 Appendix E, the NJIIS Request for Change of User Security Authorization/Request for Password Reset form, which recodified N.J.A.C. 8:57-3.6(f) would require an NJIIS coordinator to submit when requesting a change in an NJIIS user's NJIIS access level or password.

The Department proposes to amend existing subsection (g) to indicate that, following an NJIIS coordinator's approval of an NJIIS user applicant's application and designation of the applicant's appropriate NJIIS access level, the applicant's completion of the training that corresponds to the applicant's NJIIS access level is a precondition to the NJIIS coordinator's issuance of NJIIS user access credentials to the applicant. The Department proposes to delete existing paragraph (g)<sup>1</sup>.

The Department proposes to recodify existing N.J.A.C. 8:57-3.9, Authorized user access to information, which establishes standards for NJIIS user access to NJIIS information, as N.J.A.C. 8:57-3.7, NJIIS user access to NJIIS information regarding withdrawn registrants; Department investigation of NJIIS system threats; reinstatement of NJIIS user and NJIIS site access. The Department proposes to amend the section to delete existing subsections (a), (b), and (c), as redundant of recodified N.J.A.C. 8:57-

3.3, as proposed for amendment, which would address an NJIIS user's means and level of access to NJIIS information. The Department proposes to recodify existing subsection (d) as (a) and amend it to indicate that NJIIS users would receive an indication that the record of a registrant who has withdrawn from the NJIIS is inaccessible (hereinafter referred to as an "inactive record").

The Department proposes to recodify existing subsection (e) as (b) and amend it to indicate that NJIIS user support and assistance is available upon reviewing and selecting from among available support topics under the NJIIS "Submit a Request" heading, and thereupon submitting a completed NJIIS Online Ticketing Intake form at proposed new N.J.A.C. 8:57 Appendix F. Proposed new subsection (c) would indicate that NJIIS use is subject to audit by the Department and the applicable NJIIS coordinator. Proposed new subsection (d) would establish the duty of each NJIIS user and NJIIS site to cooperate with, and provide information and documentation upon request to, the Department and the applicable NJIIS coordinator in support of NJIIS audit and oversight activities. Proposed new subsection (e) would identify the authority of the Department to suspend NJIIS access to address NJIIS system threats and deny and/or impose conditions on reinstatement of access, depending on the result of the Department's investigation of the threat.

The Department proposes to recodify existing N.J.A.C. 8:57-3.10, Authorized user withdrawal, which establishes procedures by which an NJIIS site administrator can request the withdrawal or change of an NJIIS user or NJIIS site's access, as N.J.A.C. 8:57-3.8, Process for NJIIS user and NJIIS site withdrawal; access level change request. The Department proposes to amend the section to indicate that an NJIIS site

administrator, rather than the NJIIS or the VPDP, is to process such requests, using the NJIIS Request for Change of User Security Authorization/Request for Password Reset form at N.J.A.C. 8:57 Appendix E. The Department proposes to delete subsection (b), which establishes the timeline within which the VPDP is to address these requests.

The Department proposes to recodify existing N.J.A.C. 8:57-3.11, Informing parents, which establishes standards for notifying parents about the NJIIS, as N.J.A.C. 8:57-3.9, Informing parents of newborns about the NJIIS pursuant to N.J.S.A. 26:4-134i(3). The Department proposes to delete existing subsection (a). The Department proposes to amend recodified subsection (a) to delete existing paragraphs (b)1 through 4, and to require a birthing facility to establish procedures to ensure that the parent of a newborn receives the NJIIS Informational Brochure. The Department proposes to amend recodified subsection (b) to delete existing paragraph (c)2 and indicate that a healthcare professional providing care to a minor who is not enrolled in the NJIIS is to make the NJIIS Informational Brochure available to the minor's parent, in either a paper or electronic format.

The Department proposes to recodify existing N.J.A.C. 8:57-3.12, Registrant enrollment, which establishes procedures by which to enroll a person in the NJIIS, as N.J.A.C. 8:57-3.10, Registrant enrollment. Existing subsection (a) reflects the Department's reconfiguration of the NJIIS system as of January 1, 1998, to enroll every newborn upon a birthing facility's creation of that newborn's electronic birth certificate. The Department proposes to amend subsection (a) to delete the reference to the 1998 reconfiguration of the NJIIS and the description of a procedure by which a parent can preemptively prevent a newborn's enrollment. Pursuant to N.J.S.A. 26:4-134, enrolled

adults who do not want their immunization records, and parents who do not want their minor children's immunization records, to appear in the NJIIS must affirmatively request that the immunization records be made inactive in accordance with the procedure at recodified N.J.A.C. 8:57-3.13.

Subsection (b) would require the use of the Request for Change to NJIIS Immunization Record form, which is an existing form at Subchapter 3 Appendix H, proposed for recodification as N.J.A.C. 8:57 Appendix H. The Department proposes to amend existing subsection (d) to indicate that a healthcare professional treating a minor who does not appear as enrolled in the NJIIS (typically one born in another jurisdiction) is to register the minor in the NJIIS, unless the minor's record appears as an inactive record, thereby indicating the parent's withdrawal of the minor's participation in the NJIIS pursuant to recodified N.J.A.C. 8:57-3.15. The Department proposes to delete existing subsection (e) and reorganize existing paragraphs (e)1 and 2 as newly codified subsection (e), to provide the instructions by which a non-enrolled person can obtain NJIIS enrollment through paper or electronic submission to an NJIIS user of an executed form of NJIIS Consent to Participate, which is an existing form incorporated by reference at Subchapter 3 Appendix F that the Department proposes to recodify as N.J.A.C. 8:57 Appendix G.

The Department proposes to amend existing subsection (f) to indicate that an NJIIS user described at proposed new subsection (e) is to enroll a person upon receiving a request pursuant to proposed new subsection (e). The Department proposes to delete existing subsection (g) as redundant of proposed new subsection (e) and (f). The Department proposes to recodify existing paragraph (g)1 as new

subsection (g) and amend the subsection to indicate that withdrawal of a person from NJIIS participation does not affect the obligation of an administrator to exclude that person from attendance at a child care center, a school, or an IHE, if the person does not provide evidence of immunity or immunization pursuant to N.J.A.C. 8:57-4 and 6. The Department proposes to recodify existing paragraph (g)2 as subsection (h) and amend the subsection to indicate that one can reenroll in NJIIS after having withdrawn from participation therein, by adhering to the enrollment procedure at proposed new subsection (e). The Department proposes to delete existing subsections (h) and (i) as redundant of existing N.J.S.A. 26:4-136.

The Department proposes to recodify existing N.J.A.C. 8:57-3.13, Registrant access to information, which establishes standards by which registrants can obtain their NJIIS records, as N.J.A.C. 8:57-3.11, Registrant access to registrant's NJIIS information. The Department proposes to amend subsection (a) to indicate that a registrant can obtain a printout of the registrant's NJIIS record by: (1) making a request to a healthcare professional who is an NJIIS user; (2) submitting a completed NJIIS Request for NJIIS Immunization Record to the VPDP, which is an existing form at Subchapter 3, Appendix I, proposed for recodification as N.J.A.C. 8:57 Appendix I; or (3) at proposed new paragraph (a)3, using the Docket® mobile application or website, or a successor application administered by an entity with which the Department may elect to enter into a cooperative data-sharing agreement. The Department proposes to delete existing subsection (b), which establishes a blanket deadline for responses to requests. Although fulfillment of a request can be made upon receipt, the Department anticipates that a healthcare professional will fulfill a request by no later than the time

that State and Federal standards establish for response to a patient request for other health records. The VPDP would continue to respond to these requests upon receipt, as staffing and other resources permit.

N.J.S.A. 26:4-134i(4) requires the Department to establish procedures by which one can “review and correct information contained in the [NJIS].” The Department proposes to recodify existing N.J.A.C. 8:57-3.14, Registrant amendment of record, which establishes standards by which a registrant can request a change to the registrant’s NJIS record, as N.J.A.C. 8:57-3.12, Registrant amendment of NJIS record. The Department proposes to amend subsection (a) to indicate that a registrant can request a change in accordance with procedures the registrant’s healthcare professional establishes, if the healthcare professional is an NJIS user, and require a healthcare professional who is an NJIS user to memorialize a change request and related information in the registrant’s NJIS record and notify the requester of the opportunity to seek VPDP reconsideration of a denied change request. The Department proposes to reorganize existing paragraph (a)1 as subsection (b) with amendments to establish that a registrant can submit an NJIS record change request to the VPDP if the registrant’s healthcare professional either denies a change request or is not an NJIS user. The Department proposes to delete existing paragraph (a)2. The Department proposes to recodify existing subsection (b) as (d) and delete existing subsection (c). The Department proposes to delete existing subsection (f), which establishes an opportunity for rebuttal of a statement of a requester’s disagreement with a decision not to change an NJIS record. The Department anticipates that the statement that the VPDP would issue to explain its rationale for not making a requested



change, pursuant to existing subsection (e), would be sufficient to establish its position without need for additional rebuttal. The Department proposes to delete existing subsection (i), which requires a healthcare professional to send documentation supporting denied change requests to the VPDP and establishes a procedure for VPDP review of an NJIIS user's denial of a change request. These standards are unnecessary because the proposed amendment at subsection (a) would require an NJIIS user to memorialize, in the NJIIS, a requested change and the documentation submitted in support of the change request, to which the VPDP has access, and the proposed amendment at subsection (b) would establish an opportunity for a requester to submit a denied change request to the VPDP for *de novo* review.

N.J.S.A. 26:4-134i(5) requires the Department to establish procedures by which one can “request to not participate in the [NJIIS] and to remove or inactivate information from the [NJIIS].” The Department proposes to recodify existing N.J.A.C. 8:57-3.15, Registrant withdrawal, which establishes procedures by which a registrant can withdraw from participation in the NJIIS and can re-enroll following a withdrawal, as N.J.A.C. 8:57-3.13, NJIIS registrant withdrawal; reenrollment. Subsection (a) would require a requester to use the NJIIS Registrant Withdrawal from NJIIS form, which is an existing form incorporated by reference at Subchapter 3 Appendix J, proposed for recodification as N.J.A.C. 8:57 Appendix J. The Department proposes to amend existing subsection (b) to extend from three to five business days, the time within which the VPDP is to respond to a withdrawal request and indicate that the NJIIS shows the record of a withdrawn registrant as inactive due to the registrant's withdrawal from participation. This is necessary to prevent inadvertent reenrollment by health care facilities and

healthcare professionals, who would have patient enrollment and reporting obligations pursuant to recodified N.J.A.C. 8:57-3.10 and 3.14, as proposed for amendment, following a health care encounter with a patient who has withdrawn from participation. The Department proposes to amend existing subsection (c) by cross-referencing the procedure by which a withdrawn participant can reenroll in the NJIIS at recodified N.J.A.C. 8:57-3.12, as proposed for amendment.

The Department proposes to recodify existing N.J.A.C. 8:57-3.16, Mandatory participation for health care providers, which establishes standards requiring mandatory participation in the NJIIS, as N.J.A.C. 8:57-3.14, Mandatory NJIIS participation of healthcare professionals. The Department proposes to delete references throughout the section to the term “health care provider” and add in place thereof, references to the defined term “healthcare professional” and delete references throughout the section to NJIIS participation and reporting by birthing facilities as redundant, because recodified N.J.A.C. 8:57-3.10, as proposed for amendment, addresses each birthing facility’s obligation to enroll every newborn upon birth through completion of the EBC.

Existing subsection (a) limits the obligation of a healthcare professional to participate in the NJIIS to those who provide immunizations to patients under age seven. Recodified N.J.A.C. 8:57-3.12(d), which requires every healthcare professional who provides health care to a minor who is not enrolled in the NJIIS to enroll the minor in the NJIIS, has been in effect since October 19, 2009. 40 N.J.R. 5908(a); 41 N.J.R. 3899(c). Thus, there is no basis to limit the obligation of a healthcare professional to become an NJIIS user to those who vaccinate minors under age seven, because a healthcare professional who treats any minor is subject to an existing obligation to

ensure that the minor is enrolled in the NJIIS, and to do so, the healthcare professional must be at least an NJIIS user, if not an NJIIS site. Therefore, the Department proposes to amend existing subsection (a) to require each healthcare professional who provides health care to a minor to become an NJIIS user and, subject to proposed new subsection (h), an NJIIS site, and report each vaccination administration to a minor in accordance with subsections (d), (e), and (f), as proposed for amendment.

The experience of the Department and the State during the COVID-19 public health emergency and recent natural disasters that resulted in family displacements from other states and territories to New Jersey have demonstrated the benefit to the State and the public of the NJIIS as a Statewide resource to document the immunization status of all New Jerseyans. For example, during the COVID-19 public health emergency, the mobile telephone application, Docket®, which sources its content from NJIIS data, enabled users to readily demonstrate evidence of their immunization status and thereby obtain admission to places of public accommodation that conditioned entry upon proof of immunization. NJIIS data also enabled the Department to configure regional mapping of under-immunized populations and thereby appropriately direct its COVID-19 vaccination outreach efforts to those potential contagion “hot spots.” Moreover, the NJIIS is a lifespan registry that facilitates the recreation of health records when records stored in other locations are lost or destroyed, such as in natural disasters, and helps families who are thereby displaced to avoid repeat vaccinations when their paper records are lost. The NJIIS’s ability to share and receive data through interconnectivity with other states’ immunization registries enables families who relocate to or from other jurisdictions to easily retrieve their immunization records.

Given the many benefits that the NJIIS affords the State and its people, the Department is proposing to require all healthcare professionals who administer vaccines to adults to become NJIIS sites and NJIIS users, and to report immunizations administered to adults, in addition to their existing obligation to report immunizations administered to minors. Adults, and minors through their parents, would retain the ability to withdraw from participation in the NJIIS in accordance with the procedure at recodified N.J.A.C. 8:57-3.13.

Executive Order No. 207 (2020) requires every entity, including healthcare professionals, administering COVID-19 vaccinations to persons of any age to enroll unenrolled persons into the NJIIS, and to report the administration of COVID-19 vaccinations to those persons to the NJIIS. Therefore, the Department anticipates that healthcare professionals who administered COVID-19 vaccinations during the public health emergency will have already become NJIIS sites and/or NJIIS users to comply with Executive Order No. 207 (2020), and that the obligation to become NJIIS sites and/or NJIIS users would impose a new requirement only on healthcare professionals that newly elect to administer immunizations to adults.

The ACIP recommendations for childhood immunizations apply to persons from birth through age 18, that is, until the 19th birthday. The ACIP recommendations for adult immunizations apply to persons from age 19 and above. To ensure that the NJIIS captures immunizations that healthcare professionals administer to non-minors pursuant to the childhood immunization ACIP recommendations, the Department proposes to amend existing subsection (b) to require a healthcare professional who administers a vaccine to a person who has attained their 18th birthday, but is under age

19, to become an NJIIS site and NJIIS user, and thereupon commence reporting in accordance with subsections (d), (e), and (f), within one year of the effective date of this rulemaking, as proposed for amendment. To capture immunizations administered to persons pursuant to the adult ACIP recommendations, the Department proposes new subsection (c) to require a healthcare professional who administers an immunization to a person of any age to become an NJIIS site and NJIIS user, and thereupon commence reporting in accordance with subsections (d) , (e), and (f), within 545 days (one year plus 180 days, or roughly a year and a half) of the effective date of this rulemaking.

The Department proposes to reorganize content from existing subsection (b) as newly codified subsection (d) to reflect that some healthcare professionals fulfill their reporting obligations by entering individual patient information directly to the NJIIS and others by reporting to the NJIIS through vendor software and/or services. The Department proposes to delete existing subsection (c). The Department proposes to recodify existing subsection (d), which identifies information that healthcare professionals are to report, as subsection (e) and proposes amendments to correct the list of required data fields that a healthcare professional must report to the NJIIS. The Department proposes to delete, as unnecessary, existing subsection (e), which restates healthcare providers' reporting responsibility, regardless of any delegation. The Department proposes to amend existing subsection (f) to require, rather than suggest, that a healthcare professional submit missing information required pursuant to subsection (e) or correct inaccurate information in a registrant's NJIIS record, to the extent the correct information is available. The Department proposes to amend existing subsection (g) to require a healthcare professional who is not an NJIIS user to correct or

update a registrant's NJIIS record by submitting information to the VPDP by using the paper Request for Change to NJIIS Immunization Record form at N.J.A.C. 8:57

Appendix H. Proposed new subsection (h) would exempt a healthcare professional who is subject to subsections (a), (b), or (c) from the obligation to become an NJIIS site if the healthcare professional has NJIIS user status at an existing NJIIS site and at an NJIIS access level that enables the healthcare professional to report in full compliance with subsections (d), (e), and (f).

The Department proposes to repeal existing N.J.A.C. 8:57-3.17, Application of the NJIIS tracking/reminder recall function, because it does not reflect existing NJIIS operations. The Department also proposes to repeal existing N.J.A.C. 8:57-3.18, Acceptance of NJIIS record as evidence of immunization, because N.J.S.A. 8:57-4 and 6, as proposed for amendment, would address evidence of immunization.

The Department proposes to recodify existing N.J.A.C. 8:57-3.19, Data exchange, as N.J.A.C. 8:57-3.15, Data exchange. The Department proposes to amend existing subsections (a) and (b) to delete paragraph (a)1 and to indicate that an NJIIS site that reports by means of a secure electronic interface pursuant to N.J.A.C. 8:57-3.14(d)2 is to conform to either, at proposed new paragraph (b)1, as a maximum standard, the CDC and American Immunization Registry Association (AIRA), HL7 Version 2.5.1, Implementation Guide for Immunization Messaging (CDC and AIRA HL7 Implementation Guide), or at proposed new paragraph (b)2, as an alternative lesser standard, the NJIIS Interface Management System HL7 Version 2.5.1, Local Implementation Guide: Immunization Messaging (NJIIS Local Implementation Guide),

both of which are proposed to be incorporated by reference, as amended and supplemented.

The CDC and AIRA HL7 Implementation Guide establishes specifications for reporting data relating to the administration of vaccinations to immunization registries of the USA, including messaging content and transmission dynamics. Each USA jurisdiction that requires vaccine administrators to submit vaccine administration data to an immunization registry specifies the minimum data content of required reports. Some EHR vendors may facilitate their clients' reporting of, and some HIEs, HINs, and HIOs may report, vaccinations to multiple jurisdictions and may elect to report the plenary content of the CDC and AIRA HL7 Implementation Guide to ensure compliance with differences in interface requirements among health authorities and jurisdictions. To accommodate EHR vendors and HIEs, HINs, and HIOs that are not multijurisdictional, or that customize their reports by jurisdiction, proposed new N.J.A.C. 8:57-3.15(b)2 would authorize an entity to elect to report vaccinations in accordance with the NJIIS Local Implementation Guide, which is a subset of the content that the CDC and AIRA HL7 Implementation Guide requires. The Department proposes to delete existing paragraphs (b)1, 2, and 3.

The Department proposes to amend existing subsections (c) and (d) to indicate that the Department may engage in immunization data interchange with immunization registries that another state or region recognizes as official pursuant to the health oversight function of that state or region, in accordance with standards of the AIRA Public Health Immunization Information System Interjurisdictional Memorandum of Understanding (AIRA-PHIIS-IMOU). The proposed amendment at subsection (d) would

indicate that the VPDP would defer to the processes and procedures of either the AIRA-PHIS-IMOU or, if inapplicable, the sending entity, with respect to data it receives from registries outside of New Jersey.

The Department proposes to recodify existing N.J.A.C. 8:57-3.20, Reports, which addresses reports that the Department issues using data from the NJIIS, as N.J.A.C. 8:57-3.16, Reports pursuant to N.J.S.A. 26:4-134.i(8). The Department proposes to amend subsection (a) to delete text that is redundant of N.J.S.A. 26:4-134.i(8). The Department proposes to delete existing subsections (b), (c), and (d), which unnecessarily describe reports that the Department may issue pursuant to N.J.S.A. 26:4-137. The Department proposes to amend recodified subsection (b) to indicate that information included in the NJIIS is confidential pursuant to N.J.S.A. 26:4-137.

The Department proposes to repeal existing N.J.A.C. 8:57-3.21, Authorized user immunity, because it is redundant of N.J.S.A. 26:4-135.

The Department proposes to recodify existing N.J.A.C. 8:57-3.22, Penalties, which addresses sanctions that are available for improper activity relating to the NJIIS, as N.J.A.C. 8:57-3.17, Enforcement, and amend the section to include noncompliance with the Statewide Immunization Registry Act, N.J.S.A. 26:131 et seq., as being subject to sanction; cross-reference N.J.S.A. 26:4-137 and N.J.A.C. 8:57-1.4, which identify available sanctions; delete specific descriptions of offenses; and identify, generally, the Department's option of referring improper activity relating to the NJIIS to applicable regulatory entities with jurisdiction and facility administrators. The Department proposes to delete existing subsections (b) and (c) because the applicable enforcement provisions are described above.



The Department proposes to repeal existing N.J.A.C. 8:57-3.23, Appeals, which addresses appeals.

#### **Subchapter 4**

N.J.S.A. 26:1A-7 authorizes the Public Health Council to establish, amend, and repeal “reasonable sanitary regulations not inconsistent with [N.J.S.A. 26:1A-1 et seq.] or ... any other law of this State as may be necessary properly to preserve and improve the public health in this State. The regulations so established shall be called the State Sanitary Code. The State Sanitary Code may cover any subject affecting public health, or the preservation and improvement of public health and the prevention of disease in the State ... including the immunization against disease of all school children in the State ...” As described above, the Reorganization Plan operated to allocate the rulemaking authority of the Public Health Council to the Department. In accordance with the Reorganization Plan, the Department makes this rulemaking in consultation with the Public Health Council.

N.J.S.A. 26:1A-9 states, in part, that “the State Sanitary Code shall have the force and effect of law[,] shall be observed throughout the State and shall be enforced by each local board of health, the local police authorities and other enforcement agencies” and that “[e]very person[,] organization[,] or board of education having control of any public or private school in this State shall insure compliance with the State Sanitary Code as it pertains to the immunization against disease of children attending or having the right to attend such school, including any provision of the code which prohibits attendance by a child who has not been immunized.”

N.J.S.A. 26:1A-9.1 states, “[p]rovisions in the State Sanitary Code in implementation of this act shall provide for exemption for pupils from mandatory immunization if the parent or guardian of the pupil objects thereto in a written statement signed by the parent or guardian upon the ground that the proposed immunization interferes with the free exercise of the pupil’s religious rights. This exemption may be suspended by the State Commissioner of Health during the existence of an emergency as determined by the State Commissioner of Health.”

N.J.S.A. 26:2-137.1, in part, directs the Department “to specify [through rulemaking, the] childhood immunizations recommended by the Advisory Committee on Immunization Practices of the United States Public Health Service and the Department of Health.”

N.J.S.A. 26:4-6 states, “[a]ny body having control of a school may, on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases, prohibit the attendance of any teacher or pupil of any school under their control and specify the time during which the teacher or scholar shall remain away from school.”

N.J.S.A. 18A:40-21.1 states, “[t]he Commissioner of Health shall require the immunization of a child for hepatitis B as a condition of enrollment in grades nine through 12”; prohibits principals, directors, and other persons in charge of public or private schools in the State from “knowingly admit[ting] or retain[ing] in grades nine through 12 a child whose parent or guardian has not submitted acceptable evidence of the child’s immunization for hepatitis B prior to or during enrollment in ninth grade, as

provided by regulation of the Commissioner of Health,” and directs the Commissioner to promulgate rules implementing this law.

Existing Subchapter 4, Immunization of Pupils in School, implements the rulemaking obligations of the Department pursuant to the laws identified above. The Department proposes to amend the heading of the subchapter to Immunization of Children in Child Care Centers and Schools.

The Department proposes to amend existing N.J.A.C. 8:57-4.1, Applicability, to change the heading to “Scope,” and to reflect, at newly codified subsection (a), that the subchapter does not impose direct obligations on minors. Rather, the subchapter establishes the obligations of administrators of schools and child care centers, consistent with the laws described above that impose obligations on persons in charge of such facilities, to exclude from attendance persons who do not present evidence of immunization against or immunity to the vaccine-preventable diseases that the subchapter identifies. Proposed new subsection (b) would indicate that, within the subchapter, the term “facility” would refer collectively to schools and child care centers. Proposed new subsection (c) would state that, notwithstanding a person’s claim of a religious exemption, the subchapter would not limit a private facility’s authority to exclude a person from attendance who has not received an immunization that this subchapter requires, the Department recommends or requires pursuant to proposed new N.J.A.C. 8:57-1.8, or is consistent with ACIP recommendations or the AAP Red Book, including applicable Catch-up Schedules, medical contraindications, and recognition of serologic immunity.

The Department proposes to amend existing N.J.A.C. 8:57-4.2, Proof of immunization, as N.J.A.C. 8:57-4.2, Administrator to require evidence of immunization or immunity, to indicate that the section addresses an administrator's obligation to require evidence of immunization or immunity. Proposed new N.J.A.C. 8:57-4.2(a) would require an administrator to require evidence of a minor's immunization pursuant to N.J.A.C. 8:57-4.3 and 4.4, as proposed for amendment, and/or evidence of a minor's immunity pursuant to N.J.A.C. 8:57-4.5, subject to the existence of a medical contraindication pursuant to N.J.A.C. 8:57-4.7, a religious exemption pursuant to N.J.A.C. 8:57-4.8, and compliance with immunization standards in effect prior to the operative date of this rulemaking, as specified at proposed new N.J.A.C. 8:57-4.2(d), (e), and (f). N.J.A.C. 8:57-4.2, as proposed for amendment, would require an administrator to obtain evidence of a minor's immunization or immunity, as a condition of the minor's continued enrollment in the facility and would require the use of the Standard School/Child Care Center Immunization Record form at proposed new N.J.A.C. 8:57 Appendix K, which contains fields for each immunization as to which an administrator is to require evidence of a minor's immunization or immunity.

Proposed new subsection (b) would establish that an administrator is to adhere to the ACIP recommendations and the AAP Red Book in determining whether the evidence presented on behalf of a minor is acceptable with respect to the timing of doses, the criteria for a determination of immunity, and the validity of a medical contraindication. The Department proposes to amend existing subsection (c) to refer to evidence of immunity pursuant to subsection (a). Proposed new subsection (d) would refer to the McKinney-Venton Homeless Assistance Act, 42 U.S.C. §§ 11431 through

11435, and N.J.A.C. 6A:32, and provide a 10-day grace period for the transfer of a minor's immunization record from a previously attended New Jersey public or private school or other facility, during which an administrator is to admit the minor to the facility. Proposed new subsection (e) would make the section apply prospectively by authorizing an administrator to recognize, as valid, doses of certain vaccines that were administered on dates that were inconsistent with ACIP recommendations for minimum age and dose intervals if these were administered in accordance with rules in effect as of their administration and prior to the operative date of this rulemaking. Proposed new subsection (f) similarly would authorize an administrator to recognize, as valid, untimely administered doses of the following, if administered prior to January 7, 2008, which was the effective date of amendments to the chapter that were consistent with then-existing ACIP recommendations for minimum age and dose intervals for the following: measles, mumps, and rubella; hepatitis B; pneumococcal conjugate vaccine; *Haemophilus influenzae* type B; and varicella. See 38 N.J.R. 5284(a); 40 N.J.R. 151(a).

Proposed new N.J.A.C. 8:57-4.3, Immunizations as to which an administrator shall require evidence, would identify the vaccines as to which an administrator is to require evidence of immunization or immunity pursuant to N.J.A.C. 8:57-4.2 and the ACIP recommendations. Proposed new subsections (a) and (c) would establish the vaccines to be required as a condition of admittance to, respectively, a child care center and a school. Subsection (a) would require a child care center administrator to require evidence of a minor's immunization, in accordance with the ACIP recommendations, with the following vaccines, or immunity to the diseases corresponding thereto: DTaP, Hib, PCV, polio virus, influenza, MMR, and VAR. Proposed new subsection (b) would

require a child care center administrator to accept, as an alternative to evidence of a minor's immunity to, or immunization in accordance with the ACIP recommendations schedule against, influenza, evidence of a minor's immunization by November 30 of each year with one dose of the applicable influenza vaccine that is formulated for each influenza season as announced by the CDC. Proposed new subsection (c) would require a school administrator to require evidence of a minor's immunization, in accordance with the ACIP recommendations, with the following vaccines, or immunity to the diseases corresponding thereto: DTaP, Td, or Tdap; Hep B; IPV, or OPV; MMR; VAR; and Meningococcal serogroups A, C, W, Y vaccine (MenACWY). Proposed new subsection (d) would authorize an administrator to accept evidence of a minor having received at least one dose of varicella vaccine, instead of requiring adherence to the ACIP recommendations as to the number of varicella vaccine doses. Proposed new subsection (e) would authorize an administrator to accept evidence of a minor having received at least one dose of the MenACWY vaccine, instead of requiring adherence to the ACIP recommendations as to the number of MenACWY vaccine doses. Proposed new subsection (f) would oblige an administrator to require evidence of a minor having received the doses of DTaP, IPV or OPV, and MMR vaccines that the ACIP recommendations categorize as due during the ages of four through six years of age prior to the minor's first attendance at kindergarten or a higher grade, depending on which occurs first.

The Department proposes to recodify existing N.J.A.C. 8:57-4.6, Documents accepted as evidence of immunization, as N.J.A.C. 8:57-4.4, Evidence of immunization. The Department proposes to amend existing subsection (a) to cross-reference an

administrator's obligation to require evidence of immunization at N.J.A.C. 8:57-4.2, as proposed for amendment, the immunizations as to which administrators are to require evidence at proposed new N.J.A.C. 8:57-4.3, and administrators' recordkeeping obligations pursuant to proposed new N.J.A.C. 8:57-4.6, described below; and indicate that evidence of immunization can consist of more than one of the acceptable forms of documentation if the documents, viewed alone or in combination, identify the month, day, and year of administration of each required dose, or only the month and year, if the totality of the documentation enables the administrator to comply with proposed new subsection (c). The Department proposes to reorganize existing paragraphs (a)1, 2, 3, and 4 as paragraphs (b)1 through 6. A proposed amendment at recodified paragraph (b)1 would specify that the official facility record may consist of an electronic health record. A proposed amendment at recodified paragraph (b)2 would identify health authority records issued by the government of the USA as acceptable forms of evidence. A proposed amendment at recodified paragraph (b)3 would change the undefined term "certificate" to "record" and would delete text that would be redundant of the definition of the term "health care professional." The Department proposes to amend proposed paragraph (b)4 to delete text that restates the required content of a record, which subsection (a), as proposed for amendment, would address, and to identify a record from the Docket® application or website, or a successor application, as an official NJIIS record. Proposed new paragraph (b)5 would include an official State School Immunization Record as proof of immunization. Proposed new paragraph (b)6 would identify records issued by a foreign health services provider and a foreign government agency as acceptable forms of evidence, provided that, if the record is in a

language other than English, it is accompanied by an English translation that the translator certifies, under penalty of perjury, to be true, accurate, and complete. The Department proposes to delete existing subsection (c), which addresses immunity from disease, because proposed new N.J.A.C. 8:57-4.5 would address this topic. Proposed new subsection (c) would identify the analysis that an administrator is to undertake in reviewing submitted evidence of immunization, that is, to confirm that the evidence shows that a minor received valid doses of required immunizations in accordance with N.J.A.C. 8:57-4.2 and 4.3.

The Department proposes to repeal existing N.J.A.C. 8:57-4.5.

As described above, proposed new N.J.A.C. 8:57-4.2(a)2 would require an administrator to accept evidence of a minor's immunity to a vaccine-preventable disease, as an alternative to requiring evidence of the minor's immunization against that disease. Proposed new N.J.A.C. 8:57-4.5, Evidence of immunity, would identify records that an administrator is to accept as evidence of a minor's immunity to vaccine-preventable diseases, provided the evidence is consistent with the ACIP recommendations and the AAP Red Book as to schedules, laboratory testing, and other indicators of positive immunity. Paragraph (a)1 would identify conditions as to which a positive serologic test is evidence of immunity, which are measles, mumps, rubella, varicella, and poliomyelitis virus types one, two, and three. Paragraph (a)2 would identify positive surface antibody or antigen laboratory test results as indicative, respectively, of immunity to or ongoing infection with hepatitis B. Paragraph (a)3 would establish that a record signed by one of the indicated health care professionals stating that the professional diagnosed or verified that the minor had chicken pox is evidence of



immunity that obviates the need for varicella vaccination. Subsection (b) would implement Holly's Law, N.J.S.A. 26:2N-9, which requires an administrator to accept a positive serologic test, also known as an antibody titer, in lieu of requiring evidence of a minor's receipt of the second dose of the measles, mumps, and rubella vaccine in accordance with the ACIP recommendations.

Proposed new N.J.A.C. 8:57-4.6, Administrator obligations with respect to documentation of compliance and recordkeeping, would establish the obligations of an administrator with respect to documentation of compliance and recordkeeping. Subsection (a) would require an administrator to establish a discrete file for each minor to whom the administrator grants and/or denies admission or enrollment to a facility, to maintain the file separately from a minor's medical and educational records, and to make the file available for inspection on request of a local health official with jurisdiction and the Department, for auditing and related public health oversight and enforcement activities. Subsection (b) would require an administrator to maintain original paper records of immunization, immunity, or exemption evidence submitted on behalf of a minor, regardless of whether the administrator also elects to maintain the records in an electronic form, and would indicate that the Department will treat material generated from electronically stored records to be supplemental to, and not as a substitute for, an original record. Subsection (c) would identify the file that an administrator creates pursuant to proposed new subsection (a) to be the minor's "immunization record" as the Department of Education construes that term and would cross-reference the rules of that department at N.J.A.C. 6A:16-2.4, Required student health records, and 6A:32-7,

Student Records, which establish standards relating to the establishment and handling of such records, such as access, retention, transfer, and disposal.

The Department proposes to repeal existing N.J.A.C. 8:57-4.7, Records required, because N.J.A.C. 8:57-4.6 would address these matters.

The Department proposes to recodify existing N.J.A.C. 8:57-4.3, Medical exemptions, as N.J.A.C. 8:57-4.7, Exemption due to medical contraindication; required documentation; administrator review. The Department proposes to amend existing subsection (a) to indicate that the section imposes obligations on an administrator, not a minor, and prohibits an administrator from requiring evidence of a minor's immunization against, or immunity from, the vaccine-preventable conditions specified at N.J.A.C. 8:57-4.2 if the immunization is medically contraindicated or presents as a medical precaution for the minor for a reason that the ACIP recommendations and the AAP Red Book identify as a vaccine contraindication or precaution. The Department proposes to amend existing subsection (b) to identify the evidence an administrator is to require in support of an exemption based on medical contraindication or precaution, that is, a statement from one of the indicated health care professionals that identifies the vaccine that presents a contraindication or precaution, the period during which the contraindication or precaution exists, and the reason that the vaccine is contraindicated or presents a precaution for the minor. N.J.A.C. 8:57-4.7 would prohibit an administrator from requiring evidence of a minor's immunization pursuant to N.J.A.C. 8:57-4.2 when an immunization is medically contraindicated for a minor or as a precaution when the risk for adverse reaction outweighs its medical benefit. In these cases, the section would require an administrator to require submission on the minor's

behalf of the Request for Medical Exemption from Mandatory Immunization form at N.J.A.C. 8:57 Appendix L, signed by one of the indicated health care professionals who identifies the applicable contraindication or precaution. The Department proposes to delete existing subparagraph (b)1, as redundant of the defined term “ACIP recommendations.”

The Department proposes to amend existing subsection (c) to indicate that the subsection would oblige an administrator to review both the statement for compliance with subsections (a) and (b), in consultation with the VPDP, if necessary, and a granted exemption by the earlier of either the end of the specified period of exemption or annually, to ensure that upon the conclusion of a period of contraindication or precaution, the administrator requires evidence of the minor’s immunization or immunity in accordance with N.J.A.C. 8:57-4.2, as proposed for amendment, and applicable ACIP recommendations. The Department proposes to delete existing subsections (d) and (e), as redundant of proposed new N.J.A.C. 8:57-4.10, discussed below.

The Department proposes to repeal existing N.J.A.C. 8:57-4.8, Reports to be sent to Department of Health and Senior Services, as redundant of proposed new N.J.A.C. 8:57-4.11, Reports to be sent to the Department and local health agency.

The Department proposes to recodify existing N.J.A.C. 8:57-4.4, Religious exemptions, as 4.8. Existing statutes that authorize administrators to admit and enroll unimmunized and non-immune minors vary depending on the facility to which a minor seeks admission. N.J.S.A. 30:5B-5 states, with respect to licensure of a child care center, that rules “involving ... immunization ... shall [exempt] any child whose parent or parents object thereto on the ground that it conflicts with the tenets and practice of a

recognized church or religious denomination of which the parent or child is and adherent or member.” The Department proposes to amend existing subsection (a) to implement this requirement as applicable to a child care center administrator. N.J.S.A. 26:1A-9.1 exempts “pupils from mandatory immunization if the parent or guardian of the pupil objects thereto ... upon the ground that the proposed immunization interferes with the free exercise of the pupil’s religious rights.” Proposed newly codified subsection (b) would implement this requirement as applicable to a school administrator. Proposed new subsection (c) would establish the documentation that the administrator of a child care center or school is to require in support of a request for exemption on religious grounds. Proposed newly codified subsection (d) would reflect the ineligibility of moral or philosophical objections as a basis for religious exemption from required vaccinations. Proposed new subsection (e) would require an administrator to secure evidence of immunization or immunity as to those required immunizations to which religious exemption on the minor’s behalf is not submitted.

In deference to a religious-affiliated institution’s authority and expertise to determine whether the religion with which the institution affiliates recognizes the receipt of a specific vaccine as conflicting or interfering with that religion, proposed amendments at recodified subsection (f) would reflect the authority of the administrator of a religious-affiliated institution to grant a request for religious exemption without challenge by a secular health authority. Proposed amendments at recodified subsection (g) would establish an administrator’s record-retention duties with respect to the written statement submitted on a minor’s behalf in support of a religious exemption request. The Department proposes to delete existing subsections (d) and (e).

Proposed amendments at recodified subsection (h) would indicate that an administrator is not to require annual resubmission of a religious exemption request that appears of record. Proposed new subsection (i) would require an administrator to deem withdrawn, a religious exemption of record if the minor, with a parent's consent, obtains an immunization in contravention of the assertion contained in the written statement submitted in support of the religious exemption, and to require submission of a new request for a religious exemption if the reinstatement of the exemption is sought with respect to subsequent vaccine doses of which this chapter would require evidence of the minor's receipt.

The Department proposes to repeal existing N.J.A.C. 8:57-4.9, Records available for inspection, and replace it with new N.J.A.C. 8:57-4.9, Provisional and foreign admission. Subsection (a) would establish conditions within which an administrator is to admit and/or continue the enrollment of a minor, to whom applicable ACIP recommendations apply, who is missing vaccinations, or unable to present evidence of immunizations or immunity to vaccine-preventable diseases. Subject to subsection (b), subsection (a) would require an administrator to require submission of evidence that the minor has received at least one dose of the missing immunization and is no later than 14 days behind an applicable Catch-up Schedule in receiving any remaining required doses. Subsection (b) would establish conditions within which an administrator is to admit and/or continue the enrollment of a minor from outside the United States of America for no longer than 30 days, if, during that period, evidence is submitted of the minor's required immunization or immunity, or that that minor has received at least one

dose of a missing immunization and is no later than 14 days behind an applicable Catch-up Schedule in receiving any remaining required doses.

Effective January 17, 2010, New Jersey “enacted and entered into” the “Interstate Compact on Educational Opportunity for Military Children” (compact), which the Military Interstate Children’s Compact Commission (MIC3) originally promulgated in 2009. N.J.S.A. 18A:75A-1; <https://mic3.net>. The purpose of the compact is “to remove barriers to educational success imposed on children of military families because of frequent moves and deployment of their parents,” by facilitating, among other things, “the timely enrollment of children of military families and ensuring that they are not placed at a disadvantage due to difficulty in the transfer of education records from the previous school district or districts.” N.J.S.A. 18A:75A-2(a). N.J.S.A. 18A:75A-4 identifies the minors to whom the compact applies by reference to the status of their parents as members of the uniformed services. N.J.S.A. 18A:75A-5(c) is consistent with existing MIC3 compact rule § 3.102(a), in providing 30 days from the date of enrollment within which a parent is to submit evidence of a minor’s immunization or immunity, and/or having obtained an initial vaccination with respect to an immunization series. See MIC3, Interstate Compact on Educational Opportunity for Military Children, Third Edition (2023), 1776 Avenue of the States Lexington, Kentucky 40511, available at [https://mic3.net/wp-content/uploads/2020/06/MIC3-Rules-Book\\_Dec2023\\_WEB\\_1-10-24.pdf](https://mic3.net/wp-content/uploads/2020/06/MIC3-Rules-Book_Dec2023_WEB_1-10-24.pdf). This compliance period is consistent with the period the Department establishes at proposed new N.J.A.C. 8:57-4.9(b) with respect to a minor entering, or transferring into, a facility from outside of the USA. Therefore, proposed new N.J.A.C. 8:57-4.9(c) would reflect the applicability of the compact to eligible minors, and would

make them subject to the same compliance periods as at proposed new subsection (b), subject to proposed new paragraph (c)<sup>1</sup>, which would acknowledge that subsection (c) could be preempted or superseded, pursuant to N.J.S.A. 18A:75A-13, if the MIC3 were to amend its rules to provide longer compliance periods. Proposed new N.J.A.C. 8:57-4.9(c)<sup>2</sup> would provide contact information for the MIC3.

The Department proposes to repeal existing N.J.A.C. 8:57-4.10, Diphtheria and tetanus toxoids and pertussis vaccine, and proposes to replace it with new N.J.A.C. 8:57-4.10, Exclusion of persons during actual or threatened vaccine-preventable disease outbreak. As described above, N.J.S.A. 26:1A-9.1 and 26:4-6 authorize the Commissioner to require an administrator to exclude a person who is unimmunized or under-immunized from attendance at a facility during an emergency. Proposed new N.J.A.C. 8:57-4.10(a) would implement N.J.S.A. 26:1A-9.1 and 26:4-6 by requiring an administrator, upon the direction of the Commissioner or the health officer with jurisdiction, to exclude unimmunized, under-immunized, and provisionally admitted minors from attendance at a facility during an actual or threatened communicable disease outbreak or a public health emergency. Subsection (b) would reiterate the authority of an administrator to exclude a person from attendance, “on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases,” and would indicate that the Commissioner or the local health agency would determine whether a communicable disease is “prevalent,” whether exclusion of any person is necessary to prevent the spread of a communicable disease, and the period of exclusion. To facilitate the prompt implementation of proposed new N.J.A.C. 8:57-4.10(a) and (b), subsection (c) would require an administrator to maintain an up-to-date

list of unimmunized, under-immunized, and provisionally admitted minors and to make the list available to the Department and/or the local health agency upon request during an actual or a suspected communicable disease outbreak, or a public health emergency. Subsection (d) would authorize an administrator to notify a parent requesting an immunization exemption on behalf of a minor, pursuant to proposed new N.J.A.C. 8:57-4.7 or 4.8, or provisional admission, pursuant to N.J.A.C. 8:57-4.9, that, if an administrator grants these requests, the minor is subject to exclusion from attendance during an actual or a suspected communicable disease outbreak, or a public health emergency.

The Department proposes to repeal existing N.J.A.C. 8:57-4.11, Poliovirus vaccine, and proposes to replace it with new N.J.A.C. 8:57-4.11, Reports to be sent to the Department and local health agencies. Proposed new N.J.A.C. 8:57-4.11 would identify administrator responsibilities to report the immunization status of facility attendees into the NJIIS using the Annual Immunization Status Report at proposed new N.J.A.C. 8:57 Appendix M. Subsection (a) would require this report to be submitted to the NJIIS by December 1 of each year. Subsection (b) would indicate that the Department would notify applicable State agencies and local health agencies of facility or administrator delinquencies in compliance with this section.

The Department proposes to repeal existing N.J.A.C. 8:57-4.12, Measles virus vaccine, and replace it with new N.J.A.C. 8:57-4.12, Meningitis-Containing Vaccination Immunization Information Fact Sheet established. N.J.S.A. 26:2X-3 directs the Commissioner, in consultation with the Commissioner of the Department of Education, to “develop an educational fact sheet” that addresses, at a minimum, “the causes,



symptoms, and means of transmission of meningococcal meningitis ... the availability, effectiveness, and risks of the meningitis vaccine; and ... where additional information concerning the disease can be obtained.” N.J.S.A. 18A:40-21.2 directs the Commissioner of the Department of Education to establish requirements by which school districts are annually to disseminate “the educational fact sheet to parents or guardians of students in the sixth grade,” and “make the educational fact sheet available to private schools educating students in grades [six] through 12, or any combination thereof,” and encourages schools “to distribute the fact sheet to parents or guardians of students at the school.” Proposed new N.J.A.C. 8:57-4.12 would establish the brochure “Meningococcal Disease: Are You Protected?” as the fact sheet that the Commissioner is to promulgate, in consultation with the Commissioner of the Department of Education, pursuant to N.J.S.A. 26:2X-3, and for which the Commissioner of the Department of Education is to establish school district dissemination procedures pursuant to N.J.S.A. 18A:40-21.2.

The Department proposes to repeal existing N.J.A.C. 8:57-4.13, Rubella vaccine, and replace it with new N.J.A.C. 8:57-4.13, Immunization of children at public expense authorized, which would reiterate the authority of boards of education and local boards of health to undertake immunization of minors at public expense, pursuant to N.J.S.A. 18A:40-20 and 26 and 26:4-8.1.

The Department proposes to repeal existing N.J.A.C. 8:57-4.14 through 4.21. As at N.J.A.C. 8:57-4.10, 4.11, 4.12, and 4.13, proposed for repeal, N.J.A.C. 8:57-4.14 through 4.21 identify immunization requirements with respect to individual vaccines. These provisions would no longer be needed because N.J.A.C. 8:57-4.2, as proposed

for amendment, and proposed new N.J.A.C. 8:57-4.3, would incorporate by reference, as amended and supplemented, the ACIP recommendations for vaccines as to which an administrator is to require evidence of immunization or immunity as a precondition to attendance at a facility.

The Department proposes to recodify existing N.J.A.C. 8:57-4.22, Emergency powers of the Commissioner, Department of Health and Senior Services, as N.J.A.C. 8:57-4.14, Emergency powers of the Commissioner, and proposes amendments to require an administrator to exclude any person failing to meet existing or modified immunization requirements as set forth by the Commissioner, including persons with a medical contraindication or religious exemption, in cases of outbreak, or public health emergency. Subsection (d), as proposed for amendment, would indicate that the Commissioner can determine that New Jersey is affected by a vaccine supply shortage as referenced in the subsection.

## **Subchapter 5**

Existing N.J.A.C. 8:57-5, Management of Tuberculosis, establishes standards addressing the management of tuberculosis in the State. The Department proposes to make technical changes throughout the chapter to correct grammar and spelling, improve readability, delete binary gender terminology, and reflect a change in the name of a Federal public health authority.

N.J.A.C. 8:57-5.2, Incorporated documents, identifies and incorporates by reference, publications and forms to which the chapter refers. The Department proposes to repeal and replace N.J.A.C. 8:57-5 Appendices A and B, to replace the

existing forms with updated versions that include instructions for their completion. The Department proposes to amend existing subsections (b)1 and 2 to indicate that the appendices consist of both the forms and the instructions, and proposes to amend subsection (c) to refer to the TB program and correct the reference to the Department's forms page.

N.J.A.C. 8:57-5.3, Definitions, establishes definitions of terms the subchapter uses. The Department proposes to amend the section to add a definition of, and communication information for, the "TB Program" and proposes corresponding amendments throughout the chapter to delete redundant references to the TB Program's communication information.

Existing N.J.A.C. 8:57-5.5, Hospital discharge, establishes standards by which a TB patient is to be discharged from a hospital. The Department proposes to amend the section to delete subparagraph (a)3ii, to remove the discharge eligibility of a person who obtains a negative nucleic acid amplification test result.

The Department proposes to amend existing N.J.A.C. 8:57-5.6, 5.8, and 5.9 to delete references to a Department publication that formerly existed but is no longer in use, the "Standards of Care for Tuberculosis Disease and Latent TB Infection."

The Department proposes to amend existing N.J.A.C. 8:57-5.16, Annual report, to make a technical change to update the website where the TB program's annual reporting describing trends in prevalence and incidence of TB in New Jersey is located and to delete an unnecessary reference to the TB Program Manager.

## **Subchapter 6**

Existing N.J.A.C. 8:57-6, Higher Education Immunization, establishes standards applicable to certain institutions of higher education (IHEs), with respect to obtaining and maintaining records of immunization or immunity of IHEs' admitted and enrolled attendees. The Department proposes to repeal and replace N.J.A.C. 8:57-6.1 through 6.15.

Proposed new N.J.A.C. 8:57-6.1, Scope, would establish the scope of the subchapter as applicable to institutions of higher education. Proposed new subsection (b) would indicate that the subchapter does not limit a private entity's ability to exclude from enrollment persons who do not have: immunization against or serologic immunity to vaccine-preventable diseases that the subchapter requires; the Department recommends or requires pursuant to N.J.A.C. 8:57-1.8, or the subchapter does not require but are consistent with the ACIP recommendations or the AAP Red Book, including the applicable Catch-up Schedules, medical contraindications, and recognition of serologic immunity.

Proposed new N.J.A.C. 8:57-6.2, Designation of institutional liaison for IHEs, at subsection (a), would establish a procedure by which an IHE is to designate an institutional liaison, and to notify the Department of any change in this designation, by use of the Institutional Liaison Designation form at proposed new N.J.A.C. 8:57 Appendix P. Subsection (b) would establish that the duties and access of the institutional liaison are to: (1) serve as the IHE's representative to and primary point of communication with the Department, specifically the VPDP, with respect to the Department's oversight of the IHE's compliance with N.J.A.C. 8:57-6 and other

applicable laws governing immunization of a graduate or undergraduate student (collegian); (2) have access to immunization records that the subchapter requires an IHE to maintain; and (3) administer and implement any corrective action that the Department requires the IHE to undertake to maintain the IHE's compliance with this subchapter. Proposed new subsection (c) would require the highest-ranking official within an IHE to notify the Department of any changes to the identity or communication information of an institutional liaison through submission of a new Institutional Liaison Designation form, N.J.A.C. 8:57 Appendix P.

N.J.S.A. 18A:61D-1 requires an IHE in New Jersey, in accordance with rules that the Department is to promulgate, to condition admission or continued enrollment of a collegian who is 30 years old and under, and enrolled full-time or part-time in a program or course of study leading to an academic degree, upon a collegian's submission to the IHE of a record documenting the collegian's receipt of required immunizations against vaccine-preventable diseases, or evidence of immunity from these diseases, and to maintain these records.

Proposed new N.J.A.C. 8:57-6.3, IHE to require certain collegians to submit a record of compliance with N.J.A.C. 8:57-4 pursuant to N.J.S.A. 18A:61D-1, would implement this requirement by requiring an IHE to condition a collegian's enrollment on the collegian's submission of evidence of immunization compliant with N.J.A.C. 8:57-6.4 for the diseases against which N.J.A.C. 8:57-4 requires immunization, including Catch-up Schedules then-applicable to that collegian, and to exclude a collegian who is unable to provide evidence of immunization. A typical collegian would be required to provide evidence of immunization or immunity against measles, mumps, and rubella, subject to

N.J.A.C. 8:57-6.5, 6.6, 6.7, 6.8, and 6.12. For a collegian who provides insufficient evidence of immunization, subsection (b) would condition the collegian's admission and/or continued admission to the IHE on the collegian obtaining the required immunizations and thereafter submitting the required documentation consistent with subsection (a). Subsection (c) would direct an IHE to not admit or retain any student who does not meet the immunization requirements in accordance with the section.

Proposed new N.J.A.C. 8:57-6.4, Evidence of immunization, would establish the forms of evidence of immunization that an IHE would be authorized to accept to comply with N.J.A.C. 8:57-6.13, and associated recordkeeping requirements, and would require an IHE that does not receive evidence that is satisfactory to the institutional liaison or the VPDP of a collegian's receipt of a required immunization to require the collegian to obtain missing, and/or repeat invalid, doses and to submit evidence of immunization to the IHE. Subsection (a) would require an IHE to accept and maintain documentation, listed at subsection (b), as evidence of a collegian's immunization from diseases identified at N.J.A.C. 8:57-6.4, 6.10, and/or 6.11, and identify the required elements to satisfy these requirements. Subsection (b) would identify the following as acceptable forms of evidence: (1) an official school record; (2) a record from a government health authority of the USA; (3) a record signed by one of the indicated health care professionals; (4) an official record from NJIIS or the Docket® application or website, or a successor application; and (5) a record signed by a foreign health service provider or government agency, provided any records in a language other than English are accompanied with a certified translation. Subsection (c) would establish the criteria an IHE is to use in evaluating evidence submitted by a collegian. Subsection (d) would

require a collegian who is unable to present satisfactory evidence to obtain missing doses and/or repeat doses and submit evidence thereof within 10 days. Subsection (e) would require an IHE to make reasonable efforts to verify any document submitted by a collegian if the IHE or the VPDP has reason to doubt the document's authenticity.

Proposed new N.J.A.C. 8:57-6.5, Evidence of immunity, at subsection (a), would authorize an IHE to accept evidence of a laboratory serologic test result consistent with ACIP recommendations as indicative of a collegian's immunity to, or ongoing illness with, a vaccine-preventable disease, in place of requiring the collegian to submit evidence of the collegian's receipt of required immunizations for that disease. Subsection (a) would also identify the forms of evidence of a collegian's immunity that an IHE would be authorized to accept. Subsection (b) would direct an IHE to make reasonable efforts to verify the authenticity and/or content of any document submitted pursuant to this subsection if the IHE or VPDP has reason to doubt the document's authenticity or content.

Proposed new N.J.A.C. 8:57-6.6, Provisional admission and/or continued enrollment, would establish standards for provisional admission of a collegian who would otherwise be excluded from attendance at an IHE due to the collegian's inability to present required evidence of immunization against or immunity to a vaccine-preventable disease. Subsection (a) would establish conditions through which an IHE is to admit and/or continue the enrollment of a collegian who is unable to present evidence of a required immunization against or immunity to a vaccine-preventable disease, that is, the collegian must have received at least one dose of the missing immunization, is no later than 14 days behind an applicable Catch-up Schedule in receiving any

remaining required doses, and presents evidence of timely immunization or immunity. Subsection (b) would establish conditions through which an IHE is to admit and/or continue the enrollment of a collegian from outside the USA, for no longer than 30 days, if, during that period, the collegian obtains, and provides to the institution, evidence of required immunizations or immunity, and maintains compliance with an applicable Catch-up Schedule.

Proposed new N.J.A.C. 8:57-6.7, Medical exemption from compliance with N.J.A.C. 8:57-6.3, 6.10, and/or 6.11 pursuant to N.J.S.A. 18A:61D-10 and 18A:62-15.2, would establish, at subsection (a), an exemption from a collegian's obligation to present evidence of a required immunization if compliance would be medically contraindicated or present a precaution. Subsection (b) would require a collegian seeking to use the exemption to submit a Request for Medical Exemption from Mandatory Immunization at proposed new N.J.A.C. 8:57 Appendix L, or the information requested therein, in writing, executed by one of the indicated health care professionals. Subsection (c) would establish the process by which an IHE is to review, retain, and condition admission based on the submission of the form or document submitted pursuant to subsections (a) and (b). Subsection (d) would identify the ability of an IHE to consult with the VPDP to obtain assistance in reviewing statements submitted pursuant to the section.

N.J.S.A. 18A:61D-3 directs an IHE to exempt a collegian from compliance with N.J.S.A. 18A:61D-1 if the collegian submits "a written statement that immunization conflicts with [the collegian's] religious beliefs." As N.J.S.A. 18A:61D-1 requires an IHE to confirm a collegian's receipt of primary childhood immunizations, the religious exemption available at N.J.S.A. 26:1A-9.1, which requires submission of a written



statement “that the proposed immunization interferes with the free exercise of the pupil’s religious rights,” is also available to a collegian for those primary childhood immunizations.

Proposed new N.J.A.C. 8:57-6.8, Religious exemption from compliance with N.J.A.C. 8:57-6.3 pursuant to N.J.S.A. 18A:61D-3 and 26:1A-9.1, at subsection (a), would implement N.J.S.A. 18A:61D-3 and 26:1A-9.1 by establishing the procedure by which an IHE is to exempt a collegian from compliance with N.J.A.C. 8:57-6.3 on religious grounds, and the associated recordkeeping requirements. Subsection (b) would require a collegian to comply with N.J.A.C. 8:57-6.3 for immunizations to which they do not assert a religious conflict or interference. Subsection (c) would specify that an IHE is not to grant an exemption solely on a moral or philosophical objection. Subsection (d) would require an IHE to retain any statement submitted pursuant to the subchapter. Subsection (e) would indicate that an IHE is not to require a collegian to annually resubmit an exemption request for which the IHE has a record of an approved exemption. Subsections (f) and (g) would require an IHE to deem nullified, a collegian’s religious exemption of record if the collegian obtains an immunization in contravention of the assertion contained in the collegian’s written statement, and to require a collegian to submit a new request for a religious exemption if the collegian seeks to reinstate the exemption with respect to subsequent doses.

Proposed new N.J.A.C. 8:57-6.9, Exclusion of collegian due to vaccine-preventable diseases pursuant to N.J.S.A. 18A:62-15.2, 26:1A-9.1, and 26:4-6, at subsection (a), would require an IHE, in the event of a confirmed or suspected preventable disease outbreak, to exclude an unimmunized, under-immunized, and

provisionally admitted collegian who has otherwise been admitted to the IHE.

Subsection (b) would state the authority by which a school can prohibit attendance in accordance with subsection (a). Subsection (c) would require the local health agency or the Department to provide direction to the institutional liaison related to communicable disease prevalence, necessity of prohibition of attendance, categories of excluded persons based on immunization status, and the period during which these persons are to be prohibited from attendance. Subsection (d) would require an institutional liaison to maintain a record of each collegian admitted pursuant to N.J.A.C. 8:57-6.6, 6.7, 6.8, and 6.12, and make that list available to the Department and/or the local health agency upon request.

N.J.S.A. 18A:61D-9 directs an IHE to exclude from continued attendance, a collegian who does not present evidence of immunization against hepatitis B within nine months of attendance. This requirement applies to all collegians, regardless of age, who register for 12 or more credit hours of course study per semester or term and enroll in a program of the IHE leading to an academic degree. Proposed new N.J.A.C. 8:57-6.10, would require the IHE to require certain collegians to submit a record of compliance with N.J.S.A. 18A:61D-9 regarding immunization against or immunity to hepatitis B, and would implement N.J.S.A. 18A:61D-9 by directing an IHE to require a collegian to whom the section applies to submit evidence of immunization against, or immunity to, hepatitis B that is compliant with N.J.A.C. 8:57-6.4 or 6.5.

Some collegians to whom N.J.S.A. 18A:61D-9 applies concurrently would be required to submit evidence of hepatitis B immunization or immunity pursuant to 18A:61D-1, as implemented by proposed new N.J.A.C. 8:57-6.3. For example, see

N.J.S.A. 18A:40-21.1, described above in the discussion of Subchapter 4, which requires high school students to receive the hepatitis B vaccination. Proposed new N.J.A.C. 8:57-6.10(c) would specify the section would not extend the time within which an IHE is to obtain evidence of hepatitis B immunization or immunity from a collegian who is subject to N.J.A.C. 8:57-6.3. Proposed new N.J.A.C. 8:57-6.10(d) would indicate that an IHE that obtains evidence of hepatitis B immunization or immunity from a collegian to comply with proposed new N.J.A.C. 8:57-6.4 or 6.5 is not to require a collegian to submit redundant evidence to comply with proposed new N.J.A.C. 8:57-6.10. N.J.S.A. 18A:61D-9 establishes a compliance grace period, that is, within nine months of attendance. Proposed new subsection (e) would direct an IHE to not admit or retain a collegian who is not compliant. Subsection (f) would reiterate that provisional admission pursuant to N.J.A.C. 8:57-6.6 is inapplicable to an IHE's compliance with N.J.A.C. 8:57-6.10.

N.J.S.A. 18A:62-15.1 directs an IHE to exclude from continued attendance, a collegian who does not present evidence of having received a meningococcal-containing vaccine. This requirement applies to all collegians, regardless of age, as a condition of attendance. Proposed new N.J.A.C. 8:57-6.11, IHEs to require collegian to submit record of compliance with N.J.S.A. 18A:62-15.1 regarding meningococcal-containing vaccination, would implement N.J.S.A. 18A:62-15.1 by directing an IHE to require a collegian to whom the section applies to submit evidence of immunization compliance with N.J.A.C. 8:57-6.4. Subsection (a) would indicate that the requirement would apply to a collegian for whom applicable ACIP recommendations to receive the vaccine exist. Subsection (b) would state that the obligation to receive a

meningococcal-containing vaccine applies to a collegian who enrolls in an IHE, regardless of age. Subsection (c) would direct an IHE not to admit or retain a collegian who is not in compliance with the section.

N.J.S.A. 18A:61D-10 and 18A:62-15.2 authorize IHEs to exempt a collegian on religious grounds from compliance with the hepatitis B immunization required pursuant to N.J.S.A. 18A:61D-9 (to be implemented by proposed new N.J.A.C. 8:57-6.10) and the meningococcal-containing immunization required pursuant to N.J.S.A. 18A:62-15.1 requires (to be implemented at proposed new N.J.A.C. 8:57-6.11). N.J.S.A. 18A:61D-10 and 18A:62-15.2 specify the required content of the written statement that a collegian is to submit to an IHE in support of a request for exemption from these immunizations, which is different from the required content of the written statement that a collegian must submit in support of a religious exemption from compliance with N.J.S.A. 18A:61D-1, pursuant to N.J.S.A. 18A:61D-3. N.J.S.A. 18A:61D-10 and 18A:62-15.2 require a collegian seeking an exemption from compliance with N.J.S.A. 18A:61D-9 or 18A:62-15.1 on religious grounds to submit a written statement to the institution “explaining how the administration of the vaccine conflicts with the bona fide religious tenets or practices of the student, or the parent or guardian, as appropriate.”

Proposed new N.J.A.C. 8:57-6.12, Religious exemption from compliance with N.J.A.C. 8:57-6.10 and 6.11 pursuant to N.J.S.A. 18A:61D-10 and 18A:62-15.2, would implement N.J.S.A. 18A:61D-10 and 18A:62-15.2 by establishing procedures by which an institution is to exempt a collegian from compliance with proposed new N.J.A.C. 8:57-6.10 and 6.11 on religious grounds, and associated recordkeeping requirements. Subsection (a) would require a collegian to submit a written statement as to the basis of

the religious exemption. Subsection (b) would prohibit an IHE from granting an exemption on the sole basis of a general philosophical or moral objection. In deference to a religious-affiliated IHE's authority and expertise to determine whether the religion with which the IHE affiliate recognizes the receipt of a specific vaccine as conflicting or interfering with that religion, subsection (c) would reflect a religious-affiliated IHE's authority to withhold or grant a request for religious exemption pursuant to this section without challenge by a secular health authority. Subsection (d) would require an IHE to retain any statement submitted pursuant to subsection (a) in accordance with the recordkeeping requirements at N.J.A.C. 8:57-6.13. Subsection (e) would require an IHE to not require a collegian who obtains an exemption pursuant to the section to reapply annually for the exemption.

N.J.S.A. 18A:61D-1 requires an IHE to maintain collegians' immunization records "on file in such form and manner as prescribed by the [Department]." N.J.S.A. 18A:61D-9 and 18A:62-15.1 direct the Department to promulgate rules to implement the immunization requirements therein. Proposed new N.J.A.C. 8:57-6.13, IHE's obligations with respect to collegians' immunization records pursuant to N.J.S.A. 18A:61D-1, would establish the obligations of an IHE with respect to collegians' immunization records. Subsection (a) would require an IHE to segregate immunization records from collegians' other confidential records without compromising the confidentiality of the collegian's other educational or medical records; make immunization records available on request to the Department and local health agencies with jurisdiction; and ensure that each record includes the required content. Subsection (b) would require an IHE to establish policies and procedures, consistent with its

handling of other record requests, to provide collegians with their immunization transcripts. Subsection (c) would require an IHE to address a collegian's request for a copy or transmittal of the collegian's immunization transcript consistent with the policies and procedures that the IHE establishes pursuant to subsection (b).

N.J.S.A. 18:61D-9 directs the Commissioner to establish rules requiring an IHE to offer hepatitis B vaccines through its student health service or a contractual agreement with a community health care provider. N.J.S.A. 18A:62-15.1 directs the same in reference to the meningococcal-containing vaccination. Proposed new N.J.A.C. 8:57-6.14, IHEs to offer hepatitis B and meningococcal-containing vaccine pursuant to N.J.S.A. 18:61D-9 and 18A:62-15.1, would implement these statutes by requiring an IHE to make the hepatitis B and meningococcal-containing vaccines available to collegians through either the IHE's student health services program or through a contractual agreement with a health care professional in the community.

N.J.S.A. 18A:61D-7(a), directs the Commissioner to establish rules by which "each four-year public or private institution of higher education in this State" is to "provide information about meningitis," and the meningococcal-containing vaccination requirement, "to all prospective students prior to their matriculation, and include with that information notice of the availability and benefits of a meningococcal vaccination." N.J.S.A. 18A:61D-7.b directs the Commissioner to establish rules requiring these IHEs to "develop procedures for facilitating, receiving and recording student responses to the information provided pursuant to subsection a. of this section," including compliance with meningococcal-containing vaccination requirements "and the decision of any student who is exempted from that requirement to receive the vaccination."

Proposed new N.J.A.C. 8:57-6.15, Certain IHEs to offer information about meningitis and meningococcal-containing vaccine immunization requirement pursuant to N.J.S.A. 18A:61D-7, would implement this statute by requiring an IHE to disseminate the Department brochure “Meningococcal Disease: Are You Protected?” to all prospective collegians, regardless of age, prior to their matriculation, and to develop procedures to obtain and record each prospective collegian’s response to the brochure, assess prospective collegians’ compliance with meningococcal-containing vaccination requirements, and memorialize whether prospective students who are exempt from compliance with meningococcal-containing vaccination requirements nonetheless decide to receive the meningococcal-containing vaccine following receipt of the brochure.

The Department proposes to repeal existing N.J.A.C. 8:57-6.16, Institutional records required, as it would be redundant of other provisions of the proposed new rules that establish recordkeeping requirements.

Existing N.J.A.C. 8:57-6.17, Reports to be submitted to the Department, identifies reports that an IHE is required to submit to the Department. The Department proposes to recodify existing N.J.A.C. 8:57-6.17, as 6.16 and amend subsection (a) to establish a submission deadline of December 1 for each year’s Annual College Immunization Status Report, which the Department proposes to recodify from existing Subchapter 6 Appendix as new N.J.A.C. 8:57 Appendix Q. The Department proposes to amend the form to add fields relating to the meningococcal-containing and hepatitis B vaccines, and the delivery method of these vaccines.

The Department proposes to repeal N.J.A.C. 8:57-6.18, 6.19, 6.20, and 6.21, as these sections would be redundant of other provisions of the proposed new rules in Subchapter 6.

### **Social Impact**

The proposed amendments throughout the chapter to reorganize sections and improve style would make the chapter more user-friendly.

#### **N.J.A.C. 8:57-1**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-1 would have a beneficial social impact on the regulated public. The reorganization of this subchapter would provide a more user-friendly framework for N.J.A.C. 8:57, thus making it easier to understand by the regulated public.

The proposed repeal and new rule at N.J.S.A. 8:57-1.1 would guide users by specifying the legal standards and topics the chapter would address and implement.

The proposed amendment at recodified N.J.A.C. 8:57-1.2 would ensure that the regulated public understands the meaning of terms the chapter uses.

Proposed new N.J.A.C. 8:57-1.4, recodified from N.J.A.C. 8:57-1.15, and the proposed amendment at existing N.J.A.C. 8:57-4.24, to be recodified as N.J.A.C. 8:57-1.5, would ensure that the regulated public is cognizant of available sanctions for noncompliance with the chapter.

Proposed new N.J.A.C. 8:57-1.6 would facilitate unimpeded access of Department staff to premises and things in the implementation of the chapter.

The proposed amendment at existing N.J.A.C. 8:57-1.14, to be recodified as new N.J.A.C. 8:57-1.7, would identify confidentiality protections applicable to records and



information relating to the matters the chapter addresses that the Department and local public health authorities may generate or hold, thereby enhancing public confidence in the security of their personal health information.

#### **N.J.A.C. 8:57-2**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-2 would have a beneficial social impact on the regulated public. Communicable diseases continue to be a leading cause of preventable morbidity and mortality. Reporting of communicable diseases to public health officials facilitates early intervention and implementation of control measures to prevent disease spread. Rapid response to prevent the spread of communicable diseases improves population health, avoids worker and student absenteeism due to illness, and prevents sequelae associated with communicable diseases. By updating this subchapter, the public health system would be able to more efficiently prepare for and respond to public health issues and thereby protect public health.

The proposed amendment at existing N.J.A.C. 8:57-1.4, to be recodified as N.J.A.C. 8:57-2.2, would ensure that entities with reporting obligations are aware of the processes and requirements for reporting cases.

The proposed amendment at existing N.J.A.C. 8:57-1.5, to be recodified as N.J.A.C. 8:57-2.3, reclassifying the reporting deadlines for certain diagnoses and changing the types of cases that are reportable, would reflect changes in the relative urgency with which public health authorities must respond to these reports, based on changes to available treatments and/or enhanced understanding of certain bioterrorism concerns.

The proposed amendment at existing N.J.A.C. 8:57-1.6, to be recodified as N.J.A.C. 8:57-2.4, would restate and simplify reporting obligations and processes to ensure they are understandable to those who must report cases.

Proposed new N.J.A.C. 8:57-2.5 would enable clinical laboratories with reporting obligations to adhere to national standards for electronic reporting, thereby enhancing or maintaining their eligibility for Federal financial incentives associated with use of electronic health records, and standardizing reporting by clinical laboratories that participate in multijurisdictional result reporting.

Similar to proposed new N.J.A.C. 8:57-2.4, the proposed amendment at existing N.J.A.C. 8:57-1.7, to be recodified as N.J.A.C. 8:57-2.6, reclassifying the reporting deadlines for laboratory results indicative of the presence of certain organisms that cause communicable diseases, infections, or conditions, and outbreaks thereof, and modifying the types of results that are reportable with respect to certain organisms, would reflect changes in the relative urgency with which public health authorities must respond to those reports, based on changes to available treatments and/or enhanced understanding of certain organisms, diseases, and bioterrorism concerns, and thereby promote more efficient and effective use of available public health authority resources. The proposed amendment at existing N.J.A.C. 8:57-1.8, to be recodified as N.J.A.C. 8:57-2.7, revising the reporting obligations and procedures applicable to veterinarians, would reflect changes in the relative urgency of public health authority response to veterinary and zoonotic diseases, and thereby promote more efficient and effective use of available public health authority resources.

The proposed amendment at existing N.J.A.C. 8:57-1.9, to be recodified as N.J.A.C. 8:57-2.8, would ensure that health officers who receive and make reports of cases and laboratory results process these in the manner, and to the public health authority, that is most appropriate under the circumstances, depending on the nature of the disease or organism reported and applicable jurisdictional factors.

The proposed amendment at existing N.J.A.C. 8:57-1.10, to be recodified as N.J.A.C. 8:57-2.9, identifying, and requiring health officers' adherence to, specified best practices for investigating confirmed and suspected cases, infections, and outbreaks, specifying the minimum content of investigation reports, and requiring health officers to submit status reports pending their issuance of final reports and closing investigations, would ensure that the Department has uniform, timely, and comprehensive information to determine and implement Statewide responsive measures, and would incentivize health officers to conclude investigations, rather than indefinitely maintaining them in pending status.

The proposed amendment at existing N.J.A.C. 8:57-1.11, to be recodified as N.J.A.C. 8:57-2.10, and the proposed amendments to the Model Ordinance for Quarantine and Isolation, would ensure that local governing bodies have appropriate standards in place to address isolation and quarantine of persons, as well as pet birds and other domestic companion animals, as necessary, to protect public health.

The proposed amendment at existing N.J.A.C. 8:57-1.13, to be recodified as N.J.A.C. 8:57-2.11, would protect food establishment, drug establishment, and cosmetic establishment workers and patrons from exposure to communicable diseases that are transmissible through food, drugs, and cosmetics, would implement N.J.S.A. 24:15-10

more fully by including drug and cosmetic workers within the scope of the rule, and would ensure that employers exclude workers in consultation with the Department or the local health authority, thereby discouraging arbitrary exclusion of workers.

Proposed new N.J.A.C. 8:57-2.12 and 2.13, which would establish reporting requirements for schools and nursing homes, would ensure that the Department has routine information to respond to a public health concern affecting these facilities' vulnerable populations.

### **N.J.A.C. 8:57-3**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-3 would have a beneficial social impact on the regulated public by:

Reestablishing, simplifying, and updating the norms and procedures for enrollment in and use of the NJIIS to make the NJIIS more user friendly, and thereby ease NJIIS user participation;

Establishing requirements for NJIIS participation and enrollment by eligible entities, thereby fostering a more robust NJIIS userbase;

Restating NJIIS user access levels to ensure that each NJIIS user has access to the minimum necessary NJIIS information that is appropriate to the NJIIS user's role, thereby protecting NJIIS information confidentiality;

Establishing NJIIS training requirements to ensure accurate and proper use and data collection;

Alerting NJIIS sites and NJIIS users of their expected conduct in NJIIS interactions, including adherence to security and confidentiality standards;

Establishing secure procedures for viewing, sharing, and correcting information in NJIIS;

Facilitating Department oversight actions and intervention to address system threats;

Protecting the confidentiality and ensuring the accuracy of NJIIS content;

Facilitating and identifying procedures by which an individual can ensure that the NJIIS contains the individual's accurate immunization record through the correction request process, obtain access to the individual's NJIIS record, and deactivate the individual's NJIIS record by withdrawal; and

Identifying procedures by which the NJIIS can engage with immunization registries in other jurisdictions to collect and share data securely and in accordance with updated and nationally recognized data exchange policies and procedures, thereby promoting the accuracy and robustness of the information in the NJIIS and enabling an enrolled person who relocates to another jurisdiction to have their NJIIS records transferred to the new jurisdiction.

#### **N.J.A.C. 8:57-4**

Vaccine-preventable diseases remain a threat to school-aged and preschool-aged children. Prevention of individual cases and outbreaks of vaccine-preventable diseases require high immunization levels among school-aged and preschool-aged children. These prevention efforts, in turn, help individuals and communities avoid the physical sequelae, morbidities, and mortalities that these diseases can cause, and

curtail the associated high social costs that otherwise would burden children, their families, and the community.

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-4 would have a beneficial social impact on the regulated public by ensuring that health care professionals adhere to nationally recognized best practices and immunization schedules in administering vaccines to the people of New Jersey, thereby promoting their health and safety and protecting them and others from contracting vaccine-preventable diseases; ensuring that each facility administrator obtains appropriate evidence of each minor's immunization or immunity to vaccine-preventable diseases, thereby protecting each minor and others admitted to the facility, including attendees who are unable to receive vaccinations due to medical contraindications and who must rely on "herd immunity" to avoid exposure to diseases; and enabling minors to avoid unnecessary or duplicative vaccination through the submission of laboratory evidence of protective immunity from vaccine-preventable diseases.

#### **N.J.A.C. 8:57-5**

The proposed amendment at N.J.A.C. 8:57-5.5 deleting reference to the nucleic acid amplification test would have a beneficial social impact because the test is inadequate to confirm that a person's TB disease is not transmissible and could unnecessarily prolong a person's hospital stay.

Except as described above, the Department does not anticipate that the proposed amendments at N.J.A.C. 8:57-5 would have a social impact because the proposed amendments would make only technical changes to the subchapter.

**N.J.A.C. 8:57-6**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-6 would have a beneficial social impact on the regulated public by facilitating Department interaction and coordination with each IHE to ensure that each IHE provides a safe environment that is free from vaccine-preventable diseases, thereby reducing the risk of avoidable illnesses and outbreaks on campuses; allowing IHEs to use campus spaces at which enrolled collegians can congregate without risking the spread of disease, thereby ensuring that IHEs can continue to offer and maintain collegians' social and educational opportunities; promoting high overall immunization levels at IHE campuses by the establishment of limited provisional admission periods during which collegians can obtain missing vaccinations at IHE health centers, if necessary, upon their arrival at campus, and thereby enabling these collegians to avoid exclusion from attendance; and promoting collegian awareness and education about the risk of meningitis and the availability of the meningococcal-containing vaccine to protect them from this disease.

**Economic Impact****N.J.A.C. 8:57-1**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-1 would have a beneficial economic impact on the regulated public. Prevention and/or limitation of the spread of communicable disease is a cost-efficient use of financial resources to support public health. By promulgating legal standards, explaining the definitions used within the chapter, and providing information about

sanctions and confidentiality, this chapter will allow the rules of this chapter to be clear and easily implemented by the public and other health institutions. Consequently, this will have a positive effect on the overall public health, which will avoid healthcare costs and reduced absenteeism resulting from the sequelae, morbidities, and mortalities associated with contraction of vaccine-preventable diseases.

#### **N.J.A.C. 8:57-2**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-2 would have a beneficial economic impact on the regulated public. Prevention and/or limitation of the spread of communicable disease continues to be a cost-efficient use of financial resources that are available to support public health, because reporting facilitates cost-saving interventions that protect and improve population health, avoid worker, student, and associated parent absenteeism due to illness, and prevent incurring health care costs to treat communicable diseases.

The proposed amendments and new rules at N.J.A.C. 8:57-2 and 3 would support these efforts. Entities with reporting obligations are likely to have the necessary infrastructure in place to submit required reports. They would continue to incur administrative expenses associated with reporting cases and laboratory results, such as staff time, and information technology acquisition and maintenance. The types of entities upon which the chapter would impose reporting obligations would not change, making it unlikely that the existing economic burden of compliance would change. Compliance with electronic laboratory reporting obligations may facilitate clinical



laboratories' eligibility for Federal financial incentives associated with electronic health recordkeeping.

#### **N.J.A.C. 8:57-3**

Entities with reporting obligations that the proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-3 would establish would remain the same as in the existing rules. NJIIS sites and NJIIS users would continue to incur administrative costs associated with staff retention to comply with immunization reporting requirements and the time needed for NJIIS users to receive required NJIIS training.

#### **N.J.A.C. 8:57-4**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-4 would require each facility to incur administrative and material costs associated with the collection, review, and retention of each student's submissions of evidence of immunization against or immunity to vaccine-preventable diseases and/or records supporting exemptions due to medical contraindications and religious objections, and reporting facility immunization status reports to the VPDP.

At the same time, an administrator's enforcement of Subchapter 4 would result in cost savings to a facility by promoting a high facility immunization level, thereby avoiding costs associated with staff and student absenteeism due to illness.

**N.J.A.C. 8:57-5**

The proposed amendment at N.J.A.C. 8:57-5.5 could have a beneficial economic impact because it would avoid unnecessarily prolonging a patient's hospital stay to await the result of a nucleic acid amplification test, which is inadequate to confirm whether a patient has transmissible TB, thereby avoiding the costs associated with an unnecessarily prolonged stay and the cost of an unnecessary laboratory test.

Except as described above, the Department does not anticipate that the proposed amendments at Subchapter 5 would have an economic impact because they are primarily technical in nature.

**N.J.A.C. 8:57-6**

The proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57-6 would continue to require IHEs to incur costs associated with the retention and maintenance of information technology equipment, the retention and identification of an institutional liaison, and other staffing and administrative expenses associated with the collection, review, and retention of each collegian's immunization or immunity record and/or exemption request due to medical contraindication or religious objection, and reporting immunization census information to the VPDP.

At the same time, Subchapter 6 would promote a high immunization level at IHE campuses, which would help IHEs avoid costs associated with staff and collegian absenteeism due to illness. Avoidance of preventable illnesses, in turn, could help lower costs that IHEs would otherwise incur at IHE health centers to provide health care services to collegians who contract vaccine-preventable illnesses. Collegians and their families would also realize cost savings that they might otherwise incur, due to illness

with vaccine-preventable disease, associated with obtaining health care, absenteeism from classes and employment, and the sequelae, morbidity, and mortality resulting from vaccine-preventable disease.

### **Federal Standards Statements**

At Subchapter 1, within the definitions at N.J.A.C. 8:57-1.2, as proposed for recodification with amendment from N.J.A.C. 8:57-1.3, the Department elects to incorporate by reference Federal guidance documents and publications and Federally endorsed or supported publications that establish best practices and procedures to which Subchapters 2 and 5 refer with respect to the identification, electronic reporting, epidemiologic investigation, and response to communicable diseases, infections, and conditions, outbreaks thereof, and laboratory test results relating to the identification of the causative organisms thereof. These include the CDC *Laboratory Recommendations for Syphilis Testing*, the FDA *Food Code*, the CDC *Notifiable Condition List*, the CLSI *M100™ Performance Standards for Antimicrobial Susceptibility Testing*, the United States Department of Human Services *Systematized Nomenclature of Medicine—Clinical Terms (SNOMED-CT) United States (US) Edition*, and the CDC, *Surveillance Case Definitions for Current and Historical Conditions*. No applicable Federal standard requires the Department to incorporate by reference these guidance documents and recommended standards.

At Subchapter 1, the Department further elects to incorporate by reference Federal publications and Federally supported or endorsed publications, to which Subchapters 3, 4, and 6 refer. These publications establish best practices and

procedures, and identify immunization types, schedules, laboratory serology testing, and contraindication and precaution recommendations, for children and adults. These include the several publications that the chapter collectively refers to as the ACIP recommendations.

Section 222 of the Public Health Service Act (42 U.S.C. § 217a), as amended, established the ACIP. The ACIP has statutory roles under subsections 1928(c)(2)(B)(i) and 1928(e) of the Social Security Act (42 U.S.C. §§ 1396s(c)(2)(B)(i) and 1396s(e)) and subsection 2713(a)(2) of the Public Health Service Act (42 U.S.C. § 300gg-13(a)(2)).

The ACIP provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for effective control of vaccine-preventable diseases in the civilian population of the United States. The ACIP recommendations include schedules governing appropriate doses and dosing intervals, guidance on contraindications and precautions for use of vaccines and related agents, and information on recognized adverse events. The ACIP periodically reviews and, as appropriate, revises its recommendations. The CDC Director reviews and, if the Director determines to adopt them, publishes the ACIP recommendations as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR). The Patient Protection and Affordable Care Act, Section 2713 of the Public Health Service Act, as amended, requires health plans subject thereto to cover the cost of immunizations that the ACIP recommends, without copayment or cost-sharing, if the CDC Director adopts the ACIP recommendations.

The ACIP recommendations (including the vaccines, doses, and dosing interval schedules, and the precautions and contraindications) serve as the list of vaccines for administration to children and adolescents who are eligible to receive vaccines through the Vaccines For Children (VFC) program established at section 1928 of the Social Security Act. The VFC program is a Federally funded program that provides vaccines at no cost to children who might not otherwise be vaccinated because of inability to pay. The Secretary, and as delegated, the CDC Director, use the ACIP recommendations in the purchase, delivery, and administration of pediatric vaccines in the VFC program.

The Department is the VFC program coordinator in New Jersey. N.J.A.C. 8:57 does not implement the VFC program; however, in administering the VFC program, the Department requires VFC providers (such as pediatricians and Federally Qualified Health Centers) to administer VFC program vaccines to eligible children in accordance with the ACIP recommendations.

As described in the Summary, N.J.A.C. 8:57-1.2 would incorporate by reference the ACIP recommendations, as amended and supplemented. No applicable Federal standard requires the Department to incorporate by reference the ACIP recommendations. N.J.S.A. 26:2-137.1 requires the Department to identify required and recommended immunizations in consideration of the ACIP recommendations. The proposed amendments, repeals, recodifications, and new rules at Subchapters 4 and 6 would require an administrator to require evidence of immunization or immunity as a condition of one's admission to and continued enrollment at a child care center, school, or IHE, in adherence to the ACIP recommendations for dose timing and intervals, laboratory serology testing, contraindications, and precautions, with respect to the

vaccinations that the Department identifies as required. An administrator's adherence to the ACIP recommendations would be subject to the exceptions at N.J.A.C. 8:57-4.3 and the provisional admission schedules at N.J.A.C. 8:57-4.9 and 6.6.

At Subchapter 1, the Department also elects to incorporate by reference nationally and internationally accepted information technology standards and coding languages that the Federal government publishes, supports, or accepts as authoritative, to which Subchapters 2 and 3 refer. These standards facilitate electronic reporting of communicable diseases, infections, and conditions, occurrences of outbreaks thereof, and laboratory test results relating to the identification of the causative organisms thereof, to the CDRSS, and immunizations and related information to the NJIIS. These include the *HL7 Implementation Guide*, the *Healthcare Effectiveness Data and Information Set®*, and the *Logical Observation Identifiers Names and Codes®*. In addition, at N.J.A.C. 8:57-3.15(c), as proposed for recodification with amendment from N.J.A.C. 8:57-3.19, the Department identifies its election to adhere to and comply with the American Immunization Registry Association *Public Health Immunization Information System Interjurisdictional Memorandum of Understanding*, which is a cooperative agreement that facilitates secure interjurisdictional data-sharing among immunization information systems.

These Federally issued, supported, or endorsed standards facilitate interconnectivity and interoperability among data systems and enable the Department to collect and share data with State partners and governmental public health authorities in other jurisdictions, such as other states' communicable disease reporting systems and immunization information systems, and the CDC. The Department's election to

incorporate by reference and, in some cases, either recommend or require the regulated community to adhere to, the types of standards described above, enables the State to participate in Federal grant funding opportunities that require system interconnectivity and interoperability sufficient for the Department to engage in electronic public health data sharing with the United States Department of Health and Human Services and public health authorities within the State and in other regions, states, and jurisdictions. In addition, the Department's adherence, and its recommendation or requirement within this chapter that members of the regulated community adhere to these standards make the Department and members of the regulated community eligible to participate in Federal grant funding opportunities that support data modernization initiatives designed to encourage "minimum use" of electronic health recordkeeping technology. To the extent these standards could be considered Federal standards to which the rules at N.J.A.C. 8:57 are subject to the terms and conditions of Federal grant funding agreements, the proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57, would meet, but not exceed, these standards.

As the Summary above describes, the proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57 would be subject to the Federal standard articulated in the McKinney-Vento Homeless Assistance Act, 42 U.S.C. §§ 11431 through 11435. N.J.A.C. 8:57-4.2(d), as proposed for amendment, would require compliance with, but would not exceed, this applicable Federal standard, with respect to the period during which an administrator is to admit an unhoused person, to whom the

Federal standard applies, to a school pending submission of evidence of immunization or immunity.

As the Summary above describes, pursuant to N.J.S.A. 18A:75A-19, the Interstate Compact on Educational Opportunity for Military Children (Compact), and rules promulgated in accordance therewith, as amended and supplemented pursuant to N.J.S.A. 18A:75A-13, the Military Interstate Children's Compact Commission (MIC3), would apply to the proposed amendments, recodifications, repeals, and new rules at N.J.A.C. 8:57. The MIC3 rules supersede and preempt any State requirement to demonstrate a minor's immunization or immunity in accordance with ACIP recommendations. Proposed new N.J.A.C. 8:57-4.9(c) would require compliance with, but would not exceed, this standard with respect to the period during which an administrator is to permit a student or collegian, who is a military child to whom the compact applies, to attend provisionally pending submission of evidence of immunization or immunity.

The Department promulgates the rules at Subchapter 5 to comply with State statutes requiring the identification, treatment, management, and confinement of persons with suspected or confirmed TB, which the rulemaking authority above identifies. The Department receives funding from the Agency for Toxic Substances and Disease Registry of the CDC, pursuant to a Federal Award Project entitled Tuberculosis Elimination and Laboratory Cooperative Agreement (Award) that is intended to support prevention and control activities and laboratory services to reduce TB morbidity and mortality, prevent transmission of TB, and prevent progression from latent TB infection to active TB disease.



The rules at N.J.A.C. 8:57-5 facilitate the Department's compliance with the terms and conditions of the award by enabling the Department to ensure the compliance of, and collect Statewide data and information from, its local partners throughout the State relating to the State's efforts toward the advancement of the award's goals. These partners include local health agencies, health care facilities, correctional facilities, clinical laboratories, institutions, and other entities with compliance and reporting obligations. The Department, in turn, can comply with required reporting to the CDC as to the State's use of the award and its achievement of performance measures and other deliverables. These reports address the State's efforts to diagnose and treat persons with TB disease and persons with latent TB infection; examine immigrants and refugees who have an overseas B classification for TB; strategically direct testing for, and treatment of, latent TB infection; engage in program planning, evaluation, and improvement activities; perform epidemiologic surveillance and response; facilitate human resource development and partnership activities; and strengthen public health laboratory services. The existing rules at Subchapter 5, and the proposed amendments thereto, would meet but not exceed the terms and conditions of the award.

Except as described above, the Department does not propose the amendments, repeals, recodifications, and new rules pursuant to the authority of, or to implement, comply with, or participate in any program established pursuant to Federal law, or a State statute that incorporates or refers to Federal law, standards, or requirements. Therefore, a Federal standards analysis is not required.

### **Jobs Impact**

The proposed repeals, new rules, recodifications, and amendments at N.J.A.C. 8:57 could maintain or increase demand for administrative, health information, data privacy, information technology, and healthcare professionals, at institutions upon which the rules would impose the same or additional data collection, recordkeeping, and reporting obligations using information technology and other recordkeeping systems. Required activities would continue to include collecting and maintaining records, making records available for public health official inspection, and ensuring that records are compliant with applicable content requirements.

The Department is unable to estimate the number of jobs that would be maintained or increased, as this would depend up on the type and size of the institution, the nature of its operations, and the number of persons it serves, all of which would affect the amount of data the institution would generate that would be subject to the chapter's data collection, recordkeeping, and reporting requirements. To the extent the rules would require institutions to train personnel to use existing or new information technology systems, the proposed repeals, new rules, recodifications, and amendments at N.J.A.C. 8:57 could maintain or increase demand for instructors to provide this training.

### **Agriculture Industry Impact**

N.J.A.C. 8:57-2.7, as proposed for recodification with amendment from N.J.A.C. 8:57-1.8, would require a veterinarian, a certified animal control officer, an animal facility manager, and an animal rescue organization to report suspected or confirmed rabies in livestock (or any other type of animal, including a domestic companion animal), to

facilitate proper case investigation and potential quarantine of other exposed animals. The rule would continue to require the Department to notify the Secretary of Agriculture upon receiving a report indicative of a suspected or confirmed reportable zoonotic disease or an outbreak of any disease that could affect animals, plants, or crops within the Secretary's jurisdiction. Except as described above, the proposed amendments, repeals, recodifications, and new rules at N.J.A.C. 8:57 would not have an impact on the agricultural industry of the State.

### **Regulatory Flexibility Analysis**

The proposed amendments, repeals, recodifications, and new rules at N.J.A.C. 8:57 would establish standards applicable to healthcare professionals, clinical laboratory directors, health officers, veterinarians, certified animal control officers, animal facility managers, and employers, and other persons in charge, at food establishments, drug establishments, and cosmetic establishments. In addition, the proposed amendments, repeals, and new rules at N.J.A.C. 8:57 would establish standards applicable to administrators of the following: health care facilities, correctional facilities, other State operated or licensed facilities, schools, youth camps, child care centers, institutions, farm and migrant labor camps, and insurers.

The entities listed above, other than hospitals, certain large institutions, and government-operated facilities or agencies, could be small businesses within the meaning of the New Jersey Regulatory Flexibility Act, N.J.S.A. 52:14B-16 et seq. The Summary describes the reporting, recordkeeping, and compliance requirements

applicable to entities subject to the chapter. The Economic and Jobs Impact statements describe the costs of compliance and the need for retention of professionals to comply.

The Department has determined that the proposed amendments, repeals, recodifications, and new rules at N.J.A.C. 8:57 would establish the minimum standards necessary for the Department to fulfill its various statutory public health oversight mandates, protect the public from the spread of communicable and vaccine-preventable diseases, and maintain accurate public health data. Therefore, the Department proposes no lesser or differing standards for small businesses than those that would apply to all businesses. However, the proposed amendments, repeals, and new rules necessarily self-scale the compliance burden to business size. For example, the number of reports that the chapter would require entities to submit to the NJIIS or the CDRSS would depend on the number of persons the small business serves who generate reportable data.

### **Housing Affordability Impact Analysis**

The Department anticipates that the proposed amendments, repeals, recodifications, and new rules at N.J.A.C. 8:57 would not have an impact on the affordability of housing in New Jersey and would not evoke a change in the average costs associated with housing because the proposed amendments, repeals, recodifications, and new rules would establish procedures for public health reporting and oversight and would not have any bearing on housing costs.

### **Smart Growth Development Impact Analysis**

The proposed amendments, repeals, recodifications, and new rules at N.J.A.C. 8:57 would have no impact on smart growth and would not evoke a change in housing production in Planning Areas 1 or 2, or within designated centers, pursuant to the State Development and Redevelopment Plan in New Jersey because the proposed amendments, repeals, recodifications, and new rules, would establish procedures for public health reporting and oversight and would not have any bearing on housing production.

### **Racial and Ethnic Community Criminal Justice and Public Safety Impact**

The Department has evaluated this rulemaking and determined that it will not have an impact on pretrial detention, sentencing, probation, or parole policies concerning adults and juveniles in the State. Accordingly, no further analysis is required.

**Full text** of the rules proposed for repeal may be found in the New Jersey Administrative Code at N.J.A.C. 8:57-1.1, 1.2, 1.12, 8:57-1 Appendices A and B, 3.2, 3.3, 3.17, 3.18, 3.21, 3.23, 8:57-3 Appendices A through J, 4.5, 4.7 through 4.21, 4.23, 8:57-4 Appendix, 8:57-5 Appendices A and B, 6.1 through 6.16, 6.18, 6.19, 6.20, 6.21, and 8:57-6 Appendix.

**Full text** of the proposed amendments, new rules, and recodifications follows (additions indicated in boldface **thus**; deletions indicated in brackets [thus]):

## CHAPTER 8

### COLLECTION, PROCESSING, STORAGE, AND DISTRIBUTION OF BLOOD

#### SUBCHAPTER 5. RECORDS AND REPORTING REQUIREMENTS

##### 8:8-5.2 Reporting requirements

(a)-(b) (No change.)

(c) Blood banks shall report prospective donors testing positive for hepatitis B, hepatitis C, syphilis, and infectious diseases that are reportable pursuant to N.J.A.C. 8:57[-1] to the Communicable Disease Service of the Department or the local health agency in accordance with N.J.A.C. 8:57[-1].

(d)-(g) (No change.)

## CHAPTER 25

### NEW JERSEY YOUTH CAMP SAFETY STANDARDS

#### SUBCHAPTER 1. GENERAL PROVISIONS

##### 8:25-1.4 Definitions

The following words and terms, when used in this chapter, shall have the following meanings unless the context clearly indicates otherwise:

...

“Communicable disease” shall have the meaning established at N.J.A.C. 8:57[-1].

...

## SUBCHAPTER 5. HEALTH

### 8:25-5.5 Health records

(a)-(c) (No change.)

(d) All campers shall:

1. Be immunized, with the vaccinations required for child-care center, preschool, or school attendance, as appropriate for the camper's age, according to the immunization schedule set forth at [Immunization of Pupils in School,] N.J.A.C. 8:57[-4]; or

2. (No change.)

(e) The youth camp shall adhere to the requirements established at N.J.A.C. 8:57[-4.3(a) and (b)] regarding [medical] exemption[s for] **of a camper[s]** from immunization[, where the immunization is medically contraindicated] **based on medical contraindication.**

1. (No change.)

(f) The youth camp shall adhere to the requirements established at **N.J.S.A. 26:12-16 and N.J.A.C. 8:57-[4.4(a)]4** regarding religious exemption[s for] **of a camper[s]** from immunization.

1. (No change.)

(g) (No change.)

## CHAPTER 28

### TANNING FACILITIES

#### SUBCHAPTER 1. GENERAL PROVISIONS

##### 8:28-1.2 Definitions

The following words and terms, when used in this chapter, shall have the following meanings, unless the context clearly indicates otherwise:

...

“Communicable disease” means **communicable** disease[s or conditions as defined in] **pursuant to** N.J.A.C. 8:57[-1].

...

## CHAPTER 36

### STANDARDS FOR LICENSURE OF ASSISTED LIVING RESIDENCES, COMPREHENSIVE PERSONAL CARE HOMES, AND ASSISTED LIVING PROGRAMS

#### SUBCHAPTER 18. INFECTION PREVENTION AND CONTROL SERVICES

8:36-18.4 Employee health and resident policies and procedures for infection prevention and control

(a)-(k) (No change.)

(l) The facility shall maintain records documenting [contagious] **communicable** diseases contracted by employees during employment, as specified at N.J.A.C. 8:57[-1.5].



## CHAPTER 39

### STANDARDS FOR LICENSURE OF LONG-TERM CARE FACILITIES

#### SUBCHAPTER 19. MANDATORY INFECTION CONTROL AND SANITATION

##### 8:39-19.4 Mandatory general policies and procedures for infection control and sanitation

(a)-(e) (No change.)

(f) The facility shall have a system for investigating, evaluating, and reporting the occurrence of all reportable infections and diseases as specified [in Chapter II of the State Sanitary Code (] **at** N.J.A.C. 8:57[-1)].

(g)-(n) (No change.)

#### SUBCHAPTER 27. MANDATORY QUALITY OF CARE

##### 8:39-27.4 Mandatory post-mortem policies and procedures

(a)-(d) (No change.)

(e) The body of a deceased resident who, at the time of death, had a communicable disease [as defined in] **pursuant to N.J.S.A. 26:6-8.2 and 8.3 and N.J.A.C. 8:9 and 8:57[-1.3]** shall be tagged accordingly before being released from the facility.

(f) (No change.)

## CHAPTER 43A

### MANUAL OF STANDARDS FOR LICENSING OF AMBULATORY CARE FACILITIES

#### SUBCHAPTER 14. INFECTION PREVENTION AND CONTROL SERVICES

##### 8:43A-14.2 Infection control policies and procedures

(a) (No change.)

(b) The infection control committee, with assistance from each service in the facility, shall develop, implement, and review, every three years or more frequently, as necessary, written policies and procedures regarding infection prevention and control, including, but not limited to, policies and procedures regarding the following:

1. In accordance with N.J.A.C. 8:57 [(Communicable Diseases)], a system for investigating, reporting, and evaluating the occurrence of all infections or diseases which are reportable or conditions which may be related to activities and procedures of the facility;

2. Identifying and reporting [of HIV/AIDS] **HIV infection** as specified [in] **at** N.J.A.C. [8:57-2] **8:65, HIV Infection** Reporting [of Acquired Immunodeficiency Syndrome and Infection with Human Immunodeficiency Virus];

3.-9. (No change.)

## CHAPTER 43B

### STANDARDS FOR LICENSURE OF ADULT FAMILY CARE CAREGIVERS AND SPONSOR AGENCIES

#### SUBCHAPTER 6. GENERAL REQUIREMENTS FOR AFC SPONSOR AGENCY

##### 8:43B-6.10 AFC caregiver and employee health status

(a) (No change.)

(b) An AFC sponsor agency shall establish a policy and procedure addressing the content and frequency of health evaluations subsequent to the initial health evaluation required at (a) above, and policies and procedures addressing precautionary measures

to prevent the transmission of communicable diseases (as **N.J.A.C. 8:57 defines** that term [is defined at N.J.A.C. 8:57-1.3]) to clients.

(c)-(f) (No change.)

## CHAPTER 43D

### STANDARDS FOR LICENSURE OF PEDIATRIC COMMUNITY TRANSITIONAL HOMES

#### SUBCHAPTER 15. INFECTION PREVENTION AND CONTROL SERVICES

8:43D-15.4 Employee health and resident policies and procedures for infection prevention and control

(a)-(k) (No change.)

(l) The facility shall maintain records documenting communicable diseases contracted by employees during employment or residents during their stay in the facility and complete required reporting, as specified at N.J.A.C. 8:57[-1.3(a) and (b), 2 or 5], as applicable.

(m) (No change.)

## CHAPTER 43G

### HOSPITAL LICENSING STANDARDS

#### SUBCHAPTER 14. INFECTION CONTROL

8:43G-14.1 Infection control program structural organization

(a)-(c) (No change.)

(d) The infection control program shall oversee, but not be limited to, the following activities:

1.-4. (No change.)

5. Identifying and reporting communicable diseases throughout the hospital, with the cooperation of the clinical laboratory, medical records, and the medical staff, as specified [in] **at** N.J.A.C. 8:57[-1, “Reportable Communicable Diseases”]; and

6. Identifying and reporting of [HIV/AIDS as specified] **HIV infection** in **accordance with** N.J.A.C. [8:57-2, “[**8:65, HIV Infection** Reporting [of Acquired Immunodeficiency Syndrome and Infection with Human Immunodeficiency Virus].”]

(e)-(g) (No change.)

## SUBCHAPTER 19. OBSTETRICS

### 8:43G-19.15 Newborn care policies and procedures

(a)-(c) (No change.)

(d) The newborn nursery shall identify and report any outbreak of a disease, or any single case of disease as specified [in] **at** N.J.A.C. 8:57[-1.1 through 1.5].

(e)-(h) (No change.)

## CHAPTER 52

### PUBLIC HEALTH PRACTICE STANDARDS OF PERFORMANCE FOR LOCAL

### BOARDS OF HEALTH IN NEW JERSEY

## SUBCHAPTER 3. PUBLIC HEALTH PRACTICE

### 8:52-3.3 Local health agency’s minimum capacity

(a) Each local health agency shall, at a minimum, have the capacity to deliver:

1.-6. (No change.)

7. All other public health services required [by] **pursuant to N.J.A.C. 3A:52, 5:17, and 7:9A**, the State Sanitary Code (N.J.A.C. 8:21, 8:22, 8:23, 8:23A, 8:24, 8:25, 8:26, 8:27, 8:51, **and** 8:57[-1 through 4, 10:122, 5:17 and 7:9A]), and N.J.S.A. 24:14A-1 et seq., 26:3-69.1, and 58:11-23[;], unless the population or entity requiring the services does not exist within the local health agency's jurisdiction or the services are otherwise [assured] **ensured** through formal written linkages with another local health agency;

8.-10. (No change.)

## SUBCHAPTER 12. DIAGNOSIS AND INVESTIGATION OF HEALTH PROBLEMS AND HAZARDS

### 8:52-12.3 Surveillance

(a)-(c) (No change.)

(d) Each local health agency shall ensure that there is a mechanism to receive reports and to respond to immediately reportable communicable diseases and conditions in accordance with N.J.A.C. 8:57[-1.5]. This mechanism shall be capable of operating 24 hours per day, seven days per week, including weekends and holidays.

## SUBCHAPTER 14. ENFORCEMENT OF PUBLIC HEALTH LAWS

### 8:52-14.1 Scope and purpose

This subchapter addresses the enforcement of **N.J.A.C. 3A:52, 5:17, and 7:9A**, the State Sanitary Code (N.J.A.C. 8:21, 8:22, 8:23, 8:23A, 8:24, 8:25, 8:26, 8:27, 8:51, **and** 8:57[-1 through 4, 10:122, 5:17, and 7:9A]), and N.J.S.A. 24:14A-1 et seq., 26:3-

69.1, and 58:11-23[]]; the protection of food and potable water supplies; **and** environmental health activities related to air, water, noise, and public health nuisances and health hazards, preventable injuries, and exposure-related diseases in both the workplace and community settings.

N.J.A.C. 8:52

## APPENDIX

### PROGRAMMATIC GUIDELINES FOR BEST PRACTICES

#### I. Environmental Health Activities

##### Recreational Bathing

(a) The local board of health shall:

1. (No change.)

2. Inspect, using an inspection form designed by the Department of Health [and Senior Services], each public bathing place at least twice during the operating season, make follow-up inspections when deficiencies are found, and take necessary enforcement actions;

3.-4. (No change.)

5. Conduct investigations within 24 hours of all deaths and serious injuries and report such occurrences [as outlined] in [the Recreational Bathing Regulations (] **accordance with** N.J.A.C. 8:26[]], **Public Recreational Bathing**, on a form developed by the Department of Health [and Senior Services].

...

## Youth camps

(a) The local board of health shall conduct a youth camp sanitation and safety program

(N.J.A.C. 8:25) and shall:

1.-2. (No change.)

3. Submit copies of each inspection to Consumer and Environmental Health Services, Department of Health [and Senior Services].

## Food surveillance

(a) The local board of health shall maintain surveillance of retail food establishments, food and beverage vending machines and shall:

1. (No change.)

2. Inspect retail food establishments using forms approved by the Department of Health [and Senior Services] at least once a year, inspect vending machines dispensing potentially hazardous foods at least once a year and those dispensing non-potentially hazardous foods on a complaint basis or as required by local ordinance;

3.-7. (No change.)

8. Assist the Department of Health [and Senior Services] upon request in conducting recalls and recall effectiveness checks of foods found to be contaminated, adulterated, or misbranded; and

9. (No change.)

## Occupational health (operative January 1, 1989)

(a) The local board of health shall conduct an occupational health program operative January 1, 1989; and shall:

1.-2. (No change.)

3. Train or obtain at least one staff person in Occupational Health and Industrial Hygiene through a continuing education program provided or made available by the Occupational Health Services of the Department of Health [and Senior Services];

4. Conduct initial and follow-up interviews, utilizing standardized procedures and forms developed by the Department of Health [and Senior Services], upon receipt of reports of occupational disease cases (N.J.A.C. [8:57-1.13] **8:58**); and

5. Conduct preliminary surveys in response to reported occupational diseases or referrals from the Department of Health [and Senior Services], using standardized forms provided by the Department of Health [and Senior Services] to record observations and collect information. (These standardized forms shall be forwarded to the Department of Health [and Senior Services'], Occupational Health Services, for follow-up).

...

## II. Communicable Disease Activities

### Reportable diseases

(a) The local board of health shall conduct a program for the surveillance, investigation, and control of reportable diseases and shall:

1. Document episodes of reportable diseases including occupational diseases and/or incidents and transmit the information to the State and other agencies as required by [chapter 2, Reportable Diseases (N.J.A.C. 8:57[-1) of the State Sanitary Code] **and 8:58**, and N.J.S.A. 26:4;

2. Conduct prompt investigations of reportable illnesses as well as unusual manifestations of disease not listed as reportable [in chapter 2 of the State Sanitary



Code ([ **at** N.J.A.C. 8:57[-1]) and **8:58**, institute appropriate control measures, and promptly report all findings to the Department of Health [and Senior Services];

3.-4. (No change.)

#### Immunization

(a) The local board of health shall promote and provide immunizations for protection against childhood vaccine-preventable diseases and shall:

1. Promote and provide primary and booster immunizations to preschool and school age children for protection against diseases in accordance with current recommendations of the Department of Health [and Senior Services];

2. Assist all schools, with an emphasis on preschool facilities, in implementing and enforcing the immunization requirements [contained in Chapter 14, of the State Sanitary Code ([ **at** N.J.A.C. 8:57[-4])] by providing immunization services and conducting periodic surveys and representative record audits every year;

3. Secure prompt reporting of vaccine-preventable disease as required by [chapter 2 of the State Sanitary Code ([N.J.A.C. 8:57[-1.2])]; and

4. (No change.)

#### Rabies and zoonosis control

(a) The local board of health shall conduct a program for the control of rabies and other zoonoses and shall:

1.-2. (No change.)

3. Inspect kennels, pet shops, shelters, and pounds, to ensure compliance with the State laws and regulations prescribed by the Department of Health [and Senior

Services], and ensure that licenses issued to these facilities are in compliance with existing laws;

4. Report and investigate animal bites, ensure that persons bitten are advised to see a physician, quarantine biting animals as indicated, and report immediately to the Department of Health [and Senior Services] clinically suspicious cases of rabies in animals as determined by a veterinarian, **and** ensure availability of impounding facility where biting animals may be appropriately quarantined and observed for rabies;

5. Ensure that heads of animals that have died within 10 days after biting a person are delivered immediately to the Department of Health [and Senior Services'], Public Health and Environmental Laboratories for examination (Unwanted dogs or cats or any another animal which has bitten a human may be sacrificed immediately and the head promptly delivered to the Public Health and Environmental Laboratories for examination);

6. (No change.)

7. Inspect annually, or more often, if necessary, records of dealers in [psittacine] **pet** birds as required by [chapter] **Chapter** 3 of the State Sanitary Code (N.J.A.C. 8:23); and

8. (No change.)

#### Tuberculosis control

(a) The local board of health shall control the spread of tuberculosis and shall:

1. Ensure that all of the tuberculosis control services or services elements listed in the "Guidelines for Ambulatory or Outpatient Tuberculosis Control" (available at the

New Jersey Department of Health [and Senior Services]) are available and accessible to all persons living within the jurisdiction of the local agency;

2. Secure prompt reporting of tuberculosis and transmit reports as required by the State Sanitary Code (N.J.A.C. 8:57[-1.2]) and encourage the reporting of suspects;

3. (No change.)

4. Ensure that [contracts] **contacts** are identified and brought to examination, diagnostic conclusion, and treatment in accordance with the policy of the Department of Health [and Senior Services];

5. Ensure the provision of preventive therapy in accordance with current recommendations of the Department of Health [and Senior Services];

6. Ensure reporting of the current status of diagnosed cases of tuberculosis in accordance with the policy of the Department of Health [and Senior Services] using forms provided by the State;

7. Provide for the discharge from tuberculosis supervision of patients whose treatment has been completed in accordance with current recommendations by the Department of Health [and Senior Services];

8. Provide for testing using currently approved intradermal tuberculin tests, of pupils, teachers, employees, and volunteers in the non-public schools, and for follow-up of those in both the public and non-public schools as recommended in the current edition of "School Tuberculin Testing in New Jersey," published by the Department of Health [and Senior Services]; and

9. (No change.)

## Sexually transmitted diseases

(a) The local board of health shall control sexually transmitted diseases and shall:

1. (No change.)
2. Secure prompt reporting of any case of STD and forward reports immediately to the Department of Health [and Senior Services], [Communicable Disease Field Program] **Division of HIV, STD, and TB Services**, [as required by chapter 2 of the State Sanitary Code (] **in accordance with** N.J.A.C. 8:57[-1.2)];
3. Provide interview and investigation services to priority STD cases in accordance with the policy established by the Department of Health [and Senior Services] and report results of these services on appropriate forms provided by the Department;
- 4.-6. (No change.)

## Human Immunodeficiency Virus (HIV) infection

(a) The local board of health shall administer a planned program to prevent and control HIV infection and shall:

1. Utilizing seroprevalence and case reporting data provided by the Department of Health [and Senior Services], identify ways to reach persons at high risk within the community and develop and implement a strategy to disseminate HIV prevention and control information to these groups;
- 2.-7. (No change.)

### III. Maternal and Child Health Activities

#### Infants and preschool children

(a) The local board of health shall provide health supervision for infants and preschool children and shall:

1. Provide child health conferences for comprehensive preventive health care of infants and preschool children, with particular emphasis on the medically indigent, based upon the current Department of Health [and Senior Services] publication, "Guidelines For the Child Health Conference";

2. Prepare a Child Health Service Report CH-7 or subsequent form number for each session, and submit promptly on at least a quarterly basis to the Maternal and Child Health Program in the [New Jersey] Department of Health [and Senior Services];

- 3.-4. (No change.)

#### Childhood lead poisoning

(a) The local board of health shall provide for the prevention and control of lead poisoning in young children and shall:

1. (No change.)

2. Develop a program plan based on elements [in] **at** (a)1 above and on the degree of risk in the community as identified through the "Community Health Profile" and "Community Hazard Score for Lead Poisoning in Children" issued by the Department of Health [and Senior Services];

- 3.-6. (No change.)

Improved pregnancy outcome

(a) The local board of health shall reduce infant mortality by improving access to prenatal care and related services in accordance with guidelines established by the Department of Health [and Senior Services] and shall:

1.-4. (No change.)

5. Cooperate with the Department of Health [and Senior Services], Newborn Biochemical Screening Program to locate and secure repeat specimens from infants when the sample cannot be obtained through the normal channels of a hospital and/or physician.

#### IV. Adult Health Services Activities

Cancer services

(a) The local board of health shall provide cancer prevention for populations at high risk according to criteria outlined in the Department of Health [and Senior Services'] publication, "Adult Health Services Guidelines," and as identified through the Community Health Profile and shall:

1.-4. (No change.)

5. Provide yearly instruction to three percent of individuals over age 40 in these particular areas:

i. (No change.)

ii. The importance of compliance with the guidelines on colon/rectal cancer prescribed in Department of Health [and Senior Services'] Adult Health Services Guidelines; and

iii. (No change.)

6.-9. (No change.)

#### Diabetes services

(a) The local board of health shall provide for diabetes education services per the Department of Health [and Senior Services] “Adult Health Services Guidelines” and shall:

1.-4. (No change.)

#### Cardiovascular disease services

(a) The local board of health shall provide cardiovascular disease control services according to the Department of Health [and Senior Services] “Adult Health Services Guidelines” and shall:

1.-5. (No change.)

#### Health services for older adults

(a) The local board of health shall provide for a health program at locations selected by the health department which identifies the health needs of adults age 65 and older, and shall:

1. Provide a health needs assessment yearly on one percent of the non-institutionalized elderly in accordance with “Guidelines for Health Services for Older Adults” contained in the Adult Health Services Guidelines (available at the [New Jersey] Department of Health [and Senior Services]);

2.-6. (No change.)

#### V. Health Education/Health Promotion

(a) A structured program shall be provided by the Health Educator or Field Representative, Health Education, in accordance with community health education needs, which shall include health components for Alcohol Abuse Control, Drug Abuse Control, Smoking Prevention and Cessation, Nutrition, Injury Control, and Physical Fitness and Exercise and shall include the following:

1. An assessment of health education needs and identification of target population based on information from the New Jersey Department of Health [and Senior Services] Community Health Profile and other relevant health related data;

2.-8. (No change.)

...

## CHAPTER 57

**REPORTABLE COMMUNICABLE DISEASES, INFECTIONS, AND CONDITIONS;**

**REPORTABLE ZOO NOTIC DISEASES OCCURRING IN ANIMALS;**

**COMMUNICABLE DISEASE REPORTING AND SURVEILLANCE SYSTEM; NEW**



**JERSEY IMMUNIZATION INFORMATION SYSTEM; CHILDHOOD IMMUNIZATION;  
AND IMMUNIZATION OF COLLEGIANS**

**SUBCHAPTER 1. [REPORTABLE COMMUNICABLE DISEASES] GENERAL  
PROVISIONS**

**8:57-1.1 Purpose**

**(a) The purpose of this chapter is to establish standards for:**

**1. Detection, reporting, investigation, and control of communicable diseases, infections, and conditions pursuant to N.J.S.A. 26:4-1 et seq., and reportable zoonotic diseases occurring in animals pursuant to N.J.S.A. 4:19-15.14 et seq., and 26:4-78 et seq.;**

**2. The Communicable Disease Reporting and Surveillance System;**

**3. An automated and electronic immunization registry, known as the “New Jersey Immunization Information System,” pursuant to the Statewide Immunization Registry Act, N.J.S.A. 26:4-131 et seq.;**

**4. Childhood immunization pursuant to N.J.S.A. 26:1A-7 and 26:2-137.1;  
and**

**5. Immunization of collegians entering and attending institutions of higher education pursuant to N.J.S.A. 18A:61D-1 et seq., and 18A:62-15.1 and 15.2.**

**8:57-[1.3]1.2 Definitions**

The following words and terms, as used in this chapter, shall have the following meanings, unless the context clearly indicates otherwise [or another subchapter defines one of the following words or terms differently for the purposes of that subchapter.]:

**“AAP Red Book” means Kimberlin DW, Banerjee R, Barnett ED, Sawyer MH, eds., *Red Book: 2024 Report of the Committee on Infectious Diseases*, 33rd edition, American Academy of Pediatrics (2024), incorporated herein by reference, as amended and supplemented, available at <https://www.aap.org/en/shopaap>.**

**“Academic degree” means academic degree as N.J.A.C. 9A:1-1.2 defines that term.**

**“Academic term” means a semester or quarter within an academic year, as determined by an institute of higher education’s structure.**

**“ACIP recommendations” means the Child and Adolescent Immunization Recommendations, and the Adult Immunization Recommendations.**

**“Administrator” [shall] means the person [having control or supervision over a] who controls or supervises the following types of facility, collectively, unless the context indicates a specific type of facility, in which case, the term applies only to that type of facility:**

- 1. A health care facility[.];**
- 2. A correctional facility[.];**
- 3. A State psychiatric hospital as N.J.S.A. 30:1-7 and 30:4-3.23 define that term;**
- 4. A facility within the jurisdiction of the New Jersey Department of Children and Families;**
- 5. A facility within the jurisdiction of the New Jersey Department of Human Services;**

**6. A facility within the jurisdiction of the Youth Justice Commission of the New Jersey Department of Law and Public Safety;**

**7. A school[.];**

**8. A youth camp[.];**

**9. A child care center[, preschool, or];**

**10. An institution [of higher education];**

**11. A farm or migrant labor camp as N.J.S.A. 34:9A-2 defines those terms, within the jurisdiction of the Department of Labor and Workforce Development pursuant to N.J.S.A. 34:9A-12;**

**12. An insurer as N.J.S.A. 17:23A-1 et seq., specifically 17:23A-13.1, and/or 17B:17-1 et seq., specifically 17B:12-2, uses that term; and/or**

**13. A residential health care facility that is:**

**i. Not located within, and operated by, a licensed health care facility; and**

**ii. Operating pursuant to N.J.S.A. 30:11A-3 and N.J.A.C. 5:27A within the jurisdiction of the Department of Community Affairs.**

**“Adult Immunization Recommendations” means:**

**1. CDC and ACIP, *Recommended Adult Immunization Schedule for ages 19 years or older, United States 2025* (August 7, 2025), including the Tables, Notes, Appendices, and Addendum thereto, incorporated herein by reference, as amended and supplemented, available at**

**<https://www.cdc.gov/vaccines/hcp/imz-schedules>; and**

**2. CDC and National Center for Immunization and Respiratory Diseases, *General Best Practices for Immunization* (General Best Practices) (July 24, 2024), incorporated herein by reference, as amended and supplemented, available at <https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html>.**

**“Advisory Committee on Immunization Practices” or “ACIP” means the Advisory Committee on Immunization Practices, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta, Georgia 30329-4027, Telephone: (404) 639-8836, electronic mail address [acip@cdc.gov](mailto:acip@cdc.gov), and website <https://www.cdc.gov/acip/index.html>.**

**“Animal facility” [shall have the meaning established for] means “facility” [at] as N.J.A.C. 8:23A-1.1 defines that term.**

**[“Bioterrorism” shall have the meaning established at N.J.S.A. 26:13-2.]**

**“Animal rescue organization” means “animal rescue organization” as N.J.S.A. 4:19-15.1 defines that term.**

**“Billing vendor” means an entity that a healthcare professional retains to prepare invoices, claims, and/or statements of services performed by the healthcare professional and submit them to a third party for payment or reimbursement.**

**“Biologic” means a medicinal compound prepared from living organisms and their products.**

**“Bioterrorism” means “bioterrorism” as N.J.S.A. 26:13-1 et seq., specifically 26:13-2, defines that term.**

**“Birthing facility” means a health care facility that provides birthing and newborn care services and includes a “birth center” as N.J.A.C. 8:43G-19.1 defines that term.**

**“Carbapenemase gene” means DNA that encodes to produce enzymes that break down carbapenem drugs, such as blaKPC, blaNDM, blaVIM, blaIMP, blaOXA-48, blaOXA-23, blaOXA-24/40, blaOXA-58, blaDIM, blaSIM, blaGIM, and blaSPM.**

**“Carbapenemase-producing organism” or “CPO” means an organism that produces carbapenemase as evidenced by any of the following laboratory results:**

- 1. Positive phenotypic test detecting or indicating carbapenemase production;**
- 2. Positive genotypic test detecting one or more carbapenemase genes using a validated laboratory-developed platform; or**
- 3. Positive culture-independent diagnostic test detecting one or more carbapenemase genes.**

**“Case” means a person who:**

- i. Has, or is suspected of having, a disease, infection, or condition that is reportable pursuant to N.J.A.C. 8:57-2; and/or**
- ii. Is, or is suspected of being, infected with an organism that is reportable pursuant to N.J.A.C. 8:57-2.**

**“Catch-up Schedule” means *Table 2, Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2025*, within the Child and Adolescent Vaccine Recommendations.**

**“CDC Laboratory Recommendations for Syphilis Testing” means Papp JR, Park IU, Fakile Y, Pereira L, Pillay A, Bolan GA, *CDC Laboratory Recommendations for Syphilis Testing, United States, 2024*, MMWR Recomm Rep 2024; 73 (No. RR-1):1–32 (February 8, 2024), incorporated herein by reference, as amended and supplemented, available at <http://dx.doi.org/10.15585/mmwr.rr7301a1> and <https://www.cdc.gov/mmwr/volumes/73/rr/pdfs/rr7301a1-H.pdf>.**

**“Centers for Disease Control and Prevention” or “CDC” means the Centers for Disease Control and Prevention of the Public Health Service of the United States Department of Health and Human Services.**

**“Certified animal control officer” [shall have the meaning established at] means “certified animal control officer” as N.J.S.A. 4:19-15.1 and N.J.A.C. 8:23A-2.1 define that term.**

**“Child and Adolescent Immunization Recommendations” means:**

**1. CDC and ACIP, *Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States 2025* (August 7, 2025), including the Tables, Notes, Appendices, and Addenda thereto, incorporated herein by reference, as amended and supplemented, available at <https://www.cdc.gov/vaccines/hcp/imz-schedules>; and**

2. CDC and National Center for Immunization and Respiratory Diseases, *General Best Practices for Immunization* (General Best Practices) (July 25, 2024), incorporated herein by reference, as amended and supplemented, available at <https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html>.

“Child care center” [shall have the meaning established at N.J.A.C. 10:122-1.2.]  
means:

1. A “child care center,” as the “Child Care Center Licensing Act,” N.J.S.A. 30:5B-1 et seq., specifically at 30:5B-3, defines that term; and
2. An “early childhood program” as N.J.A.C. 3A:52, specifically N.J.A.C. 3A:52-1.2 and 1.4, and 6A:14-1.3, define that term.

“Class B1 or B2 referral” means a referral from the Division of Global Migration Health, CDC, to the Department of a person who is a refugee, parolee, asylee, or recent legal immigrant to the USA, and whom an overseas medical provider screened and classified as either Class B1, meaning the individual has signs or symptoms, physical exam findings, or chest x-ray findings suggestive of tuberculosis, but has negative sputum smears and cultures, or Class B2, meaning the individual has a positive test for tuberculosis, but other evaluation for active tuberculosis is negative.

“Clinical laboratory” [shall have the meaning established at] or “laboratory” means “clinical laboratory” as N.J.S.A. 45:9-42.27 defines that term.

“Clinical laboratory director” [shall have the meaning established at] means “clinical laboratory director” as N.J.S.A. 45:9-42.27 defines that term.

**“Collegian” means an undergraduate or a graduate student of an institution of higher education.**

**“Commissioner” means the Commissioner of the [New Jersey] Department of Health [and Senior Services or his or her designee].**

**“Communicable disease” means [an illness due to a specific infectious agent or its toxic products which arises through transmission of that agent or its products from an infected person, animal, or inanimate reservoir to a susceptible host, either directly or indirectly through an intermediate plant or animal host, vector, or the inanimate environment] “communicable disease” as N.J.S.A. 26:4-1 defines that term.**

**“Communicable Disease Reporting and Surveillance System” or “CDRSS” means a secure electronic system that the Department uses and maintains, and through which entities with reporting obligations pursuant to this chapter engage in disease surveillance and case management, accessible at <https://cdrss.nj.gov>.**

**“Communicable Disease Service” or “CDS” means the Communicable Disease Service of the Division of Epidemiology, Environmental and Occupational Health of the Public Health Services Branch of the Department, for which the mailing address is PO Box 369, Trenton, NJ 08625-0369, the telephone number during business hours is (609) 826-5964, the telephone number after business hours is (609) 392-2020, the telefacsimile number is (609) 826-4874, and the webpage is <https://www.nj.gov/health/cd>.**

**“Condition” means a diagnosable health issue or illness identified through clinical evaluation, including the presence of characteristic signs and symptoms, diagnostic testing, or other medically accepted criteria.**



**"Contact" means a person whom a health official identifies as having had exposure:**

- 1. To a case of suspected or confirmed infectious or potentially infectious tuberculosis; and**
- 2. That is sufficient in both duration and proximity to make the person at increased risk for recent transmission of latent tuberculosis infection.**

**"Contraindication" means a condition in a person that increases the risk for a serious adverse reaction to a vaccine, under which a vaccine should not be administered to the person, as specified in the General Guidelines.**

- 1. As used in this chapter, the term "contraindication" may include a precaution, provided the statement that is required pursuant to N.J.A.C. 8:57-4.7 or 6.7:**

- i. Identifies the basis of the precaution, as specified in the General Guidelines and the period of deferral; and**
  - ii. Contains a patient-specific analysis that explains how the risk of an adverse reaction to a vaccine would outweigh the benefit of protection from the vaccine.**

**"Cosmetic establishment" means "cosmetic establishment" as N.J.S.A. 24:15-1 defines that term.**

**"Council of State and Territorial Epidemiologists" or "CSTE" means the entity by that name for which the mailing address is CSTE, 2635 Century Parkway**

NE, Suite 700, Atlanta, GA 30345, the telephone number is (770) 458-3811, and the website is [www.cste.org](http://www.cste.org).

“Department” means the New Jersey Department of Health [and Senior Services.] **for which the mailing or other transmittal information is as follows, unless otherwise specified:**

- 1. To the Division of HIV, STD, and TB Services as specified at N.J.A.C. 8:65, with respect to HIV-related submittals;**
- 2. To the Division of HIV, STD, and TB Services with respect to submittals related to sexually transmitted diseases as specified at N.J.A.C. 8:57-2 and/or tuberculosis as specified at N.J.A.C. 8:57-5;**
- 3. To the CDS with respect to submittals related to N.J.A.C. 8:57-2, other than sexually transmitted diseases;**
- 4. To the VPDP with respect to submittals related to N.J.A.C. 8:57-4 or 6; and**
- 5. To the NJIIS with respect to submittals related to N.J.A.C. 8:57-3.**

“Designated agent” means a person to whom a site administrator delegates responsibility pursuant to N.J.A.C. 8:57-3.8(b) to:

- 1. Submit information to the NJIIS;**
- 2. Obtain access to information in the NJIIS;**
- 3. Receive information from the NJIIS; and/or**
- 4. Review information contained in the NJIIS.**

“Directory of Local Health Departments in New Jersey” means Division of Local Public Health, Department, *Directory of Local Health Departments in New*

*Jersey* (2025), which is an online resource available at

<http://www.nj.gov/health/lh/community>.

“Division of HIV, STD, and TB Services” means the Division of HIV, STD, and TB Services of the Public Health Services Branch of the Department, for which the mailing address is Division of HIV, STD, and TB Services, New Jersey Department of Health, PO Box 363, Trenton, NJ 08625-0363, website

<https://www.nj.gov/health/hivstdtb>, telephone:

1. HIV program (609) 984-5940;
2. Tuberculosis program (609) 826-4878; and
3. STD program (609) 826-4869.

“Division of Local Public Health” means the Division of Local Public Health of the Public Health Services Branch of the Department, for which the mailing address is Division of Local Public Health, New Jersey Department of Health, PO Box 360, Trenton, NJ 08625-0360, the website is <https://www.nj.gov/health/lh>, and the telephone number is (609) 292-4993.

“DNA” means deoxyribonucleic acid.

“Domestic companion animal” [shall] means [any domestic dog, cat, ferret, bird, reptile, rodent, rabbit not raised for food or fiber, or other animal kept primarily as a household pet for personal appreciation and companionship.

1. Domestic] “domestic companion animal” as N.J.S.A. 4:19A-16 and 45:16-8.3 define that term and includes feral and free-roaming dogs and cats.

[2.] 1. Domestic companion animal does not include:

i. Livestock and aquaculture as defined at N.J.A.C. 2:2-1.1 and regulated by the New Jersey Department of Agriculture; and

ii. Animals regulated [under] **pursuant to** the Animal Welfare Act, 7 U.S.C. [§§2131,] **§§ 2131** et seq., and the regulations promulgated thereunder at 9 CFR [§§1.1] **1.1** through 4.11 as research animals.

**“Drug establishment” means “drug establishment” as N.J.S.A. 24:15-1 defines that term.**

**“EBC” means the electronic birth certificate generated through the Vital Events Registration and Information platform.**

**“Electronic case reporting” means the automated, real-time exchange of case report information between an electronic recordkeeping system for health records and a public health agency.**

**“Electronic health record” or “EHR” means an individual patient’s comprehensive digital medical record, or a portion thereof.**

**“Electronic health record vendor” or “EHR vendor” means an entity that provides software and/or ancillary maintenance and administrative services to maintain an electronic system of recordkeeping for health records.**

**“Electronic laboratory reporting [(l) or “ELR(l)]” means submission of laboratory test results [through] in an electronic file to [the Department’s Office of Information Technology Services] a dedicated secure server [via Secure File Transfer protocol (l) of the Department using a secure file transfer protocol (SFTP), [Virtual Private Network] virtual private network (VPN), or any other secure transmission acceptable to the Department.**

1. The **reporting entity shall submit the electronic file in the** format [of the electronic file must be one that is] specified in [the Electronic Laboratory Reporting Technical Manual, available at subchapter Appendix A.

2. Further information on transmission protocols, file formats, laboratory coding, test plans to initiate electronic laboratory reporting with the Department and contact information can be found in the Electronic Laboratory Reporting Technical Manual, available at subchapter Appendix A.] **either:**

**i. The HL7 Implementation Guide; or**

**ii. The NJ ELR Implementation Guide.**

“Electronic reporting” means submission of data [via] **by means of direct** web entry into the [Department’s Communicable Disease Reporting and Surveillance System (]CDRSS[)].

[1. Information regarding CDRSS is available in the CDRSS Information Guide, which is written and published by the Communicable Disease Service, New Jersey Department of Health and Senior Services and is available by written request to the Communicable Disease Service, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369 or online through the Department’s web page at <http://www.state.nj.us/health/cd/index.html>.]

**“Endemic level” means the usual prevalence of a given disease within a geographic area.**

“Ethnicity” means cultural background, [for example,] **such as** Hispanic or Latino.

[“Health care facility” shall have the meaning established at N.J.S.A. 26:2H-2.]

**“Farm or migrant labor camp” means a “farm labor camp” or a “migrant labor camp” as N.J.S.A. 34:9A-2 defines those terms.**

**“FDA Food Code” means United States Food and Drug Administration, *Food Code, 2022 Recommendations of the United States Public Health Service, Food and Drug Administration* (January 18, 2023), incorporated herein by reference, as amended and supplemented, available at <https://www.fda.gov/food/fda-food-code/food-code-2022>.**

**“Food employee” means “food employee” as the FDA Food Code defines that term.**

**“Food establishment” means “food establishment” as N.J.S.A. 24:15-1 defines that term.**

**“Full-time collegian” means a collegian whom an institution of higher education enrolls for the number of credit hours or courses that the institution of higher education categorizes as full-time matriculation.**

**“Health benefits plan” means policy, contract, certificate, or agreement offered or issued by a health carrier to provide, deliver, arrange for, pay for, or reimburse any costs of healthcare services.**

**“Healthcare Effectiveness Data and Information Set®” or “HEDIS®” means the HEDIS® measurement tool created by the National Committee for Quality Assurance to collect data about the quality of care and services that health plans provide, and which is available from the National Committee for Quality Assurance, for which the mailing address is 1100 13th St NW, Third Floor,**

Washington, DC 20005, the telephone number is (202) 955-3500, and the website is [www.ncqa.org](http://www.ncqa.org).

**“Health care facility” means “health care facility” as N.J.S.A. 26:2H-2 defines that term.**

**“Healthcare personnel” means:**

**1. Paid and unpaid persons serving in healthcare settings who have potential direct or indirect exposure to patients or infectious materials, including:**

**i. Bodily substances (such as blood, tissue, and certain body fluids);**

**ii. Contaminated medical supplies, devices, and equipment;**  
**and**

**iii. Contaminated environmental surfaces or contaminated air;**

**2. Depending on a person’s assigned job functions, emergency medical services personnel, advanced practice nurses, nurses, nursing assistants, physicians, physician assistants, technicians, therapists, phlebotomists, pharmacists, students and trainees, and contractual staff who work in, but are not employees of, a health care facility; and**

**3. Persons who work in a health care facility, but do not engage in direct patient care and who have potential exposure to infectious agents that can be transmitted among direct care workers and patients, such as the following types of workers: clerical, dietary, environmental services,**

**laundry, security, maintenance, engineering and facilities management, administrative, billing, and volunteer.**

**“Healthcare professional” means a person who holds a credential to provide health services pursuant to Title 45 of the New Jersey Revised Statutes and its implementing rules, and whose authorized scope of practice includes the diagnosis of illness or disease, including a communicable disease, infection, or condition in humans.**

...

[“Health officer” means a person who is licensed as a health officer pursuant to N.J.S.A. 26:1A-38 et seq. and N.J.A.C. 8:7-1 and is employed full-time, as the chief executive officer of a municipal, regional, county or contractual health agency, or his or her designee.

1. This person is responsible for evaluating health problems, planning appropriate activities to address these health problems, developing necessary budget procedures to finance these activities, and directing staff to carry out these activities efficiently and economically.]

**“Health History and Appraisal form” means the New Jersey Department of Education, *State of New Jersey Health History and Appraisal* (Form A-45), incorporated herein by reference, as amended and supplemented, available at <https://www.nj.gov/education/safety/health/records>.**

**“Health information exchange” or “health information network” means “health information network or health information exchange” as 45 CFR 171.102 defines that term (hereinafter referred to respectively as an “HIE” or an “HIN”).**



“Health information organization” or “HIO” means a legal entity comprising at least two, distinct, corporate entities that share and/or exchange health information and other patient care data.

“Health officer” means “health officer” as N.J.S.A. 26:3A2-3 defines that term.

1. The Directory of Local Health Departments in New Jersey sets forth the mailing address, telephone number, and, if available, the website and other transmittal information for each local health agency and health officer in the State.

“HL7 Implementation Guide” means Health Level Seven International, *HL7 Version 2.5.1 Implementation Guide: Electronic Laboratory Reporting to Public Health, Release 1 (US Realm)*, (2021), incorporated herein by reference, as amended and supplemented, available at [https://www.hl7.org/implement/standards/product\\_brief.cfm?product\\_id=98](https://www.hl7.org/implement/standards/product_brief.cfm?product_id=98), or from Health Level Seven International, 3300 Washtenaw Avenue, Suite 227, Ann Arbor, MI 48104, telephone (734) 677-7777, website <https://www.hl7.org>.

“Hospital” means a hospital as N.J.A.C. 8:43G-1.3 defines that term.

“Hospital-onset [methicillin-resistant *Staphylococcus aureus* (]MRSA[)] invasive infection[s]” means **an [isolation] identification of the presence of MRSA in a specimen** from a normally sterile site, such as blood, [cerebro-spinal fluid, or] **cerebrospinal**, joint, pleural, or pericardial fluid, greater than 48 hours after admission to [the] **a** hospital.

[“Influenza virus, novel strain” shall mean a virus subtype that is different from the human influenza A viruses that have been circulating that influenza season.]

**“Immunization” means:**

- 1. An immunizing agent, typically referred to as a vaccine; or**
- 2. The process and procedures associated with introducing an immunizing agent into a person to prevent disease, also referred to as a vaccination.**

**“Infection” means the invasion and multiplication of a pathogenic microorganism in the body, which may include a bacterium, virus, fungus, parasite, or other agent capable of causing disease.**

**“Influenza A virus, novel” means “novel influenza A virus infection” as the Surveillance Case Definition defines that term.**

**“Institution” means a health care facility, a youth camp, a child care center, a school, and an institution of higher education.**

**“Institution of higher education” or “IHE” means a public or independent institution of higher education in New Jersey and includes on-campus and off-campus facilities, premises, and events that the IHE authorizes or sponsors, or at which collegians might congregate.**

**1. An IHE does not include an institution that:**

- i. Exclusively provides instruction by means of independent home study and/or electronic media; and**

ii. Does not sponsor or authorize, or require collegians to congregate at, on-campus or off-campus facilities or events for instructional, educational, or extracurricular activity purposes.

**“Insurer” means “insurer” as N.J.S.A. 17:23A-13.1 or 17B:17-2 use that term.**

**“Invalid dose” means a dose of a vaccination that, in accordance with N.J.A.C. 8:57-4 and/or applicable ACIP recommendations:**

- 1. Is age-inappropriate for a recipient when the recipient receives the dose; and/or**
- 2. Is spaced inappropriately following a prior dose that the recipient received.**

**“Invasive disease” means an infection that [has invaded] **invades** body tissues and an **identification of the disease’s** causative bacterium [has been isolated] in a **specimen** from a **normally sterile site, such as** blood, **or** cerebrospinal [fluid], **joint, pleural, or pericardial** fluid [or other normally sterile site].**

**[“Isolation” shall have the meaning established at N.J.S.A. 26:13-2.**

**“Kennel” shall have the meaning established at N.J.A.C. 8:23A-1.1.**

**“Local health department” means the board of health of a region or municipality or the boards, bodies, or officers in such region or municipality lawfully exercising any of the powers of a local board of health under the laws governing such region or municipality.]**

**“Isolation” means “isolation” as N.J.S.A. 26:13-2 defines that term.**

**“Line list” means a table summarizing information about cases associated with an outbreak, the required content of which the Department identifies upon notification of the outbreak, depending on the disease and the manner of disease transmission, in which each row represents a specific case (containing identifying information), and each column represents a specific demographic (such as age or race), clinical data (such as dates of onset of symptoms, symptomology, and outcome), or epidemiologic characteristic about each case (such as location at which exposure occurred and occupational information).**

**“Local health agency” means “local health agency” as N.J.S.A. 26:2F-3 defines that term.**

**1. The Directory of Local Health Departments in New Jersey sets forth the mailing address, telephone number, and, if available, the website and other transmittal information for each local health agency and health officer in the State.**

**“Local Information Network and Communications System” or “LINCS” means “Local Information Network and Communications System” or “LINCS” as N.J.A.C. 8:52 defines that term.**

**“Logical Observation Identifiers Names and Codes®,” or “LOINC” means Regenstrief Center for Biomedical Informatics, *Logical Observation Identifiers Names and Codes®*, version 2.80 (February 2025), incorporated herein by reference, as amended and supplemented, available at <http://www.loinc.org>.**

**“Manager” means the person who has control or supervision of an animal facility or animal rescue organization.**

**“Maternal and Child Health Consortia” or “MCHC” means “Maternal and Child Health Consortia” or “MCHC” as N.J.A.C. 8:33C-1.2 defines that term.**

“Methicillin-resistant *Staphylococcus aureus* [(])” or “MRSA[(])” means any *Staphylococcus aureus* isolate with resistance to oxacillin or methicillin, detected and defined according to the [Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement (M100-S17) available as set forth at N.J.A.C. 8:57-1.2(b)] **PSAST**.

[“Multidrug-resistant organisms” or “MDROs” means bacteria (excluding *Mycobacterium tuberculosis*) that are resistant to one or more classes of antimicrobial agents and usually are resistant to all but one or two commercially available antimicrobial agents (for example, MRSA, vancomycin-resistant enterococcus (VRE), extended spectrum beta-lactamase (ESBL)-producing or intrinsically resistant gram-negative bacilli).

“Neonatal” shall mean a child less than 90 days of age.

“Nosocomial infection” means an infection occurring in a patient in a health care facility and in whom it was not present or incubating at the time of admission, or the residual of an infection acquired during a previous admission.

1. This term includes infections acquired in the health care facility but appearing after discharge, and also such infections among the staff of the facility.]

**“Minor” means a person who has not attained majority status pursuant to N.J.S.A. 9:17B-1 et seq., that is, a person who is under the age of 18 years.**

**“Morbidity and Mortality Weekly Report” or “MMWR” means the serial publication by that name published by the Office of Science, CDC, United States Department of Health and Human Services, Atlanta, GA 30329-4027, available at <http://www.cdc.gov/mmwr/index.html>.**

**“MRSA laboratory identification event” or “MRSA LabID event” means a laboratory’s identification of MRSA in a blood sample.**

**“Neonatal” means occurring in a newborn.**

**“Newborn” means a minor who is 28 or fewer days old.**

**“New Jersey Immunization Information System” or “NJIS” means the registry established pursuant to N.J.S.A. 26:4-131 et seq.**

**“NJ ELR Implementation Guide” means Department, *Electronic Laboratory Reporting Inbound HL7 Implementation Guide*, Version 2.40 (June 26, 2014) (hereinafter referred to as the NJ ELR Implementation Guide), as amended and supplemented, at <https://cdrss.nj.gov/cdrss/common/cdrssELREnrollment>.**

**“NJIS access level” means the information in, and functions of, the NJIS that an NJIS user is authorized to view, enter, change, and/or administer, from among the following levels:**

**1. “General reader access” means access to view registrant records and generate standard reports;**

**2. “General user access” means general reader access and access to modify or add information to existing registrant records, add new registrants, maintain vaccine inventory, and perform outreach functions to registrants for whom the NJIS site has primary responsibility;**

**3. “NJIS site administrator access” means general user access, plus access to modify critical fields and maintain vaccine inventory control records;**

**4. “Educational facility user access” means general reader access, plus access to modify or add information to existing registrant records, add new registrants, and perform outreach functions to registrants who are then-enrolled, and/or have a pending application to enroll, in the educational facility, which is an institution, school, or child care center; or**

**5. “Health benefits plan access” means access for health benefits plan users to run HEDIS® and other data quality assurance reports, and for the purposes established at N.J.S.A. 26:4-134i(7).**

**“NJIS Personal Immunization Record” means a paper or electronic version of a registrant's immunization and preventive health screening information that is a true and accurate representation of the information in the NJIS and that is not a part of a minor's educational record.**

**“NJIS site” coordinates the administrative functions and activities for its NJIS users and means one of the following entities:**

- 1. A healthcare professional;**
- 2. An early childhood program;**
- 3. A school;**
- 4. An institution;**
- 5. A hospital or health care facility;**
- 6. A health benefits plan;**

7. A billing and practice management vendor;
8. A private health or social services program;
9. A local health agency of a municipal subdivision of New Jersey;
10. A State agency;
11. An EHR vendor authorized pursuant to N.J.S.A. 26:4-134(c) and (g) and N.J.A.C. 8:57-3.9; and
12. An HIE, HIN, or HIO.

**“NJIS site administrator”** means a person who enrolls an eligible entity in the NJIS as an NJIS site and who serves as liaison to the Department with respect to enrollment of NJIS users at the NJIS site and resolution of NJIS administrative and information technology matters.

**“NJIS user”** means a person who, acting on behalf and pursuant to the authority of an NJIS site, obtains access or submits information to, and/or receives or reviews information contained in, the NJIS.

**“NJIS webpage”** means the webpage of the NJIS at <https://www.njis.nj.gov/core/web/index.html#/home>.

**“NJ Medicaid Program”** means the health insurance program administered by the Division of Medical Assistance and Health Services in the Department of Human Services pursuant to the New Jersey Medical Assistance and Health Services Act, N.J.S.A. 30:4D-1 et seq., also known as NJ FamilyCare.

**“Notifiable Condition List”** means CDC, *National Notifiable Infectious Diseases of the National Notifiable Diseases Surveillance System*, available at <https://ndc.services.cdc.gov>.



**“Nucleic acid amplification test” means a laboratory test that detects and amplifies specific DNA or RNA sequences for the organism being tested.**

**“Nursing home” or “nursing facility” means “nursing home” or “nursing facility” as N.J.A.C. 8:33H-1.2 defines that term.**

**“Official State of New Jersey School Immunization Record” means:**

**1. Standard School/Child Care Center Immunization Record, provided at N.J.A.C. 8:57 Appendix K, incorporated herein by reference;**

**2. Health History and Appraisal form or any equivalent electronic record maintained by a school district pursuant to N.J.A.C. 6A:16-2 or 6A:32-7; or**

**3. A paper or electronic version of an NJIIS Personal Immunization Record, including a record of the Docket® mobile phone application or Docket® website application at <https://myhealthnj.com>, or a successor application administered by an entity with which the Department may elect to enter into a cooperative data sharing agreement.**

**“Outbreak” means [any]:**

**1. An unusual occurrence of a disease; or [any]**

**2. An occurrence of a disease above [background or] its applicable endemic level[s].**

**[1. “Endemic level” means the usual prevalence of a given disease within a geographic area.**

**2. “Suspected outbreak” means an outbreak, which appears to meet the definition of an outbreak, but has not yet been confirmed.**

“Overlap agent or toxin” shall have the meaning established at N.J.S.A. 26:13-2.

Pediatric” means a person who has not yet attained the age of 18 years.

“Pet shop” shall have the meaning established at N.J.A.C. 8:23A-1.1.

“Pound” shall have the meaning established at N.J.A.C. 8:23A-1.1.

“Public health emergency” shall have the meaning established at N.J.S.A. 26:13-

2.

“Quarantine” shall have the meaning established at N.J.S.A. 26:13-2.]

**“Pan-non-susceptible organism” means an organism that is resistant or not susceptible to all antimicrobial drugs that a laboratory introduces to the organism to assess antimicrobial susceptibility.**

**"Parent" means:**

**1. A biological parent;**

**2. An adoptive parent;**

**3. A "resource family parent" as N.J.S.A. 30:4C-26.4 defines that term; and**

**4. A person or an entity serving as guardian of the person of a minor pursuant to an applicable statute, court rule, court order, or duly executed delegation of parental rights, including a kinship legal guardian pursuant to N.J.S.A. 3B:12A-1 et seq.**

**“Part-time collegian” means a collegian whom an institution of higher education enrolls for the number of credit hours or courses that the institution of higher education categorizes as part-time matriculation.**

**“Pediatric” means occurring in a minor.**

**“Pharmacist” means “pharmacist” as N.J.S.A. 45:14-41 defines that term.**

**“Point-of-care test” or “POC test” means a diagnostic test performed at or near the place at which a specimen is collected that provides results within minutes, such as at the office of a healthcare professional, a pharmacy, or a school.**

**“Polymerase chain reaction” or “PCR” means a type of nucleic acid amplification test that is used to make multiple copies of a segment of DNA.**

**“Practice management vendor” means a company that develops and sells electronic information technology applications or software primarily relating to patient medical recordkeeping.**

**“Precaution” means a precaution as the term is described at the CDC and the National Center for Immunization and Respiratory Diseases, *General Best Practices for Immunization* (General Best Practices), incorporated herein by reference, as amended and supplemented, available at <https://www.cdc.gov/vaccines/hcp/imz-best-practices/index.html>.**

**“PSAST” means Clinical and Laboratory Standards Institute (CLSI), *CLSI M100™ Performance Standards for Antimicrobial Susceptibility Testing, 35th edition* (2025), available at <https://clsi.org>, specifically <https://clsi.org/shop/standards/m100>, incorporated herein by reference, as amended and supplemented.**

**“Public Health and Environmental Laboratories” or “PHEL” means the Public Health and Environmental Laboratories of the Public Health Services Branch of the Department, for which the telephone number during business**

hours is (609) 406-6860 and after business hours is (609) 392-2020, website: <https://www.nj.gov/health/phe1>, and for which the delivery addresses are:

**1. For regular mail deliveries:**

**Public Health and Environmental Laboratories  
NJ Department of Health  
PO Box 361  
Trenton, NJ 08625-0361**

**2. For specimen deliveries:**

**Specimen Receiving  
Public Health and Environmental Laboratories  
NJ Department of Health  
3 Schwarzkopf Drive  
Ewing, NJ 08628**

**“Public health emergency” means “public health emergency” as N.J.S.A. 26:13-2 defines that term.**

**“Pupil” or “student” means a minor enrolled in, or attending, any school in the State.**

**“Quarantine” means quarantine as N.J.S.A. 26:4-1 et seq., and 26:13-1 et seq., define and describe that term.**

**“Rabies post-exposure prophylaxis administration” or “rabies PEP administration” means the administration of rabies immune globulin and/or rabies vaccine to persons exposed and/or potentially exposed to the rabies virus to prevent infection.**

**“Referral laboratory” means a laboratory that receives a specimen from another laboratory and that performs one or more tests on such specimen.**

**“Registrant” means a person as to whom the NJIIS contains a record of the person’s demographic, immunization, or preventive health screening information.**

**“Religious-affiliated facility” means a self-identified association of a school or child care center with:**

- 1. A religion, denomination, church, or faith;**
- 2. Religious or spiritual beliefs and practices; or**
- 3. A religious group.**

**“RNA” means ribonucleic acid.**

**“SARS” means sudden acute respiratory syndrome.**

**“Satellite emergency department” means “satellite emergency department” as N.J.A.C. 8:43G-36.2 defines that term.**

...

**“Serologic test” means a laboratory test performed on blood specimens to measure antibodies and other immunological properties.**

**“Sexually transmitted disease” means **infection with** syphilis, gonorrhea, chancroid, lymphogranuloma venereum, granuloma inguinale [and chlamydial genital infections], or *Chlamydia trachomatis*.**

**[“Shelter” shall have the meaning established at N.J.A.C. 8:23A-1.1.]**

**“Site administrator” means the person at an NJIIS site who undertakes onsite coordination and oversight of the site’s access to and use of the NJIIS and who holds authorization to accept official notices regarding the NJIIS.**

**“SNOMED” means National Library of Medicine, National Institutes of Health, United States Department of Health and Human Services, *Systematized Nomenclature of Medicine—Clinical Terms (SNOMED-CT) United States (US) Edition*, Version 20250301 (March 2025), incorporated herein by reference, as amended and supplemented, available at [https://www.nlm.nih.gov/healthit/snomedct/us\\_edition.html](https://www.nlm.nih.gov/healthit/snomedct/us_edition.html).**

**“Surveillance case definition” means CDC, *Surveillance Case Definitions for Current and Historical Conditions* (April 12, 2024), incorporated herein by reference, as amended and supplemented, available at <https://ndc.services.cdc.gov>.**

**“United States of America” or “USA” means:**

- 1. The 50 states;**
- 2. The five territories of the USA, which are:**
  - i. American Samoa;**
  - ii. The Commonwealth of the Northern Mariana Islands;**
  - iii. Guam;**
  - iv. Puerto Rico; and**
  - v. The United States Virgin Islands; and**
- 3. The three Freely Associates States Under Compact of Free Association with the USA, which are:**
  - i. The Federated States of Micronesia;**
  - ii. The Republic of the Marshall Islands; and**
  - iii. The Republic of Palau.**

**“Vaccine” means an agent that is:**

- 1. Composed of substances derived and/or manufactured from a biologic; and**
- 2. Administered to persons to evoke an immune response to prevent illnesses associated with one or more specific pathogens.**

**“Vaccine-Preventable Disease Program” or “VPDP” means the program within the Department that is responsible for administering and overseeing the operations of the NJIIS, and for which the mailing address is Vaccine-Preventable Disease Program, NJ Department of Health, PO Box 369, Trenton, NJ 08625-0369, the telephone number during business hours is (609) 826-4861, and the website is <https://www.nj.gov/health/cd/vpdp.shtml>.**

**“Valid dose” means a dose of a vaccination that, in accordance with, as applicable, N.J.A.C. 8:57-4 and 6 and the ACIP recommendations:**

- 1. Is age-appropriate for the recipient when the recipient receives the dose; and**
- 2. Is spaced appropriately following a prior dose administered to the recipient.**

**“[Vancomycin-intermediate *Staphylococcus aureus* (VISA) and]**

**“Vancomycin-resistant *Staphylococcus aureus* [(]” or “VRSA[)]” mean any *Staphylococcus aureus* isolate with [intermediate susceptibility or] resistance to vancomycin, detected [and defined according to Clinical and Laboratory Standards Institute’s Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement (M100-S17)] **in accordance with PSAST.****

“Veterinarian” [shall] means a person [licensed by] **whom** the State Board of Veterinary Medical Examiners **licenses** to engage in the practice of veterinary medicine, surgery, and dentistry, pursuant to [N.J.A.C. 13:44] **N.J.S.A. 45:16-1 et seq.**

**“Veterinary diagnostic laboratory” means a facility used for the performance of chemical, bacteriologic, virologic, parasitologic, serologic, hematologic, immunohematologic, biophysical, cytologic, or other examinations of materials derived from animals for the purpose of yielding information for the diagnosis, prevention, or treatment of disease, or the assessment of medical condition in animals.**

**“Veterinary diagnostic laboratory director” means a person who is responsible for the administration of the technical and scientific operation of a veterinary diagnostic laboratory, including, but not limited to, supervision of testing procedures and result reporting.**

**“Virtual private network” or “VPN” means a method to provide secure access to a remote computer over the internet employing encryption.**

“Zoonotic disease” [shall] means a communicable disease **that is** transmissible from vertebrate animals to humans, and may include transmission by intermediate vectors, such as mosquitoes or ticks.

**8:57-1.3 (Reserved)**



8:57-[1.15]**1.4 Enforcement**

(a) A [physician] **person or entity whom this chapter obliges, and who fails or refuses,** to report pursuant to [the requirements of this subchapter shall be], **or otherwise comply with, this chapter is** subject to [a] fines [as set forth at] **pursuant to applicable laws, including N.J.S.A. 26:1A-10, 26:4-129, and 130, [or 26:1A-10] and may be subject to disciplinary or enforcement measures in accordance with applicable laws and standards of credentialing bodies and other entities with jurisdiction.**

1. The Department may issue a written [notification] **warning to the noncompliant person or entity the person or entity** of [this failure and a warning to comply] **the noncompliance** prior to initiating [any other] **an** enforcement action.

2. The Department may [also] report the [physician's] failure **or refusal** to comply with [the provisions of] this [subchapter] **chapter** to [the New Jersey Board of Medical Examiners, which may initiate disciplinary actions as set forth at N.J.A.C. 13:35-6.24] **applicable professional boards and/or regulatory agencies that have licensing or credentialing jurisdiction over the noncompliant person or entity.**

[(b) An administrator of a health care facility who fails to report pursuant to the requirements of this subchapter shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report the health care facility's failure to comply with the provisions of this subchapter to the New Jersey Department of Health and Senior

Services, Division of Health Care Quality and Oversight, which may initiate enforcement actions as set forth at N.J.A.C. 8:43E-3.

(c) A clinical laboratory director who fails to report pursuant to the requirements of this subchapter shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report the clinical laboratory director's failure to comply with the provisions of this subchapter to the New Jersey Department of Health and Senior Services, Clinical Laboratory Improvement Service which may initiate enforcement actions as set forth at N.J.S.A. 45:9-42.40, 42.41, and 42.43.

(d) A veterinarian, certified animal control officer, or manager of an animal facility who fails to report pursuant to the requirements of this subchapter shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report a veterinarian's failure to comply with the provisions of this subchapter to the New Jersey Board of Veterinary Medical Examiners, which may initiate disciplinary actions as set forth at N.J.S.A. 45:1-21.

(e) A health officer who fails to report pursuant to the requirements of this subchapter shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report the health officer's failure to comply with the provisions of this subchapter to the Department's Public Health Licensing and Examination Board, which may initiate disciplinary actions as set forth at N.J.A.C. 8:7-1.7 and N.J.S.A. 26:1A-43.

(f) A child care center or preschool, which fails to report pursuant to the requirements of this subchapter shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report the administrator's failure to comply with the provisions of this subchapter to the New Jersey Department of Human Services, Office of Licensing, which may initiate disciplinary actions as set forth at N.J.A.C. 10:122-2.4.

(g) A school or institution of higher education, which fails to report pursuant to the requirements of this subchapter, shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 130, or 26:1A-10.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

(h) The administrator of a youth camp, which fails to report pursuant to the requirements of this subchapter, shall be subject to a fine as set forth at N.J.S.A. 26:4-129 and 26:4-130.

1. The Department may issue a written notification of this failure and a warning to comply prior to initiating any other enforcement action.

2. The Department may also report the administrator's failure to comply with the provisions of this subchapter to the New Jersey Department of Health and Senior Services, Division of Consumer and Environmental Health, which may initiate disciplinary actions as set forth at N.J.A.C. 8:25-14.4 and 14.5.]

8:57-[4.24]1.5 [Penalties] **State Sanitary Code; penalties**

**(a) This chapter is part of the State Sanitary Code.**

**(b)** Each violation of this [subchapter shall be] **chapter is** subject to [the penalty set forth at] **penalties and sanctions in accordance with applicable law, including, but not limited to, N.J.S.A. 26:1A-10, 26:4-129, 26:4-137, and other applicable laws.**

**8:57-1.6 (Reserved)**

8:57-[1.14]1.7 Confidentiality

**(a) [The] A record and/or report[s made] that the Department and/or a local health agency makes, maintains, receives, or files** pursuant to this [subchapter] **chapter** shall be used only by the local health [department] **agency**, the Department, and [such] other [agencies as] **entities the Commissioner** may [be designated by the Commissioner] **designate in accordance with applicable law and/or** to carry out mandated duties, including the duty to control and suppress communicable infectious diseases.

[(b) Information the Department shares with the Secretary of Agriculture involving an overlap agent or toxin that causes or has the potential to cause a public health

emergency where the Commissioner suspects or detects conditions that could potentially affect animals, plants or crops under the jurisdiction of the Department of Agriculture pursuant to the provisions of Title 4 of the Revised Statutes shall be held confidential, in accordance with N.J.S.A. 26:13-3d.]

[(c)] **(b) The [reports submitted to] Department may release personally identifiable information obtained pursuant to this chapter:**

**1. Unless restricted or prohibited by State or Federal law, for research, as defined by 45 CFR Part 46, Protection of Human Subjects, at 45 CFR 46.102, Definitions for purposes of this policy, through the Integrated Population Health Data (iPHD) Project, established pursuant to N.J.S.A. 30:4D-65 et seq.;**

**2. With written consent of the person identified;**

**3. When the Commissioner determines that disclosure is necessary to enforce public health laws or protect the life or health of one or more persons in accordance with applicable State and Federal laws;**

**4. To provide information to a Federal or another state public health authority when needed to comply with Federal reporting requirements or to coordinate public health investigations across jurisdictions;**

**5. To provide information to an individual's health care professional; or**

**6. Pursuant to the order of a court of competent jurisdiction.**

**(c) A record and/or report that the Department or a local health agency makes, maintains, receives, or files, including isolation and/or quarantine orders, material containing the health information of individuals who participate in medical testing, treatment, vaccination, isolation, or quarantine, and any correspondence,**

**records, reports, and other material associated with medical testing, treatment, vaccination, isolation, or quarantine** pursuant to [N.J.A.C. 8:57-1, except for the reports submitted pursuant to N.J.A.C. 8:57-1.8, contain] **this chapter that sets forth demographic and medical information related to [the Department's] public health investigations and epidemiological studies of communicable diseases, infections, and conditions** [and shall] **are** not [be considered] "government records" subject to public access or inspection within the meaning [of] **at** N.J.S.A. 47:1A-1 et seq., and [shall be] **are** deemed, **not by way of limitation and subject to any other applicable exemption from disclosure, to be:**

1.-3. (No change.)

(d) [Medical] **The Department may use health, medical,** or epidemiologic information collected pursuant to this [subchapter may be disclosed] **chapter** in statistical or other [form] **reports that the Department may elect to issue,** which [does] **do** not disclose the identity of any person.

(e) **Regardless of the deletion or redaction of personal identifiers therefrom, a record that the Department or a local health agency holds pursuant to this chapter that might be subject to public access and disclosure within the meaning at N.J.S.A. 47:1A-1 et seq., is not subject thereto if the agency has actual knowledge, or reason to believe, that the remaining unredacted information could be used, alone or in combination, with other publicly accessible information, to identify an individual who is the subject of the record or link an individual to the information contained in the record.**

**(f) Absent the order of a court of competent jurisdiction finding the need to provide access to avert a clear danger to an individual or to public health, access to isolation and/or quarantine orders and the health information of individuals who participate in medical testing, treatment, vaccination, isolation, or quarantine pursuant to this chapter is limited to persons having a legitimate need to acquire or use the information to:**

**1. Provide treatment to the individual who is the subject of the order or the health information, as applicable;**

**2. Conduct an epidemiologic investigation;**

**3. Investigate the causes of the transmission;**

**4. Assist law enforcement agencies in identification and location activities;**

**or**

**5. Facilitate payment by a responsible party for treatment or services rendered.**

**(g) Subsections (a) through (f) above do not apply with respect to reports and records relating to diseases in animals made pursuant to N.J.A.C. 8:57-2.7 unless information in the record could be used alone, or in combination, with other information to identify information about an individual that:**

**1. Is health information or other information about which the individual may have a reasonable expectation of privacy; and/or**

**2. The agency is required or authorized to protect from public access or disclosure.**

**(h) Subject to (i) below, to prevent, control, and/or contain the spread of disease and/or an outbreak or a suspected outbreak, the Department may release records and/or information about the medical testing, treatment, vaccination, isolation, or quarantine of a person to:**

- 1. The person's employer;**
- 2. The person who is the subject of the record, upon request;**
- 3. Healthcare personnel;**
- 4. A person who is employed by a food establishment at which a case is employed or attends;**
- 5. A school health official; or**
- 6. An institutional liaison for an institution of higher education.**

**(i) As a condition of release of information and records pursuant to (h) above, the Commissioner must determine that:**

**1. The release is necessary to enable the administrator of a place that an ill or potentially ill person attends, to protect the health and well-being of the potentially ill person, other persons at the place, and the public; and**

**2. No alternative to release would reliably protect public health, such as if the Commissioner were to determine that a person refuses and/or is unlikely to comply with a directive to refrain from engaging in work or educational activities that can spread disease, in accordance with a prohibition issued pursuant to N.J.A.C. 8:57-2.12.**



**8:57-1.8 Department procedure for the establishment of vaccine-preventable disease immunization recommendations and requirements**

**(a) The Department may identify a vaccine-preventable disease for which:**

- 1. There are no applicable ACIP recommendations;**
- 2. The ACIP recommendations are insufficient to protect the health and safety, or inapposite to the needs, of the people of New Jersey; or**
- 3. The ACIP recommendations lack scientific validity and merit as standards upon which the Department should rely in establishing immunization recommendations and requirements for vaccine-preventable diseases.**

**(b) In the circumstances described at (a) above, the Department shall evaluate whether the ACIP recommendations for the immunization of all populations of the State against vaccine-preventable diseases are sufficient to ensure the required high levels of immunization that are necessary to protect the people of New Jersey and, in particular, attendees at child care centers, schools, and IHEs, from vaccine-preventable diseases, upon consideration of:**

- 1. Evidence-based best practices and guidance materials issued by nationally recognized advisory and advocacy bodies with respect to preventive health, pediatric, internal, and family medicine services, such as the American Academy of Pediatrics, the American College of Physicians®, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists; and/or**
- 2. Vaccine-preventable disease epidemiology, and State- and region-specific characteristics, such as population density and demographics.**

(c) Upon conclusion of the evaluation described at (b) above, the Department may promulgate a rule in accordance with the Administrative Procedure Act, N.J.S.A. 52:14B-1 et seq., notwithstanding the ACIP recommendations:

1. Specifying the types of vaccine-preventable disease immunizations, and/or the number or scheduling of vaccine doses, required for admission to and attendance at child care centers, schools, and IHEs; and/or

2. Specifying the types of vaccine-preventable disease immunizations, and/or the number or scheduling of vaccine doses, recommended for populations of the State, within the meaning at N.J.S.A. 17:48-6i and 6m, 17:48A-7h, 17:48E-35.6 and 35.10, 17B:26-2.1h, 17B:27-46.1h and 46.1l, 17B:27A-7 and 19, and 26:2J-4.6.

## **SUBCHAPTER 2. [(RESERVED)] REPORTABLE COMMUNICABLE DISEASES, INFECTIONS, AND CONDITIONS**

### **8:57-2.1 Scope**

(a) This subchapter establishes standards applicable to:

1. An administrator;
2. An animal facility manager;
3. A certified animal control officer;
4. A clinical laboratory director;
5. An employer, and/or other person in charge, at a food establishment, drug establishment, and/or cosmetic establishment;
6. A healthcare professional;
7. A health officer;

**8. A veterinarian; and**

**9. A veterinary diagnostic laboratory director.**

8:57-[1.4]**2.2** [Health care provider] **Healthcare professional** and administrator reporting [of] **and compliance obligations with respect to** reportable communicable diseases, **infections, and conditions**

(a) Every [health care provider] **healthcare professional** and administrator shall report [any person who is ill or infected] **in accordance with N.J.A.C. 8:57-2.4:**

**1. Each case of suspected or confirmed illness** with [any] **a reportable disease, infection, or condition** listed [in] **at N.J.A.C. 8:57-[1.5]2.3(a)**, within the [required timeframe, and shall make a report as set forth in N.J.A.C. 8:57-1.6.] **time specified at N.J.A.C. 8:57-2.3(a);**

**2. Each case of confirmed illness with a reportable disease, infection, or condition** listed at **N.J.A.C. 8:57-2.3(b) and (c)**, within the time specified therein;

**3. A positive POC test result for the organisms listed at N.J.A.C. 8:57-2.6;**  
**and**

**4. Each confirmed case of a disease, infection, or condition not listed at N.J.A.C. 8:57-2.3**, if the disease, infection, or condition is included on the **Notifiable Condition List of infectious conditions for the year in which the disease, infection, or condition is identified, in accordance with N.J.A.C. 8:57-2.3(b).**

(b) Duplicate reporting of the same case by [health care providers] **healthcare professionals** and administrators is not necessary[.

(c) Health care providers and administrators may delegate these reporting requirements to a member of the staff, but this delegation does not relieve the health care provider or administrator of the ultimate reporting responsibility.], **but each person or entity upon whom this chapter establishes reporting obligations, with respect to a case and/or a point-of-care laboratory test result, retains responsibility to ensure that the case and/or the result is reported in accordance with this subchapter, regardless of any understanding or agreement among reporting entities with respect to the delegation of ministerial reporting tasks when entities have mutual case-reporting responsibility.**

**(c) A healthcare professional and an administrator shall comply with infection control measures for an individually identified case that the Department or a health officer issues in writing.**

8:57-[1.5]**2.3 Reportable communicable diseases, infections, and conditions**

(a) [Health care providers and administrators shall immediately report by telephone as set forth at N.J.A.C. 8:57-1.6 confirmed] **Confirmed** and suspected cases of **an event listed at (f) below, and** the following, **are immediately** reportable [communicable diseases] **(text in parentheses following a disease, infection, or condition listed below is the causative organism):**

[1. List of immediately reportable diseases]

...

[Brucellosis (*Brucella spp.*);]

**Biological intoxication, including, but not limited to, intoxication with ricin, abrin, cerberin, and/or harmful algal bloom;**

**Coronavirus, novel, causing severe acute respiratory syndrome, including, but not limited to, SARS, and Middle East respiratory syndrome (commonly referred to as MERS);**

...

Foodborne intoxication[s], including, but not limited to, ciguatera, paralytic shellfish poisoning, scombroid, [or] mushroom poisoning, **tetrodotoxin, or *Staphylococcal enterotoxin B*;**

**Free-living amebic infection (*Acanthamoeba* species (spp.), *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia* spp.);**

...

Hantavirus [pulmonary syndrome];

Hepatitis A[, acute];

Influenza **A virus**, novel [strains only] **and/or unsubtypeable;**

...

**Melioidosis (*Burkholderia pseudomallei*);**

**Mpox (*Orthopoxvirus* monkeypox);**

...

[Outbreak or suspected outbreak of illness, including, but not limited to, foodborne, waterborne or nosocomial disease or a suspected act of bioterrorism;

Pertussis, (*Bordetella pertussis*);]

**Plague (*Yersinia pestis*);**

**Poliomyelitis (poliovirus);**

...

[SARS-CoV Disease (SARS);]

**Rubella; and**

...

[Tularemia (*Francisella tularensis*); and]

Viral hemorrhagic fever[s], including, but not limited to, **Chapare, Crimean-Congo hemorrhagic fever, Ebola, Guanarito, Junin, Lassa, [and] Lujo, Machupo, Marburg [viruses], Rift Valley Fever, and Sabia.**

(b) [Health care providers and administrators shall report within 24 hours of diagnosis as set forth at N.J.A.C. 8:57-1.6 confirmed] **Confirmed** cases of the following **are** reportable **by the close of the next business day following the date of confirmation of a communicable disease[s], infection, or condition diagnosis, receipt of a positive laboratory or POC test result, or other confirmation of a communicable disease, infection, or condition:**

[Amoebiasis (*Entamoeba histolytica*);]

**Alpha-gal syndrome;**

**Anaplasmosis (*Anaplasma phagocytophilum*);**

Animal bite[s treated for rabies] **of a human;**

Arboviral disease[s], **including, but not limited to, Bourbon, Cache Valley fever, California serogroup, Heartland, Japanese encephalitis, La Crosse encephalitis, St. Louis encephalitis, and yellow fever virus diseases;**

...

**Bacterial tickborne disease, including hard tick relapsing fever (*Borrelia miyamotoi*);**

**Brucellosis (*Brucella* spp.);**

...

***Candida auris* infection or colonization (*Candida auris*);**

**Carbapenemase-producing organism infection or colonization;**

...

[Chlamydial infections, sexually transmitted (]*Chlamydia trachomatis* (**electronic case reporting only**);

[Chlamydial conjunctivitis, neonatal (*Chlamydia trachomatis*);]

**Chikungunya virus;**

...

[Creutzfeldt-Jakob disease;]

**COVID-19 infection (SARS-CoV-2);**

***Cronobacter* infection (*Cronobacter* spp.), invasive, in minors of up to one year of age;**

...

[Diarrheal disease, either in a child who attends a day care center or in a foodhandler;]

**Dengue virus;**

**Eastern equine encephalitis;**

...

*Escherichia coli*, [shiga toxin producing] **Shiga toxin-producing** strains (STEC)  
only;

**Extrapulmonary nontuberculous mycobacteria (NTM) infection;**

Giardiasis (*Giardia lamblia* also known as *Giardia intestinalis* and *Giardia duodenalis*);

...

[Hemolytic uremic syndrome, post-diarrheal;]

Hepatitis B, **only if the case:**

1. **Is** newly diagnosed [acute, perinatal and chronic infections, and pregnant women];
2. **Occurs in a person** who [have tested], **while pregnant, tests** positive for [Hepatitis] **hepatitis B** surface antigen, **hepatitis B virus DNA**, and/or **hepatitis B virus e antigen**, regardless of prior diagnosis;
3. **Was originally diagnosed in a jurisdiction or geographic subdivision other than New Jersey; or**
4. **Occurs in a minor of up to 36 months of age born to a person who had hepatitis B during the minor's gestation and/or birth;**

Hepatitis C, [acute and chronic,] **only if the case:**

1. **Is** newly diagnosed [cases only];
2. **Occurs in a person who, while pregnant, tests** positive for **hepatitis C RNA** and/or **hepatitis C antigen**, regardless of prior diagnosis;
3. **Was originally diagnosed in a jurisdiction or geographic subdivision other than New Jersey; or**



**4. Occurs in a minor of up to 36 months of age born to a person who had hepatitis C during the minor's gestation and/or birth;**

...

**Influenza (electronic case reporting only);**

**Jamestown Canyon virus;**

Legionellosis (*Legionella* [spp.] spp.);

**Leptospirosis (*Leptospira* spp.);**

...

Lyme disease (*Borrelia burgdorferi*, **electronic case reporting only**);

[Lymphogranuloma venereum (*Chlamydia trachomatis*);]

...

**Pertussis (*Bordetella pertussis*);**

**Powassan virus disease;**

...

Q fever (*Coxiella* [burnetti] **burnetii**);

[Rocky Mountain Spotted Fever (*Rickettsia rickettsii*);]

**Rabies and rabies PEP administration;**

**Respiratory syncytial virus (RSV)-associated pediatric mortality;**

...

Shigellosis (*Shigella* [spp.] spp.);

**Spotted fever group rickettsiosis (*Rickettsia* spp.);**

*Staphylococcus aureus*, [with intermediate (VISA) or high-level-resistance (**only** VRSA[]) to vancomycin only];

Streptococcal disease, invasive group A[,] (*Streptococcus pyogenes* [group A]);

Streptococcal disease, invasive group B[, neonatal] (***Streptococcus agalactiae***)

**in minors of fewer than 90 days old;**

...

Syphilis, all stages, **including congenital** (*Treponema pallidum*);

[Syphilis, congenital;]

...

Toxic [Shock] **shock** syndrome, [(]other than Streptococcal[)];

Trichinellosis (*Trichinella [spiralis] spp.*);

[Tuberculosis, confirmed or suspect (*Mycobacterium tuberculosis*) (additional reporting requirements set forth at N.J.A.C. 8:57-5.3;]

**Tularemia (*Francisella tularensis*);**

Typhoid fever (*Salmonella [typhi] Typhi*);

Varicella (chickenpox) (**varicella-zoster virus**);

Vibriosis, **non-cholerae (*Vibrio spp.*)**;

...

[Yellow fever (*Flavivirus*); and

*Yersiniosis* (]

**West Nile virus;**

**Yersiniosis (*Yersinia [spp.] spp.*); and**

**Zika virus.**

[(c) Health care providers and administrators shall immediately report to the Department by telephone as set forth at N.J.A.C. 8:57-1.6 any disease or health condition that may

reasonably be a potential case of a public health emergency as set forth at N.J.S.A. 26:13-4.]

[(d)] **(c) [An] The** administrator of a [general] hospital [licensed by the Department in accordance with N.J.S.A. 26:2H-1 et seq., and as classified in the Hospital Licensing Standards at N.J.A.C. 8:43G-1.2 and 1.3(b)] shall[,] **collect all MRSA LabID events and submit them to the National Healthcare Safety Network (NHSN)** within 30 calendar days of the end of each month[, submit to the Department:

1. The number of cases of hospital-onset MRSA bloodstream infections per 1,000 patient days that have occurred in his or her general hospital, specified by hospital unit where active surveillance testing for MRSA is being performed; and

2. The percentage of eligible patients who have a MRSA surveillance test performed on admission to a hospital unit where active surveillance testing for MRSA is being performed.

i. The administrator shall submit the information set forth in (d)1 and 2 above using a web-based interface to be developed and communicated by the Department] **in accordance with N.J.A.C. 8:56, Health Care Facility Infection Reporting.**

**(d) A suspected or confirmed case of tuberculosis (*Mycobacterium tuberculosis*) is to be reported in accordance with N.J.A.C. 8:57-5, Management of Tuberculosis.**

(e) [Reporting of Acquired Immunodeficiency Syndrome (AIDS) and infection with Human Immunodeficiency Virus] **A suspected or confirmed case of human**

**immunodeficiency virus (HIV) infection [shall be in the manner set forth at] is to be reported in accordance with N.J.A.C. [8:57-2] 8:65, HIV Infection Reporting.**

**(f) Subject to (g) below, the following are immediately reportable in accordance with (a) above:**

- 1. A suspected or confirmed outbreak of any communicable disease, infection, or condition;**
- 2. A suspected or confirmed act of bioterrorism; and**
- 3. Pursuant to N.J.S.A. 26:13-4, a case of a suspected or confirmed disease, infection, or condition that may be reasonably believed to be a potential cause of a public health emergency.**

**(g) A report that (f) above requires is to be made:**

- i. By a “health care provider,” as N.J.S.A. 26:13-1 et seq., specifically 26:13-2, defines that term; and**
- ii. To both the Department and the health officer of the municipality in which the case is located.**

8:57-[1.6]**2.4** Method of reporting and content of report

**(a) [Health care providers and administrators shall] A report of a case that is immediately [report by telephone] reportable pursuant to N.J.A.C. 8:57-2.3(a) and/or a suspected or confirmed outbreak of any communicable disease, infection, or condition, or an act of bioterrorism pursuant to N.J.A.C. 8:57-2.3(f), including the information [set forth] at [(c) and] (d) and, if applicable, (e) below [on confirmed and**

suspected cases of immediately reportable communicable diseases set forth in N.J.A.C. 8:57-1.5(a) to], **is to be made by telephone call:**

**1. To the health officer of the jurisdiction [where] in which the [ill or infected person lives] case resides, [or] but if that health officer is unavailable, to the Department;**

**2. If the residence of the case is unknown [, wherein] to the health officer of the jurisdiction in which the [diagnosis is made, except that health care providers and administrators shall report ill or infected persons in State-owned institutions, such as State correctional facilities, directly to the Department.**

1. If the health officer is unavailable, the health care provider or administrator shall make the report to the Department by telephone to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours.] **reporting entity is located and at which the case presented, but if that health officer is unavailable, to the Department; and**

[2.] **3. [Health care providers and administrators] Persons with reporting obligations** may use the Directory of Local Health Departments in New Jersey to locate health officers and local health departments in New Jersey.

[i. The Directory of Local Health Departments in New Jersey is written and published by the New Jersey Department of Health and Senior Services, Office of Public Health Infrastructure and is available by written request to the Office of Public Health Infrastructure, New Jersey Department of Health and Senior Services, PO Box 360, Trenton, NJ 08625-0360 or online through the Department's web page at <http://www.state.nj.us/health/lh/lhdirectory.pdf>.]

(b) [Health care providers and administrators shall] **A** report [by mail or by electronic reporting within 24 hours of diagnosis, the information set forth in (c) below on confirmed] **of a case[s of] that is** reportable [communicable diseases set forth in] **pursuant to N.J.A.C. 8:57-[1.5(b) to]2.3(b), containing the information specified at (d) and, if applicable, (e) below, is to be made:**

**1. By means of telefacsimile or secure email, if the reporting entity is an entity other than those specified at (b)2 below:**

**i. Subject to (b)2iii and iv below, to the health officer of the jurisdiction [where] in which the [ill or infected person lives, or if] case resides;**

**ii. Subject to (b)2iii and iv below, if the residence of the case is unknown, [wherein] to the [diagnosis] health officer of the jurisdiction in which the reporting entity is [made, except that health care providers and administrators shall report persons with hepatitis C, sexually transmitted diseases and tuberculosis and all persons in State-owned institutions, such as State correctional facilities,] located and in which the case presented;**

**iii. With respect to cases of hepatitis C and tuberculosis, report additionally to the Department; and**

**iv. With respect to sexually transmitted diseases, report** directly to the Department.

[1. If the health officer is unavailable, the health care provider or administrator shall make the report to the Department by telephone to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours.]

**2. By means of electronic reporting if the reporting entity is:**

**i. The administrator of a hospital;**

**ii. A point-of-care test administrator; or**

**iii. A healthcare professional to whom the Department has provided access to electronic reporting.**

**3. By means of electronic case reporting if the reporting entity is:**

**i. A hospital; or**

**ii. A health care facility that has established a linkage (individually or as part of a larger entity) with the Department to submit electronic case reports.**

[2.] **(c)** [Health care providers and administrators] **Persons with reporting obligations** may use the Directory of Local Health Departments in New Jersey to locate health officers and local health [departments] **agencies** in New Jersey.

[3. Health care providers and administrators may mail reports to the Department at the following address: Communicable Disease Service, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369.]

[(c)] **(d)** [The disease] **A** report [set forth at] **that** (a) and (b) above **and N.J.A.C. 8:57-**

**2.3** **require** shall include, **at a minimum:**

1. The name of the disease, **infection, or condition;**

2. The name, age, date of birth, **sex assigned at birth, current gender identity, sexual orientation**, race, ethnicity, home address, and **all known** telephone numbers **and email addresses** of the [person who is ill or infected with such disease] **case;**

3. (No change.)

4. The name, address, institution, **email address**, and telephone number of the reporting [health care provider] **healthcare professional** or administrator;

5. Clinical laboratory data[, which] **that** support the diagnosis, **if available**;

6. [Any] **A description of provided** treatment [provided (for sexually transmitted diseases only)];

**7. The hospitalization and mortality status of the case;** and

[7.] **8.** Such other information [as] **that** the Department **or a health officer** requires concerning a specific [disease] **case, which may include clinical information and medical records.**

[(d)] **(e)** [In addition to the information set forth at (c) above,] **A report of a suspected** outbreak [reports] shall include, **at a minimum, the information required at (d) above, and:**

1. The name, [municipality] **address**, and telephone number of the location [where] **at which** the outbreak occurred;

2. The number [ill] **of cases**;

3. A description of symptoms; **and**

4. Pertinent medical history and available diagnostic confirmation[, and].

[5. Such other information as may be requested by the health officer or the Department concerning a specific disease.

(e) Health care providers and administrators shall immediately report to the Department all cases of persons who harbor or are suspected of harboring any illness or health condition that may be reasonably believed to be a potential cause of a public health emergency as set forth in the Emergency Health Powers Act, N.J.S.A. 26:13-4.



1. Health care providers and administrators shall make reports to the Department by telephone to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours.]

**(f) Each hospital that has a web-based mechanism by which the Department and a local health agency with jurisdiction can obtain access to the hospital's electronic health records on suspected or confirmed cases or outbreaks shall notify the Department at [dhssmu@doh.nj.gov](mailto:dhssmu@doh.nj.gov) of the mechanism and the procedure by which the Department can obtain access.**

**8:57-2.5 Clinical laboratory reporting procedures and obligations with respect to reportable laboratory results; establishment of electronic interface for ELR**

**(a) Unless N.J.A.C. 8:57-2.6 requires reporting of an organism or result by telephone or another means, clinical laboratories that are to report results to the Department pursuant to N.J.A.C. 8:57-2.6 shall report by means of ELR or electronic reporting.**

**(b) To establish an ELR interface between the CDRSS Electronic Laboratory Reporting System and a clinical laboratory's electronic system, a clinical laboratory director shall adhere to the ELR On-Boarding Manual, available at N.J.A.C. 8:57 Appendix S, incorporated herein by reference.**

**(c) A clinical laboratory shall submit laboratory test results that are reportable by means of ELR pursuant to N.J.A.C. 8:57-2.6 using the LOINC and SNOMED terminology standards and in accordance with:**

**1. As a maximum standard, the HL7 Implementation Guide; or**

**2. As an alternative lesser standard, NJ ELR Implementation Guide.**

**(d) A clinical laboratory director who sends a laboratory specimen to a referral laboratory for testing that yields a result that is subject to reporting or culture isolate submission pursuant to N.J.A.C. 8:57-2.5 and 2.6, shall:**

**1. Report, and/or ensure the reporting of, reportable laboratory results pursuant to N.J.A.C. 8:57-2.5 and 2.6; and**

**2. Submit, and/or ensure the submission of, culture isolates pursuant to N.J.A.C. 8:57-2.6.**

**8:57-[1.7]2.6 [Reporting of positive] Reportable laboratory results [denoting diseases] for certain organisms; reporting procedures; submission of culture isolates and other test specimens**

**(a) A clinical laboratory director shall [immediately] report [by telephone] the information [set forth] at [(c)] (b) below [on any positive,] upon obtaining, as indicated at (a)1 through 6 below, a culture, a specimen suspected to contain, and/or laboratory test [or assay] result [specific for] indicating the [following] presence and, if specified, absence, of a listed organism[s], in the time and manner specified, to, as indicated, the Department, and/or the applicable local health [officer] agency of the jurisdiction [where] in which the person [lives] whose specimen is tested resides, or if the residence is unknown, to the local health [officer in whose] agency of the jurisdiction in which the [health care provider or health care facility requesting] entity that requested the laboratory [examination] test is located.**

**1. A laboratory shall report immediately to the Communicable Disease Service, by telephone to (609) 826-5964 during business hours and (609) 392-2020 outside of business hours, a culture that is suspected to contain the following organisms:**

[Arboviruses;]

...

[*Bordetella pertussis*;]

*Brucella* [spp.]; spp.;

*Burkholderia mallei*;

*Burkholderia pseudomallei*;

*Francisella tularensis*; and

*Yersinia pestis*.

**2. A laboratory shall report immediately by issuance of telephone notice to the applicable local health agency and by means of electronic reporting, including a laboratory that ordinarily reports by means of ELR, a laboratory result that indicates, or is positive (and, if indicated, negative) for, the presence of the following organisms or antibodies:**

*Acanthamoeba* spp.;

*Bacillus anthracis*;

*Balamuthia mandrillaris*;

*Burkholderia pseudomallei*;

*Clostridium botulinum*[.];

*Corynebacterium diphtheriae*[.];

[Ebola virus;

Foodborne intoxications, including, but not limited to, ciguatera, paralytic shellfish poisoning, scombroid, or mushroom poisoning;

*Francisella tularensis*;

*Haemophilus influenzae* isolated from cerebrospinal fluid, blood, or any other normally sterile body site;]

...

[Hepatitis A, (IgM tests only);]

Influenza **A** virus, novel [strains only] **and/or unsubtypeable**;

[Lassa virus;

Marburg virus;]

***Naegleria fowleri***;

*Neisseria meningitidis* isolated from cerebrospinal fluid, blood, or [any other] **a** normally sterile site;

[Polio virus] **Poliovirus**;

...

[Rubella virus;]

...

**Rubeola virus, as follows:**

i. Immunoglobulin M (IgM) antibody to rubeola virus and, if performed on the same specimen collection, the result (positive or negative) of an immunoglobulin G (IgG) antibody test;

ii. Detection of rubeola virus RNA; and/or

**iii. Identification of rubeola virus in culture;**

**Variola virus spp.;**

**Viruses causing viral hemorrhagic fever, such as Ebola, Lassa, and  
Marburg viruses;**

...

[1. If the health officer is unavailable, the clinical laboratory director shall make the report to the Department by telephone to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours.

2. In addition to the telephone report, the clinical laboratory director shall report the information set forth at (c) below by electronic reporting, by electronic laboratory reporting or by mail within 72 hours of obtaining the result.

i. The clinical laboratory director may use the Directory of Local Health Departments in New Jersey to locate health officers and local health departments in New Jersey.

3. Effective September 1, 2010, in addition to the telephone report, the clinical laboratory director shall report the information set forth at (c) below through electronic laboratory reporting within 24 hours of obtaining the result.

i. The clinical laboratory director may substitute electronic reporting if electronic laboratory reporting is not available.

ii. The clinical laboratory director may substitute reporting by mail upon approval of the Department for equipment failure or other circumstances, which prevent electronic communications with the Department.

iii. Clinical laboratory directors shall utilize the Electronic Laboratory Reporting Technical Manual available at subchapter Appendix A to establish electronic laboratory reporting.

(b) A clinical laboratory director shall report by electronic laboratory reporting, or by electronic reporting, or by mail within 72 hours of obtaining the result the information set forth at (c) below on any positive culture, test, or assay result specific for one of the following organisms to the local health officer of the jurisdiction where the person lives, or if unknown, to the local health officer in whose jurisdiction the health care provider or health care facility requesting the laboratory examination is located, except that the clinical laboratory director shall report positive results for hepatitis C, tuberculosis and sexually transmitted diseases directly to the Department:]

**3. A laboratory shall report immediately by means of electronic reporting, including a laboratory that ordinarily reports by means of ELR, a result that is positive, and, if specified below, negative for the following organisms, except that a negative culture or blood smear shall not be reported unless preceded by a positive result for the specified organism:**

[Acid fast] **Acid-fast** bacilli;

[Antibiotic-resistant organisms (hospital-based laboratories only);]

***Haemophilus influenzae* isolated from cerebrospinal fluid, blood, or a normally sterile site;**

**Hepatitis A virus (commonly referred to as HAV) that is identified using the following tests:**

i. Immunoglobulin M (commonly referred to as IgM) antibody to HAV (commonly referred to as anti-HAV);

ii. Nucleic acid amplification test, such as polymerase chain reaction (commonly referred to as PCR) or genotyping for HAV RNA positive; and

iii. If a positive result is obtained from a test listed at subparagraphs i or ii above, the results of the following tests, if performed on the same specimen collection used to obtain the positive results:

(1) Alanine transaminase (commonly referred to as ALT or SGPT);

(2) Aspartate aminotransferase (commonly referred to as AST or SGOT); and

(3) Total bilirubin;

Orthopoxvirus monkeypox (positive and negative); and

Rubella virus, as follows:

i. Immunoglobulin M (IgM) antibody to rubella virus and, if performed on the same specimen collection, the IgG test result (positive or negative);

ii. Detection of rubella virus RNA; and

iii. Identification of rubella virus in culture.

4. A laboratory shall report by means of ELR or electronic reporting by the close of the business day next following the date on which the result is obtained,

a result that is positive, and, if specified below, negative, for the following organisms, except that a negative culture or blood smear shall not be reported unless preceded by a positive result for the specified organism:

**Alpha-gal;**

***Anaplasma* spp. (positive and negative);**

**Arboviruses, including, but not limited to, Bourbon, Cache Valley, California serogroup, Heartland, Japanese encephalitis, La Crosse encephalitis, St. Louis encephalitis, and yellow fever viruses (positive and negative);**

***Babesia* spp. (positive and negative);**

***Bordetella pertussis*;**

***Borrelia* [*burgdorferi*] spp.;**

***Brucella* spp. (other than culture, positive and negative);**

...

***Candida auris* (positive and negative);**

**Carbapenemase-producing organism (positive and negative);**

**Chikungunya virus (positive and negative);**

***Chlamydia psittaci* (positive and negative);**

...

***Coxiella* [*burnetti*] *burnetii* (other than culture, positive and negative);**

***Cronobacter* spp., invasive infection, in a minor of up to one year of age;**

***Cryptosporidium* [spp.] spp.;**



...

[*Entamoeba histolytica*];

**Dengue virus (positive and negative);**

**Eastern equine encephalitis virus;**

*Ehrlichia* spp. **(positive and negative);**

*Escherichia coli*, [shiga toxin producing] **Shiga toxin-producing strains**

**(commonly referred to as STEC) only (positive and negative);**

*Francisella tularensis* **(other than culture, positive and negative);**

*Giardia lamblia* **(also known as *G. intestinalis* and *G. duodenalis*);**

...

Hepatitis B[;] **virus (commonly referred to as HBV, positive and negative), as follows:**

i. **Hepatitis B surface antigen (commonly referred to as HBsAg);**

ii. **Hepatitis B core antibody (commonly referred to as anti-HBc IgM);**

iii. **Hepatitis B e-antigen (commonly referred to as HBeAg);**

iv. **NAAT for HBV DNA (including qualitative, quantitative, and genotype testing); and**

v. **If a positive result is obtained from a test listed at subparagraphs i through iv above, the results of the following tests, if performed on the same specimen collection used to obtain the positive result:**

**(1) Alanine transaminase (commonly referred to as ALT or SGPT);**

**(2) Aspartate aminotransferase (commonly referred to as AST or SGOT); and**

**(3) Total bilirubin;**

**Hepatitis C[;] virus (commonly referred to as HCV, positive and negative), as follows:**

**i. NAAT for HCV RNA positive (including qualitative, quantitative, or genotype testing);**

**ii. HCV antigen;**

**iii. Antibodies to HCV (commonly referred to as anti-HCV, Hepatitis C Ab, or Hepatitis C S/CO); and**

**iv. If a positive result is obtained from a test subparagraphs listed at i, ii, and iii above, the results of the following tests, if performed on the same specimen collection used to obtain the positive results:**

**(1) Alanine transaminase (commonly referred to as ALT or SGPT);**

**(2) Aspartate aminotransferase (commonly referred to as AST or SGOT); and**

**(3) Total bilirubin;**

**Influenza, [all isolates] ([only] for laboratories reporting [electronically, or] by [electronic laboratory reporting] ELR) (positive and negative);**

**Jamestown Canyon virus;**

*Klebsiella granulomatis* (positive and negative);

*Legionella* [spp.] spp. (positive and negative);

***Leptospira* spp. (positive and negative);**

...

Mumps virus, **as follows:**

i. Immunoglobulin M (commonly referred to as IgM) antibody to mumps virus, and, if performed on the same specimen collection, the IgG test result (positive and negative);

ii. Detection of mumps virus RNA; or

iii. Identification of mumps virus in culture;

[*Mycobacterium, atypical*;]

...

*Mycobacterium tuberculosis*, including antibiotic sensitivity tests for [M.]

***Mycobacterium tuberculosis*;**

...

**Nontuberculous mycobacteria (NTM);**

[Plasmodium] ***Plasmodium* spp. (positive and negative);**

**Powassan virus, all lineages (positive and negative);**

**Respiratory syncytial virus (RSV);**

*Rickettsia* [*rickettsii*] spp. (positive and negative);

[Rubeola virus;]

*Salmonella* [spp.] spp. (positive and negative);

***Salmonella enterica* serotype Typhi (positive and negative);**

**SARS-CoV-2 (positive and negative);**

***Shigella* [spp.] spp. (positive and negative);**

***Staphylococcus aureus*, [with intermediate- (]only [VISA) or high-level-resistance (]VRSA[) to vancomycin only];**

***Streptococcus agalactiae*, Group B, [neonatal] isolated from cerebrospinal fluid, blood, or a normally sterile site;**

***Streptococcus pneumoniae* isolated from cerebrospinal fluid, blood, or [any other] a normally sterile site, and antimicrobial susceptibility test results, if performed;**

***Streptococcus pyogenes*, Group A, isolated from cerebrospinal fluid, blood, or [other] a normally sterile site;**

***Treponema pallidum*, including all treponemal tests and non-treponemal tests (for example, rapid plasma reagin), in accordance with the CDC Laboratory Recommendations for Syphilis Testing, and as follows:**

**i. When using a traditional testing algorithm, a laboratory shall report all subsequent test results (including positive/reactive, negative/non-reactive, and indeterminate treponemal test results) associated with a positive or reactive non-treponemal test result;**

**ii. When using a reverse testing algorithm, a laboratory shall report all subsequent test results (including positive/reactive, negative/non-reactive, and indeterminate treponemal and non-**

treponemal test results), following an initial reactive treponemal test result;

iii. If a treponemal test result is indeterminate, a laboratory shall perform, or refer the specimen to another laboratory for the performance of, a second treponemal test on the same specimen using an alternative treponemal test within 24 hours of obtaining the indeterminate test result, and shall report the results of both tests, regardless of the result of the second treponemal test, whether performed by the same laboratory or a different laboratory;

iv. If a non-treponemal test result is indeterminate, a laboratory shall perform, or refer the specimen to another laboratory for the performance of, a second non-treponemal test on the same specimen using the same or an alternative non-treponemal test within 24 hours of obtaining the indeterminate result, and shall report the result of the second test, regardless of the result, whether performed by the same laboratory or a different laboratory; and

v. When non-treponemal tests are done alone without a treponemal order, and the non-treponemal test is reactive, the laboratory shall confirm with the ordering physician that additional testing is not required and must document the physician's response;

*Trichinella [spiralis] spp.*;

[Varicella] **Varicella-zoster** virus (except IgG tests);

*Vibrio [spp.] spp. (positive and negative, including ***Vibrio cholerae***);*

[and]

**West Nile virus (positive and negative);**

*Yersinia spp.*; and

**Zika virus (positive and negative).**

[1. The clinical laboratory director may use the Directory of Local Health Departments in New Jersey to locate health officers and local health departments in New Jersey.

2. The clinical laboratory director may mail reports to the Department at the following address: Communicable Disease Service, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369.

3. Effective September 1, 2010, the clinical laboratory director shall report the information set forth at (c) below by electronic laboratory reporting within 24 hours of obtaining the result.

i. The clinical laboratory director may substitute electronic reporting if electronic laboratory reporting is not available.

ii. The clinical laboratory director may substitute reporting by mail upon approval of the Department for equipment failure or other circumstances, which prevent electronic communications with the Department.

iii. Clinical laboratory directors shall utilize the Electronic Laboratory Reporting Technical Manual, available at subchapter Appendix A, to establish electronic laboratory reporting.]

**5. A laboratory shall report by the close of the business day next following the day on which the result is obtained by means of ELR or electronic reporting a result that is positive for the presence of a causative organism for an infectious condition that appears on the Notifiable Condition List of infectious conditions for the year in which the result is obtained.**

**6. A laboratory shall report HIV in accordance with N.J.A.C. 8:65, HIV Infection Reporting.**

[(c)] **(b) [The] A report pursuant to (a) above, unless otherwise specified, shall [contain the] include:**

- 1. The reporting laboratory's name, address, and telephone number; [the]**
- 2. The name, age, date of birth, [gender, race, ethnicity,] home address, and telephone number of the [person tested] case; [the]**
- 3. Consistent with N.J.S.A. 45:9-42.46, the race, ethnicity, sexual orientation, and gender identity of the case;**
- 4. The test performed; [the]**
- 5. The source or type of specimen tested, the date the specimen was collected, and the date of testing; [the]**
- 6. The test result[s]; [and the health care provider's]**
- 7. The name, address, and telephone number[.] of the healthcare professional that ordered the test; and**
- 8. Upon request of a health officer or the Department, with respect to a particular case:**
  - i. The laboratory test result report; and/or**

**ii. The report of the results of other laboratory tests performed with respect to the case that the laboratory performed prior, and/or performs subsequent, to the test that was the subject of the original report.**

[(d) A clinical laboratory director may delegate reporting and specimen submission requirements, as delineated in (a) and (b) above, and (e) below, to a staff member, but this delegation does not relieve the clinical laboratory director of the ultimate reporting responsibility.]

[(e)] **(c)** A clinical laboratory director shall submit **to PHEL**, within three days of identification, [to the New Jersey Department of Health and Senior Services, Division of Public Health and Environmental Laboratories, John Fitch Plaza, Market and Warren Streets, Trenton, NJ 08625-0361,] all [microbiologic] culture isolates [obtained from human or food specimens] of the following organisms, **and, if a culture isolate is not available, the specimen obtained from a human that is associated with the identification of, or potentially containing, one of the following organisms:**

***Candida auris*;**

**Carbapenemase-producing organisms (commonly referred to as CPO);**

**Chikungunya virus, IgM-positive;**

*Escherichia coli* 0157: H7 and enrichment broths containing [shiga-toxin producing *E. coli*] **Shiga toxin-producing *Escherichia coli*;**

*Haemophilus influenzae* isolated from cerebrospinal fluid [or], blood, **or a normally sterile site;**

**Influenza A virus, novel and/or unsubtypeable;**



**Influenza virus, severe and fatal pediatric;**

*Legionella [pneumophila;] spp.;*

...

[Multidrug-resistant organisms upon the request of the Department;]

*Neisseria meningitidis* **isolated from cerebrospinal fluid, blood, or a normally sterile site;**

**Nontuberculous mycobacteria (commonly referred to as NTM) excluding *Mycobacterium leprae* and *Mycobacterium gordonae*, when collected from cerebrospinal fluid, blood, or a normally sterile site, excluding lower respiratory tract specimens;**

**Pan-non-susceptible organisms;**

**Respiratory syncytial virus (RSV), severe and fatal pediatric;**

*Salmonella [spp.] spp.;*

*Shigella [spp.] spp.; [and]*

[Vancomycin-intermediate *Staphylococcus aureus* (VISA) and vancomycin-resistant] **Vancomycin-resistant *Staphylococcus aureus* (VRSA) [from any body site];**

***Vibrio* spp. (including *Vibrio cholerae*); and**

**West Nile virus, IgM-positive.**

[(f)] (d) [A] **Upon written request of the Department, a clinical laboratory director shall submit [all initial Tuberculosis isolates to the Public Health and Environmental Laboratories or a designated entity for the purpose of universal genotyping] each**

**specimen or culture isolate obtained from a human, food, or other source, associated with an outbreak or a public health investigation.**

[(g) A clinical laboratory director for a clinical laboratory, operated by or located within a hospital licensed under N.J.A.C. 8:43G, performing culture and sensitivity testing on isolates from human specimens shall annually report a cumulative summary of the names of the species identified, the number of isolates tested per species, the names of antimicrobial agents tested and the percentage of microorganisms susceptible to the antimicrobial agents tested in the manner described below:

1. Submit the data in the format of antibiograms as defined by Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data, Approved Guideline — Second Edition (M39-A2);

2. Include only data from the first unique isolate from each patient;

3. Exclude duplicate cultures when compiling these antibiograms; and

4. Send the antibiograms for the preceding year to the Communicable Disease Service, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369 by July 1 of the following year (for example, data for January 1, 2006 through December 31, 2006 is due on July 1, 2007).

(h) A clinical laboratory director who sends a laboratory specimen to a referral laboratory for testing shall be responsible for:

1. Reporting to the Department any test result on that specimen as required under (a) and (b) above; and

2. Submitting to the Department any culture isolate from that specimen as required under (g) above.

i. A clinical laboratory director may delegate the reporting and specimen submission requirements in this subsection to the referral laboratory, but this delegation does not relieve the clinical laboratory director of the ultimate reporting and submitting responsibility.]

**(e) Within 72 hours of collection of a human respiratory specimen, a clinical laboratory director shall submit to PHEL:**

i. **From June through September of each year, three human respiratory specimens per month that have tested positive for influenza virus, or, if fewer than three are available, all influenza virus-positive specimens; and**

ii. **From October to May of each year, three human respiratory specimens per month that are tested for influenza virus, regardless of the result obtained, or, if fewer than three are available, all specimens tested for influenza virus.**

8:57-[1.8]**2.7** Reporting [of zoonotic diseases and any disease outbreaks in domestic companion animals by] **obligations and procedures applicable to a** veterinarian[s], **a** certified animal control officer[s], [and] **an animal rescue organization, an animal facility [management] manager, and a veterinary diagnostic laboratory**

(a) A veterinarian, **a** certified animal control officer, **an animal rescue organization manager** [or manager of an], **and an** animal facility **manager** shall **submit a** report [any case of a domestic companion animal that is ill or infected with] **in accordance with (e)**

**below, upon the diagnosis of the following zoonotic diseases[, as set forth in (d) and (e) below] in a domestic companion animal:**

...

Avian [Chlamydiosis] **chlamydiosis** ([Chlamydophila] ***Chlamydia psittaci***);

[*Brucella canis*];

...

**Canine brucellosis (*Brucella canis*);**

*Escherichia coli*, [shiga toxin producing] **Shiga toxin-producing** strains (STEC)

only;

**Glanders (*Burkholderia mallei*);**

**Illness caused by exposure to harmful algal blooms;**

Leishmaniasis (***Leishmania* spp.**);

Leptospirosis (***Leptospira* spp.**);

Lymphocytic choriomeningitis (**lymphocytic choriomeningitis virus**);

[*Mycobacterium tuberculosis*];

**Melioidosis (*Burkholderia pseudomallei*);**

...

Q Fever (*Coxiella [burnetti] burnetii*);

...

**SARS-CoV-2;**

**Tuberculosis (*Mycobacterium tuberculosis*); and**

...

(b) A veterinarian, **a** certified animal control officer, [or manager of] an animal facility **manager, and an animal rescue organization manager** shall **submit a** report **of** an animal [affected with rabies or] **that is** suspected of being [affected] **or confirmed to be infected** with rabies, in [the manner set forth at] **accordance with** N.J.A.C. 8:23-1.2.

(c) A veterinarian, **a** certified animal control officer, [or manager of] an animal facility **manager, and an animal rescue organization manager** shall **submit a** report [any], **in accordance with (e) and (f) below, upon identifying an** outbreak or **a** suspected outbreak [occurring] of **any disease, infection, or condition** in domestic companion animals [as set forth in (d) and (e) below].

(d) [A] **Subject to (d)1 below, in accordance with N.J.S.A. 26:4-81, a** veterinarian, **a** certified animal control officer, [or] **an** animal facility manager [providing care for any domestic companion animal, which is ill or infected with any disease listed in (a) above or any outbreak as stated in (c) above, shall within 24 hours of diagnosis or the next working day after diagnosis make a report via mail, telephone, telefacsimile, or electronic reporting as set forth in (e) below], **and an animal rescue organization manager who is informed, and/or becomes aware, of a person having been bitten by a dog, a cat, or another animal (including a domestic companion animal, livestock, and wildlife), or otherwise potentially exposed to rabies, shall report to the health officer having jurisdiction over the locality in which the [animal or animal facility is located] bitten or exposed person is located, within 12 hours of the occurrence of the bite or the identification of the case, provided:**

**1. A report pursuant to (d) above, need not be submitted if the exposed or bitten person is under the care of a healthcare professional.**

[1. If the health officer is unavailable, the veterinarian, certified animal control officer, or animal facility manager shall make the report to the Department by telephone to 609-588-3121 between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays.

2. Veterinarians, certified animal control officers, and animal facility managers may use the Directory of Local Health Departments in New Jersey to locate health officers and local health departments in New Jersey.

(e) The report shall include the name, address and telephone number of the animal owner, if the animal is owned; the name, address and telephone number of the animal facility, if the animal is housed in an animal facility; the name of the disease or suspected disease; the number of animals housed on the premises; the species of animal(s) housed on the premises; the species and number that are ill; date of onset; date purchased or acquired and origin of animals; symptomology; pertinent medical history; and diagnostic test results.]

**(e) A report required pursuant to (a) or (c) above, shall be made:**

- 1. By telephone, electronic mail, or telefacsimile;**
- 2. By the close of the business day next following the date of the suspected or confirmed diagnosis or outbreak identification;**
- 3. To the health officer who has jurisdiction over the locality in which each animal that has the suspected or confirmed diagnosis, or is associated with the suspected or confirmed outbreak, is located; and**
- 4. By submission of a completed Zoonotic Disease Incident Report (provided at N.J.A.C. 8:57 Appendix A, and incorporated herein by reference) or a written report including the information requested therein.**

(f) [Animal] **An animal** facility [staff] **manager immediately** shall [immediately report any suspected zoonotic disease or suspected outbreak of any illness in animals currently or recently housed at that animal facility to] **notify** the veterinarian [responsible for] **who is supervising the program of disease control and health care** at that animal facility, **pursuant to N.J.A.C. 8:23A-1.9, upon the identification of a suspected or confirmed outbreak of any illness in one or more animals then presently or recently housed at that animal facility.**

(g) [A] **Duplicate reporting by a** veterinarian, a certified animal control officer [or], **and an** animal facility manager [may delegate the reporting activities set forth at (d) and (e) above to a member of the staff] **is not necessary**, but [this] **a person upon whom this section establishes reporting obligations retains responsibility to ensure that reporting occurs in accordance with this chapter, regardless of any understanding or agreement with respect to the** delegation [does not relieve the veterinarian, certified animal control officer, or animal facility manager] of [the ultimate] **ministerial reporting tasks among reporting entities having concurrent** reporting responsibility.

(h) The Department shall notify the **Commissioner of the** Department of Environmental Protection or **the Secretary of the Department of** Agriculture, **as applicable**, of any report made pursuant to this section[, where the Commissioner suspects or detects conditions] **indicative of a suspected or confirmed reportable zoonotic disease or an outbreak of any disease** that could [potentially] affect animals, plants, or crops [under] **within** the jurisdiction of the Departments of Environmental Protection or [Department of] Agriculture.

(i) A laboratory that tests samples from animals shall report to the Department in accordance with (j) below, within one business day of obtaining a laboratory test result that is positive for the presence of the following organisms in a domestic companion animal:

*Bacillus anthracis*;

*Brucella canis*;

*Burkholderia mallei*;

*Burkholderia pseudomallei*;

*Campylobacter* spp.;

*Chlamydia psittaci*;

*Coxiella burnetii*;

*Escherichia coli*, Shiga toxin-producing strains (STEC) only;

*Francisella tularensis*;

*Leishmania* spp.;

*Leptospira* spp.;

Lymphocytic choriomeningitis virus;

*Mycobacterium tuberculosis*;

*Salmonella* spp.;

SARS-CoV-2; and

*Yersinia pestis*.

(j) A report pursuant to (i) above shall be made by telefacsimile to (609) 826-4874 or secure electronic mail to [zoonoticrn@doh.nj.gov](mailto:zoonoticrn@doh.nj.gov), and contain:

1. The reporting laboratory's name, address, and telephone number;



2. The name, age, and species of the animal;
3. The address of the animal owner if the animal is owned, and, if applicable, the animal facility at which the animal is located;
4. The test performed;
5. The source or type of specimen tested, the date the specimen was collected, and the date of testing;
6. The test result; and
7. The name, address, and telephone number of the veterinarian or veterinary clinic that ordered the test.

8:57-[1.9]2.8 [Reporting of diseases by health] **Health officer[s] reporting obligations and procedures**

(a) A health officer who [is notified of the existence] **receives a report** of [any] a disease, **an infection**, or [illness listed in] **a condition that is reportable pursuant to N.J.A.C. 8:57-[1.5(a)]2.3(a)** [or laboratory report listed in N.J.A.C. 8:57-1.7(a)] **immediately** shall [immediately] notify the Department by telephone [to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours] **and report the case by electronic reporting, except telephone notice is not required for the following: *Haemophilus influenzae*, hepatitis A, mpox, and rubella.**

(b) A health officer who receives a report of a disease, an infection, or a condition that is reportable pursuant to N.J.A.C. 8:57-2.3(b) shall report the case by

**electronic reporting by the close of the business day next following the date of receipt.**

**(c) A health officer who receives a report pursuant to N.J.A.C. 8:57-2.3(f) immediately shall notify the Department by telephone.**

**(d) A health officer who receives a report of a laboratory result that is reportable pursuant to N.J.A.C. 8:57-2.6(a)2 immediately shall report the result to the Department by telephone and, if the reporting laboratory has not already electronically reported the result, electronic reporting.**

**[(b)] (e) A health officer who [is notified of the existence] receives a report of [any disease or illness listed in N.J.A.C. 8:57-1.5 or] a laboratory [report listed in] result that is reportable pursuant to N.J.A.C. 8:57-[1.7]2.6(a)3 shall[, within 24 hours of receipt of the] report[, forward] the [information to the Department via] result by electronic reporting within 12 hours of receipt of the report, if the reporting laboratory has not already electronically reported the result.**

**(f) A health officer who receives a report of a laboratory result that is reportable pursuant to N.J.A.C. 8:57-2.6(a)4 shall report the case by electronic reporting by the close of the business day next following the date of receipt, if the reporting laboratory has not already electronically reported the result.**

**(g) A health officer who receives a Zoonotic Disease Incident Report (provided at N.J.A.C. 8:57 Appendix A) or a report pursuant to N.J.A.C. 8:57-2.7 shall submit the report to the CDS by telefacsimile or electronic mail at [zoonoticrn@doh.nj.gov](mailto:zoonoticrn@doh.nj.gov) by the close of the business day next following the date of receipt of the report.**

[1.] (h) [If the initial] **A health officer who receives a report pursuant to this subchapter that** is incomplete[, the health officer] shall [seek complete] **obtain the information needed to complete the report** and shall [provide all available] **submit the supplemental** information [to the Department] **in the manner established at (a) through (g) above, as applicable,** within five [working] **business days of the date of receipt** of [receiving] the [initial] report.

[2.] (i) [The] **A health officer** [may substitute reporting by mail upon approval of the Department for] **whom this section obliges to report a case or laboratory result to the Department by means of electronic reporting, and who is unable to report thereby, due to equipment technical or power** failure or other circumstance[s, which prevent] **that impedes** electronic communication[s with], **shall notify** the Department **by telephone of the obstacle to electronic reporting and obtain Department instruction as to an alternate means of reporting, which instruction will depend on the nature of the reportable case and the urgency with which response is necessary.**

[(c)] (j) A health officer who [is notified] **receives a report** of [the existence of any] a disease [or illness listed in], **infection, or condition that is reportable pursuant to N.J.A.C. 8:57-[1.5]2.3 or 2.7, which is known or believed to have been contracted in another jurisdiction or to which persons in another jurisdiction may have been exposed, shall notify the health officer for the jurisdiction in which the case is known or believed to have contracted the disease, infection, or condition, and/or in which persons may have been exposed, pursuant to the reporting schedule at N.J.A.C. 8:57-2.3 or 2.7, as applicable.**

**(k) A health officer who receives a report of a laboratory [report listed in] result that is reportable pursuant to N.J.A.C. 8:57-[1.7, which is]2.6 regarding a case who does not reside within that health officer's jurisdiction shall [immediately] notify the health officer in whose jurisdiction the [disease or illness is believed to have been contracted and the health officer in whose jurisdiction the home address of the ill or affected person is located] case resides, pursuant to the reporting schedule at N.J.A.C. 8:57-2.6.**

[1.] **(l) If [either of the above health] a jurisdiction[s are] to which a health officer must issue notice pursuant to (j) or (k) above is not located in New Jersey, the health officer shall forward [this information] the required notice to the Department [by telephone to 609-588-7500, between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours].**

[(d) A health officer may delegate reporting requirements to a staff member, but this delegation shall not relieve the health officer of the ultimate reporting responsibility.]

#### 8:57-[1.10]2.9 Health officer investigations

(a) A health officer[,] **shall conduct an investigation in accordance with this section and the Guidance for Prioritizing Communicable Disease Investigations, provided at N.J.A.C. 8:57 Appendix T, incorporated herein by reference, upon receiving a report or notification of the existence within the health officer's jurisdiction of:**

**1. A confirmed or suspected case of a reportable [communicable] disease, infection, or condition; or**

**2. A confirmed or suspected outbreak[, shall investigate the facts contained in the report] of any disease, infection, or condition.**

[1. The health officer may use the Control of Communicable Diseases Manual, 18th Edition, which provides guidelines for the characteristics and control of communicable diseases.

i. The Control of Communicable Disease Manual, 18th Edition, edited by David L. Heymann, M.D., is available from the American Public Health Association, 800 I Street NW, Washington, DC, 20001, telephone (202) 777-2742.

(b) A health officer shall follow direction given by the Department regarding the investigation set forth in (a) above.]

[(c)] **(b)** [The] **A** health officer, **in** performing [the] **an** investigation [set forth in] **that** (a) above **requires, at a minimum**, shall:

1. Determine whether a single case [or an outbreak] of a reportable [communicable] disease, **infection, or condition, or an outbreak of any disease, infection, or condition**, exists;

**2. Determine the number of cases;**

[2.] **3.** Ascertain the source and [spread] **mode of transmission** of the [illness] **disease, infection, or condition**[; and].

i. **The Department may collaborate with a health officer to support an investigation, as necessary, to ensure timely identification of the source and/or mode of transmission;**

[3.] **4.** Determine and implement appropriate control measures[.];

**5. Collaborate with the Department with respect to public health notifications, such as the issuance of news releases and correspondence to constituents; and**

**6. Adhere to special direction that the Department might issue pursuant to the circumstances of the case or outbreak with respect to the conduct of the investigation.**

[(d) Upon determining that a single case of an immediately reportable communicable disease or an outbreak of a reportable communicable disease exists, the health officer shall immediately relay all available information pertaining to the investigation to the Department by telephone to 609-588-7500 between 8:00 A.M. and 5:00 P.M. on non-holiday weekdays or to 609-392-2020 during all other days and hours.

1. The health officer shall follow telephone reports of immediately reportable communicable diseases and outbreaks with electronic reporting within 24 hours.

2. Reports of investigations of other reportable communicable diseases shall be submitted via electronic reporting, except that sexually transmitted diseases and tuberculosis reports shall be submitted in writing.]

[(e)] **(c)** The Department may require [more than one] **other** health officers to participate in [the] **an** investigation[,] **that this section requires**, [including] **in addition to the health officer of the jurisdiction in which a case resides or an outbreak occurs, provided the other** health officers [who] have jurisdiction over **locations**:

1. [The location of suspected transmission of] **At which the disease, infection, or condition is known or suspected to have been transmitted;**

[2. Areas of residence or occupation of person(s) believed to be ill or infected;]

**2. At which a case is employed, maintains an additional residence, and/or conducts other activities;**

3. [Sites where such persons] **At which a case** may be located [or] **and/or** receiving care; [and] **and/or**

4. [Other jurisdictions, which the] **That the** Department determines [are appropriate and necessary] **to have a geographic nexus to the investigation.**

[(f)] **(d)** If the Department determines that **either** an outbreak is occurring in more than one jurisdiction, **or additional public health measures are indicated**, the Department shall coordinate the investigation, in conjunction with the affected **local** health [departments] **agencies**, and **State and Federal entities, including, but not limited to**, the Centers for Disease Control and Prevention, as [needed] **appropriate in the circumstances.**

**(e)** Pursuant to N.J.S.A. 26:1A-7, 26:4-2, 26:4-4, and App. A:9-33 et seq., a health officer shall conduct the investigation that this section requires within the health officer's jurisdiction, including an investigation that involves a State-owned or State-affiliated building or facility.

[(g)] **(f)** [The] **A** health officer shall submit **to the Department** a [summary] **status** report [to the Department within], **pursuant to (g) below, of the health officer's investigation of each case and/or outbreak occurring within the health officer's jurisdiction, at least every 30 days** [of the completion of each outbreak] **during the pendency of the investigation**[, and to all physicians who reported cases of illness connected with that outbreak.

1. The report shall include, but not be limited to, a] **until the completion thereof, and more frequently as the Department might require, depending on the nature of the threat to public health that a particular disease, infection, condition, or outbreak holds and as necessary to prevent further transmission.**

**(g) A status report that (f) above requires shall contain, at a minimum:**

- 1. A summary of the health officer's findings[, actions];**
- 2. A description of public health actions that the health officer has taken [to control disease, and recommendations] in response to the case and/or outbreak;**
- 3. A list of recommendations the health officer has issued to affected parties[.];**
- 4. The number of cases;**
- 5. Line lists; and**
- 6. Copies of inspection reports and/or preliminary findings associated with site visits to locations associated with the public health investigation.**

[(h) Health officers shall establish quarantine, test and transport procedures for pet birds infected with, or exposed to, avian chlamydiosis in the manner set forth at N.J.A.C.

8:23-1.4.

(i) The Commissioner shall exercise his or her jurisdiction, responsibility and authority during a public health emergency pursuant to N.J.S.A. 26:13-3(c).]

**(h) The Department makes available investigation worksheets for optional use by health officers in conducting investigations of various communicable diseases, infections, and conditions, at <https://www.nj.gov/health/cd/topics>.**



8:57-[1.11]**2.10** Isolation and quarantine for communicable disease, **infection, or condition**

(a) A health officer or the Department, upon receiving a report of a **confirmed or suspected case of a** communicable disease, **infection, or condition**, shall[, by] **issue a** written order[, establish such] **that establishes** isolation **and/or** quarantine measures as medically and epidemiologically necessary to prevent or control the spread of the disease, **infection, or condition**, and in accordance with applicable provisions at **N.J.S.A. 26:4-1 et seq., and/or 26:13-1 et seq.**

**1. A geographic subdivision may elect to enact, in whole or in part, the Model Ordinance for Quarantine and Isolation, provided at N.J.A.C. 8:57 Appendix R, incorporated herein by reference.**

**2. Subject to Department consent, an order issued pursuant to this section shall remain in force until terminated by the health officer or the Department.**

[1.] **3.** If, in the medical and epidemiologic judgment of the health officer or the Department, it is necessary to hospitalize [the ill person in order] **a case** to provide adequate isolation, a health officer or the Department shall promptly remove, or cause to be removed, [that person] **the case** to a hospital.

[2. Such order shall remain in force until terminated by the health officer or the Department.

**3.** A health officer may use Quarantine and Isolation — Model Rules for Local Boards of Health, available at subchapter Appendix B, as a guide for establishing isolation and quarantine measures.

i. Quarantine and Isolation - Model Rules for Local Boards of Health, is written and published by the Communicable Disease Service, New Jersey Department of Health and Senior Services, and is available at subchapter Appendix B, and by written request to the Communicable Disease Service, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369, or online through the Department's web page at <http://www.state.nj.us/health/cd/index.html>;

(b) A health officer or the Department may restrict **the** access of [the] persons permitted to come in contact with or visit a [person] **case** who is hospitalized, [or] isolated, **or quarantined** pursuant to this section [where] **as** medically or epidemiologically necessary to prevent the spread of [the] disease.

[(c) The Department or health officer may, by written order, isolate or quarantine any person who has been exposed to a communicable disease as medically or epidemiologically necessary to prevent the spread of the disease, providing such period of restriction shall not exceed the period of incubation of the disease.]

[(d)] **(c)** [Any] **A** person who is responsible for the care, custody, or control of a person who is ill or infected with a communicable disease shall take all measures necessary to prevent transmission of the disease to other persons.

**(d) A health officer shall establish quarantine, testing, and transport procedures for a pet bird that is infected with, or exposed to, avian chlamydiosis, in the manner set forth at N.J.A.C. 8:23-1.4.**

**(e) In accordance with N.J.S.A. 26:4-2, a health officer, in consultation with the Department, shall isolate, quarantine, test, and/or transport, a domestic**

companion animal that is confirmed to be, or suspected of being, infected with, or exposed to, a reportable zoonotic disease, infection, or condition set forth at N.J.A.C. 8:57-2.7, as necessary, in the circumstances to protect public health and prevent further transmission.

8:57-[1.13]2.11 [Foodhandlers ill or infected with communicable diseases] **Work restrictions associated with a food establishment, drug establishment, or cosmetic establishment, and other worksite at which food, drugs, or cosmetics are handled.**

(a) A person who works at a food establishment, drug establishment, or cosmetic establishment, or is a food employee, who is confirmed as or suspected of being ill or infected with a communicable disease, infection, or condition shall comply with a directive of the Department or a local health agency with jurisdiction prohibiting the person from working at a food establishment, drug establishment, or cosmetic establishment, or other worksite at which food, drugs, or cosmetics are handled.

[(a)] (b) [The] Pursuant to N.J.S.A. 24:15-10, the Department or a health officer may prohibit a person [who] from working in a food establishment, drug establishment, and/or cosmetic establishment, or other worksite at which food, drugs, or cosmetics are handled, if the person is, or has come in contact with a person who is, confirmed as, or suspected of, being ill or infected with a communicable disease, [which may be transmitted] infection, or condition that is transmissible through food [from working with food as set forth at N.J.A.C. 8:24-2.2], drugs, and/or cosmetics.

[(b) The Department or a health officer may prohibit a person who resides in, boards at, lodges in, or visits a household where that person may have come in contact with any person who is ill or infected with a communicable disease, which may be transmitted through food from working with food as set forth at N.J.A.C. 8:24-2.2.]

(c) [The] **As a condition of the removal of a directive or prohibition issued pursuant to (a) and/or (b) above, the** Department or a health officer may require [a] **the** person who is [employed in any establishment where food is manufactured, processed, stored, prepared, or served for public consumption and who is suspected of being ill or infected with a communicable disease, which may be transmitted through food] **subject to the directive and/or prohibition** to submit to a physical examination and/or submit specimens [of blood, bodily discharges, or other specimens] for [the purpose of ascertaining] **laboratory testing to determine** whether [or not] the person is [ill or infected with] **capable of transmission of** a communicable disease[.], **infection, or condition that is transmissible through food, drugs, and/or cosmetics.**

**1. The Department and/or the health officer shall not lift a directive or prohibition issued pursuant to (a) and/or (b) above, unless the person subject to the prohibition is incapable of transmission of a communicable disease, infection, or condition that is transmissible through food, drugs, and/or cosmetics.**

(d) The Department or a health officer may prohibit the sale or distribution of food [which], **drugs, and/or cosmetics that:**

**1. [A] Are manufactured, processed, stored, prepared, and/or served by a** person who is [ill or infected with] **capable of transmission of** a communicable

disease, [which may be transmitted] **infection, or condition that is transmissible** through food [has prepared], **drugs, and/or cosmetics**; or

2. [Is considered] **The Department or a health officer determines** to be a possible [vehicle] **vector or fomite** for **the** spread of disease **or infection**.

**(e) Pursuant to N.J.S.A. 24:15-10, the owner, operator, and other person in charge of a food establishment, drug establishment, or cosmetic establishment, or other worksite at which food handling is performed, shall comply with a directive of the Department or a local health agency with jurisdiction prohibiting a person who is capable of transmission of a communicable disease, infection, or condition that is transmissible through food, drugs, and/or cosmetics, from working at the establishment or worksite.**

#### **8:57-2.12 School data reporting**

**(a) A school administrator shall ensure that the school reports the following data into the CDRSS between 12:01 A.M. Tuesday and 5:00 P.M. Wednesday (reporting date):**

**1. Student census (total number of enrolled students) as of the Tuesday of the reporting date;**

**2. Number of students absent on the Tuesday of the reporting date;**

**3. Reason for each student's absence on the Tuesday of the reporting date;**

**and**

**4. During the Monday through Sunday of the week preceding the reporting date, the number of outbreaks of a communicable disease, infection, or condition**

that were known or suspected to have occurred, and, if an outbreak occurred, the communicable disease, infection, or condition that was known or suspected to have occurred as an outbreak.

#### **8:57-2.13 Nursing home data reporting**

(a) A nursing home administrator shall ensure that the nursing home reports the following data on both Monday and Thursday of each week (reporting date) through REDCap, the CDRSS, or a successor vendor that the Department designates:

1. The total number of residents and staff as of each reporting date;
2. The total number of residents and staff who received a vaccine in compliance with the ACIP recommendations vaccine schedules for COVID-19, influenza, and respiratory syncytial virus, as of each reporting date;
3. During the Monday through Sunday of the week preceding each reporting date, the number of new cases of a reportable communicable disease, infection, or condition among staff and/or residents; and
4. Whether, during the Monday through Sunday of the week preceding the reporting date, an outbreak of any disease, infection, or condition was known or suspected to have occurred, and, if so, the disease, infection, or condition that was confirmed or suspected to have occurred as an outbreak.

(b) The CDS shall report to the Office of Health Care Facility Survey and Field Operations of the Department the failure of a nursing home to timely report in accordance with this section.

**(c) The Department shall issue written and electronic notice to nursing homes if the platform vendor changes.**

### SUBCHAPTER 3. THE NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS)

#### 8:57-3.1 Purpose and scope

(a) The purpose of this subchapter is to[:

1. Implement] **implement** N.J.S.A. 26:4-131 et seq. [(P.L. 2004, c. 138)], the Statewide Immunization Registry Act, which designates [and authorizes] the New Jersey Immunization Information System (NJIIS) as the official Statewide immunization registry, **to be** operated by the Department as the single repository of immunization records and [a repository of] preventive health screening records[;].

[2. Set forth standards for maintaining confidentiality; and

3. Set forth standards for the establishment, use, and maintenance of the NJIIS.

(b) The purpose of the NJIIS is to:

1. Aid in coordinating and promoting effective and cost-efficient disease screening, prevention, and control efforts throughout the State;

2. Allow authorized users to have wider access to a registrant's immunization and preventive health screening information to promote health maintenance;

3. Provide a mechanism to facilitate notice to registrants of an upcoming or overdue vaccination; and

4. Assist health authorities in identifying registrants that require immediate vaccination in the event of a vaccine preventable disease outbreak or other health emergency.]

[(c)] **(b)** This subchapter applies to [all authorized] **applicants for NJIIS user and NJIIS site access, and persons serving as NJIIS coordinators, NJIIS sites, NJIIS site administrators, NJIIS users, and NJIIS registrants.**

#### 8:57-[3.4]**3.2 Confidentiality**

(a) The Department shall [keep confidential all NJIIS] **maintain the confidentiality of individually identifiable** information [that individually identifies] **in the NJIIS regarding** a registrant[.], **subject to the following:**

1. [The] **Pursuant to N.J.S.A. 26:4-134i(8), the Department, in disseminating statistical information and supporting commentary,** shall [use information contained in the NJIIS for NJIIS purposes set forth in N.J.S.A. 26:4-131 et seq. and this subchapter, including the identification of areas with low immunization coverage rates or public health planning activities and as such, may] release aggregate[, statistical] or summary data or information [in which] **that does not, and/or cannot be used, alone or in combination, with other information to identify an individual** registrant[s are not, and cannot be, identified];

[2. Providers furnishing services, health care payors, and State or local health officers or agencies may exchange information contained in the NJIIS for purposes directly connected to the administration of the NJIIS;]



[3.] **2.** [The] **Other than with respect to a person who has requested to not participate in the NJIIS pursuant to N.J.S.A. 26:4-134(i)4 and N.J.A.C. 8:57-3.15,** the Department may release NJIIS information that individually identifies a registrant [or an NJIIS site to]:

i. **To a State or Federal law enforcement [agencies or agencies having investigatory] authority[, in cooperation with investigations of fraud or abuse, or as required for] in connection with a criminal and/or civil law enforcement action;**

ii. **For public health purposes; and**

iii. **As authorized or required by applicable law.**

[4.] **3.** The Department may transmit, share, or exchange information [contained] in the NJIIS with [other] out-of-State regional or state immunization registries [as set forth at] **in accordance with N.J.A.C. 8:57-[3.19(c)]3.15.**

(b) [All] NJIIS sites and [authorized] **NJIIS** users shall [keep medical and personal] **maintain the confidentiality of** information [contained] in the NJIIS [confidential] pursuant to the [terms of the] **NJIIS and User Confidentiality Statement for Access to the NJIIS and User Confidentiality** Agreement[, available] at [subchapter] **N.J.A.C. 8:57 Appendix [C] D, incorporated herein by reference,** and consistent with **and subject to applicable State and Federal law and sanctions contained therein, including N.J.S.A. 26:4-137.**

(c) [Health] **A health** benefits plan[s] may request from the Department the NJIIS immunization record[s] of [their] **a registrant who is its existing or** prior member[s], **customer,** or [beneficiaries that are registrants] **beneficiary** for the purposes stated at

N.J.S.A. 26:4-134(i)7[, which includes completing mandatory HEDIS reports or similar quality assurance or accreditation reports] by submitting a written request[, including a list of] **to the VPDP that provides the name[s] and birthdate[s] of the existing or prior member[s], customer, or [beneficiaries to the VPDP mailing address] beneficiary, or by submitting a mandatory HEDIS® report or a similar quality assurance or accreditation report.**

### 8:57-[3.5]3.3 Administration

(a) The [Department's Vaccine Preventable Disease Program is responsible for the administration of] **VPDP administers** the NJIIS.

[1. The VPDP shall ensure that the NJIIS conforms to the 12 technical functional standards for immunization registries as outlined in the 2001 Immunization Registry Minimum Functional Standards.]

(b) The VPDP designates [the local] **each** MCHC [to coordinate the] **as the NJIIS coordinator within that MCHC's jurisdiction for the purposes of NJIIS site and NJIIS user** enrollment[,] **and** training, **and the conduct of NJIIS** quality assurance [components of the NJIIS, which requires the comparison of] **and auditing activities (NJIIS coordinator).**

**1. An NJIIS coordinator has authority to compare** immunization information contained within [the registrant's medical] **registrants' health** records at [the health care provider's] **NJIIS sites** to [the immunization] information documented in the NJIIS[, under the supervision of the VPDP].

[1.] **2.** [In the event that] **If** the VPDP designates another [organization] **entity** to [coordinate the enrollment, training, and quality assurance components of the] **serve as an NJIIS coordinator**, the VPDP shall provide notice of [such] **the** designation, including [contact information for] the **communication information for the** newly designated [organization, through] **entity using** any of the following methods:

i.-iii. (No change.)

[2.] **3.** [The VPDP-designated organization] **An entity that the VPDP designates as an NJIIS coordinator pursuant to (a)2 above** shall have the same role and obligations as [the] **an** MCHC pursuant to this subchapter.

(c) [A list of the MCHC contact persons and] **NJIIS coordinator** [contact] information is available [by mailing a written] **upon** request to the VPDP [mailing address or] **and** online at the NJIIS webpage.

(d) [The local MCHC offices shall have the responsibility] **An NJIIS coordinator has authority to undertake the following duties** in the enrollment process [to]:

1. [Accept letters of interest from applicants, NJIIS enrollment forms, and user confidentiality agreements] **Administer enrollment applications pursuant to N.J.A.C. 8:57-3.7;**

**2. Make enrollment eligibility determinations pursuant to N.J.A.C. 8:57-3.6;**

**3. Ensure that each applicant executes the User Confidentiality Statement for Access to the NJIIS and User Confidentiality Agreement at N.J.A.C. 8:57 Appendix D, and undergoes training** pursuant to N.J.A.C. 8:57-[3.8 and review them for completeness, eligibility and consistency between the applicant's stated purposes in

becoming an authorized user and the purposes of] **3.5 and 3.6 before granting access**  
to the NJIIS [as set forth in N.J.S.A. 26:4-132 and 134 and this subchapter];

**4. Specify user permissions and access rights pursuant to N.J.A.C. 8:57-3.6;**

[2.] **5. Provide [the mandatory] NJIIS training [for authorized] to applicants for NJIIS user[s as set forth at] status pursuant to N.J.A.C. 8:57-[3.8(g)]3.6; [and]**

[3.] **6. Issue [a] NJIIS user [identification for each authorized user that has completed the] access credentials; and**

**7. Audit NJIIS [training] user and NJIIS site compliance with the Statement for Access to the NJIIS and User Confidentiality Agreement at N.J.A.C. 8:57 Appendix D, incorporated herein by reference.**

8:57-[3.6] **3.4 Eligibility to become an [authorized] NJIIS user and NJIIS site**

(a) [The] **Each of the** following [persons and] entities [are] **is** eligible to become [authorized] **an NJIIS user[s]:**

1. [Health] **A health** care [providers, primary health care providers, child care centers,] **professional;**

**2. A health care facility;**

**3. A State psychiatric hospital as that term is defined at N.J.S.A. 30:1-7 and 30:4-3.23;**

**4. An early childhood center;**

**5. A school[s, colleges, universities,];**

**6. An IHE;**

7. **A** health benefits plan[s,];
  8. **An EHR vendor;**
  9. **An HIE, HIO, and HIN;**
  10. **A** billing and practice management vendor[s,];
  11. **A State agency that has** public health [or State] **and/or** social services [programs,] **functions;**
  12. **A** local health [agencies, the] **agency; and**
  13. **The** Department [and designated agents thereof].
- [(b) The Commissioner in his or her discretion may expand the list of persons and entities eligible to become authorized users in (a) above through agency rulemaking, if provision of access to the NJIIS would advance the purposes of the NJIIS as set forth at N.J.S.A. 26:4-132 and 134, and this subchapter.]

8:57-[3.7]**3.5** [Authorized] **NJIIS** user enrollment **eligibility** requirements

(a) To enroll as an NJIIS [authorized] user, an applicant shall:

[1. Agree to use the NJIIS to further the purposes of promoting public health or providing patient care;

2. Submit a completed]

**1. Execute the NJIIS User Confidentiality Statement for Access to the NJIIS and User Confidentiality Agreement** [, available] at [subchapter] **N.J.A.C. 8:57 Appendix [C,] D and submit it** to the [local MCHC office] **NJIIS coordinator with jurisdiction; [and]**

[3.] **2.** Complete [the mandatory] NJIIS training [as set forth at] **pursuant to N.J.A.C. 8:57-[3.8(g)]3.6; and**

**3. Be associated with an approved NJIIS site.**

8:57-[3.8]3.6 [Authorized] **NJIIS site and NJIIS** user applicant enrollment process

(a) [The administrator of any prospective eligible entity wishing] **An entity seeking** to enroll as an NJIIS site [and as an authorized user] shall submit to the [local] **applicable** [MCHC office, via mail, facsimile or electronic submission,] **NJIIS coordinator with jurisdiction** an application package consisting of:

[1. A statement of interest in enrolling in the NJIIS;]

[2.] **1.** A completed **NJIIS** Enrollment Request for New **NJIIS** Site form[, available] at [subchapter] **N.J.A.C. 8:57** Appendix [A] **B**; [and]

[3.] **2.** [An original] **A fully executed NJIIS** User Confidentiality **Statement for Access to the NJIIS and User Confidentiality** Agreement, available at [subchapter] **N.J.A.C. 8:57** Appendix [C, signed and dated by the responsible person] **D**; **and**

**3. A completed NJIIS Interface Enrollment Request form at N.J.A.C. 8:57 Appendix U, incorporated herein by reference, if the entity intends to submit vaccination information to the NJIIS by means of an electronic interface.**

(b) [The site administrator of any enrolled site wishing to designate agents to access and utilize the] **To enroll a person as an NJIIS** [shall assist the designated agents in enrolling as authorized] user[s by submitting], **an NJIIS site administrator shall submit** to the [local MCHC office, via mail, facsimile or electronic submission, an application package consisting of] **applicable NJIIS coordinator with jurisdiction:**

[1. A statement of interest in enrolling in the NJIIS;]

[2.] **1.** A completed **NJIIS** User Enrollment and Training Request form [, available at subchapter Appendix B, through which the administrator shall request the appropriate level of access for the designated agent:

i. “General reader access” means access to view patient information and to run standard reports;

ii. “General user access” means general reader access and access to modify or add information to existing patient records, add new patients, perform inventory, and perform outreach functions to patients for whom the designated agent’s NJIIS site has primary responsibility;

iii. “Site manager access” means general user access and access to modify critical fields, and maintain inventory control records;

iv. “School/college general user access” means general reader access and access to modify or add information to existing student immunization records, add new students, and perform outreach functions to students for whom the designated agent’s NJIIS site has primary responsibility;

v. “School/college general reader access” means access to view student’s information and to run standard reports; or

vi. “VFC data entry access” means access assigned by the New Jersey VFC Program for vaccine accountability] (**provided at N.J.A.C. 8:57 Appendix C**); and

[3.] **2.** [An original NJIIS] **A** User Confidentiality [Agreement] **Statement for Access to the NJIIS**, available at [subchapter] **N.J.A.C. 8:57 Appendix [C] D**, for each

designated agent individually signed and dated **which the prospective NJIIS user has fully executed.**

(c) The [local MCHC offices] **applicable NJIIS coordinator with jurisdiction** shall [enroll or deny] **review an application for NJIIS site** enrollment [of the prospective entity or designated agent as an NJIIS site and authorized user respectively based on:

1. Consistency between the entity's or designated agent's purposes in enrolling as an NJIIS site and an authorized user, respectively, and the purposes of the NJIIS as set forth in N.J.S.A. 26:4-132 and 134 and this subchapter;

2. Whether the entity or designated agent will use the NJIIS to further the purposes of promoting public health or providing patient care;

3. Whether the selected level of access for each designated agent] **and, if the NJIIS coordinator determines that the applicant is eligible to become an NJIIS site pursuant to N.J.A.C. 8:57-3.4, grant the application, and allocate the applicable NJIIS access level to the applicant.**

(d) **The applicable NJIIS coordinator with jurisdiction shall review an application for NJIIS user enrollment and shall:**

1. **Grant the application and the requested NJIIS access level if the NJIIS coordinator determines that:**

i. **The applicant is eligible to be an NJIIS user pursuant to N.J.A.C. 8:57-3.4; and**

ii. **The requested NJIIS access level** is appropriate [as determined by the description of the designated agent's] **to the proposed NJIIS user's** employment functions **as described in the application;**



**2. If the application is granted pursuant to (d)1 above, enroll the NJIIS user;**  
and

[4. Whether the entity or designated agent complies with the eligibility requirements set forth at N.J.A.C. 8:57-3.6.]

**3. Notify the NJIIS site administrator of the applicant's enrollment as an NJIIS user and that the NJIIS coordinator will issue access credentials upon the NJIIS user's completion of NJIIS training pursuant to (g) below.**

[(d)] **(e) If [the MCHC denies] an NJIIS coordinator determines to deny an enrollment [of an entity or designated agent] application or the requested NJIIS access level, the [MCHC] NJIIS site coordinator shall notify [the]:**

**1. The VPDP of the proposed denial, and the reasons therefor, in writing, within 10 days of the denial determination; and**

**2. The NJIIS site administrator of the [decision] denial, and the reasons therefor, in writing, within [30] 20 days [of the date on which the MCHC makes the decision] after issuing notice pursuant to (e)1 above.**

[1. The MCHC shall notify the VPDP of all enrollment denials and the reasons thereof, within 10 days of such a decision prior to notifying the administrator.

(e) If the MCHC enrolls an entity as an NJIIS site or a designated agent, the MCHC in conjunction with the Department's Office of Information Technology Services (OITS), shall establish access for the NJIIS site or designated agent and assign a user identification and temporary password that allows each authorized user to have the appropriate level of access described in (b) 2 above, upon confirmation of the successful completion of the mandatory NJIIS training as set forth in (g) below.]

(f) An [administrator or] **NJIS** site administrator [may] **can** request a change in an [authorized] **NJIS** user's **NJIS** access level or password [reset] by submitting a completed **NJIS** Request for Change of User Security Authorization/Request for Password Reset form[, available at subchapter Appendix D, to the NJIS Help Desk at the facsimile number indicated on the NJIS webpage or to the local MCHC] **in accordance with the instructions on the form at N.J.A.C. 8:57 Appendix E, incorporated herein by reference.**

[1. An authorized user must periodically change his or her password as prompted by the NJIS.]

(g) [All enrolled authorized] **An NJIS coordinator shall issue access credentials to an applicant for NJIS user[s, shall complete a mandatory] status whose application is approved when the applicant completes the** NJIS training [conducted by an NJIS certified trainer] **that is applicable to the NJIS user's NJIS access level.**

[1. Each NJIS certified trainer shall notify site administrators in writing of authorized users' completion of training.]

**1. The schedule of classroom NJIS training dates and locations, available online NJIS training resources, and the applicable course registration procedures are on the NJIS website.**

8:57-[3.9]**3.7 [Authorized] NJIIS user access to NJIIS information regarding withdrawn registrants; Department investigation of NJIIS system threats; reinstatement of NJIIS user and NJIIS site access**

[(a) Authorized users shall have access to the NJIIS through a web-enabled application after completing the enrollment process set forth at N.J.A.C. 8:57-3.8.

(b) An authorized user will have access to a registrant's NJIIS information limited to the level of access for which the authorized user was approved by the MCHC pursuant to N.J.A.C. 8:57-3.8(b).

(c) Authorized users shall only access information on a registrant contained in the NJIIS under the following circumstances:

1. Health care providers and primary health care providers shall only access information on a registrant whom they have claimed in the NJIIS as their patient and/or to whom they are currently providing health care services;

2. Child care centers, schools, colleges, and universities shall only access immunization information on a registrant that they have enrolled or are in the process of enrolling into their institutions;

3. Health benefits plans shall only access information on a registrant that they have enrolled as a member or beneficiary of their health coverage plan or as set forth at N.J.A.C. 8:57-3.4(c);

4. Billing and practice management vendors shall only access information on a registrant who is the subject of the billing or practice management function the vendor is performing;

5. State public health programs, State or county social services agencies and programs, the collaborating public health programs, NJ Medicaid Program and NJ Family Care Program, shall only access information on a registrant who is enrolled in their specific State public health or State social services agency or program; and

6. Local health officers and agencies or their designees shall only access information on a registrant who resides within the respective local health jurisdiction or authorized service area for performing and fulfilling their public health functions as they relate to the NJIIS.]

[(d)] **(a)** An [authorized] **NJIIS** user [attempting to obtain access to NJIIS information on a registrant that has withdrawn from the NJIIS] will not [be able to] **have** access [the] to information **with respect to a registrant who has withdrawn from the NJIIS pursuant to N.J.A.C. 8:57-3.15**, and, **instead**, will receive a message indicating that [the registrant withdrew from the NJIIS and] the immunization information is not accessible **(hereinafter referred to as an “inactive record”)**.

[(e)] **(b)** [Anyone] **An NJIIS user** seeking technical information or online assistance may [contact the NJIIS Help Desk at 1-800-883-0059 between 8:00 A.M. and 5:00 P.M., Monday through Friday or by email at [helpdesk@doh.state.nj.us](mailto:helpdesk@doh.state.nj.us)] **go to the NJIIS website and select “Submit a Request,” select an NJIIS support topic, and thereupon submit a completed NJIIS Online Ticketing Intake Form at N.J.A.C. 8:57 Appendix F, incorporated herein by reference.**

**(c) Use of the NJIIS by an NJIIS user is subject to audit by the Department and/or the NJIIS coordinator.**

(d) Each NJIIS user and NJIIS site is subject to a duty of cooperation with the Department and/or the NJIIS coordinator in the conduct of NJIIS enrollment, training, quality assurance, and auditing activities, and shall provide information and documentation in support of these activities upon request.

(e) The Department may suspend the access of an NJIIS user and/or an NJIIS site at any time if the Department suspects or confirms, and/or to prevent, a threat to data or system security and integrity and, upon conclusion of its investigation of a threat, may prohibit, and/or impose restrictions and conditions on, the reinstatement of the access of an NJIIS user and/or an NJIIS site to the NJIIS, depending on the result of the investigation and the particular circumstances giving rise to the threat.

8:57-[3.10]3.8 [Authorized] **Process for NJIIS user and NJIIS site withdrawal; access level change request**

[(a) Any administrator or] **An NJIIS** site administrator [may withdraw] **can request the withdrawal** or change **of** an [authorized] **NJIIS** user's access to the NJIIS [at any time] by submitting a completed Request for Change of **NJIIS** User Security

Authorization/Request for Password Reset form, available at [subchapter] **N.J.A.C. 8:57** Appendix [D] **E**, to the [NJIIS Help Desk at the facsimile number indicated on the NJIIS webpage or to the local MCHC] **NJIIS coordinator**.

[(b) The VPDP shall address an administrator's or site administrator's request for withdrawal of an authorized user's NJIIS access within one business day of receipt of the request.]

8:57-[3.11]**3.9** Informing parent[s] **of a newborn about the NJIIS pursuant to N.J.S.A.**

**26:4-134i(3)**

[(a) The VPDP shall make available an NJIIS Informational Brochure, available at subchapter Appendix E.]

[(b)] **(a)** [Birthing facilities] **A birthing facility** shall [complete the following process with regard to informing parents about the NJIIS:

1. Maintain] **maintain** written procedures to document and ensure [each] **that the** parent [is provided a copy of] **of each newborn receives** the NJIIS Informational Brochure before or upon the newborn's discharge from the facility[;].

[2. Document the parent's receipt of the NJIIS Informational Brochure by making a notation in the newborn's permanent medical record.

3. Provide a Declination of Newborn Automatic Enrollment form, available at subchapter Appendix G, to any parent of a newborn that does not wish to participate in the NJIIS; and

4. Retain a copy of the signed and dated Declination of Newborn Automatic Enrollment form as a part of the permanent medical record of the newborn.]

[(c)] **(b)** [Health care providers] **A healthcare professional** providing [medical care] **healthcare** to a [newborn or] minor [born after January 1, 1998,] **who is not enrolled in the NJIIS** shall [complete the following process with regard to informing parents about the NJIIS:

1. Record the provision of] **give either** the NJIIS Informational Brochure, **in a paper or an electronic format, or the link to the brochure on the NJIIS**

**Documents/Forms webpage**, to the **minor's** parent [by documenting the provision of the brochure in the permanent medical record of the newborn or minor;] and

[2. Make a written notation, if the parent declines to participate in the NJIIS, in the permanent medical record of the newborn or] **enroll the minor in the NJIIS in accordance with N.J.A.C. 8:57-3.10(d).**

8:57-[3.12]**3.10** Registrant enrollment

(a) [Birthing facilities] **A birthing facility** shall [automatically] enroll [all] **each** newborn[s born on or after January 1, 1998,] in the NJIIS through submittal of the [electronic birth certificate (]EBC[)] to the [Department's Bureau of Vital Statistics and Registration, unless a parent of a newborn has declined participation and completed a Declination of Newborn Automatic Enrollment form, available in subchapter Appendix G, which shall be noted on the EBC] **Department.**

(b) [When] **In enrolling** a newborn [is enrolled], **a birthing [facilities] facility** shall[:

1. Record and report] **record therein**, information about any vaccine or biologic [administered at] **that** the birthing facility [on the EBC] **administers to the newborn** prior to [the] discharge [of the newborn; and].

[2. Submit the EBC to the Department no later than 14 days following the discharge of the newborn.]

(c) If the birth of a newborn takes place outside of a birthing facility and the newborn is then transferred to a birthing facility, [it shall be the responsibility of] the receiving birthing facility **shall issue the NJIIS Informational Brochure** to [inform] the parent

[about] **pursuant to N.J.A.C. 8:57-3.9(a) and enroll the newborn in the NJIIS by means of the EBC.**

(d) [Health care providers] **Subject to (d)1 below, a health care professional providing [medical care] health care services, and a pharmacist who administers an immunization,** to a [newborn or] minor [born after January 1, 1998,] who [was] **is not [already] enrolled [by a birthing facility] in the NJIIS** shall [automatically] enroll the [newborn or] minor in the NJIIS[, unless the parent of the newborn or minor has declined participation].

**1. An entity listed at (d) above shall not enroll a minor for whom an inactive record appears in the NJIIS.**

[(e) A parent of a newborn or minor not enrolled by a birthing facility, or a parent of a minor born prior to January 1, 1998, may enroll the newborn or minor in the NJIIS by completing the following process:]

[1.] **(e) [Make a request for] An adult person who is not enrolled in the NJIIS can obtain enrollment in the NJIIS upon request,** to any [authorized] **NJIIS user**[, excluding] **whose user access includes access to record immunizations, other than an NJIIS user that is** a billing vendor, health benefits plan, **read-only user**, or practice management vendor[; or] **by:**

[2.] **1. [Submit a completed] Submitting an executed NJIIS Consent to Participate form**[, available] at [subchapter] **N.J.A.C. 8:57 Appendix [F] G,** **incorporated herein by reference,** to the [VPDP at the VPDP mailing address.] **NJIIS user, who shall maintain the executed form in the registrant's health record; or**



**2. Electronically consenting to participate in the NJIIS by means of an EHR that the NJIIS user maintains if the electronic consent format contains the text of the NJIIS Consent to Participate form at N.J.A.C. 8:57 Appendix G.**

(f) An [authorized] **NJIIS** user[, as described in (e)<sup>1</sup> above, or the VPDP respectively,] shall [enroll]:

**1. Enroll** a [newborn or minor in the NJIIS at the request of his or her parent, or enroll an adult registrant, using the process set forth in (e) above or (g) below, respectively] **person in accordance with a request made pursuant to (e) above by** no later than 30 days from the date of the request; and [provide the parent, or an adult registrant, with]

**2. Give the requester** an NJIIS Informational Brochure.

[(g) An adult registrant may enroll in the NJIIS, after receipt of an NJIIS Informational Brochure, available at subchapter Appendix E, by completing the process as set forth at (e)<sup>1</sup> or 2 above.]

[1.] (g) Enrollment in, **and/or withdrawal from**, the NJIIS [shall] **does** not [diminish the responsibility of] **effect** a [parent or an adult registrant,] **person's obligation to provide evidence of immunity or immunization and otherwise** comply with [the immunization rules established at] N.J.A.C. 8:57-4 and 6, as applicable.

[2.] (h) A registrant who [has previously declined participation in, or withdrawn from] **withdrew from participation in** the NJIIS[, in order to] **pursuant to N.J.A.C. 8:57-3.13** **can** resume participation [shall submit a completed Consent] **therein by requesting enrollment and consenting** to [Participate Form, available at subchapter Appendix F to the VPDP mailing address] **participate in accordance with (e) above.**

[(h) A registrant or parent of a registrant, if he or she is a minor, shall not be discriminated against in any way because of his or her refusal to enroll in the NJIIS.

(i) Enrollment in the NJIIS shall not diminish the right of a registrant or his or her parent, if he or she is a minor, to request an exemption from recommended immunizations for medical or religious reasons pursuant to N.J.A.C. 8:57-4.3 and 4.4 or 6.14 and 6.15.]

8:57-[3.13]**3.11** Registrant access to **registrant's NJIIS** information

(a) [Any] **A** registrant or **the** parent of a registrant, if [he or she] **the registrant** is a minor, [shall have access to] **can obtain** a printout of the registrant's NJIIS immunization record[, and may obtain a copy of the record] by [completing the following process]:

1. [Make a written request for record release to] **Requesting the printout from any entity that is** an [authorized] **NJIIS** user[.

i. The authorized user may request verification of identification.

ii. If the authorized user is a health care provider, the provider shall keep a copy of the written request for record release in the permanent medical record of the registrant] **whose NJIIS access level includes the ability to view and print the registrant's NJIIS immunization record**; [or]

2. [Submit] **Submitting** a completed **NJIIS** Request for Copy of NJIIS Immunization Record form [, available] at [subchapter] **N.J.A.C. 8:57** Appendix I, **incorporated herein by reference**, to the VPDP [at the VPDP mailing address.]; **or**

[(b) The authorized user or the VPDP shall respond to a request for a copy of a registrant's NJIIS immunization record made pursuant to (a) above within 15 days from the date of receipt of the request.]

**3. Obtaining the record from the Docket® mobile phone application or Docket® website application at <https://myhealthnj.com>, or a successor application administered by an entity with which the Department may elect to enter into a cooperative data sharing agreement.**

8:57-[3.14]**3.12** Registrant amendment of **NJIIS** record

(a) [Any] **A** registrant, or **the registrant's** parent [of a registrant], if [he or she] **the registrant** is a minor, [may] **can** request [an amendment] **modification and/or supplementation** of [demographic or medical information contained in] the registrant's NJIIS record by submitting a request [for an amendment of:

1. Demographic information] to [an authorized user utilizing] **any of the following in the manner the entity to whom the request is made specifies, provided the entity is an NJIIS user:**

i. **The registrant's healthcare professional;**

ii. **A person licensed pursuant to Title 45 of the New Jersey Revised Statutes whose authorized scope of practice includes the ordering of a vaccine, with respect to an amendment request related to a vaccine that the licensee administered; or**

iii. **A pharmacist, with respect to an amendment request related to a vaccine that the pharmacist administered.**

**(b) An entity receiving a request for NJIIS record modification or supplementation pursuant to (a) above shall:**

**1. Annotate the NJIIS record of the person who is the subject of a request made pursuant to this section to indicate the requested modification or supplementation, the determination that the entity makes thereon, if applicable, and any additional information a requester submits in support, and/or in rebuttal to a denial, of a request; and**

**2. Notify the requester of the opportunity to seek the VPDP's consideration of a denied request.**

**(c) A registrant, or the registrant's parent if the registrant is a minor, can request modification and/or supplementation of the registrant's NJIIS record by submitting a completed NJIIS Request for Change to NJIIS Immunization Record form[, available] at [subchapter] N.J.A.C. 8:57 Appendix H, incorporated herein by reference, to the VPDP with [appropriate] documentation [necessary to modify existing information contained in an] supporting the requested modification and/or supplementation of the NJIIS record[; or].**

[2. Medical information to the VPDP utilizing the Request for Change to NJIIS Immunization Record form with appropriate documentation necessary to modify existing information contained in an NJIIS record.

i. The VPDP shall process the request for an amendment of medical information in compliance with the Health Insurance Portability and Accountability Act (HIPAA) of 1996, 42 U.S.C. §§ 1301 et seq. and the rules promulgated

thereunder by the United States Secretary of Health and Human Services,  
specifically 45 CFR 164.526.]

[(b)] **(d)** The VPDP may deny a request [to amend medical information, upon  
determining] **made pursuant to (c) above, if it determines** that the [information]  
**registrant's existing NJIIS record** is accurate [and complete as documented in the  
NJIIS].

[(c)] The authorized user or the VPDP shall respond to the request for an amendment no  
later than 60 days after receipt of the request.]

[(d)] **(e)** If the [authorized user or the] VPDP [grants the requested amendment  
completely] **determines to grant, in whole** or in part, **a request made pursuant to (c)**  
**above**, the [authorized user or] VPDP[, respectively,] shall:

1. [Make the appropriate amendment to] **Modify or supplement** the registrant's  
[information] **NJIIS record, as appropriate**; and

2. [Inform] **Issue a written notice to** the [registrant of] **requester, indicating** the  
**VPDP's** acceptance of the request [in accordance with (c) above].

[(e)] **(f)** If the [authorized user or] VPDP [denies the requested amendment] **determines**  
**to deny, in whole or in part, a request made pursuant to (c) above**, the [authorized  
user or] VPDP[, respectively,] shall [provide the registrant or parent of the registrant, if  
he or she is a minor, with] **issue** a written [denial pursuant to (c) above that contains the  
basis] **notice to the requester, indicating the reasons** for the denial, and [notification]  
**informing the requester** of the [registrant's] **requester's** right to submit a written  
statement of reasonable length disagreeing with the denial **to the VPDP for inclusion**  
**in the NJIIS record of the registrant who is the subject of the request.**

[(f) If the authorized user or VPDP denies the requested amendment after review of the registrant's or parent of the registrant's written statement pursuant to (e) above, the authorized user or VPDP, respectively, may prepare a written rebuttal to the requestor's statement of disagreement and shall provide a copy of the rebuttal to the requestor.]

(g) The VPDP shall [make a notation in] **annotate** the [registrant's] NJIIS record [under the NJIIS Notepad tab of the] **of a registrant who is the subject of a request** [for an amendment, the denial of the request, any] **made pursuant to (c) above, to indicate the requested modification or supplementation, the determination that the VPDP makes thereon pursuant to (e) and/or (f) above and, if the requester submits a written statement of disagreement[, and any written] pursuant to (f) above, the content of the statement [of rebuttal] or a summary thereof.**

(h) [The authorized] **An NJIIS** user [or] **and the** VPDP[, respectively,] shall maintain all documents related to [the amendment of record process set forth in (a) though (f) above] **a request made pursuant to this section.**

[(i) Any authorized user or health care provider that denies a request for an amendment pursuant to this section shall send a copy of the denial and all related documents to the VPDP at the VPDP mailing address for additional review.

1. The VPDP shall:

- i. Evaluate the denial;
- ii. Make recommendations to the authorized user; and
- iii. Retain all related denial documentation on file.]

8:57-[3.15]**3.13** [Registrant] **NJIS registrant** withdrawal; **reenrollment**

(a) A registrant or **the registrant's** parent [of a registrant], if [he or she] **the registrant** is a minor, [may] **can** withdraw from the NJIS [at any time] by [completing the following process:

1. Submit] **submitting** a completed **NJIS** Registrant Withdrawal from NJIS form[, available] at N.J.A.C. 8:57[-3] Appendix J, **incorporated herein by reference**, to the VPDP [at the VPDP mailing address].

[i.] **1.** The VPDP shall retain the [copy of the] **submitted** form on file.

(b) The VPDP shall respond to a request for withdrawal [made by a registrant, or parent of a registrant, if he or she is a minor,] within [three] **five** business days [from] **of** the date of receipt of the request.

1. The VPDP shall [deactivate the complete immunization] **make inactive the registrant's NJIS** record [within the NJIS] and send [a] **written** confirmation [letter] to the [registrant, or parent of a registrant, if he or she is a minor stating that the immunization record was deactivated within the NJIS Registry] **requester**.

(c) A registrant, or **the registrant's** parent [of a registrant], if [he or she] **the registrant** is a minor, [may] **can** reenroll [the registrant] in the NJIS by [completing the process established at] **consenting to participate pursuant to** N.J.A.C. 8:57-[3.12]**3.10**.

8:57-[3.16]**3.14** Mandatory **NJIS** participation [for health care providers]

(a) [Every health care provider administering vaccines to children less than seven years of age] **Subject to (h) below, a healthcare professional who provides health care services or administers an immunization to a minor, and a pharmacist who**

**administers an immunization to a minor**, shall [register as] **become** an NJIIS site and [authorized] **NJIIS** user and [commence online reporting of vaccinations, prior to December 31, 2011,] **report** in [compliance] **accordance** with **(d) through (f) below** and this [subchapter] **chapter**.

(b) [Any health care provider that participates in the] **Subject to an applicable earlier NJIIS registration and reporting obligation that (a) above establishes, and subject to (h) below, a healthcare professional or pharmacist who administers an immunization to a person who is 18 years of age and under 19 years of age shall become an NJIIS site and NJIIS user and report in accordance with (d) through (f) below and this chapter, by (one year after the operative date of this rulemaking).**

(c) **Subject to an applicable earlier registration and reporting obligation that (a) or (b) above establish, and subject to (h) below, each healthcare professional or pharmacist who administers an immunization to a person who is 19 years of age or older shall register as an NJIIS site and NJIIS user and report in accordance with (d) through (f) below and this chapter, by (545 days after the operative date of this rulemaking).**

**(d) An entity that is subject to (a), (b), or (c) above** shall report [vaccinations of NJIIS registrants through the following ways:

1. Birthing facilities that complete information on the EBC;
2. The collaborating public health programs, NJ Medicaid Program, or NJ FamilyCare Program;



3. An intermediary authorized user with an electronic connection to] the information required pursuant to (e) and (f) below, within 14 days of the entity's administration of a vaccine:

1. By manual data entry into the NJIIS[, such as a health benefit plan, practice management vendor, or billing management vendor]; or

[4. An authorized user entering data manually for an NJIIS site directly into the NJIIS through an internet connection.]

2. Through an EHR vendor, HIO, HIE, or HIN that establishes an NJIIS interface in accordance with N.J.A.C. 8:57-3.15.

[(c) Health care providers shall report to the NJIIS the administration of a vaccine to a child less than seven years of age within 30 days of administration.]

[(d)] (e) [Health care providers] **An entity that is subject to (a), (b), or (c) above** shall report, update, **correct**, or verify, as applicable, the following [required data fields for the] **with respect to a** registrant [within 30 days of vaccine administration]:

1.-2. (No change.)

[3. Ethnicity/Race;]

**3. Ethnicity;**

**4. Race;**

[4.] **5.** (No change in text.)

[5. Address;

6. Name of responsible party and relationship;]

**6. Relationship of enrollee to head of household at address at which enrollee resides;**

7. Full name of head of household at address at which enrollee resides;
8. Address at which enrollee resides and type of address;
9. Telephone number;
10. Birth country;
11. Plurality (whether enrollee was part of a multiple birth), and if plural birth, birth order of enrollee;
12. Vaccines For Children program eligibility and basis;
13. Insurance type and insurance name;
14. If enrollee is born prior to January 1, 1998, consent information pursuant to N.J.S.A. 26:4-134; and
15. Dose information for each dose administered, including:
  - i. Date enrollee received dose;
  - [7.] ii. Name of the **administered** vaccine [administered];
  - iii. Administration route;
  - iv. Funding source of the administered vaccine; and
  - [8.] v. [Vaccine lot] **Lot number, manufacturer, and expiration date** of the [vaccine] administered[;] **vaccination**.
  - [9. Funding source of the vaccine administered; and
  10. The month, day, and year the health care provider administered the vaccine.

(e) A health care provider may delegate the reporting requirement to a designated agent but such delegation shall not relieve the health care provider of the responsibility to report the administration of vaccines.]

(f) To the extent the information is available, [participating NJIIS health care providers may] **a healthcare professional who is subject to (a), (b), or (c) above shall** report [the following] to the NJIIS[, in order] to complete [the] **and/or correct** a registrant's [immunization history] **NJIIS record**:

1. Any doses of vaccinations **that the healthcare professional or another entity** previously administered to [the] **a registrant** [by the health care provider] that [may not have been reported to] the **registrant's NJIIS record does not fully and accurately reflect, including the information required pursuant to (e) above; [or]**

2. Any doses of vaccinations previously administered to the registrant by [a prior health care provider,] **another entity** for which there is documentation **executed by an entity that is subject to (a), (b), or (c) above, or a healthcare professional or pharmacist in another jurisdiction whose authorized scope of practice includes the administration of immunizations.**

(g) [Non-participating NJIIS health care providers may notify the VPDP of a potential] **A healthcare professional to whom (a), (b), or (c) above do not apply and who does not participate in the NJIIS as an NJIIS site or NJIIS user shall report a known or suspected** error in [the] **an enrolled NJIIS registrant's NJIIS record, and, if known to** the [health care provider believes any information is inaccurate or false] **healthcare professional, the correct information,** by submitting [a] **an NJIIS** Request for Change to NJIIS Immunization Record form, available at [subchapter] **N.J.A.C. 8:57** Appendix H[, to the VPDP at the VPDP mailing address].

(h) **An entity to whom (a), (b), or (c) above apply need not become an NJIIS site if the entity is an NJIIS user at an existing NJIIS site through which the entity has an**

**NJIS access level that enables the entity to report in full compliance with (d), (e), and (f) above.**

8:57-[3.19]**3.15** Data exchange

(a) [Any authorized] **An NJIS** user reporting vaccinations pursuant to N.J.A.C. 8:57-[3.16, or performing or reporting preventive health screenings]**3.14(d)2** shall submit all vaccination [and preventive health screening] information to the NJIS in a secure electronic format [as established by the Department] **pursuant to (b) below.**

[1. The Department shall inform authorized users, as described in (a) above, of the secure electronic file format upon completion of the enrollment and training process established at N.J.A.C. 8:57-3.8.]

(b) [Health] **An EHR vendor, an HIO or HIE/HIN, a health** benefits plan[s], **a** billing vendor[s], and **a** practice management vendor[s should] **shall** submit all vaccination [and preventive health screening] information to the NJIS in accordance with [the NJIS interface file specifications.] **either:**

[1. The Department's Office of Information Technology Services (OITS) VPDP will distribute NJIS interface file specifications to authorized users that will be made available on the NJIS webpage at: <http://njiis.nj.gov/njiis/jsp/uploadshots.jsp>.

2. Interface file specifications may be requested by calling the NJIS helpdesk at (800) 883-0059.

3. Data exchange requestors should develop the interface according to format specifications and contact the NJIS helpdesk at (800) 883-0059 to establish the secure file transfer protocol.]

1. As a maximum standard, CDC and American Immunization Registry Association (AIRA), *HL7 Version 2.5.1 Implementation Guide for Immunization Messaging, Release 1.5, 2018 Update* (October 15, 2018), incorporated herein by reference, as amended and supplemented, available at <https://www.cdc.gov/iis/technical-guidance/hl7.html>; or

2. As an alternative lesser standard, the Department, *NJIIS Interface Management System HL7 Version 2.5.1, Local Implementation Guide: Immunization Messaging (Release 1.5)* (February 11, 2025), incorporated herein by reference, as amended and supplemented, available at <https://njiis.nj.gov/core/web/index.html#/home/interfaceEnrollment>.

(c) The Department may permit the transmission, sharing, or exchange of immunization data contained in the NJIIS, in part or in its entirety, with another state or regional immunization registry that is officially **recognized by those states or regions, or by** the [United States Department of Health and Human Services, Centers for Disease Control and Prevention ([CDC])], National Center for Immunization and Respiratory Diseases [through voluntary certification as set forth in the IRC,] pursuant to its health care oversight function if:

1. (No change.)
2. The NJIIS data is to be exchanged in [good faith in order to further the purposes of promoting public health and/or providing patient care] **accordance with the AIRA, Public Health Immunization Information System Interjurisdictional Memorandum of Understanding (AIRA-PHIIS-IMOU)**, which is available at

<https://repository.immregistries.org/resource/public-health-iis-interjurisdictional-memorandum-of-understanding-mou>.

(d) [To the extent that the Department permits the exchange of] **With respect to any** data [contained in] the [NJIIS, the Department's data exchange policies will be consistent with the Implementation Guide for Immunization Data Transactions] **VPDP receives from a state or regional immunization registry outside of the State of New Jersey, the VPDP will adhere to the processes and procedures established in the AIRA-PHIIS-IMOU, to the extent applicable, or, if the AIRA-PHIIS-IMOU is inapplicable, the processes and procedures of the sending entity.**

8:57-[3.20]**3.16 Reports pursuant to N.J.S.A. 26:4-134i(8)**

(a) [The] **If the** Department [may release summary statistical data and supporting narrative information collected from the] **disseminates statistical information and supporting commentary in a report using data from the NJIIS, the report will represent the NJIIS data** in an aggregate form that does not identify [an] individual registrants [or authorized user, to local health agencies or other State public health or State social service agencies].

[(b) The Department shall prepare statistical and narrative reports or related documents as requested by the NJIIS funding agency, the United States Department of Health and Human Services, CDC and as required by the cooperative grant agreement between the Department and the CDC.

(c) Individuals or entities shall not utilize information contained in the NJIIS or reports generated from the NJIIS in a punitive manner against any authorized user.

(d) Individuals or entities shall not utilize information contained in the NJIIS or reports generated from the NJIIS for a pecuniary or profit motive, marketing, or a similar purpose.

(e) Reports and records of registrants including individual level data generated from the NJIIS or with NJIIS data shall not be included under materials available for public inspection pursuant to N.J.S.A. 47:1A-1 et seq., and shall be]

**(b) Information in the NJIIS is confidential pursuant to N.J.S.A. 26:4-137 and deemed to be** “information relating to medical history, diagnosis, treatment, or evaluation” within the meaning of Executive Order **No. 26**, § 4(b)1 ([McGreevey, August 13,] 2002), and therefore, not **a** government record[s] subject to public access or inspection within the meaning [of] **at** N.J.S.A. 47:1A-1 et seq.

#### 8:57-[3.22]**3.17 [Penalties] Enforcement**

[(a) Any authorized] **An NJIIS user or NJIIS site** that fails to comply with this subchapter **or the Statewide Immunization Registry Act, N.J.S.A. 26:131-1 et seq.**, or knowingly enters false information into the NJIIS [shall be] **is** subject to suspension or revocation of access to the NJIIS, **and applicable penalties, including, but not limited to, those described at N.J.S.A. 26:4-137 (establishing improper disclosure of information in the NJIIS as a disorderly persons offense) and N.J.A.C. 8:57-1.4.**

[(b) The Department may issue a written notification and warning to a health care provider that fails to complete required reporting of vaccination information pursuant to N.J.A.C. 8:57-3.16, after consideration of the following:

1. Whether the health care provider failed to report within 30 days of administration; and/or

2. Whether the health care provider failed to register as an NJIIS site and authorized user and commence online reporting of vaccinations prior to January 1, 2011.

(c) If a health care provider continues to be deficient in required reporting of vaccination information 30 days after receiving notification and warning from the Department as set forth in (b) above, the Department may impose other actions, such as:

1. Notification violation to the State Board of Medical Examiners or State Board of Nursing, as appropriate; and/or

2. Notification of the violation to the appropriate hospital medical director or administrator.]

#### SUBCHAPTER 4. IMMUNIZATION OF [PUPILS IN SCHOOL] **CHILDREN IN CHILD CARE CENTERS AND SCHOOLS**

##### 8:57-4.1 [Applicability] **Scope**

**(a)** This subchapter [shall apply] **applies** to [all children attending any public or private] **the administrator (administrator) of one of the following types of facility in New Jersey:**

**1. A public or private school[, child care center, nursery school, preschool or kindergarten in New Jersey.] from pre-kindergarten through the 12th grade or a comparable age-level special education program with an unassigned grade (school); and**



**2. A child care center.**

**(b) As used in this subchapter, the term “facility” collectively refers to a school and a child care center.**

**(c) This subchapter shall not be construed to limit a private entity’s ability to exclude persons from attendance, notwithstanding religious exemptions that would otherwise be available to those persons, who do not have:**

**1. Immunizations that this chapter requires;**

**2. Immunizations that the Department recommends or requires pursuant to N.J.A.C. 8:57-1.8; and/or**

**3. Additional immunizations that this chapter does not require, but that are consistent with ACIP recommendations or the AAP Red Book, including ACIP recommendations or the AAP Red Book with respect to applicable Catch-up Schedules, medical contraindications, and recognition of serologic immunity.**

**8:57-4.2 [Proof] Administrator to require evidence of immunization or immunity**

**(a) [A principal, director or other person in charge of a school, preschool, or child care facility] Subject to N.J.A.C. 8:57-4.7 and 4.8, an administrator of a facility shall require a submission on a minor’s behalf, as a condition of the minor’s admission to and continued enrollment in the facility, of evidence of the minor’s:**

**1. Immunization compliant with N.J.A.C. 8:57-4.3 and 4.4 and 6A:32;**

**2. Immunity pursuant to N.J.A.C. 8:57-4.5; and**

**3. If the applicant for admission or enrollment has attained majority, immunization in accordance with applicable Child and Adolescent Immunization**

**Schedule and the Catch-up Schedule, and the Adult Immunization**

**Recommendation with respect to the MMR, Tdap or TD, VAR, Hep-B, and Men-ACWY.**

**(b) Subject to (d), (e), and (f) below and N.J.A.C. 8:57-1.8, with respect to an administrator's review of the timing of doses identified in documentation submitted as evidence pursuant to N.J.A.C. 8:57-4.3 of a minor's immunization pursuant to N.J.A.C. 8:57-4.4, immunity pursuant to N.J.A.C. 8:57-4.5, and medical contraindication pursuant to N.J.A.C. 8:57-4.7, the ACIP recommendations and the AAP Red Book control as to the validity of doses, and determinations of immunization, immunity, and medical contraindications or precautions.**

**(c) An administrator shall not knowingly admit to or retain at a facility [any child] a minor upon whose [parent or guardian has not submitted acceptable] behalf evidence of the [child's] minor's immunization[, according to the schedules specified in this subchapter. Exemptions to this requirement are identified at N.J.A.C. 8:57-4.3 and 4.4] or immunity pursuant to (a) above, is not submitted.**

**(d) In accordance with the McKinney-Vento Homeless Assistance Act, 42 U.S.C. §§ 11431-11435, and N.J.A.C. 6A:32, an administrator of a facility shall allow 10 days for the transfer of a minor's immunization record from a previously attended facility that meets the requirements of this subchapter, during which time the administrator shall admit the minor to the facility.**

**(e) An administrator shall not exclude a minor from attendance at a facility on the grounds that the immunization evidence submitted on the minor's behalf shows that the minor received doses of the following vaccines on dates that are**

inconsistent with the ACIP recommendations for minimum age and dose intervals if the immunization evidence shows that the minor received one or more doses of that vaccine prior to (the operative date of this amendment):

1. In lieu of compliance with N.J.A.C. 8:57-4.3(a)1:

i. Diphtheria, tetanus, and acellular pertussis vaccine (commonly referred to as DTaP);

ii. Tetanus, diphtheria, and acellular pertussis vaccine (commonly referred to as Tdap); and/or

iii. Tetanus and diphtheria toxoids vaccine (commonly referred to as Td); and

2. In lieu of compliance with N.J.A.C. 8:57-4.3(a)4, poliovirus (commonly referred to as IPV or OPV).

(f) An administrator shall not exclude a minor from attendance at a facility on the grounds that the immunization evidence submitted on the minor's behalf shows that the minor received doses of the following vaccines on dates that are inconsistent with the ACIP recommendations for minimum age and dose intervals if the immunization evidence shows that the minor received one or more doses of that vaccine prior to January 7, 2008:

1. Measles, mumps, and rubella (commonly referred to as MMR);

2. Hepatitis B (commonly referred to as HepB);

3. Pneumococcal conjugate vaccine (commonly referred to as PCV);

4. *Haemophilus influenzae* type B (commonly referred to as Hib); and

5. Varicella (commonly referred to as VAR).

**8:57-4.3 Immunizations as to which an administrator shall require evidence**

**(a) With respect to a minor entering or attending a child care center, and subject to (b) below, an administrator shall require submission of evidence of the minor's immunization with the following vaccines in accordance with the ACIP recommendations, administered by a healthcare professional, a pharmacist, or a healthcare professional or pharmacist in a jurisdiction other than New Jersey whose licensed scope of practice includes the administration of immunizations, as a condition of the minor's admission to and continued enrollment therein:**

- 1. DTaP;**
- 2. Hib;**
- 3. PCV;**
- 4. Poliovirus (commonly referred to as IPV or OPV);**
- 5. Influenza (commonly referred to as inactivated influenza vaccine (IIV)) or live-attenuated influenza vaccine (commonly referred to as LAIV), subject to (b) below;**
- 6. MMR; and**
- 7. VAR.**

**(b) Notwithstanding applicable ACIP recommendations with respect to the influenza vaccine, as an alternative to (a)5 above, an administrator shall admit a minor upon the submission of evidence of the minor's immunization by November 30 of each year with one dose of the applicable influenza vaccine that is formulated for each influenza season as announced by the CDC.**

**(c) With respect to a minor entering or attending a school, and subject to (d), (e), and (f) below, an administrator shall require the submission evidence of the minor's immunization with the following vaccines in accordance with the ACIP recommendations, and as administered by a healthcare professional, pharmacist, or a healthcare professional or pharmacist in a jurisdiction other than New Jersey whose licensed scope of practice includes the administration of immunizations, as a condition of the minor's admission to and continued attendance therein:**

- 1. DTaP, Tetanus diphtheria toxoid (commonly referred to as Td), Tdap, or DT;**
- 2. Hep B;**
- 3. IPV or OPV;**
- 4. MMR;**
- 5. VAR; and**
- 6. Meningococcal serogroups A, C, W, Y vaccine (MenACWY).**

**(d) Notwithstanding the ACIP recommendations with respect to the number of varicella vaccine doses, as an alternative to (c)5 above, a school administrator shall admit a minor upon the submission of evidence of the minor's immunization with at least one varicella vaccine dose administered in accordance with the ACIP recommendations as to minimum age.**

**(e) Notwithstanding the ACIP recommendations with respect to the number of doses of Meningococcal serogroups A, C, W, Y vaccine (MenACWY), as an alternative to (c)6 above, a school administrator shall admit a minor upon the**

submission of evidence of the minor's immunization with at least one dose of MenACWY vaccine administered in accordance with the ACIP recommendations.

(f) Notwithstanding ACIP recommendations stating that a minor should receive certain doses of the following vaccines during the ages of four through six years of age (four- to six-year dose), an administrator of a school shall require the submission of evidence of a minor's immunization with the four- to six-year doses of the following vaccines by the earlier of the minor's attendance at either kindergarten or a higher grade, as a condition of the minor's admission to and attendance therein:

1. DTaP;
2. IPV or OPV; and
3. MMR.

8:57-[4.6]4.4 [Documents accepted as evidence] **Evidence** of immunization

(a) [The following documents shall be accepted] **An administrator shall accept, and maintain as part a minor's immunization record pursuant to N.J.A.C. 8:57-4.6, the types of documentation listed at (b) below** as evidence of a [child's] minor's immunization [history provided that the type of immunization and the date when each immunization was administered is listed] **pursuant to N.J.A.C. 8:57-4.2 and 4.3 if, alone or in combination with other items listed at (b) below, the submitted record identifies:**

1. The month, day, and year of administration of each required vaccine dose; or

**2. Only the month and year of administration of each required vaccine dose if the totality of the documentation presented enables the administrator to undertake the analysis and make the determination that (c) below, requires.**

**(b) Subject to (a) above, the following are acceptable forms of evidence of immunization:**

1. An official [school] **facility** record [from any school, pre-school, or child care center] indicating compliance with the immunization requirements of this subchapter, **including electronic health records;**

2. A record [from any public health department] **issued by a governmental health** [TB indicating compliance with the immunization requirements of this subchapter] **authority of the USA;**

3. A [certificate] **record** signed by [a physician licensed to practice medicine or osteopathy, or an advanced practice nurse (certified registered nurse practitioner, or clinical nurse specialist)]:

**i. A healthcare professional;**

**ii. A pharmacist;**

**iii. Any other entity licensed pursuant to Title 45 of the Revised Statutes of New Jersey whose authorized scope of practice includes the ordering of a vaccine; or**

**iv. A person who holds a credential in good standing that is equivalent or corresponds to a credential at (b)3i, ii, or iii above, in [any] a jurisdiction [of the United States indicating compliance with the immunization requirements of this subchapter] other than New Jersey, whose authorized**

**scope of practice includes the ordering of vaccines, provided that if the record is in a language other than English, it is accompanied by an English translation consistent with (a)6 below; [or]**

4. [The] **An** official record [of immunization] from the New Jersey Immunization Information System [indicating compliance with the immunization requirements of this subchapter.

(b) All immunization records submitted by a parent or guardian], **including a record from the Docket® mobile phone application or Docket® website application at <https://myhealthnj.com>, or a successor application administered by an entity with which the Department may elect to enter into a cooperative data sharing agreement;**

**5. An official State of New Jersey School Immunization Record; and/or**

**6. A signed record issued by a foreign governmental agency; provided that, if the record is** in a language other than English [shall be accompanied by a], **it is accompanied by an English** translation [sufficient to determine compliance with the immunization requirements of this subchapter.

(c) Laboratory evidence of protective immunity, as enumerated by the Advisory Committee on Immunization Practices (ACIP) of the United States Public Health Service, shall be accepted as evidence of immunization if a parent or guardian cannot produce a documented history of immunization.] **thereof, certified to be true under penalty of perjury, as follows:**



i. A certification pursuant to (b)5 above from any adult is acceptable, provided the certification contains the following statement, and, below the statement, the printed name and signature of the translator, and the date:

“I certify that the translation above faithfully and accurately reproduces in English the closest natural equivalent of the attached document without embellishment, omission, or explanation. I certify that the foregoing statements made by me are true. I am aware that if any of the foregoing statements made by me are willfully false, I am subject to punishment.”

(c) An administrator shall evaluate the evidence submitted on a minor’s behalf pursuant to this chapter, in consultation with the VPDP as may be necessary in the circumstances, to confirm that:

1. The minor received the immunizations of which this subchapter requires the administrator to confirm that minor’s receipt;

2. The required doses were administered by a healthcare professional or a pharmacist; and

3. The dose of each vaccination was a valid dose pursuant to N.J.A.C. 8:57-4.2 and 4.3.

#### **8:57-4.5 Evidence of immunity**

(a) An administrator shall accept any of the following as evidence of a minor’s immunity to a vaccine-preventable disease against which an administrator is to require evidence of immunization pursuant to N.J.A.C. 8:57-4.3, subject to the

**ACIP recommendations and the AAP Red Book for scheduling, laboratory testing, and other indicators of immunity:**

**1. A positive serologic test result indicative of immunity to:**

**i. Measles;**

**ii. Mumps;**

**iii. Rubella;**

**iv. Varicella; and/or**

**v. Poliovirus (demonstrated by a positive test result for types one, two, and three);**

**2. With respect to hepatitis B, a positive:**

**i. Surface antibody laboratory test result after completion of the ACIP recommendations schedule; or**

**ii. Surface antigen laboratory test result and/or core antibody test result, indicating infection with hepatitis B virus; and**

**3. With respect to varicella, a record signed by a healthcare professional stating that the healthcare professional diagnosed or verified that the minor has had varicella (chicken pox).**

**(b) Pursuant to N.J.S.A. 26:2N-8 through 11, commonly known as “Holly’s Law,” in lieu of requiring evidence of a minor’s immunization with a second dose of vaccine for measles, mumps, and rubella, an administrator shall admit to school a minor upon the submission of documentation of a positive serologic test result, also known as an antibody titer, for measles, mumps, and rubella.**

**8:57-4.6 Administrator obligations with respect to documentation of compliance and recordkeeping**

**(a) Subject to (b) below, an administrator shall:**

**1. Maintain all original documents and evidence submitted on a minor's behalf pursuant to this subchapter in a discrete file (file) with respect to each minor that an administrator:**

**i. Enrolls and admits to a facility; and**

**ii. Excludes from attendance at a facility;**

**2. Keep the file separate from the minor's educational and medical records; and**

**3. Make the file available for inspection on request of the local health official with jurisdiction and/or the Department for immunization record auditing and related public health oversight and enforcement activities.**

**(b) While an administrator may elect to store, electronically, some or all information that this subchapter requires the administrator to collect and maintain, the administrator's ability to generate documents or lists from that electronically stored information does not obviate the administrator's obligation to maintain the original (paper) documents and evidence pursuant to (a) above.**

**1. The Department shall treat any documents or lists the administrator generates from electronically stored information to be in supplement to, and not in replacement of, the file containing the original material.**

**(c) A file that an administrator creates pursuant to (a) above is a minor's "immunization record," as laws and rules that are within the administration of the**

**New Jersey Department of Education use that term, specifically with respect to access, retention, transfer, and disposal. (See N.J.A.C. 6A:16-2.4 and 6A:32-7)**

**8:57-[4.3]4.7 [Medical exemptions] Exemption due to medical contraindication; required documentation; administrator review**

(a) [A child] **An administrator** shall not [be required to have any specific] **require evidence of** immunization[(s) which are] **or immunity pursuant to N.J.A.C. 8:57-4.2 if a particular immunization is** medically contraindicated **or presents a precaution for a reason that the ACIP recommendations or the AAP Red Book specify as a vaccine contraindication or precaution.**

(b) [A written statement submitted to the school, preschool, or child care center from] **In support of an exemption pursuant to (a) above from a particular required immunization, the administrator shall require the submission of a Request for Medical Exemption from Mandatory Immunization (provided at N.J.A.C. 8:57 Appendix L, incorporated herein by reference) executed by** a physician [licensed to practice medicine or osteopathy] or an advanced practice nurse [(certified registered nurse practitioner or clinical nurse specialist) in any jurisdiction of the United States indicating that an] **licensed to practice pursuant to Title 45 of the New Jersey Revised Statutes, including a person who holds a credential in good standing in a jurisdiction of the USA that is equivalent or corresponds to a New Jersey licensed physician or advanced practice nurse, that specifies:**

**1. The immunization that is medically contraindicated or presents a precaution for [a] the specific minor;**

**2. The period [of time,] during which the immunization is medically contraindicated or presents a precaution for the minor; and [the]**

**3. The medical reason[(s) for the medical contraindication, based upon valid medical reasons as enumerated by the Advisory Committee on Immunization Practices (ACIP) of the United States Public Health Service or the American Academy of Pediatrics (AAP) guidelines, will exempt a pupil from the specific immunization requirement for the stated] for which, and the period [of time] during which, administration of the immunization is contraindicated or presents a precaution to the minor.**

[1. The guidelines identified in (b) above are available as follows:

- i. Advisory Committee on Immunization Practices, U.S. Public Health Service, Centers for Disease Control and Prevention, Atlanta, GA 30333; and
- ii. American Academy of Pediatrics, Committee on Infectious Diseases, PO Box 927, Elk Grove, IL 60009-0927.]

(c) The [physician's or an advanced practice nurse's (certified registered nurse practitioner or clinical nurse specialist) statement] **administrator** shall [be retained]:

**1. Review the statement submitted pursuant to this section for compliance with (a) and (b) above in consultation with the VPDP, as may be necessary in the circumstances;**

**2. If the statement complies with (a) and (b) above, review the grant of exemption at least annually or by the end of the contraindication period that the statement specifies pursuant to (b)2 above, whichever is earlier, to ensure that, upon the conclusion of the contraindication period, evidence of immunization or**

**immunity in accordance with N.J.A.C. 8:57-4.2 and the ACIP recommendations is submitted; and**

**3. Retain the statement** as part of the [child's] immunization record [and shall be reviewed annually by the school, preschool, or child care facility. When the child's medical condition permits immunization, this exemption shall thereupon terminate and the child shall be required to obtain the immunization(s) from which he or she has been exempted] **pursuant to N.J.A.C. 8:57-4.6.**

[(d) Those children with medical exemptions to receiving specific immunizations may be excluded from the school, preschool, or child care facility during a vaccine-preventable disease outbreak or threatened outbreak as determined by the Commissioner, Department of Health and Senior Services or his or her designee.

(e) As provided by N.J.S.A. 26:4-6, "Any body having control of a school may, on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases, prohibit the attendance of any teacher or pupil of any school under their control and specify the time during which the teacher or scholar shall remain away from school." The Department of Health and Senior Services shall provide guidance to the school of the appropriateness of any such prohibition. All schools are required to comply with the provisions of N.J.A.C. 8:61-1.1 regarding attendance at school by pupils or adults infected by Human Immunodeficiency Virus (HIV).]

8:57-[4.4]**4.8** Religious exemption[s]

(a) [Each school, preschool, or] **Pursuant to N.J.S.A. 26:1A-9.1 and 30:5B-5, the administrator of a** child care center shall [exempt a child from mandatory] **not require**

**evidence of immunization or immunity pursuant to N.J.A.C. 8:57-4.2** if the [child's] **minor's** parent [or guardian submits to the school, preschool, or child care center a written, signed statement requesting an exemption, pursuant] **objects thereto "upon the ground that the immunization interferes with the free exercise of the pupil's religious rights" and "on the ground that it conflicts with the tenets and practice of a recognized church or religious denomination of which the parent or child is an adherent or member."**

**(b) Pursuant** to [the requirements for religious exemption established at] N.J.S.A. 26:1A-9.1, [on] **the administrator of a school shall not require evidence of a minor's immunization or immunity pursuant to N.J.A.C. 8:57-4.2 "if the parent ... of the pupil objects thereto upon the ground that the ... immunization interferes with the free exercise of the pupil's religious rights."**

**(c) In support of a request for an exemption pursuant to (a) or (b) above, the administrator of a child care center or school shall require the minor's parent to submit a written statement that includes a date and is signed by hand:**

**1. Requesting an exemption on the grounds described at (a) or (b) above, as applicable; and**

**2. If the request is with respect to a particular immunization rather than to all immunizations, specifying the immunization to which the request applies.**

**(d) An administrator shall not exempt a minor** from [1. The school, preschool, or child care center shall be prohibited from exempting a child from mandatory] **the obligation to provide evidence of immunization or immunity pursuant to N.J.A.C. 8:57-4.2** on the sole basis of a moral or philosophical objection to immunization.

**(e) An administrator shall require evidence of immunization or immunity pursuant to N.J.A.C. 8:57-4.2 with respect to immunizations from which the parent does not request exemption pursuant to this section, which a parent specifies pursuant to (c)2 above.**

[(b)] **(f)** [Religious-affiliated] **The administrator of a religious-affiliated** [schools or child care centers shall have the authority to] **facility can** withhold or grant a **request for** [religious] exemption [from the required immunization for pupils entering or attending their institutions] **pursuant to this section** without challenge by any secular health authority.

[(c)] **(g)** [Each school, preschool, or child care center] **An administrator** shall retain a [copy of the] written statement [set forth in (a)] **that a parent submits pursuant to (c)** above in the [child's] **minor's** immunization record.

[(d)] A school, preschool, or child care center may exclude children with religious exemptions from receiving immunizing agents from the school, preschool, or child care center during a vaccine-preventable disease outbreak or threatened outbreak as determined by the Commissioner, Department of Health and Senior Services, or his or her designee.

(e) As provided by N.J.S.A. 26:4-6, "Any body having control of a school may, on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases, prohibit the attendance of any teacher or pupil of any school under their control and specify the time during which the teacher or scholar shall remain away from school."



1. The Department of Health and Senior Services shall provide guidance to the school on the appropriateness of any such prohibition.

2. All schools are required to comply with the provisions of N.J.A.C. 8:61-2.1 regarding attendance at school by pupils or adults infected by Human Immunodeficiency Virus (HIV).

(f) Those children enrolled in school, preschool, or child care centers before September 1, 1991, and who have previously been granted]

**(h) Subject to (i) below, an administrator shall not require the parent of a [religious] minor to whom the administrator grants an exemption[, shall not be required] pursuant to this section to reapply annually for [a new religious] the same exemption [under N.J.A.C. 8:57-4.4(a)].**

**(i) If a minor, for whom an exemption pursuant to this section is of record, receives, with the consent of the minor's parent, an immunization that contravenes the statement the parent submitted pursuant to (c) above, the administrator shall deem the request for exemption to be withdrawn and thereafter the administrator shall require compliance with N.J.A.C. 8:57-4.2 in accordance with the ACIP recommendations and this chapter.**

#### **8:57-4.9 Provisional and foreign admission**

**(a) With respect to a minor upon whose behalf evidence pursuant to N.J.A.C. 8:57-4.2 showing compliance with applicable immunization schedules in accordance with the ACIP recommendations is not submitted, the administrator of a facility, subject to (b) below, shall neither admit the minor to, nor continue**

the minor's enrollment at, the facility, unless and until evidence is submitted compliant with N.J.A.C. 8:57-4.4 showing that the minor:

1. Has received at least one dose of each immunization that N.J.A.C. 8:57-4.3 requires; and

2. Is no later than 14 days behind in receiving the remaining doses in accordance with the applicable Catch-up Schedule.

(b) With respect to a minor who is entering, or transferring into, a facility from outside of the USA, upon whose behalf evidence pursuant to N.J.A.C. 8:57-4.2 showing compliance with applicable immunization schedules in accordance with the ACIP recommendations is not submitted, an administrator shall admit the minor to the facility for no longer than 30 days, during which evidence on the minor's behalf shall be submitted:

1. Compliant with N.J.A.C. 8:57-4.4 and/or 4.5 of the minor's immunization or immunity; and/or

2. Compliant with N.J.A.C. 8:57-4.4 that the minor:

i. Has received at least one dose of each immunization of which N.J.A.C. 8:57-4.3 requires evidence of immunization in accordance with the ACIP recommendations; and

ii. Is no later than 14 days behind in receiving the remaining doses in accordance with the applicable Catch-up Schedule.

(c) Subject to (c)1 below, (b) above applies to persons to whom the Interstate Compact on Educational Opportunity for Military Children applies, pursuant to N.J.S.A. 18A:75A-1 et seq., specifically 18A:75A-4 and 5.

**1. Pursuant to N.J.S.A. 18A:75A-19, rules of the Military Interstate Children's Compact Commission (MIC3), promulgated pursuant to N.J.S.A. 18A:75A-13, supersede and preempt (c) above, if the MIC3 rules authorize longer periods within which evidence of a person's immunization or immunity in accordance with the ACIP recommendations is to be submitted, as a condition of a person's admission to or continued attendance at a facility.**

**2. The MIC3 rules are available from the MIC3, 1776 Avenue of the States, Lexington, KY 40511, telephone: (859) 244-8000, telefacsimile: (859) 244-8001, email: [mic3info@csg.org](mailto:mic3info@csg.org), and website: <https://www.mic3.net>.**

**8:57-4.10 Exclusion of persons during an actual or threatened vaccine-preventable disease outbreak**

**(a) Notwithstanding the grant of an exemption or provisional admission pursuant to N.J.A.C. 8:57-4.7, 4.8, or 4.9, if the Commissioner determines that an actual or threatened communicable disease outbreak or a public health emergency exists, and at the direction of the Commissioner or the local health agency with jurisdiction, the administrator of a facility shall exclude unimmunized, under-immunized, and provisionally admitted persons from attendance thereat during the actual or suspected communicable disease outbreak or public health emergency.**

**(b) Pursuant to N.J.S.A. 26:4-6, "Any body having control of a school may, on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases, prohibit the attendance of any teacher or pupil of any**

**school under their control and specify the time during which the teacher or scholar shall remain away from school.”**

**1. To implement this subsection, the local health agency with jurisdiction or the Department shall determine:**

- i. The “prevalence” of the communicable disease;**
- ii. The existence of an epidemiological basis to warrant the prohibition of persons from attendance to prevent the spread of the communicable disease; and**
- iii. The time and/or circumstances during which the prohibition of persons from attendance is to remain in effect.**

**(c) The administrator shall maintain a record of persons admitted to a facility pursuant to N.J.A.C. 8:57-4.7, 4.8, and 4.9 and make an up-to-date list of those persons available to the Department and/or the local health agency upon request during a suspected or confirmed communicable disease outbreak and/or a public health emergency.**

**(d) The administrator of a facility may elect to notify a parent who submits a request for exemption of a minor pursuant to N.J.A.C. 8:57-4.7 and 4.8, or who obtains provisional admission of a minor pursuant to N.J.A.C. 8:57-4.9, of the potential exclusion of the minor from attendance at the facility pursuant to this section during a suspected or confirmed communicable disease outbreak and/or a public health emergency.**

**8:57-4.11 Reports to be sent to the Department and local health agency**

(a) The administrator of a facility shall report the immunization status of the persons attending or enrolled in the facility by submission of the information required in the Annual Immunization Status Report (provided at N.J.A.C. 8:57 Appendix M, incorporated herein by reference) in the NJIIS by December 1 of each year.

(b) The Department shall notify applicable State agencies with jurisdiction, such as the New Jersey Departments of Education and Children and Families, and the applicable local health agency with jurisdiction, if an administrator is delinquent in timely compliance with this section.

**8:57-4.12 Meningitis-Containing Vaccination Immunization Information Fact Sheet established**

Pursuant to N.J.S.A. 26:2X-3, the Department establishes the brochure entitled “Meningococcal Disease: Are You Protected?” as the educational fact sheet of which the Commissioner of Education is to establish school district procedures requiring annual dissemination pursuant to N.J.S.A. 18A:40-21.2.

**8:57-4.13 Immunization of children at public expense authorized**

Pursuant to N.J.S.A. 18A:40-20 and 26 and 26:4-8.1, a board of education and/or a local board of health can provide, at public expense, the necessary equipment, materials, and services for immunizing children with immunizing agents in accordance with this subchapter, and other immunizing agents as the

**Department may direct or authorize, and/or as the ACIP recommendations may provide.**

8:57-[4.22]**4.14** Emergency powers of the Commissioner[, Department of Health and Senior Services]

(a) [In the event that] **If the Commissioner[, Department of Health and Senior Services or his or her designee] determines [either] that [an] a suspected or confirmed [outbreak or threatened] outbreak of disease [or other public health immunization emergency] exists, or the Governor declares a public health emergency exists pursuant to N.J.S.A. 26:13,** the Commissioner [or his or her designee] may [issue either] **require additional immunizations [requirements to control the outbreak or threat of an outbreak] or modify existing immunization requirements [to meet the emergency] as a condition of a person's continued admission to or enrollment at a facility.**

(b) [All children] **An administrator shall exclude from a facility any person** failing to meet [these] additional **or modified** requirements [shall be excluded from a school, preschool, or child care center until the outbreak or threatened outbreak is over] **that the Commissioner issues pursuant to (a) above upon the direction of the local health agency with jurisdiction or the Department, which direction may include the exclusion of unimmunized and under-immunized persons, notwithstanding the existence of an otherwise applicable medical contraindication or religious exemption.**

(c) [These] **Additional or modified** requirements [or amendments to the requirements] **that the Commissioner issues pursuant to (a) above,** shall remain in effect until

[such time as] the Commissioner[, Department of Health and Senior Services or his or her designee] determines that [an] **the suspected or confirmed** outbreak[, or a threatened outbreak, no longer exists or the emergency is declared over, or for three months after the declaration of the emergency, whichever one comes first] **or other public health emergency is over, and issues a declaration to this effect that rescinds the additional or modified requirements.** [The Commissioner, Department of Health and Senior Services or his or her designee may redeclare a state of emergency if the emergency has not ended.]

(d) [In the event of] **If the CDC determines that** a national [or State] vaccine supply shortage[, as determined by the Centers for Disease Control and Prevention and Commissioner, respectively,] **or disruption exists or** the Commissioner [or his or her designee] **determines that a vaccine supply shortage or disruption affecting New Jersey exists, the Commissioner** may temporarily suspend [the] **or modify** immunization requirements [for the particular immunization affected by the supply shortage,] after provision of notice to the public[, such as] through any of the methods below:

1.-2. (No change.)

3. The Department's Local Information Network and Communications System (LINCS); **or**

[4. The Department's Vaccine Preventable Disease Program; or]

[5.] **4.** (No change in text.)

(**Agency Note:** N.J.A.C. 8:57-4.24 is proposed for recodification with amendments as N.J.A.C. 8:57-1.52.)

## SUBCHAPTER 5. MANAGEMENT OF TUBERCULOSIS

### 8:57-5.1 Purpose and scope

(a) The purpose of this subchapter is to [control the spread of] **manage** tuberculosis **disease (*Mycobacterium tuberculosis*) (TB)** by maximizing the use of currently available and highly effective treatments **and to establish standards for the reporting, diagnosis, and treatment of cases of TB in the least restrictive environment and manner.**

(b) This subchapter applies to [persons who have suspected or confirmed TB disease as diagnosed by a health care provider, especially those with suspected or confirmed infectious or potentially infectious TB disease who pose an immediate or imminent risk to the public health.

1. This includes persons identified by public health professionals as contacts to persons with suspected or confirmed infectious or potentially infectious TB disease, and]:

**1. A TB patient;**

**2. A TB patient's contact;**

**3. A Class B1 or B2 referral[s from the Centers for Disease Control and Prevention (CDC)] who [are residing] resides in New Jersey[.];**

[(c) Local health officers,]

**4. A health officer;**



**5. A** public health nurse case manager[s,];

**6. A** health care [providers] **professional**; and

**7. An** administrator[s of hospitals and correctional facilities are primarily responsible for implementation of this subchapter].

[(d)] **(c)** [Local] **This subchapter establishes standards authorizing a** health officer[s in areas where] **for** the [person with suspected or confirmed, infectious or potentially infectious] **jurisdiction in which a person with TB** [disease] resides[, frequents] or receives care [may], **or that the person frequents, to** take any action authorized [under] **pursuant to** this subchapter [if he or she] **that the health officer** determines [that it is] **to be** necessary to protect the health of the [person] **TB case** or the public.

[(e)] The guiding goals underlying this subchapter are:

1. To protect the public from the spread of TB disease and/or latent TB infection;  
and

2. To diagnose and treat persons with suspected or confirmed TB disease and those with latent TB infection at high risk for progression to TB disease in the least restrictive environment and manner.]

#### 8:57-5.2 Incorporated documents

(a) (No change.)

(b) The Department incorporates by reference the following forms in this subchapter:

1. TB-70: Tuberculosis Case, Suspect and Status Report (**N.J.A.C. 8:57-5** Appendix A), which is the form for reporting suspected or confirmed TB disease and

updating the status of these patients, **and TB-70 Instructions, which provides instructions for completion of the TB-70.**

2. TB-41: Record of Contact Interview (**N.J.A.C. 8:57-5** Appendix B), which is the form for reporting the identification, results of medical evaluation and final disposition of contacts, **and TB-41, Instructions for Completing the Record of Contact Interview (TB-41), which provides instructions for completion of the TB-41.**

(c) [All of the] **The** forms [in] **at** (b) above are available [by written] **upon** request to the [Communicable Disease Service, Public Health Services Branch, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369.

1. The TB-41 form is also available online through] **TB Program and from** the Department's "Forms" web page at [<http://web.doh.state.nj.us/forms/>] <https://www.nj.gov/health/forms>.

### 8:57-5.3 Definitions

The following words and terms, as used in this subchapter, shall have the following meanings, unless the context clearly indicates otherwise:

“Acid-fast bacilli [(**)** **or** “AFB(**)**” means organisms that remain stained after being washed in acid solution, may be detected using a microscope, and are then reported as a positive AFB on smear.

1. TB should be considered a possibility when AFB are present on a stained smear, and indicate[s] the likelihood of infectiousness if from a pulmonary source such as, but not limited to, sputum, [bronchioalveolar] **bronchoalveolar**

lavage, gastric aspirate, lung tissue, as well as other tissue of the respiratory tract, such as the larynx or epiglottis.

...

“Class B1 or B2 referral[s]” means **a** referral[s] from the CDC’s Division of Global Migration [and Quarantine] **Health**, which informs the Department of persons who are refugees, parolees, asylees, or recent legal immigrants to the [United States] **USA**, [and] who were screened overseas and classified as either B1, meaning TB, clinically active, not infectious, or B2, meaning TB, not clinically active, not infectious.

1. (No change.)

“[Interferon gamma] **Interferon-gamma** release assay” or “**IGRA**” means **a** QuantiFERON®-Gold **Plus** or [T-spot.TB assay] **T-SPOT®.TB test**.

“Latent TB infection” means the presence of [Mycobacterium tuberculosis] **Mycobacterium tuberculosis** bacteria in the body as evidenced by a significant reaction to a Mantoux tuberculin skin test or positive [interferon gamma release assay] **IGRA**.

1. A person with latent TB infection [does not have an illness] **is neither ill** nor [is he or she] infectious.

...

“[Multiple drug resistant] **Multidrug-resistant** tuberculosis [( )” or “MDR-TB[( )]” means a form of TB disease that is resistant to at least isoniazid and rifampin.

...

“Suspected or confirmed infectious or potentially infectious TB disease” means one or more of the following:

1. A [patient with a] smear **that is** positive for AFB [and/or], nucleic acid amplification test **that is** positive for [M.tb] ***Mycobacterium tuberculosis***, and/or a culture **that is** positive for [M.tb] ***Mycobacterium tuberculosis*** or [M.tb] ***Mycobacterium tuberculosis*** complex[;].

i. This applies only to specimens from sputum, [brochioalveolar] **bronchoalveolar** lavage, gastric aspirate, lung tissue, or other tissue of the respiratory tract such as the larynx or epiglottis;

2.-4. (No change.)

...

**“TB Program” means the TB Program within the Division of HIV, STD, and TB Services of the Public Health Services Branch of the Department, for which the mailing address is TB Program, Division of HIV, STD, and TB Services, New Jersey Department of Health, PO Box 369, Trenton, NJ 08625-0369, telephone (609) 826-4878, and telefacsimile (609) 826-4879.**

...

#### 8:57-5.4 Reporting requirements

(a)-(b) (No change.)

(c) Health care providers and administrators may report the information required by the TB-70 form, **provided at N.J.A.C. 8:57-5 Appendix A, incorporated herein by reference**, to the [Department’s] TB Program [Surveillance Unit by telephone (609) 588-7522, or by mail to: New Jersey Department of Health and Senior Services, TB Program, PO Box 369, Trenton, NJ 08625-0369].

1. (No change.)

2. Public health nurse case managers shall submit the TB-70 form, **provided at N.J.A.C. 8:57-5 Appendix A**, to the TB Program [through the mailing address provided above].

(d) (No change.)

(e) The public health nurse case manager for an index case shall [mail any] **submit a TB-41 form (N.J.A.C. 8:57-5 Appendix B, incorporated herein by reference)**, to the [Department's] TB Program [at New Jersey Department of Health and Senior Services, TB Program, PO Box 369, Trenton, NJ 08625-0369].

(f)-(h) (No change.)

(i) A health care provider who is not working for a public health clinic shall report verbally to the [Department's] TB Program [at (609) 588-7522,] **by telephone** whenever any patient with suspected or confirmed infectious or potentially infectious TB disease misses two consecutive appointments for medical assessment.

1.-2. (No change.)

(j) The administrator of a hospital shall report to the TB Program [at (609) 588-7522] **by telephone** within 24 hours any inpatient with suspected or confirmed infectious or potentially infectious TB disease posing an immediate or imminent public health risk as defined in this subchapter.

(k) The administrator of a hospital shall report the proposed discharge date of a patient with suspected or confirmed infectious or potentially infectious TB disease regardless of time on treatment or smear status to the TB Program [at (609) 588-7522] **by telephone** on the last business day that is at least 48 hours prior to the planned discharge date.

1.-2. (No change.)

(l) The administrator of a correctional facility shall report the release of an inmate with suspected or confirmed infectious or potentially infectious TB disease to the TB Program [at (609) 588-7522] **by telephone** at least two working days in advance of the release, if anticipated, or within one working day of the date of release, if unanticipated.

1. (No change.)

(m)-(o) (No change.)

#### 8:57-5.5 Hospital discharge

(a) A health care provider managing a patient with suspected or confirmed infectious or potentially infectious TB disease in a hospital may discharge the patient upon meeting one of the following criteria:

1.-2. (No change.)

3. The patient is a resident of a congregate living facility, is [homeless] **unhoused**, or reports a private residence that the public health department has not verified as valid and stable, and had sputum smears **that were** initially positive for AFB.

i. (No change.)

[ii. The patient must have a nucleic acid amplification test negative for M. tuberculosis;]

Recodify existing iii.-iv. as **ii.-iii.** (No change in text.)

4. (No change.)

(b) (No change.)

#### 8:57-5.6 Health officer responsibilities

(a) (No change.)

(b) Any health care provider providing medical management and treatment to residents of New Jersey with suspected or confirmed TB disease or latent TB infection shall provide these services in accordance with the MMWR Treatment of Tuberculosis as set forth at N.J.A.C. 8:57-5.2(a).

[1. A health care provider may also use the Department's Standards of Care for Tuberculosis Disease and Latent TB Infection, (hereinafter "TB Standards of Care") as guidance for the appropriate medical management of patients with suspected or confirmed TB disease or latent TB infection.

i. TB Standards of Care is available by written request to the Communicable Disease Service, Public Health Services Branch, New Jersey Department of Health and Senior Services, PO Box 369, Trenton, NJ 08625-0369 or online at <http://www.state.nj.us/health/cd/tbhome.htm>, then click on "Standards of Care for Tuberculosis Disease and Latent TB Infection."]

(c)-(e) (No change.)

#### 8:57-5.8 Diagnostic evaluations

(a)-(d) (No change.)

(e) A diagnostic evaluation for a person with suspected or confirmed infectious or potentially infectious TB shall consist of at least a physical examination including visual acuity testing, a chest x-ray, sputum collection or induction, and laboratory testing.

[1. The health care provider may utilize the Department's TB Standards of Care as a guideline for appropriate practice.]

(f) A diagnostic evaluation of a contact or Class B1 or B2 referral shall consist of at least a Mantoux tuberculin skin test or an [interferon gamma release assay] **IGRA**, and a chest x-ray if the skin test is considered significant or the [interferon gamma release assay] **IGRA** is positive.

1. (No change.)

[2. The health care provider may utilize the Department's TB Standards of Care as a guideline for appropriate practice.]

#### 8:57-5.9 Directly Observed Therapy (**DOT**)

(a) Health care providers may prescribe DOT as a method to monitor the adherence of a patient to [his or her] **the patient's** prescribed treatment for tuberculosis disease.

[1. Health care providers may utilize the Department's TB Standards of Care as a guideline for appropriate utilization of DOT.]

(b)-(e) (No change.)

#### 8:57-5.10 Management of non-adherent patients requiring a diagnostic evaluation or **Directly Observed Therapy (DOT)**

(a) This section is applicable to patients with suspected or confirmed infectious or potentially infectious TB disease, identified contacts, and Class B1 or B2 referrals [that] **who** require a diagnostic evaluation to determine their TB status.



1. A public health nurse case manager, when issuing a public health warning notice to a patient, shall seek a diagnostic evaluation on the patient to assess [his or her] **the patient's** TB status to adequately protect the public health.

2. A health officer, when issuing a health officer order to a patient, shall require a diagnostic evaluation of the patient to assess [his or her] **the patient's** TB status to adequately protect the public health.

i.-iii. (No change.)

3. A health officer, when initiating a commitment hearing on a patient, shall require a diagnostic evaluation of the patient to assess [his or her] **the patient's** TB status to adequately protect the public health.

(b)-(l) (No change.)

8:57-5.11 Management of non-adherent patients through a health officer order for isolation

(a) Pursuant to N.J.S.A. 26:4-2, the health officer in the patient's jurisdiction of residence may exclude a patient posing an immediate or imminent risk to the public health from attending [his or her] **the patient's** place of work or school, or other premises where the health officer determines that such action is necessary to protect the public health.

1.-2. (No change.)

(b) (No change.)

(c) The health officer in the patient's health jurisdiction of residence shall issue a health officer order for isolation within two working days of when the patient meets the definition of immediate or imminent risk to the public health, but is not a risk for flight.

1. (No change.)

2. If the patient has suspected or confirmed infectious or potentially infectious TB disease, is suspected or confirmed to have either MDR-TB or XDR-TB, and is non-adherent or threatens non-adherence with infection control measures, regardless of [his or her] **the patient's** risk for flight, the health officer shall serve the patient an order of temporary commitment pursuant to N.J.A.C. 8:57-5.12, rather than an order for isolation due to the severity of the consequences of transmission.

(d)-(j) (No change.)

#### 8:57-5.12 Management of non-adherent patients through health officer order for temporary commitment

(a) If the Commissioner or State Epidemiologist, or designee, or the health officer in the patient's health jurisdiction of residence determines that the patient is not only an immediate or imminent risk to the public health, but also a risk for flight, the health officer shall immediately order the temporary commitment of the patient to the site designated by the Commissioner or State Epidemiologist, or designee, pending an expedited commitment hearing before the Superior Court.

1. (No change.)

2. If the patient has suspected or confirmed infectious or potentially infectious TB disease, is suspected or confirmed to have either MDR-TB or XDR-TB, and is non-

adherent or threatens non-adherence with infection control measures, regardless of [his or her] **the patient's** risk for flight, the health officer shall immediately serve the patient an order of temporary commitment pursuant to this section, rather than an order for isolation due to the severity of the consequences of transmission.

(b)-(h) (No change.)

#### 8:57-5.14 Hearing process

(a) In accordance with N.J.S.A. 30:9-57, the health officer, Commissioner, State Epidemiologist, or designee, shall inform the patient to be committed of [his or her] **the patient's** right to a hearing in the Superior Court.

1. (No change.)

(b)-(f) (No change.)

#### 8:57-5.16 Annual report

The [Manager of the] TB Program shall submit to the Commissioner and make available to the public, through the TB Program's website at [\[http://nj.gov/health/cd/tbhome.htm\]](http://nj.gov/health/cd/tbhome.htm) <https://www.nj.gov/health/hivstdtb/tb>, an annual report describing trends in prevalence and incidence of TB in New Jersey.

# APPENDIX A

## TB-70 Instructions

### Background

Tuberculosis (TB) is a nationally notifiable disease and reporting is mandated in all states. In 1953, a national surveillance system was established to collect information on new cases of active TB disease. Since 1985, all states have been reporting TB cases to the Centers for Disease Control and Prevention (CDC) using the Report of Verified Case of Tuberculosis (RVCT), the national TB surveillance form. Data are collected by state and local TB programs and submitted electronically to CDC, Division of Tuberculosis Elimination (DTBE). These data are used to monitor national TB trends, identify priority needs, and create the DTBE annual surveillance report, *Reported Tuberculosis in the United States*.

To control and eventually eliminate TB, state and local TB control programs must be able to monitor trends in TB disease in high-risk populations, as well as identify new patterns of disease and possible outbreaks. The last major revision of the RVCT was completed in 2009. Since 2016, members of a DTBE-sponsored workgroup consisting of nearly 30 public health professionals from 15 TB control programs, DTBE, and the National TB Controllers Association (NTCA) have been working to revise the RVCT. Modifications to the RVCT data collection now accommodate the changing epidemiology of TB in terms of risk factors, new drug treatments, and enhanced laboratory capacity for diagnostic tests.

**Note:** A case of TB is defined as an episode of TB disease in a person meeting the laboratory or clinical criteria for TB as defined in Appendix A – Tuberculosis Case Definition for Public Health Surveillance.

### Tuberculosis Surveillance Data

Some states may use a modified version of the 2022 RVCT or a data collection tool that is unique to their jurisdiction. These forms are used to collect the same data contained in the Version 3 RVCT. **In New Jersey, the RVCT is called the TB-70 form.** Locally assigned numbers and characters are used for case identification and are included in State and Local Case Numbers (items 3 & 4) for use by CDC to identify cases when communicating with state or local agencies. To obtain a state case number please contact the TB Program at 609-826-4878, you will need to provide the patient's name, DOB and county.

### Impact of RVCT Data

Benefits of RVCT Data	Negative effects of Inaccurate, Incomplete, or Unknown RVCT Data
<ul style="list-style-type: none"><li>Increased ability to assess program performance, completeness of data collection, and accuracy of reporting</li><li>Improved data for program planning and policy development (e.g., personnel, resources, funding)</li><li>Facilitation of patient services (e.g., quality of care, continuity of care, sharing of accurate information with patient and health facilities)</li></ul>	<ul style="list-style-type: none"><li>Inaccurate follow-up of services to patients</li><li>Inadequate resources (e.g., funding, staff, facilities, drugs, and supplies)</li><li>Inaccurate evaluation and policy development</li><li>Misrepresentation of the public health burden of TB</li><li>Inability to measure TB program indicators that are based on surveillance data</li></ul>

### Overview

The RVCT form is designed for the collection of information on cases of TB. The expanded RVCT was approved by the Office of Management and Budget (OMB) in 2019 to become effective January 2020. However, due to COVID-19 the 2020 RVCT variables will not be collected until January 2022.

Reporting of all verified cases to CDC is required by the cooperative agreement between CDC and state and local TB programs, regardless of whether the case is counted as part of the jurisdiction's official TB case count (e.g., transfer cases already counted in another state or country). Noncountable TB cases help measure TB morbidity and case management burden.

### Pending vs. Unknown Information

Leave the item blank if the information requested is pending. If a valid value cannot be determined and there is no checkbox labeled Unknown, write the word *Unknown* inside the box that encloses the numbered item. CDC encourages active surveillance or collection of all applicable information; "unknown" information should be rare.

The RVCT instructions provide information on how to complete all items on the RVCT form. The instructions provide details about each item, explain the nuances of how to answer the items, and provide examples to illustrate how to apply the instructions for entering data for a TB case.

### **TB-70 VARIABLES**

1. **DATE REPORTED:** The Date Reported is used to determine when the health department was first notified that a person may have TB.

	Description	Comment
Month, day, and year (e.g., 01/17/2020)	Date the health department received notification (verbal or written) from a health care provider that a patient might have TB.	If the day is unknown, enter 99 as the default value (e.g., 01/99/2020).  In this item, the actual month and year <u>always</u> need to be entered.

2. **NJ STATE CASE NUMBER:** Used to uniquely identify case reports to facilitate communication between reporting areas and CDC.

	Description	Comment
Year	Year Reported is the year when the case was reported (e.g., 2020)	This year should correspond to the Report Date, which is not necessarily the same as the <i>MMWR</i> Year
State	State Code indicates the two-letter postal code of the state reporting this case, e.g., NJ for New Jersey	The term <i>state</i> is used to refer to the reporting area, though not all reporting jurisdictions are states (e.g., New York City)
Number	Nine-character string unique within the reporting area	This number is assigned by the state TB Program

**Comment: Case Numbers**

**Year + State + Number = State Case Number**

A State Case Number may not be assigned to more than one case during a calendar year.

The State Case Number is the official identification number for the case. If additional communication about a record is required between CDC and a reporting area, this number is used to identify the record. The State Case Number is also commonly known as the RVCT number.

3. **CASE REPORTED BY ANOTHER REPORTING AREA:** TB cases may be reported by multiple reporting areas if the patient moves between reporting areas while under care for a TB episode.

Option (select one)	Description	Comment
Yes, another U.S. reporting area	Case began treatment in another state then transferred to NJ	
No	Case began treatment in New Jersey	Select NO, regardless of if the patient started in another county in NJ

4. **COUNT STATUS:** Count status can only be verified at the state level in accordance with the CDC's specific reporting requirements. The purpose of this question is to identify how the patient will be followed according to the treating physician.

Check "Suspect" for all patients pending verification from the physician or awaiting labs.

Check "Recurrent TB within 12 months of completion of treatment" for patients that were previously treated for TB and have only completed this treatment within the last 12 months. These patients will use the state case number from their previous case. For patients who reoccur after 12 months of having completed therapy, do not select this option since these patients are considered, for surveillance purposes, to have a separate TB episode and should be counted as a new case.

Check "Diagnosed as TB by provider" for patients that the treating physician has determined to be active TB disease and will require a full course of treatment, regardless of lab results.

Check "MTB Positive Lab" for all cases with a laboratory confirmation of Mycobacterium Tuberculosis.

Check "Not TB" when the completed diagnostic evaluation did **not** substantiate the diagnosis of TB for this patient.

5. **GEOID-** (state use only)

6. **NAME/REPORTING ADDRESS:** Report the patient's name and document the approximate location of the patient's residence for the purpose of geographic analyses and correct assignment of the case to a public health jurisdiction.

	Patient Scenarios	How to Report	Reporting Address
Specific Populations (these groups supersede Specific Locations)	Persons temporarily living in an area	Count in the reporting area in which he/she lived at the time that the TB diagnostic evaluation was initiated	Use address where the patient was living when diagnostic evaluation was initiated
	Homeless or does not have a fixed residence	Count in the reporting area in which the patient was living at the time that the TB diagnostic evaluation was initiated (e.g., the shelter or area in which the patient was living)	Use address where the patient was living when diagnostic evaluation was initiated
	Resident of correctional facility at time of TB diagnosis	Count in the reporting area of the correctional facility the patient resided in at the time that the TB diagnostic evaluation was initiated	Use address of the correctional facility where the patient was living when diagnostic evaluation was initiated
	Resident of long-term care facility at time of TB diagnosis	Count in the reporting area of the long-term care facility the patient resided in at the time that the TB diagnostic evaluation was performed or initiated	Use address of the long-term care facility where the patient was living when diagnostic evaluation was initiated

7. **DATE OF BIRTH:** Patient's complete date of birth should be entered (i.e., month, day, and year).

8. **SEX AT BIRTH:** Report the biological sex recorded for the patient at birth.

8a. **IF FEMALE, PREGNANT AT DIAGNOSIS:** Is the patient pregnant at the time of the initial diagnosis?



9. **ETHNICITY:** To establish the patient's ethnicity for evaluation of epidemiologic trends associated with ethnicity.

Option (select one)	Description	Comment
Hispanic or Latino	Patient considers himself or herself Cuban, Mexican, Puerto Rican, South or Central American, or of other Latin American culture or origin, regardless of race	Some patients prefer the term "Spanish origin" to Hispanic or Latino
Not Hispanic or Latino	Patient does not consider himself or herself Hispanic or Latino	
Unknown	Patient's ethnicity is not reported or unknown	

10. **RACE:** To establish the patient's race(s) for evaluation of epidemiologic trends associated with race.

**Note: Self-identity or self-reporting**

The response to this item should be based on the patient's self-identity or self-reporting. Therefore, patients should be offered the option of selecting more than one racial designation.

Option (select one or more)	Description
American Indian or Alaska Native	Patient has origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment
Asian	Patient has origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent (e.g., including Bangladesh, Cambodia, China, India, Indonesia, Japan, Korea, Malaysia, Nepal, Pakistan, the Philippine Islands, Thailand, and Vietnam)
Black or African American	Patient has origins in any of the black racial groups of Africa
Native Hawaiian or Other Pacific Islander (NHOPI)	Patient has origins in any of the original peoples of Hawaii, Guam, American Samoa, or other Pacific Islands, except islands considered to be part of Asia (see table on next page)
White	Patient has origins in any of the original peoples of Europe, the Middle East, or North Africa
Other Race	Patient identifies to another race not listed above
Unknown	Patient's Race is not reported or unknown

11. **NATIVITY:** To establish the patient's country of birth and citizenship status at birth for evaluation of epidemiologic trends.

**A. Country of Birth**

	Description	Comment
Specify (e.g., United States, Mexico, China)	Enter the name of the country in which the person was born. If the person was born in a U.S. territory or a freely associated state, specify the name of the territory or state; do not enter "United States" unless the person was born in one of the 50 U.S. states or the District of Columbia.	Provide the actual country of birth for all patients regardless of whether they were U.S. citizens at birth.
Date of First U.S. Arrival (If NOT born in United States)	Date (mm/dd/yyyy) patient first arrived in one of the 50 U.S. states or the District of Columbia, if the patient was born elsewhere. This date should be provided regardless of whether the patient was already a U.S. citizen at the time of first arrival in the United States. Partial dates are acceptable.	If the day is unknown, or the month and the day are unknown, enter 99 as the default value (e.g., 04/99/1968) or 99/99/1968.

**B. Eligible for U.S. Citizenship/Nationality at Birth** (regardless of country of birth)?

Option (select one)	Description	Comment
Yes	Eligible for U.S. citizenship <i>at birth</i>	In certain circumstances, a person might be <i>eligible</i> for U.S. citizenship at birth, but the parents must take additional steps to <i>acquire</i> citizenship for their child. More information is available at: <a href="https://travel.state.gov/content/travel/en/legal/travel-legal-considerations/us-citizenship/Acquisition-US-Citizenship-Child-Born-Abroad.html">https://travel.state.gov/content/travel/en/legal/travel-legal-considerations/us-citizenship/Acquisition-US-Citizenship-Child-Born-Abroad.html</a>
No	Not eligible for U.S. citizenship <i>at birth</i>	Answer "No" if the patient was not eligible for U.S. citizenship at birth, regardless of the patient's current citizenship status
Unknown	Not known if patient was eligible for U.S. citizenship <i>at birth</i>	

**C. Countries of Birth for Primary Guardian(s)** (pediatric [ $<15$  years old] patients only)

	Country
Guardian 1	
Guardian 2	

**12. COUNTRY OF USUAL RESIDENCE:** To determine whether a patient was a resident of the United States at the time of diagnosis.

Persons with established households in more than one country should have country of usual residence determined based on which country they spent the most time in during the year preceding diagnosis.

Usual residence is defined as the place where the person lives and sleeps most of the time, which is not necessarily the same as the person's voting residence, legal residence, or the place where they became infected with a notifiable disease. Determining usual residence for most people is easy and unambiguous. However, the usual residence for some people is not obvious.

Persons, regardless of citizenship, who have established a household or are part of an established household (i.e., a "usual residence") in the United States should be reported with a country of usual residence of "United States." This includes persons who are in the United States for an extended period for work or study, even if they do not consider the United States to be "home."

Persons (including U.S. citizens) whose established household is outside of the United States (e.g., they are "just visiting") should be reported with a country of usual residence that is the country where they have established a household (including persons born in a U.S. territory or a freely associated state).

13. **STATUS AT TB DIAGNOSIS:** To determine if the patient was alive at the time of TB diagnosis.

Option	Description	Comment
Alive	Patient was alive at time laboratory results confirming a TB diagnosis (e.g., positive culture or nucleic acid amplification [NAA] test result consistent with TB) were known to the provider or TB medications were started	<p>If the patient</p> <ul style="list-style-type: none"> <li>Was known to be culture or NAA test result positive consistent with TB before the date of death, but did not start TB therapy per ATS/CDC/IDSA guidelines, classify the patient as alive at TB diagnosis</li> <li>Started empiric therapy for TB disease (per ATS/CDC/IDSA guidelines), but TB was not verified until after the patient's death, classify as alive at TB diagnosis</li> <li>Started TB therapy, regardless of laboratory or clinical confirmation for TB diagnosis, classify the patient as alive at TB diagnosis</li> </ul> <p><i>Note: Latent TB infection treatment does not count as TB treatment.</i></p>
Dead	Patient was deceased at the time laboratory results confirmed a TB diagnosis (e.g., positive culture or NAA test result consistent with TB) were known to the provider	<ul style="list-style-type: none"> <li>If diagnostic specimens were collected for evaluation of TB prior to death, but positive results to make a diagnosis of TB were not available until after death, and patient did not start TB therapy, classify as dead at TB diagnosis</li> <li>If TB diagnosis was made after death based on a constellation of clinical and other findings (e.g., symptoms, TST, and imaging studies) in the absence of laboratory confirmation, and the patient did not start therapy, classify as dead at TB diagnosis</li> <li>If patient was receiving treatment for latent TB infection at death because the patient was not believed to have TB disease, and TB was diagnosed after death, classify as dead at TB diagnosis</li> <li>If patient was diagnosed at autopsy, classify as dead at TB diagnosis</li> </ul>

14. **INITIAL REASON EVALUATED FOR TB:** Select the single initial reason the patient was evaluated for TB disease. The definition of “initial reason” is the situation or reason that led to the initial evaluation for TB disease.

Option	Description	Comment
<b>Contact investigation</b>	A health department investigation to identify persons who had close contact with an infectious TB case. This also includes source case investigations to identify the source of TB transmission to a child with TB disease	Select if TB diagnosis was made based on a contact investigation evaluation and testing results from this investigation
<b>Screening</b>	Any type of planned screening for TB in a specific population, other than among contacts of a TB case	Screening includes “targeted testing” of high-risk populations (e.g., B notification, status adjusters), administrative screening required for employment, pre-enrollment screening of students, and similar activities, regardless of whether the screening activity was consistent with CDC recommendations
<b>TB symptoms</b>	Signs and symptoms consistent with TB (e.g., prolonged persistent cough, fever, lymphadenopathy, night sweats, weight loss)	This response is most appropriate when the reason that the patient came to the attention of the medical community was because of the patient’s TB symptoms
<b>Other</b>	Reason that does not fit into any of the above categories	Other reasons such as incidental lab results or findings
<b>Unknown</b>	Reason for evaluating the patient not known	

15. **HAS THE PATIENT EVER WORKED AS ONE OF THE FOLLOWING?** (select all that apply)

Option	Description
Health care worker	Paid or unpaid person working in a health care setting, with potential for exposure to <i>M. tuberculosis</i> . Also known as "healthcare personnel."
Correctional facility employee	Person working in a correctional facility. Persons who have worked as health care personnel within a correctional facility should have both the "Health care worker" box and the "Correctional facility employee" box checked.
Migrant/seasonal worker	Person who is required to be absent from a permanent place of residence for the purpose of seeking employment, or who may vary their employment for the purpose of remaining employed while maintaining a permanent place of residence.
None of the above	Select if confirmed that the individual never worked as a health care worker, correctional facility employee, or migrant/seasonal worker.
Unknown	Select only when it cannot be confirmed or denied that the individual ever worked as a health care worker, correctional facility employee, or migrant/seasonal worker.

**15a. PATIENT'S OCCUPATION:** Current Occupation is the type of job that the patient has been doing most recently, whether paid or unpaid (volunteer). Current Occupation and Industry must be completed for all patients  $\geq 14$  years of age [NIOSH standard].

- If the patient has more than one current job, collect information on all of the patient's jobs.
- If the patient is unemployed and is not currently seeking employment (e.g., patient is retired, disabled, or a full-time student), do not leave the Current Industry and Current Occupation fields blank; instead write "unemployed," "disabled," or "student." Include the level of study for students, e.g., "college student" or "high school student."

Use this question:

"What kind of work do you do? For example, registered nurse, janitor, cashier, auto mechanic, barber, civil engineer, volunteer firefighter, etc."

**15b. PATIENT'S INDUSTRY:** Current Industry is the kind of business or industry the patient works in. For each of the patient's current occupations, the corresponding current industry should be reported. This is NOT the name of the employer, although if the correct industry is not apparent, it is acceptable to enter the name, city, and state of the specific employer.

- If industry is not obvious, ask what is the main focus or product of the employer for which the person works.  
For example, if a patient says they work in manufacturing, ask what was made at the manufacturing plant. For example:
  - Unhelpful: "manufacturing"
  - Helpful: "automobile manufacturing"

Use this question:

"What kind of business or industry do you work in? For example, a hospital, dairy farm, restaurant, trade school, library, etc."

## 16. RISK FACTORS

Option (select all that apply)	Description
Diabetic at Diagnostic Evaluation	Patient was diabetic (see description below) when TB diagnostic evaluation was performed or initiated
Homeless in the Past 12 Months	Patient has been homeless within the 12 months preceding the TB diagnostic evaluation
Homeless Ever	Patient has ever experienced homelessness
Resident of Correctional Facility at Diagnostic Evaluation	Patient was incarcerated or detained in a jail, prison, or other detention center when TB diagnostic evaluation was performed or initiated
Resident of Correctional Facility Ever	Patient has ever been incarcerated or detained in a jail, prison, or other detention center at any point in their lifetime
Resident of Long-Term Care Facility at Diagnostic Evaluation	Patient was a resident of long-term care facility when TB diagnostic evaluation was performed or initiated
Injecting Drug Use in the Past 12 Months	Patient used injection drugs in the past 12 months, not prescribed by a healthcare provider
Noninjecting Drug Use in the Past 12 Months	Patient used noninjecting drugs in the past 12 months, not prescribed by a healthcare provider or approved by FDA for over-the-counter dispensing. This includes marijuana if not prescribed by a physician
Heavy Alcohol Use in the Past 12 Months	Patient heavily used alcohol (see definition below) in the past 12 months
TNF- $\alpha$ antagonist therapy	Patient recently received, or was receiving, tumor necrosis factor-alpha (TNF- $\alpha$ ) antagonist therapy when TB diagnostic evaluation was performed or initiated
Post-organ transplantation	Patient has ever received a solid organ transplant (e.g., kidney, heart)
End-stage Renal Disease	Patient had end-stage renal disease when TB diagnostic evaluation was performed or initiated (e.g., patients on dialysis)
Viral Hepatitis (B or C only)	Patient has ever had a diagnosis of Hepatitis B or C (acute or chronic)
Other Immunocompromise (other than HIV/AIDS)	Patient is immunocompromised because of either a medical condition (e.g., leukemia, Hodgkin's lymphoma, carcinoma of the head or neck), or immunosuppressive therapy, such as prolonged use of high-doses of corticosteroids
Other (specify)	Additional risk factors as defined by the reporting area may be entered as "Other." The particular risk factor being reports should be identified in the "specify" field. An unlimited number of "other" risk factors may be reported.

**Definition for Diabetic**

The American Diabetes Association (American Diabetes Association. *Dia Care*. 2014;37:S81-S90) has established the following criteria for a diagnosis of diabetes:

- Hemoglobin A1c  $\geq 6.5\%$ , *or*
- Fasting (defined as no caloric intake for  $\geq 8$  hours) plasma glucose  $\geq 126$  mg/dL (7.0 mmol/L), *or*
- 2-hour plasma glucose  $\geq 200$  mg/dL (11.1 mmol/L) during an oral glucose tolerance test, as described by the World Health Organization, *or*
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose  $\geq 200$  mg/dL (11.1 mmol/L)

Persons who do not meet the above criteria only because they are currently receiving treatment for diabetes should still be reported as diabetic.

**Definitions for Homeless**

A homeless person may be an individual who has:

1. No fixed, regular, and adequate nighttime residence, and
2. A primary nighttime residence that is
  - a. A supervised publicly or privately operated shelter designed to provide temporary living accommodations, including welfare hotels, congregate shelters, and transitional housing for the mentally ill, *or*
  - b. An institution that provides a temporary residence for individuals intended to be institutionalized, *or*
  - c. A public or private place not designated for, or ordinarily used as, a regular sleeping accommodation for human beings.

A homeless person may also be defined as a person who has no home (e.g., is not paying rent, does not own a home, and is not steadily living with relatives or friends). Persons in unstable housing situations (e.g., alternating between multiple residences for short stays of uncertain duration) may also be considered homeless.

A homeless person may be a person who lacks customary and regular access to a conventional dwelling or residence. Included as homeless are persons who live on streets or in nonresidential buildings. Also included are residents of homeless shelters and shelters for battered women. Residents of welfare hotels and single room occupancy (SRO) hotels could also be considered homeless. In the rural setting, where there are usually few shelters, a homeless person may live in nonresidential structures, or substandard housing, or with relatives. *Homeless* does not refer to a person who is imprisoned or in a correctional facility.

**Definition of Injecting Drug Use**

Injecting drug use involves the use of hypodermic needles and syringes for the injection of drugs not prescribed by a health care provider. Route of administration may be intravenous, subcutaneous (e.g., skin popping), or intramuscular.

**Commonly injected drugs**

- |  |                                   |
|--|-----------------------------------|
| • Heroin and other opiates (e.g., Demerol, Dilaudid, morphine, fentanyl) | • Phencyclidine (PCP, angel dust) |
| • Cocaine (e.g., speedball)  | • Other hallucinogens             |
| • Methamphetamines   | • Barbiturates                    |
| • Amphetamines   | • Steroids                        |
|  | • Other hormones                  |
|  | • Other stimulants                |

**Definition of Noninjecting Drug Use**



Noninjecting drug use involves the use of licensed or prescription drugs or other drugs that were not injected and were not prescribed for the patient by a health care provider or approved for over-the-counter use by FDA, or misuse of prescribed drugs. The drugs may be ingested, inhaled, sniffed, or smoked. Marijuana use should always be recorded as noninjecting drug use, regardless of whether marijuana is legal for medicinal or recreational use in the state of residence.

**Heavy Alcohol Use in the Past 12 Months**

Heavy alcohol use is defined as binge drinking on 5 or more days in the month preceding diagnosis. Binge drinking is defined as a pattern of drinking that bring blood alcohol concentration levels to 0.08 g/dL. This typically occurs after four drinks for women and five drinks for men in about 2 hours.

**17. IF RESIDENT OF CORRECTIONAL FACILITY AT DIAGNOSTIC EVALUATION, TYPE OF FACILITY?**

Indicate type of facility.

**18. IF RESIDENT OF LONG-TERM CARE FACILITY AT DIAGNOSTIC EVALUATION, TYPE OF FACILITY?**

Indicate type of facility.

**19. CURRENT SMOKING STATUS AT DIAGNOSTIC EVALUATION**

The definition of smoking includes consumption of tobacco (or nicotine) through combustible tobacco products (e.g., cigarettes) or electronic nicotine delivery systems (ENDS; e.g., vapes or e-cigarettes). It does not include chewing tobacco. *Smoking of substances other than tobacco (e.g., marijuana) should be recorded under noninjecting drug use.*

Option	Description
Current every day smoker	Patient currently smokes every day.
Current some day smoker	Patient smokes some days, but not every day.
Former smoker	Patient has smoked at least 100 cigarettes/cigars in his/her lifetime and has quit.
Never smoker	Patient has not smoked at least 100 cigarettes/cigars in his/her lifetime.
Smoker, current status unknown	Patient was a smoker, but current status is unknown.
Unknown if ever smoked	Patient's tobacco smoking history is not known.

**20. LIVED OUTSIDE OF THE UNITED STATES FOR >2 MONTHS (UNINTERRUPTED)?**

Select YES if patient indicates that she/he has resided or traveled outside the United States (1 of the 50 states or the District of Columbia) for >2 months (uninterrupted).

Select NO if patient did not live or travel outside the United States (1 of the 50 states or the District of Columbia) >2 months (uninterrupted).

**21. DIAGNOSTIC TESTING:**

	Description	Comment
Date collected/ Placed	Month, day, and year (mm/dd/yyyy) the specimen was collected or tuberculin skin test (TST) was placed	
Date Reported/ Read	Month, day, and year (mm/dd/yyyy) the laboratory reported the result, or the date that the TST was read	This date can be found on the laboratory report as the date the report is released or made available.  In many instances, the result date and report date are the same; if not, provide the earliest date available.
Specimen Source Site	Select appropriate anatomic source site from Appendix I	
Test Result Qualitative (select one)	Description	
Positive	For tests with a qualitative (or interpreted) result, the test result was considered positive.	
Negative	For tests with a qualitative (or interpreted) result, the test result was considered negative.	
Indeterminate	For tests with a qualitative (or interpreted) result, the test result was considered indeterminate (neither positive nor negative).	
Not Done	Used to indicate that initial TST, initial IGRA, initial sputum smear, initial sputum culture, initial NAAT, or initial HIV test was not done in this case.	
Unknown	Used to indicate that the test was done but the result is unknown or that it is unknown if the test was done.	

Test Result Quantitative (select one)	Description
Quantitative result	For tests with a quantitative (numerical) result, record the result in this field. These tests include the TST, CD4 cell count, hemoglobin A1c, fasting blood glucose. Quantitative result is not required for IGRA tests.
Quantitative units	For tests with a quantitative (numerical) result, record the units of measurement, e.g., millimeters for TST, percentage for hemoglobin A1c.

**MINIMUM LAB REQUIREMENTS:**

Always enter initial TST, initial IGRA, initial sputum smear, initial sputum culture, initial NAAT, and initial HIV test. Enter "Not Done" for any tests that were not done in this case.

CD4 count should be reported for HIV-positive persons. Hemoglobin A1c or fasting blood glucose at diagnostic evaluation should be reported for diabetic patients. Also include the initial result of any other tests performed that are in the test type value set. If a type of test was done on different specimen sources, include the initial result for each unique combination of test type and specimen source.

Follow-up testing should be done according to CDC guidelines and local clinical judgment. For tests that are done multiple times, only those results for each combination of test type and specimen source where the result changed (e.g., positive to negative) should be entered.

**Note:**

- A patient's undocumented self-report of a previous positive result is not acceptable.
- At least one CD4 count should be reported for HIV-positive patients, as close to the time of TB diagnostic evaluation as possible. Subsequent CD4 counts may also be reported.
- At least one hemoglobin A1c or fasting blood glucose result should be reported for diabetic patients, as close to the time of TB diagnostic evaluation as possible. Subsequent hemoglobin A1c results may also be reported.

**22. CHEST RADIOGRAPH OR OTHER CHEST IMAGING STUDY RESULTS**

Study Type	Description
Plain Chest X-ray	Standard radiological study resulting in a 2-dimensional projection of internal thoracic structures onto film or a screen.
CT Scan	Computed tomography, an advanced imaging technique using X-rays to display 3-dimensional images of thoracic structures with computer assistance.
MRI	Magnetic resonance imaging, an advanced imaging technique using strong magnetic fields to display 3-dimensional images of thoracic structures with computer assistance.
PET	Positron emission tomography, an advanced imaging technique that uses radioactive tracers to identify areas of higher chemical activity in the body.
Other	Select this option for imaging studies that do not fit into any of the above categories.

Result Options (select one)	Description
Consistent with TB	Any initial results showing abnormalities (e.g., hilar adenopathy, effusion, infiltrate[s], cavity, scarring) consistent with TB.
Not Consistent with TB	Results showed <b>no</b> abnormalities consistent with TB. <i>This category includes any other abnormalities that are not consistent with TB.</i>
Not Done	Used to indicate that a chest X-ray or chest CT scan was not done in this case.
Unknown	Result of chest imaging is not known

Miliary (select one)	Description
Yes	Results showed evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern).
No	Results did <b>not</b> show evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern).
Unknown	It is <b>not</b> known if results showed evidence of miliary disease (e.g., miliary TB, or miliary or bilateral micronodular pattern).

Note: Miliary TB is a serious type of TB disease. It is a clinical or radiologic finding, rather than a site of disease. Miliary TB is the result of a TB infection eroding into the bloodstream and from there disseminating throughout the body to multiple organs. It appears on radiographs as a great number of small (1- to 2-mm), well-defined nodules that look like millet seeds scattered throughout the lungs, hence the name "miliary."

**MINIMUM REQUIREMENTS:** Initial plain chest x-ray; initial chest CT scan. Enter "Not Done" if applicable. Also include the initial result of any other chest imaging studies performed that are in the test type value set (i.e., MRI, PET). Subsequent results for each chest imaging study type should be entered if the result changed. Note if cavity or miliary lesions are identified for each study.

**23. HAS THE PATIENT BEEN PREVIOUSLY DIAGNOSED WITH TB DISEASE OR LTBI?**

History of Previous Illness (select one)	Description
Yes	The patient has a history of previous TB disease or LTBI diagnoses. Note: Written documentation of the previous episode of TB disease or LTBI is ideal. When written documentation is not available, self-report of a previous episode is acceptable (e.g., medication taken, length of course of medication, results of sputum smear examination).
No	The patient did not have previous TB disease or LTBI diagnoses.
Unknown	It is not known if the patient had previous TB disease or LTBI diagnoses.

If Yes:

	Description
Diagnosis Type	TB disease or LTBI
Diagnosis Date	Date of previous diagnosis (provide date to the level of specificity that is available; self-report is acceptable).
Previous State Case Number	Provide previous TB state case number or LTBI state case number, if available. Contact the NJ TB Program to obtain the previous number.

Completed Treatment (select one)	Description
Yes	The patient completed treatment.  Note: Written documentation of the previous episode of TB disease or LTBI is preferred. If the patient had a previous episode of TB that was reported to U.S. surveillance, contact the NJ TB Program so they may obtain information about previous diagnoses and case outcomes. Otherwise, self-report is acceptable.
No	The patient did not complete treatment.
Unknown	It is not known if the patient completed treatment.

**24. DATE OF ILLNESS ONSET/SYMPTOM START DATE**

	Description	Comment
Month, day, and year (e.g., 01/17/2020)	Date illness/symptoms started for this TB episode.	Supply as much of the date as is known.

**Note:** Some symptoms of TB can be nonspecific. The symptom onset date should be recorded as the approximate time when the patient first noticed one or more of the following TB symptoms:

- Severe cough that lasted at least 3 weeks
- Chest pain not explained by another condition
- Coughing up blood or sputum
- Night sweats
- Persistent fever not explained by another condition
- Unintentional weight loss not explained by another condition

**25. SITE OF TB DISEASE**

Select all anatomic sites where TB disease was identified in the patient. If there is evidence that more than one organ or disease site is involved, select all involved sites of disease.

***Miliary TB***

This form has no place to select miliary TB in Site of Disease. If the report of the initial chest radiograph or the initial chest CT scan indicates “miliary TB or a miliary or bilateral micronodular pattern,” record this finding under Initial Chest Radiograph and enter Pulmonary as a Site of Disease.

**26. CASE MEETS BINATIONAL REPORTING CRITERIA?**

Option	Description
Yes	The case meets binational reporting criteria. <i>A case is considered binational when it meets one or more of the following criteria:</i> <ul style="list-style-type: none"> <li>• Exposure to suspected product (e.g., unpasteurized milk or cheese) from Canada or Mexico</li> <li>• Has case contacts in or from Mexico or Canada</li> <li>• Potentially exposed by a resident of Mexico or Canada</li> <li>• Potentially exposed while in Mexico or Canada</li> <li>• Resident of Canada or Mexico</li> <li>• Other situations that may require binational notification or coordination of response</li> </ul>
No	The case does not meet binational reporting criteria.
Unknown	It is not known if the case meets binational reporting criteria.

Options (select all that apply)	Description
Exposure to Suspected Product from Canada or Mexico	Patient exposed to a product (e.g., dairy product for <i>M. bovis</i> case)
Has Case Contacts in or from Mexico or Canada	Patient has close contacts who live in Mexico or Canada
Potentially Exposed by a Resident of Mexico or Canada	Patient was potentially exposed to a TB patient from Mexico or Canada
Potentially Exposed while in Mexico or Canada	Patient was potentially exposed to TB while physically in Mexico or Canada
Resident of Canada or Mexico	The patient is a resident of either Mexico or Canada
Other Situations that May Require Binational Notification or Coordination of Response	Select this option if the case meets one of the following descriptions: <ul style="list-style-type: none"> <li>The patient crossed the border into the United States from Mexico during TB treatment, or</li> <li>The patient was referred to a U.S.-funded, binational TB program for treatment continuity (i.e., a patient who was being treated in the United States, but it was known that he or she would cross the border to Mexico.</li> </ul>

**27. CASE IDENTIFIED DURING THE CONTACT INVESTIGATION OF ANOTHER CASE?**

Select "Yes" if case was identified during the contact investigation of another case.  
Select "No" if case was **not** identified during the contact investigation of another case.

**28. CONTACT INVESTIGATION CONDUCTED FOR THIS CASE?**

This question should be answered "yes" if a contact investigation was conducted in order to identify contacts related to this case, even if the investigation was prompted by identification of a different case.  
*A TB-41 Contact Investigation Form must be submitted for all infectious cases.*

**29. COMPLETE TABLE BELOW FOR ALL KNOWN TB AND LTBI CASES EPIDEMIOLOGICALLY LINKED TO THIS CASE**

For this question, an "epidemiologic link" is defined as either a definite or probable link:

- Definite:* patients shared airspace at the same location at the same time during one case's infectious period
- Probable:* patients shared airspace at the same location during the same general time period, but investigator unable to document that they were there at the same time during one case's infectious period

**30. INITIAL THERAPY STARTED**

Date Therapy Started is the month, day, and year the patient began drug therapy for confirmed or possible TB disease.

**DATE OF CURRENT THERAPY REGIMEN**

Enter the date (month, day, year) the patient began the current treatment regimen.

**PATIENT'S WEIGHT**

Enter the patient's current weight at the bottom in this section in pounds and/or kilograms.

**31. DRUG REGIMEN**

Select the drugs the patient is being treated with and the daily dosage. For combination drugs, select each drug that is a component of the combination drug, e.g., for Rifater (combination of isoniazid, rifampin, and pyrazinamide). Over the counter supplements, such as B6, do not need to be reported.

**32. IF INITIAL DRUG REGIMEN NOT RIPE/HRZE (SEE NOTE), WHY NOT?**

This question should only be completed if the standard initial four-drug therapy (RIPE/HRZE, i.e., isoniazid, rifampin, pyrazinamide, and ethambutol) was not used for this patient as recorded in question 31.

Option	Description
Drug contraindication/interaction	There was a pharmacologic contraindication or interaction that prevented the use of RIPE/HRZE (combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol) in this patient.
Drug susceptibility testing results already known	The patient's drug susceptibility results were already known, so a treatment regimen based on susceptibility results was used immediately.
Suspected drug resistance	Drug susceptibility testing results were not yet available, but the provider suspected drug resistance, (e.g., the patient was a contact of a drug-resistant TB case), so a different regimen was used.
Drug shortage	One or more RIPE/HRZE drugs could not be used because of national or local shortage of the drug(s).
Other (Specify)	Other reason not covered in one of the provided categories.
Unknown	There is insufficient documentation to determine why a regimen other than standard first-line therapy was used.

33.

REPORT PREPARED BY- Name of person completing the form.

SUPERVISION- Select the appropriate box for supervision.

REMARKS- Include any other information, comments, or history you feel is pertinent to the case.



### 34. SUSCEPTIBILITY TESTING

Option (select one)	Description
Yes	Growth-based drug susceptibility testing was performed.
No	Growth-based drug susceptibility testing was <b>not</b> performed.
Unknown	It is unknown whether growth-based susceptibility testing was performed

If YES, complete table for each drug tested

	Description	Comment
Date collected	Month, day, and year (mm/dd/yyyy) the specimen was collected	
Date Reported	Month, day, and year (mm/dd/yyyy) the laboratory reported the result	This date can be found on the laboratory report as the date the report is released or made available.  In many instances, the result date and report dates are the same, if not, report the earliest date available.

For each drug listed, select result option from the following.

Result Options	Description
Resistant	Any degree of resistance reported for drug.
Susceptible	Select only if completely susceptible.
Unknown	It is <b>not</b> known whether the test was performed. or Results were <b>not</b> available, or result is not known for a reason other than pending results.

Note: Include any subsequent tests where the result changed when new test results become available.

### 35. State Use Only

**36. WAS THE PATIENT TREATED AS AN MDR TB CASE (REGARDLESS OF DST RESULTS)?**

Sometimes, TB cases are treated as if they were MDR TB, even if laboratory results are not available to confirm the MDR TB diagnosis. These cases should have "Yes" entered for this question.

Do not mark this question as "Yes" if second-line TB drugs were used for reasons other than possible or confirmed drug resistance, e.g., drug sensitivity or shortage.

**37. SPUTUM CULTURE CONVERSION DOCUMENTED?**

Provide information on sputum culture conversion only for patients with initially positive sputum cultures. This question should be completed once sputum culture conversion is documented. If the patient's sputum cultures later become positive again, the response to this question should be updated.

**38. MOVED DURING THERAPY?**

Option (select one)	Description
Yes	Patient moved to an area where another reporting area must now provide or coordinate TB care
No	Patient did not move or Patient moved within the same reporting area

**39. DATE THERAPY STOPPED**

	Description	Comment
Month, day, and year (mm/dd/yyyy)	Date the patient stopped taking medication for confirmed or possible TB disease	This may be one of several dates, ideally, when the patient last ingested medication if documented in a medical record

40. REASON THERAPY STOPPED OR NEVER STARTED?

Option (select one)	Description
Completed therapy	Patient completed the prescribed course of therapy per the medical record as recorded by the clinician caring for the patient.
Lost	Patient could not be located before the start or the completion of treatment (e.g., the patient moved to an unknown location, or the forwarding address is known but the patient was not found at that address).  Code patients who move outside the United States and cannot be followed up as Other.
Uncooperative or refused	Patient refused to start or complete therapy (e.g., stopped taking drugs).
Adverse treatment event	Therapy was permanently stopped because of an adverse event due to anti-TB medications. <i>Select this option only if the patient survived the adverse event.</i>  If the patient died because of an adverse TB treatment event, select Died as the reason therapy stopped and note that the death was TB-related in item 43.
Not TB	Completed diagnostic evaluation did not substantiate the diagnosis of TB (e.g., <i>M. avium</i> or <i>M. Bovis</i> BCG was isolated from a clinical specimen).
Died	Patient was alive at diagnosis but died before the start or completion of treatment.
Dying	Treatment was stopped by the clinician or at patient request because the patient's condition was terminal, and death was imminent.
Other	Therapy was discontinued for a known reason not included in the above choices and is not Unknown, (e.g., patient moved outside the United States, or patient moved from state A to state B, and state A notified state B, but state B never followed up).
Unknown	Reason that therapy was stopped is not known.

**41. REASON TB DISEASE THERAPY EXTENDED >12 MONTHS, IF APPLICABLE**

Option (select all that apply)	Description	Comment
Inability to use Rifampin (Resistance, Intolerance, etc.)	Rifampin (or another rifamycin) could not be used to treat the patient (e.g., drug-resistant TB, rifampin intolerance), resulting in the treatment protocol lasting more than 12 months.	
Adverse drug reaction	Patient had a significant adverse drug reaction or experienced an adverse treatment event from anti-TB medications that prolonged therapy.	
Nonadherence	There were barriers to the patient's adherence to anti-TB therapy (e.g., treatment interruption), resulting in extension of therapy beyond 12 months.	
Failure	A culture tested positive 4 or more months after treatment began, resulting in prolonged therapy.	
Clinically indicated—other reasons	Clinical indications (other than adverse drug reactions) include central nervous system TB (e.g., meningitis), severe liver disease, or other criteria as specified by the clinician.	
Other (specify)	Reason does not include any of the choices listed above. Specify the reason that therapy was extended.	
Unknown	Reason is unknown.	

**42. TREATMENT ADMINISTRATION**

Option (select all that apply)	Description
DOT	Directly Observed Therapy (DOT), in person. Response applies if DOT was used for any doses for a patient.
EDOT	Electronic DOT (EDOT), via videocall or other electronic method. Response applies if EDOT (e.g., video call, electronic medication bottle) was used to document adherence to the medication regimen for any doses.
Self-Administered	Any doses of medication were taken by the patient not under DOT or EDOT (including weekend doses).

**43. DID THE PATIENT DIE (EITHER BEFORE DIAGNOSIS OR AT ANY TIME WHILE BEING FOLLOWED BY TB PROGRAM)?**

Option	Description
Yes	The patient died (for any reason) either before the TB diagnosis was made or at any point after TB diagnosis while the TB program was following the status of the patient. If this option is selected, record the date of death.
No	The patient was alive at the time that the TB program stopped following up with the patient.
Unknown	It is unknown whether the patient was alive or dead at the time that the TB program stopped following up with the patient.

**If Yes:**

	Description	Comment
Month, day, and year (e.g., 01/02/2020)	Patient's date of death should be entered (i.e., month, day, <i>and</i> year).	If the exact date of death is unknown, provide as much specificity as possible.

**Did TB or Complications of TB Treatment Contribute to Death?**

Option (select one)	Description	Comment
Yes	TB or complications of TB treatment contributed to death.	Written documentation of the cause of death (e.g., death certificate, autopsy report, medical record) is recommended. However, oral information from a reliable source (e.g., a health care provider) will be accepted. A death certificate is not necessarily required to complete this field, and TB does not need to be listed as a cause of death on the death certificate to conclude that the death was TB-related for the purposes of the RVCT.
No	TB or complications of TB treatment did not contribute to death.	TB was not the immediate cause, an underlying cause, or another significant condition contributing to death.
Unknown	It is not known if TB or complications of TB treatment contributed to death.	Every effort should be made to determine if the death was related to TB disease before classifying as unknown.

## APPENDIX B

**Instructions for Completing the  
RECORD OF CONTACT INTERVIEW (TB-41)**

**Zip Code:** Enter zip code in which the index case/suspect resides.

**Date of Birth:** Enter the date of birth of the index case/suspect.

**Telephone Number:** Enter the phone number of the index case/suspect.

**Name of Employer/School/Congregate Setting:** Enter the name of the employer, school or congregate setting that was identified as part of the investigation.

**Address:** Enter the address of the employer, school or congregate setting that was identified as part of the investigation.

**Telephone Number of Employer/School/Congregate Setting:** Enter the telephone number of the employer, school or congregate setting which was identified as part of the investigation.

**Occupation:** Enter the occupation of the index case/suspect.

**Date of Interview:** Enter the date that the TB case/suspect was interviewed.

**Date of Reinterview:** Enter the date that the reinterview was completed.

**Infectious Period:** Document the start and end points of the investigation and probable transmission period. Refer to the "Practice Standards for Contact and Source Case Investigations" for definitions. If the end of the infectious period is pending due to the infectiousness of the patient, indicate that in this area when submitting the form to the state and revise as appropriate.

**Reason for Interview:** Enter an (X) to indicate the reason for the interview (case, suspect, child less than 5 years old).

**Contact Information:**

Enter the contact's name (last, first, middle initial), address, and telephone number in the box.

**Nature of the contact:** Enter the nature of contact using codes 1-8. Codes may be found at the bottom of the form. Multiple codes may be used. This includes all contacts identified within the infectious period in the:

1. Household: includes all family and non-family members residing in the household
2. Worksite: contacts identified at the work place
3. School: all contacts identified at the pre-school/day care, school, college or university setting
4. Jail / Prison: all contacts identified in the jail or prison that the patient resided in during the infectious period
5. Health Care Facility: all contacts identified in a hospital, nursing home or other health care facility
6. Social: all contacts identified in social settings- including friends, leisure and recreational activities
7. Shelters: all contacts identified in homeless shelters
8. Others: those contacts that do not fall into one of the above categories. Please specify in the "remarks" area

**DOB and/or Age:** Enter contact's date of birth. Contact's age (or approximate age) may be entered if date of birth is unknown.

**Sex:** Enter an (X) to indicate the sex of the contact.  
M = Male  
F = Female

**Foreign Born:** Enter an (X) to indicate if the contact is foreign-born  
Y=Yes  
N=No

**Instructions for Completing the  
RECORD OF CONTACT INTERVIEW (TB-41)**

**Last Exposure:** Enter the date of the contact's last exposure to the case during the infectious period (i.e., the point in time where the case and contact cease to share air in an environment conducive to transmission or when the index case is no longer infectious).

**Examination Results**

**TST or QFT Date Done/Results:** Enter the date the initial TST was administered with reading in millimeters (mm) or the QFT test date and results as "+" (positive) or "-" (negative). If the contact has a documented positive TST or QFT prior to this investigation indicate by writing "Prev + TST or QFT" in this section. This must be a **documented positive**, not just via patient history. If the contact does not receive an x-ray, indicate the date the symptom assessment was done by writing the date and "sx none" in the remarks section. A symptom assessment **must** be completed on all previously positive TST and QFT contacts.

**TST or QFT Date Done/Results:** Enter the date and results of the repeat TST (must be recorded in mm) or the QFT test date and results (recorded as "+" or "-").

**Chest X-Ray Date/Results:** Enter the date of the initial chest x-ray and the results:  
N=Normal Abn= Abnormal

**Therapy Date/Meds (K-P):** Enter the date the patient started treatment and enter the prescribed medication regimen, using codes K-P defined at the bottom of the TB-41.

**Completed Rx Date or Incomplete Code A-G:** Enter the date that the patient completed therapy for LTBI or enter the appropriate code. A-G at the bottom of the TB-41 indicating why the therapy was not completed.

- A. Death – use if the patient died after therapy was started.
- B. Moved and records referred - this is for out of state/country contacts only. Records with complete addresses must be sent to NJDOH TB Program for follow-up.

Please note: The initiating county is responsible for the final disposition of all contacts that move within the state.

- C. Active TB- patient develops and is being treated for active TB and is no longer being treated for LTBI.
- D. Adverse effects- therapy is stopped due to adverse reactions from the medications.
- E. Refused- use this code only when the patient started therapy and then stopped against medical advice.
- F. Lost- patient is lost to follow-up. This includes those patients that have moved without any locating information.
- G. Provider decision- the medical provider has stopped all medications.

**Remarks:** Enter additional information such as: when the patient refuses treatment for LTBI, the patient dies prior to starting treatment, date of symptom history on those contacts that have had a previous significant TST or + QFT, physician name and phone number who is testing contact(s) and date referred to health officer for follow-up.

**Name and Title of Interviewer:** Enter the name and title of the person interviewing the TB case/suspect.

**Signature:** The interviewer will sign the form before each submission.

**Date Submitted:** Enter the date the TB-41 is submitted to the NJDOH TB Program.

**Agency Name:** Enter the agency name responsible for the interview.

**Agency Telephone Number:** Enter the agency telephone number responsible for the interview.

**Reviewed by NJDOH (Initials and Date):** The NJDOH designee will initial and date the TB-41 after each review.



<b>NJDOH USE ONLY:</b>		Date Counted: _____	Final Dx (Check one):		<input type="checkbox"/> + Sputum Smear	<input type="checkbox"/> Neg. Sputum Smear/+ Sputum Culture						
			<input type="checkbox"/> Pulm-Other-Cul	<input type="checkbox"/> Pulm-Clinical	<input type="checkbox"/> Extra-Pulm							
<b>New Jersey Department of Health</b> <b>TB Program</b> <b>PO Box 363, Trenton, NJ 08625-0363</b>						<b>RECORD OF CONTACT INTERVIEW</b> <input type="checkbox"/> Initial <input type="checkbox"/> Interim <input type="checkbox"/> Final <input type="checkbox"/> No Contacts Identified <input type="checkbox"/> Interview Not Done						
						TB-70 # _____						
						Date Reported _____						
Name: Last                      First                      MI			Street Address									
City		County	Zip Code	Date of Birth		Telephone Number						
Name of Employer/School/Congregate Setting				Address								
Telephone Number of Employer/School/Congregate Setting				Occupation								
Date of Interview		Date of Reinterview		Infectious Period: From: _____ To: _____		Reason for Interview <input type="checkbox"/> Case <input type="checkbox"/> Suspect <input type="checkbox"/> Child <5 Years Old						
<b>CONTACT INFORMATION</b>				<b>EXAMINATION RESULTS</b>								
Last Name, First Name Address/Telephone Number		Nature of Contact (Codes 1-8)	DOB and/or Age	Sex	For- eign Born	Last Exposure Date	Date Done Results	Date Done Results	X-Ray Date Results	Therapy Date Meds (K-P)	Completed Rx Date or Incomplete Code A-G	Remarks
				<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
				<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
				<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
				<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
Name and Title of Interviewer				Agency Name								
Signature				Date Submitted		Agency Telephone Number		Reviewed by NJDOH (Initials and Date)				

329

# RECORD OF CONTACT INTERVIEW, Continued

TB-70 #

Name: Last		First		MI		County					
CONTACT INFORMATION						EXAMINATION RESULTS				Remarks	
Last Name, First Name Address/Telephone Number	Nature of Contact (Codes 1-8)	DOB and/or Age	Sex	For- eign Born	Last Exposure Date	Date Done	Date Done	X-Ray Date	Therapy Date		Completed Rx Date or Incomplete Code A-G
						Results	Results	Results	Meda (K-P)		
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				
			<input type="checkbox"/> M <input type="checkbox"/> F	<input type="checkbox"/> Y <input type="checkbox"/> N		<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm	<input type="checkbox"/> QFT- <input type="checkbox"/> QFT+ mm				

TB-41  
DEC 22

NATURE OF CONTACT: 1-Household 2-Worksite 3-School 4-Jail/Prison 5-Health Care Facility 6-Social 7-Shelter 8-Other  
 MEDS: K-INH L-RIF M-INH or RIF Intermittent N-Special Regimen (MDR) O-Other LTBI Rx P-Rx for TB Case/Suspect  
 RX INCOMPLETE: A-Death B-Moved, Records Referred C-Active TB D-Adverse Effects E-Refused F-Lost G-Provider Decision

## **SUBCHAPTER 6. HIGHER EDUCATION IMMUNIZATION**

### **8:57-6.1 Scope**

**(a) This subchapter applies to every IHE.**

**(b) Notwithstanding a religious exemption that might otherwise be available, this subchapter shall not be construed to limit a private entity's ability to exclude from enrollment or attendance at an IHE, a person, who does not have immunization or serologic immunity from:**

**1. A vaccine-preventable disease of which this subchapter requires evidence of immunization or serologic immunity;**

**2. Immunizations that the Department recommends or requires pursuant to N.J.A.C. 8:57-1.5; and/or**

**3. Another vaccine-preventable disease against which this subchapter does not require evidence of immunization or serologic immunity, provided the additional required immunization or serologic immunity is consistent with the ACIP recommendations or the AAP Red Book with respect to applicable Catch-up Schedules, medical contraindications, and recognition of serologic immunity.**

### **8:57-6.2 Designation of institutional liaison for IHEs**

**(a) The highest-ranking official within an IHE shall designate an institutional official, hereinafter referred to as the institutional liaison, and shall notify the Department of the designation using the Institutional Liaison Designation form at N.J.A.C. 8:57 Appendix P, incorporated herein by reference.**

**(b) An institutional liaison shall:**

**1. Serve as the IHE's representative to the Department, specifically the VPDP, with respect to the Department's oversight of the IHE's compliance with this subchapter and other applicable laws governing immunization of collegians;**

**2. Have access to the immunization records that this subchapter requires the IHE to maintain; and**

**3. Administer and implement any corrective action that the Department requires the IHE to undertake to maintain the IHE's compliance with this subchapter.**

**(c) The highest-ranking official within an IHE shall notify the Department of changes to the identity or means to communicate with its designated institutional liaison by submitting a new Institutional Liaison Designation form provided at N.J.A.C. 8:57 Appendix P to the Department within 30 days of a change.**

**8:57-6.3 IHE to require certain collegians to submit record of compliance with N.J.A.C. 8:57-4 pursuant to N.J.S.A. 18A:61D-1**

**(a) Pursuant to N.J.S.A. 18A:61D-1 et seq., and subject to N.J.A.C. 8:57-6.5, 6.6, 6.7, 6.8, and 6.12, an IHE shall require every full-time collegian who is 30 years of age or less and who enrolls full- or part-time in a program or course of study of the IHE leading to an academic degree, as a condition of the collegian's admission to and/or continued enrollment in the IHE, to submit to the IHE evidence of immunization pursuant to N.J.A.C. 8:57-6.4 for the diseases against which N.J.A.C. 8:57-4 requires immunization, according to the ACIP recommendations and any Catch-up Schedule then-applicable to the collegian.**

**(b) With respect to a collegian who provides, in whole or in part, insufficient evidence of immunization pursuant to (a) above, an IHE shall require the collegian, as a condition of the collegian's admission to and/or continued enrollment in the IHE, to:**

**1. Obtain the vaccinations with respect to which the collegian is unable to satisfy (a) above in accordance with the ACIP recommendations then-applicable to the collegian, including an applicable Catch-up Schedule; and**

**2. Submit to the IHE documentation of compliance with (a) above in accordance with N.J.A.C. 8:57-6.4.**

**(c) An IHE shall not knowingly admit to or retain at the IHE any collegian who does not provide evidence of immunization in accordance with this section.**

#### **8:57-6.4 Evidence of immunization**

**(a) An IHE shall accept, and maintain as part of a collegian's immunization record pursuant to N.J.A.C. 8:57-6.13, the types of documentation listed at (b) below as evidence of a collegian's immunization, as administered by a healthcare professional, from those diseases against which N.J.A.C. 8:57-6.3, 6.10, and/or 6.11 require the collegian to present evidence of immunization if, alone or in combination with other items specified at (b) below, the documentation identifies:**

**1. The month, day, and year of administration of each required vaccine dose; or**

**2. Only the month and year of administration of each required vaccine dose if the totality of the documentation presented enables the IHE, in consultation**

with the VPDP, as may be necessary, to undertake the analysis and make the determination that (c) below requires.

(b) Subject to (a) above, a record consistent with N.J.A.C. 8:57-4.4 , is acceptable evidence of immunization.

(c) The IHE shall evaluate the evidence a collegian submits pursuant to this section, in consultation with the VPDP, as necessary, to confirm that:

1. The collegian received those immunizations of which this subchapter requires the IHE to confirm that collegian's receipt;

2. The required doses were administered by a healthcare professional or a pharmacist; and

3. The dose of each vaccination was a valid dose.

(d) Subject to N.J.A.C. 8:57-6.5, an IHE shall require a collegian who is unable to present evidence that satisfies the IHE or the VPDP pursuant to (c)1 and 2 above:

1. As applicable, to obtain missing doses and/or repeat invalid doses; and

2. Following a collegian's receipt of missing doses and/or repeat invalid doses, submit evidence of immunization within 10 days of receipt to the IHE as to these doses.

(e) An IHE shall make reasonable efforts to verify a document a collegian submits pursuant to this section if the IHE or the VPDP has reason to doubt the document's authenticity and/or content:

- i. Upon the IHE's own initiative;

- ii. Upon consultation with the Department; and/or

- iii. Upon the request of the Department.

#### **8:57-6.5 Evidence of immunity**

**(a) If a collegian is unable or unwilling to present evidence of immunization that complies with N.J.A.C. 8:57-6.4 or 6.10, an IHE shall admit and/or continue the enrollment of the collegian if the collegian presents evidence, compliant with (b) below, of laboratory serologic test results consistent with N.J.A.C. 8:57-4.5 of a collegian's immunity from or ongoing illness with diseases against which this subchapter requires the IHE to obtain evidence of immunization.**

**(b) An IHE shall make reasonable efforts to verify the authenticity and/or content of a document that a collegian submits pursuant to this section if the IHE or the VPDP has reason to doubt the document's authenticity and/or content:**

- 1. Upon the IHE's own initiative;**
- 2. Upon consultation with the Department; and/or**
- 3. Upon the request of the Department.**

#### **8:57-6.6 Provisional admission and/or continued enrollment**

**(a) Subject to (b) below, an IHE shall provisionally admit and/or continue the enrollment of a collegian who otherwise would be excludable pursuant to N.J.A.C. 8:57-6.3, as applicable, for the duration of one academic term, but no longer than four months, if the collegian:**

- 1. Has received at least one valid dose of each immunization that N.J.A.C. 8:57-4, as applicable, requires, in accordance with the ACIP recommendations;**

**2. Is no later than 14 days behind in receiving the remaining doses in accordance with the applicable Catch-up Schedule (subject to an alternative schedule established in statute, such as that provided for the hepatitis B vaccine); and**

**3. Receives the remaining doses in accordance with the applicable Catch-up Schedule and concurrently provides to the IHE evidence of immunization therewith consistent with N.J.A.C. 8:57-6.4, as applicable.**

**(b) An IHE shall admit to and/or continue the enrollment in the IHE, a collegian, who otherwise would be excludable pursuant to N.J.A.C. 8:57-6.3, for the duration of the collegian's academic term, but no longer than four months, following admission and/or enrollment if the collegian is from outside of the USA and, within that period of admission and/or enrollment:**

**1. The collegian complies with N.J.A.C. 8:57-6.3, as applicable; or**

**2. The collegian:**

**i. Has received at least one valid dose of each required immunization that N.J.A.C. 8:57-6.3, as applicable, requires in accordance with the ACIP recommendations;**

**ii. Is no later than 14 days behind in receiving the remaining doses in accordance with the applicable Catch-up Schedule (subject to an alternative schedule established in statute, such as that provided for the hepatitis B vaccine); and**

**iii. Receives the remaining doses in accordance with the applicable Catch-up Schedule of the ACIP recommendations and concurrently**



**provides to the IHE evidence of immunization therewith consistent with N.J.A.C. 8:57-6.4, as applicable.**

**8:57-6.7 Medical exemption from compliance with N.J.A.C. 8:57-6.3, 6.10, and/or 6.11 pursuant to N.J.S.A. 18A:61D-10 and 18A:62-15.2**

**(a) An IHE shall not require a collegian who is subject to N.J.A.C. 8:57-6.3, 6.4, 6.10, and/or 6.11 to comply therewith, with respect to an immunization that is medically contraindicated or presents a precaution for that collegian for a reason that the ACIP recommendations or the AAP Red Book specifies as a vaccine contraindication.**

**(b) In support of an exemption pursuant to (a) above, an IHE shall require a collegian to submit to the IHE a Request for Medical Exemption from Mandatory Immunization at N.J.A.C. 8:57 Appendix L, incorporated herein by reference, or another document consistent with N.J.A.C. 8:57-4.7(b).**

**(c) The IHE shall:**

**1. Review a statement submitted pursuant to this section for compliance with (a) and (b) above;**

**2. Retain the statement as part of the collegian's immunization record pursuant to N.J.A.C. 8:57-6.13;**

**3. Review the grant of an exemption at least annually or by the end of the period of contraindication specified at (c)2 above, whichever is earlier; and**

**4. If applicable, as a condition of the collegian's admission to and/or continued enrollment in the IHE, ensure that the collegian complies with N.J.A.C.**

**8:57-6.3, 6.10, and 6.11, as applicable, upon the conclusion of the period of contraindication that is specified in the statement submitted pursuant to (c)2 above.**

**(d) An IHE can consult with the VPDP to obtain assistance in reviewing a statement for compliance with this section and determining whether the reason specified as a contraindication or precaution pursuant to (c)3 above, is a reason that the ACIP recommends or the AAP Red Book identifies or recognizes as a vaccine contraindication or precaution.**

**8:57-6.8 Religious exemption from compliance with N.J.A.C. 8:57-6.3 pursuant to N.J.S.A. 18A:61D-3 and 26:1A-9.1**

**(a) An IHE shall not require a collegian to submit a record of compliance in accordance with N.J.A.C. 8:57-6.3 if the collegian, or the collegian's parent if the collegian is a minor, submits a written, signed statement to the IHE that requests an exemption from a specific required immunization and indicates that:**

**1. The specific required immunization "conflicts with" the collegian's "religious beliefs" (see N.J.S.A. 18A:61D-3); or**

**2. The specific required immunization "interferes with the free exercise of the" collegian's "religious rights" (see N.J.S.A. 26:1A-9.1).**

**(b) The IHE shall require a collegian to comply with N.J.A.C. 8:57-6.3 with respect to immunizations as to which the collegian does not assert a religious conflict or interference pursuant to (a)1 or 2 above.**

**(c) An IHE shall not grant an exemption pursuant to (a) above on the sole basis of a collegian's general moral or philosophical objection to immunization.**

**(d) An IHE shall retain a statement that a collegian submits pursuant to (a) above, in the collegian's immunization record pursuant to N.J.A.C. 8:57-6.13.**

**(e) Subject to (f) and (g) below, an IHE shall not require a collegian who obtains an exemption pursuant to this section to reapply annually for the exemption.**

**(f) If a collegian obtains an exemption pursuant to this section and thereafter consents to and does receive a vaccination that N.J.A.C. 8:57-6.3 requires, in contravention of the statement the collegian submitted pursuant to (a) above, the IHE shall treat the exemption as inapplicable to further immunizations that, but for the exemption, N.J.A.C. 8:57-6.3 would require the collegian to receive.**

**(g) A collegian whose religious exemption on file with an IHE becomes inapplicable pursuant to (f) above must reapply for a religious exemption pursuant to this section if the collegian wants to assert an exemption from any subsequent doses of immunizations that N.J.A.C. 8:57-6.3 would require the collegian to receive.**

**8:57-6.9 Exclusion of collegian due to vaccine-preventable diseases pursuant to N.J.S.A. 18A:62-15.2, 26:1A-9.1, and 26:4-6**

**(a) Notwithstanding N.J.A.C. 8:57-6.6, 6.7, 6.8, and 6.12, if the Commissioner determines that a suspected or confirmed vaccine-preventable disease outbreak exists, an IHE shall exclude, in accordance with the direction of the local health agency with jurisdiction or the Department, unimmunized, under-immunized, and**

provisionally admitted collegians from attendance at the IHE during the suspected or confirmed vaccine-preventable disease outbreak.

(b) Pursuant to N.J.S.A. 26:4-6, “Any body having control of a school may, on account of the prevalence of any communicable disease, or to prevent the spread of communicable diseases, prohibit the attendance of any teacher or pupil of any school under their control and specify the time during which the teacher or scholar shall remain away from school.”

(c) To implement (a) or (b) above, the local health agency with jurisdiction or the Department shall determine, and provide corresponding direction to the IHE about:

1. The “prevalence” of a communicable disease;
2. The necessity of the prohibition from attendance of a person to prevent the spread of the communicable disease;
3. The categories of persons, based on immunization status, that the IHE is to prohibit from attendance; and
4. The time during which the prohibition from attendance is to remain in effect.

(d) An IHE, through its institutional liaison, shall maintain a record of collegians admitted to the IHE pursuant to N.J.A.C. 8-57:6.6, 6.7, 6.8, and 6.12, and make an up-to-date list of those collegians available to the Department and/or the local health agency with jurisdiction, upon request.

**8:57-6.10 IHEs to require certain collegians to submit record of compliance with N.J.S.A. 18A:61D-9 regarding immunization against or immunity to hepatitis B**

**(a) Pursuant to N.J.S.A. 18A:61D-9, and subject to N.J.A.C. 8:57-6.7, 6.8, and 6.12, and (c) below, as a condition of a collegian's admission to or continued enrollment in an IHE, an IHE shall require every collegian, regardless of age, to comply with (b) below, if the collegian:**

**1. Registers for 12 or more credit hours of course study per semester or term; and**

**2. Enrolls in a program of the IHE leading to an academic degree.**

**(b) A collegian who is subject to (a) above shall submit evidence compliant with:**

**1. N.J.A.C. 8:57-6.4, showing that the collegian has completed the hepatitis B immunization series that is applicable to that collegian as specified in the ACIP recommendations within nine months of the date the collegian first commences to attend the IHE; or**

**2. N.J.A.C. 8:57-6.5, showing that the collegian has immunity from an ongoing illness with hepatitis B consistent with N.J.A.C. 8:57-4.5(a)2.**

**(c) This section shall not extend the time within which an IHE is to obtain evidence of hepatitis B immunization or immunity from a collegian who is subject to N.J.A.C. 8:57-6.3.**

**(d) An IHE that obtains evidence of hepatitis B immunization or immunity from a collegian pursuant to N.J.A.C. 8:57-6.4 and 6.5 is deemed compliant with this section and shall not require that collegian to resubmit evidence of hepatitis B immunization or immunity pursuant to this section.**

**(e) An IHE shall not knowingly admit to, or retain at, the IHE a collegian who does not provide evidence of hepatitis B immunization or immunity compliant with this section.**

**(f) An IHE shall not grant provisional admission pursuant to N.J.A.C. 8:57-6.6 to a collegian described at (a) above with respect to submission of the evidence of immunization or immunity that this section requires.**

**8:57-6.11 IHEs to require collegian to submit record of compliance with N.J.S.A. 18A:62-15.1 regarding meningococcal-containing vaccination**

**(a) Pursuant to N.J.S.A. 18A:62-15.1, and subject to N.J.A.C. 8:57-6.8 and 6.12, as applicable, an IHE shall require a collegian specified at (b) below, as a condition of the collegian's enrollment in the IHE, to submit to the IHE evidence compliant with N.J.A.C. 8:57-6.4 that the collegian has received meningococcal-containing vaccination in accordance with ACIP recommendations then-applicable to the collegian.**

**(b) Subsection (a) above applies to all collegians, regardless of age, who enroll in an IHE.**

**(c) An IHE shall not knowingly admit to or retain at the IHE any collegian who does not comply with this section.**

**8:57-6.12 Religious exemption from compliance with N.J.A.C. 8:57-6.10 and 6.11 pursuant to N.J.S.A. 18A:61D-10 and 18A:62-15.2**

**(a) An IHE shall not require a collegian who is subject to N.J.A.C. 8:57-6.10 and/or 6.11 to comply therewith if the collegian, or the collegian's parent if the collegian is a minor, submits a written, hand-signed statement to the IHE requesting an exemption from compliance with either section that explains "how the administration of the vaccine conflicts with the bona fide religious tenets or practices of the" collegian and/or the collegian's parent, if the collegian is a minor (see N.J.S.A. 18A:61D-10 and 18A:62-15.2).**

**(b) An IHE shall not grant an exemption from a collegian's compliance with N.J.A.C. 8:57-6.10 and/or 6.11 on the sole basis of a general philosophical or moral objection to immunization on the part of the collegian and/or, if the collegian is a minor, the collegian's parent.**

**(c) A religious-affiliated IHE has the authority to withhold or grant a request for exemption made pursuant to this section without challenge by any secular health authority.**

**(d) An IHE shall retain a statement that a collegian submits pursuant to (a) above in the collegian's immunization record in accordance with N.J.A.C. 8:57-6.13.**

**(e) An IHE shall not require a collegian who obtains an exemption pursuant to this section to reapply annually for the exemption.**

**8:57-6.13 IHE's obligations with respect to collegians' immunization records pursuant to N.J.S.A. 18A:61D-1**

**(a) With respect to records that this subchapter requires an IHE to collect, establish, and/or maintain, the IHE, through its institutional liaison, shall:**

**1. Maintain the records in a manner that renders them accessible to public health officials without compromising the confidentiality of collegians' other educational or medical records;**

**2. Make the records available to authorized representatives of the Department and the local health agency with jurisdiction:**

**i. For routine inspection upon 24 hours' notice; and**

**ii. For immediate inspection during confirmed or suspected vaccine-preventable disease outbreaks or other public health emergencies; and**

**3. Ensure that each record is compliant with respect to the required content and origin of documentation of the following, as applicable:**

**i. Evidence of immunization pursuant to N.J.A.C. 8:57-6.4;**

**ii. Evidence of immunity pursuant to N.J.A.C. 8:57-6.5;**

**iii. Medical exemption pursuant to N.J.A.C. 8:57-6.7; and**

**iv. Religious exemptions pursuant to N.J.A.C. 8:57-6.8 and/or 6.12.**

**(b) Upon request of a collegian, and in accordance with policies and procedures that an IHE establishes with respect to its handling of collegians' requests for their educational, and other medical, records and transcripts, an IHE shall:**

**1. Issue a copy, an electronic print-out, or a duplicate in another medium, of a collegian's immunization record, including supporting statements, such as**



medical or religious exemption documentation (hereinafter collectively referred to as an “immunization transcript”);

2. Authenticate the immunization transcript in the same manner as that in which it would authenticate a collegian’s educational transcript; and

3. Transmit the immunization transcript to the collegian or, at the direction of the collegian, to another IHE within or outside the State.

(c) An IHE shall retain a collegian’s immunization transcript, and address a collegian’s request for copies or transmittal thereof pursuant to (b) above, consistent with the policies and procedures that the IHE establishes with respect to the retention method and period the IHE applies to, and the process by which the IHE addresses a collegian’s request for copies and/or transmittal of, a collegian’s educational, and other medical records and transcripts.

**8:57-6.14 IHEs to offer hepatitis B and meningococcal-containing vaccines pursuant to N.J.S.A. 18:61D-9 and 18A:62-15.1**

(a) An IHE shall make the following vaccinations available to collegians through the IHE’s student health services program or through a contractual agreement with a community-based health service in proximity to the IHE:

1. Hepatitis B; and
2. Meningococcal-containing vaccine.

**8:57-6.15 Certain IHEs to offer information about meningitis and meningococcal-containing vaccine immunization requirement pursuant to N.J.S.A. 18A:61D-7**

**(a) Each IHE shall:**

**1. Provide to all prospective collegians, regardless of age, prior to their matriculation, the Department brochure “Meningococcal Disease: Are You Protected,” available within the Implementation of Meningococcal Vaccine Requirements guidance at**

**[https://www.nj.gov/health/cd/documents/topics/meningo/are\\_you\\_protected.pdf](https://www.nj.gov/health/cd/documents/topics/meningo/are_you_protected.pdf);**

**and**

**2. Develop procedures:**

**i. To obtain and record each prospective collegian’s response to the information the IHE provides pursuant to (a)1 above;**

**ii. To assess prospective collegians’ compliance with N.J.S.A. 18A:62-15.1 and N.J.A.C. 8:57-6.11; and**

**iii. To memorialize whether prospective students who are exempt from compliance with N.J.S.A. 18A:62-15.1 and N.J.A.C. 8:57-6.4 and/or 6.11 nonetheless decide to receive the meningococcal-containing vaccine following receipt of the information the IHE provides pursuant to (a)1 above.**

**8:57-[6.17]6.16 Reports to be submitted to the Department**

**(a) Each [institution] IHE, through its institutional liaison, shall [provide a report of the immunization status of students] report the immunization status of the collegians**

**attending or enrolled in the IHE for each campus location by December 1 of** each year [to] **by submission of** the [Department using] **information required in** the Annual College Immunization Status Report (IMM-3), available [in the subchapter] **at N.J.A.C.**

**8:57 Appendix Q, incorporated herein by reference:**

**1. Electronically; or**

**2. In the NJIIS.**

[1. The official designated pursuant to N.J.A.C. 8:57-6.11(b) to be responsible for the administration and enforcement of this subchapter and for the maintenance of immunization records shall submit the report through the mail or submit electronically, through the addresses set forth in N.J.A.C. 8:57-6.2(a).

(b) The institution shall document the total number of students who are specifically covered by the applicable education or vaccination requirements of this subchapter relevant to that institution, the number of students who are vaccinated, the number of students in provisional status, the number of students with medical exemptions, the number of students with religious exemptions, and the number of students not receiving the required immunizations.

(c) The institution shall submit the Annual College Immunization Status Report by December 1 of the academic year which begins in September of the same year after the review of all appropriate immunization records.

(d) Each four-year institution of higher education shall complete the meningococcal section of the Annual College Immunization Status by December 1, for each academic year which begins in September of the same year.

(e) The annual meningococcal section of the Annual College Immunization Status report from each four-year institution shall document, at a minimum, the total number of new

students, the number of students' responses received, and the number of new students vaccinated.]

## APPENDIX A

New Jersey Department of Health  
ZOO NOTIC DISEASE INCIDENT REPORT

FOR STATE USE ONLY
Report Number

LOCAL HEALTH DEPARTMENT INFORMATION		
Name of Local Health Department	Date of Report	
Name of Contact Person	Telephone Number	
Street Address	PO Box, Apt., Suite	Cell Phone Number
City	Zip Code	Email Address
PERSON REPORTING		
Name (First, Last)	Affiliation (Vet, etc.)	Telephone Number
Street Address	PO Box, Apt., Suite	Cell Phone Number
City	Zip Code	Email Address
ANIMAL OWNER INFORMATION		
Name of Owner (First, Last)	Telephone Number	
Street Address	PO Box, Apt., Suite	Cell Phone Number
City	Zip Code	Email Address
ANIMAL FACILITY INFORMATION (IF APPLICABLE)		
Name of Animal Facility	Telephone Number	
Street Address	PO Box, Apt., Suite	Cell Phone Number
City	Zip Code	Email Address
DISEASE REPORT DETAILS		
<div style="display: flex; justify-content: space-between;"> <div style="width: 60%;"> <p><b>Disease</b></p> <div style="display: flex; flex-wrap: wrap;"> <div style="width: 48%;"> <input type="checkbox"/> Anthrax (<i>Bacillus anthracis</i>)  <input type="checkbox"/> Avian chlamydiosis (<i>Chlamydia psittaci</i>)  <input type="checkbox"/> Campylobacteriosis (<i>Campylobacter</i> spp.)  <input type="checkbox"/> Canine brucellosis (<i>Brucella canis</i>)  <input type="checkbox"/> <i>Escherichia coli</i>, Shiga toxin-producing strains (STEC)  <input type="checkbox"/> Glanders (<i>Burkholderia mallei</i>)  <input type="checkbox"/> Illness caused by exposure to harmful algal blooms  <input type="checkbox"/> Leishmaniasis (<i>Leishmania</i> spp.)  <input type="checkbox"/> Leptospirosis (<i>Leptospira</i> spp.)                 </div> <div style="width: 48%;"> <input type="checkbox"/> Lymphocytic choriomeningitis (Lymphocytic choriomeningitis virus)  <input type="checkbox"/> Melioidosis (<i>Burkholderia pseudomallei</i>)  <input type="checkbox"/> Plague (<i>Yersinia pestis</i>)  <input type="checkbox"/> Q fever (<i>Coxiella burnetii</i>)  <input type="checkbox"/> Salmonellosis (<i>Salmonella</i> spp.)  <input type="checkbox"/> SARS-CoV-2  <input type="checkbox"/> Tuberculosis (<i>Mycobacterium tuberculosis</i>)  <input type="checkbox"/> Tularemia (<i>Francisella tularensis</i>)  <input type="checkbox"/> Other:                 </div> </div> </div> <div style="width: 35%;"> <p><b>Check if appropriate:</b></p> <input type="checkbox"/> Outbreak (observed cases in excess of expected)   <input type="checkbox"/> Disease Agent is Unknown   <p>Number of cases: _____</p> </div> </div>		

**ZOONOTIC DISEASE INCIDENT REPORT**  
(Continued)

ANIMALS HOUSED ON PREMISES (Please provide the following information regarding additional animals on the premises or in the household)				
Species	Number Housed on Premises	Number Sick	Additional Information	
Dog				
Cat				
Pet Bird				
Ferret				
Other:				
CASE SPECIFIC INFORMATION [Complete for index (first) case on premises or in outbreak; use Continuation Sheets for additional cases.]				
Animal Name (or ID, if applicable)	Animal Age	Animal Sex	Animal Breed	Animal Color
Illness Onset Date	Clinical Signs			
Date of First Visit to Vet				
Name, Address and Telephone Number of Veterinarian (if not provided on Page 1)				
Relevant History		Treatment		
Outcome <input type="checkbox"/> Survived <input type="checkbox"/> Euthanized <input type="checkbox"/> Died	Date	Postmortem Exam Performed? <input type="checkbox"/> Yes <input type="checkbox"/> No	If Yes, Date Performed	
LABORATORY TEST RESULTS				
Name of Laboratory				
Organism/Agent	Lab Result/Value	Type of Test Performed	Specimen Type	Date Obtained
Comments				

**ZOONOTIC DISEASE INCIDENT REPORT**  
(Continued)

COMPLETE THIS SECTION ONLY IF ANIMAL WAS PURCHASED WITHIN SIX (6) MONTHS OF DISEASE ONSET		
Place Animal Purchased or Acquired		Date Animal Purchased or Acquired
Street Address		Telephone Number
City	State	Zip Code
Type of Facility <input type="checkbox"/> Kennel <input type="checkbox"/> Pet Shop <input type="checkbox"/> Shelter <input type="checkbox"/> Pound <input type="checkbox"/> Private Individual (specify): _____		

HUMAN EXPOSURE / ILLNESS	
Number of Persons Exposed to Animal	Number of Persons Ill
CDRSS Case IDs of Human Cases Linked to Animal Case	
Name, Address and Telephone Number of Physician (if seen)	
Comments / Updates	



**ZOONOTIC DISEASE INCIDENT REPORT  
CONTINUATION SHEET**

CASE SPECIFIC INFORMATION (Complete a separate form for each sick animal.)				
Animal Name (or ID)	Animal Age	Animal Sex	Animal Breed	Animal Color
Illness Onset Date	Clinical Signs			
Date of First Visit to Vet				
Relevant History		Treatment		
Outcome <input type="checkbox"/> Survived <input type="checkbox"/> Euthanized <input type="checkbox"/> Died		Date	Postmortem Exam Performed? <input type="checkbox"/> Yes <input type="checkbox"/> No	If Yes, Date Performed
LABORATORY TEST RESULTS				
Name of Laboratory				
Organism/Agent	Lab Result/Value	Type of Test Performed	Specimen Type	Date Obtained
Comments				

## APPENDIX B

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860 (Fax 609-826-4866)  
www.njiis.nj.gov

### NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS) ENROLLMENT REQUEST FOR NEW NJIIS SITE

The following information is required to enroll as a new NJIIS Site. Please complete all information requested on this form.

Fax or mail the completed form to your local Maternal and Child Health Consortia (MCHC) office or the Vaccine Preventable Disease Program, at the address listed above. Information for the local MCHC for your county can be found at <https://www.njiis.nj.gov/njiis/jsp/trainingschedule.jsp>.

County: \_\_\_\_\_ Date: \_\_\_\_\_  
Name of entity/institution (Site Name): \_\_\_\_\_  
VFC ID: \_\_\_\_\_ Tax ID (EIN): \_\_\_\_\_ NPI: \_\_\_\_\_ Tel. No.: \_\_\_\_\_  
Designated Site Administrator: \_\_\_\_\_  
Email Address: \_\_\_\_\_  
Site Address: \_\_\_\_\_  
City, State, Zip Code: \_\_\_\_\_  
Describe entity/institution interest in NJIIS enrollment: \_\_\_\_\_  
\_\_\_\_\_

Vaccine Inventory (Check (✓) if you will be using the following):

☐ Public Stock ☐ Private Stock ☐ Both ☐ Will Not Use

Type of Facility (Check (✓) only one):

<input type="checkbox"/> Public Health Department	<input type="checkbox"/> Federally Qualified Health Center (FQHC)
<input type="checkbox"/> Public Hospital	<input type="checkbox"/> Other Immunization Project
<input type="checkbox"/> Other Public	<input type="checkbox"/> College/University
<input type="checkbox"/> Private Health Care Provider	<input type="checkbox"/> Licensed Child Care Center
<input type="checkbox"/> Public School	<input type="checkbox"/> Health Insurance Company
<input type="checkbox"/> Private School	<input type="checkbox"/> Practice Management Vendor
<input type="checkbox"/> Private Hospital	<input type="checkbox"/> Billing Vendor
<input type="checkbox"/> Other Private	

Primary Health Care Provider Site? ☐ Yes ☐ No

Does your entity/institution administer immunizations? ☐ Yes ☐ No

List the names of all the users from your entity/institution who would be designated as NJIIS authorized users:

1) _____	4) _____
2) _____	5) _____
3) _____	6) _____

Name or Facility for Reminder/Recall Notices (Print)\* \_\_\_\_\_

Administrator Signature: \_\_\_\_\_ Date: \_\_\_\_\_

(\*PRINT the name you would like to appear as this provider's signature on the reminder/recall notices (i.e. Bonnie Smith, MD, etc.)

FOR NJIIS USE ONLY	
Date Received: _____	Date Site Enrolled: _____
Name: _____	Signature: _____

IMM-42  
JUL 25

## APPENDIX C

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860 (Fax 609-826-4866)  
[www.njiis.nj.gov](http://www.njiis.nj.gov)

### NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS) USER ENROLLMENT AND TRAINING REQUEST

Complete one (1) form per individual attending training.

Part 1 should be filled out by the individual attending training; Part 2 should be filled out by a Site Administrator.

All personnel to be trained must be pre-registered. Please print legibly or type.

Fax or mail the completed form to your local Maternal and Child Health Consortia (MCHC) office or the Vaccine Preventable Disease Program, at the address listed above. Information for the local MCHC for your county can be found at [www.njiis.nj.gov/njiis/softrainingschedule](http://www.njiis.nj.gov/njiis/softrainingschedule).

#### PART 1. USER INFORMATION

Name: \_\_\_\_\_ Telephone No.: \_\_\_\_\_  
Title: \_\_\_\_\_ Email Address: \_\_\_\_\_  
Address: \_\_\_\_\_  
City, State, Zip Code: \_\_\_\_\_  
How do this user's job tasks relate to NJIIS?  
\_\_\_\_\_  
\_\_\_\_\_

**NOTE:** Prior to attending a NJIIS training session, all users should have basic computer skills which include use of the keyboard and mouse and also have a basic understanding of Windows and the Internet.

#### PART 2. NJIIS SITE INFORMATION

Site Name: \_\_\_\_\_ County: \_\_\_\_\_  
Site Address: \_\_\_\_\_  
Site City, State, Zip: \_\_\_\_\_  
Telephone No.: \_\_\_\_\_ Fax: \_\_\_\_\_

**To be completed by Site Administrator:**

Please check (✓) the appropriate level of access for above authorized user.

- ☐ **General Reader:**  
Access to view patient information and to run standard reports.
- ☐ **General User:**  
General Reader access and access to modify or add information to existing patient records, add new patients, perform inventory and perform outreach functions to patients for whom the designated agent's NJIIS site has primary responsibility.
- ☐ **Site Manager:**  
General User access and access to modify critical fields and maintain inventory control records.
- ☐ **School/College General Reader:**  
Access to view student information and to run standard reports.
- ☐ **School/College General User:**  
General Reader access and access to modify or add information to existing student's records, add new students, and perform outreach functions to students for whom the designated agent's NJIIS site has primary responsibility.
- ☐ **VFC Data Entry Only:**  
Access assigned by VFC Program only for vaccine accountability.

Site Administrator Name (Print): \_\_\_\_\_ Email Address: \_\_\_\_\_  
Site Administrator Signature: \_\_\_\_\_ Date: \_\_\_\_\_

#### FOR NJIIS USE ONLY

User ID: \_\_\_\_\_ Assigned By: \_\_\_\_\_  
Initial Password: \_\_\_\_\_ Date Set Up: \_\_\_\_\_  
Date Trained: \_\_\_\_\_ Other: \_\_\_\_\_

IMM-41  
DEC 22

## APPENDIX D

### NEW JERSEY DEPARTMENT OF HEALTH

#### USER CONFIDENTIALITY STATEMENT FOR ACCESS TO THE NEW JERSEY IMMUNIZATION INFORMATION SYSTEM

The New Jersey Immunization Information System (NJIS Registry) is a Statewide automated and electronic immunization registry and the single repository of immunization records in the State. N.J.S.A. 26:4-131 et seq. authorizes the Department of Health to operate an immunization information system and allows authorized users to exchange information electronically. The information in the NJIS Registry is confidential personal preventive health information and other demographic information. The purposes of the NJIS are to coordinate and promote effective and cost-efficient disease screening, prevention, and control efforts throughout the State; provide access to a registrant's immunization and preventive health screening information to promote health maintenance; provide a mechanism to facilitate notice to registrants of an upcoming or overdue vaccination; and assist in identifying registrants that require immediate vaccination in the event of a vaccine preventable disease outbreak or other health emergency. Access to the NJIS Registry shall be limited to authorized users who sign the user confidentiality agreement.

#### USER CONFIDENTIALITY AGREEMENT

I have read and understood the User Confidentiality Statement and the obligations and responsibilities listed below. I agree that:

1. I shall keep strictly confidential all information, in any format, that I receive or have access to as an authorized user of the NJIS Registry.
2. I understand I am authorized access to the NJIS Registry at the following level and agree to keep my password secure and will not permit use of my access privileges or password by any other person or entity:  

<input type="checkbox"/> General Reader Access	<input type="checkbox"/> School/College General Reader Access
<input type="checkbox"/> General User Access	<input type="checkbox"/> School/College General User Access
<input type="checkbox"/> Site Manager Access	<input type="checkbox"/> VFC Data Entry Only
3. I will only access the NJIS Registry to access or submit information and to generate documentation in the official course of my duties and responsibilities.
4. I agree that I shall strive to provide timely, accurate and complete data into the NJIS Registry.
5. I will not divulge, disclose, use, transfer, copy, remove, or otherwise furnish personally identifiable information or documentation obtained from the NJIS Registry to any individual or organization for any use not authorized by the Department of Health or to any person or entity not directly involved with the conduct of my official duties as they relate to immunizations, except as permitted or authorized by NJIS policy, State administrative code, State or federal law.
6. I will not copy all or part of the database or software used to access the NJIS.
7. I understand that the Department may audit any record, electronic or written, that is part of the NJIS Registry or pertains to the health information entered into the NJIS Registry by an authorized user.
8. I agree to immediately report to the NJIS Site Administrator at this NJIS Site and the NJIS Help Desk any breach of confidentiality.
9. I understand that any violation of the above provisions may result in suspension or termination of user privileges, disciplinary action, and the imposition of any and all penalties as prescribed by applicable State and Federal laws.

I have read and understood the User Confidentiality Statement for Access to the New Jersey Immunization Information System and the User Confidentiality Agreement. I agree to abide by the User Confidentiality Agreement. I understand the consequences to me if I disclose confidential information without necessary authorization.

User Name (Print): \_\_\_\_\_

User Signature: \_\_\_\_\_ Date: \_\_\_\_\_

As a registered NJIS site, I will ensure that my employees/agents/assignees granted access privileges adhere to the confidentiality provisions of the NJIS in the performance of their official duties. I will promptly notify the NJIS Help Desk to deactivate their access privileges when an authorized user departs my practice/organization in order to maintain system security.

I acknowledge that as an NJIS site, this site is subject to review of immunization documentation by the Department's Vaccine Preventable Disease Program or its designated agent.

Administrator Name (Print): \_\_\_\_\_

Administrator Signature: \_\_\_\_\_ Date: \_\_\_\_\_

IMM-43  
DEC 22

## APPENDIX E

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860  
www.njiis.nj.gov

**NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIS)  
REQUEST FOR CHANGE OF USER SECURITY AUTHORIZATION/  
REQUEST FOR PASSWORD RESET**

*Please use this form for security access level for an authorized user at your NJIS Site. Fax the completed form to Central Jersey Family Health Consortium (CJFHC) - NJIS QA Unit at 732-659-9180.*

**AUTHORIZED USER AND NJIS SITE INFORMATION**

NJIS User ID: \_\_\_\_\_  
Authorized User Name: \_\_\_\_\_ Telephone No.: \_\_\_\_\_  
Title: \_\_\_\_\_ Fax Number: \_\_\_\_\_  
Site Name: \_\_\_\_\_  
Site Address: \_\_\_\_\_  
City, State, Zip Code: \_\_\_\_\_  
County: \_\_\_\_\_ Email Address: \_\_\_\_\_

**To be completed by Site Administrator:**

Please check (✓) the appropriate level of access for above authorized user.

- ☐ Password Reset  
☐ Deactivate above authorized user.  
☐ Reactivate above authorized user.  
☐ Reassign existing NJIS user to facility listed in above (additional training will be determined by NJIS staff):  
☐ Additional site access requested (site information in section above):

Site Administrator Name (Print): \_\_\_\_\_ Email Address: \_\_\_\_\_  
Site Administrator Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**FOR NJIS USE ONLY**

User ID: \_\_\_\_\_ Assigned By: \_\_\_\_\_  
Date Set Up or Access Changed: \_\_\_\_\_  
Date Deactivated: \_\_\_\_\_ Date Password Reset: \_\_\_\_\_  
Other: \_\_\_\_\_

## APPENDIX F

### NJIS Online Ticketing Intake Form

**Note:** Upon submitting the ticket, you will receive an email with a unique ticket number, specific to your request, all the email addresses you list on this page. You may securely submit any required attachments by replying to that email and attaching any documents you wish to include with your ticket. A list of required documents will also be included in that email.

**\* Indicated required**

<b>* First Name</b>	VIC/JJ/VOC/ID/State I and I/n
<input type="text"/>	<input type="text"/>
<b>* Last Name</b>	<b>* Current NJIS/VFC/BJT User?</b>
<input type="text"/>	<input type="text" value="-- None --"/>
<b>* Phone</b>	<b>Street Address 1</b>
<input type="text"/>	<input type="text"/>
<b>* E-Mail</b>	<b>Street Address 2</b>
<input type="text"/>	<input type="text"/>
<b>* County</b>	<b>City</b>
<input type="text" value="None"/>	<input type="text"/>
<b>* Facility/Organization Name</b>	<b>State</b>
<input type="text"/>	<input type="text"/>
<b>* NJIS Facility ID</b>	<b>Zip</b>
<input type="text"/>	<input type="text"/>
<b>* Description</b>	
<input type="text"/>	
<input type="text"/>	

## APPENDIX G

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860 (Fax 609-826-4866)  
www.njiis.nj.gov

**NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS)  
CONSENT TO PARTICIPATE**

- RETAIN A COPY OF THIS FORM IN THE MEDICAL RECORD -

REGISTRANT INFORMATION	PARENT/GUARDIAN INFORMATION <i>(if NJIIS Registrant is a minor)</i>
Registrant Name <i>(Print)</i>	Name <i>(Print)</i>
Date of Birth	Address
Country of Birth	City, State, Zip Code
Name of Primary Health Care Provider	Relationship to Registrant
<p>I have received information about the New Jersey Immunization Information System (NJIIS) and understand that the purpose of this program is to help remind me when my/my child's immunizations are due and to keep a central record of my/my child's immunization history.</p> <p>I understand that the medical information in the NJIIS may be shared with authorized health care providers, schools, licensed child care centers, colleges, public health agencies, health insurance companies, and others as permitted by New Jersey Law at N.J.S.A. 26:4-131 et seq. and rules at N.J.A.C. 8:57-3.</p> <p>I understand that I can get a copy of my/my child's record from my primary health care provider, my local health department, or the New Jersey Department of Health (NJDOH). The NJDOH may be contacted at the website or telephone number listed above.</p> <p>There is no cost to participate in this program.</p> <p><input type="checkbox"/> Yes, I would like to participate in this program.</p> <p><input type="checkbox"/> No, I do not want to participate in this program.</p>	
Signature of Registrant (or Parent/Guardian, IF Registrant under 18 Years of Age)	Date

Name of NJIIS Enrollment Site	Registry ID Number	Medical Record Number
-------------------------------	--------------------	-----------------------

- RETAIN A COPY OF THIS FORM IN THE MEDICAL RECORD -

IMM-32  
DEC 22



**New Jersey Department of Health**  
**Vaccine Preventable Disease Program**  
**Departamento de Salud de Nueva Jersey**  
**Programa de Enfermedades Inmunoprevenibles**  
 Dirección postal: P.O. Box 369, Trenton, NJ 08625-0369  
 Teléfono: 609-826-4860 Fax 609-826-4866  
 www.njiis.nj.gov

**AUTORIZACIÓN DE INSCRIPCIÓN EN**  
**EL SISTEMA DE INFORMACIÓN SOBRE VACUNACIÓN DE NUEVA JERSEY**  
**NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS)**

- GUARDAR UNA COPIA DEL PRESENTE DOCUMENTO EN LA HISTORIA CLÍNICA -

DATOS DEL INSCRITO	DATOS DE PADRE/MADRE/TUTOR (si se trata de un menor de edad)
Nombre y apellidos del inscrito (letra de imprenta)	Nombre y apellidos (letra de imprenta)
Fecha de nacimiento	Dirección
País de nacimiento	Ciudad, estado, código postal
Nombre y apellidos del proveedor de atención médica primaria	Relación al inscrito
<p>He recibido información acerca del Sistema de Información sobre Vacunación de Nueva Jersey (<i>New Jersey Immunization Information System, NJIIS</i>) y entiendo que el objetivo de la inscripción es para que yo reciba recordatorios de las dosis pendientes según el calendario de vacunación pertinente (ya sea el mío o el de mi hijo) y se establezca un registro central de vacunas administradas.</p> <p>Entiendo que los datos de salud que constan en el sistema pueden compartirse con los proveedores de servicios de salud autorizados, instituciones educativas entre las cuales figuran instituciones de estudios superiores, centros de cuidado infantil autorizados, entidades de salud pública, compañías de seguros de salud y otras personas autorizadas por la ley de Nueva Jersey N.J.S.A. 26:4-131, y siguientes, y las normas N.J.A.C. 8:57-3.</p> <p>Entiendo que puedo obtener un comprobante de las vacunas administradas del proveedor de servicios de salud de familia, departamento de salud local o Departamento de Salud de Nueva Jersey, y que la dirección web y el número de teléfono del Departamento de Salud figuran en la parte superior del presente documento.</p> <p>No hay costo de inscripción.</p> <p><input type="checkbox"/> Sí, opto por inscribirme.</p> <p><input type="checkbox"/> No, no opto por inscribirme.</p>	
Firma del inscrito (padre/madre/tutor si se trata de un menor de 18 años)	Fecha

Nombre del lugar de inscripción NJIIS	Número de identificación NJIIS	Número de historia clínica
---------------------------------------	--------------------------------	----------------------------

- GUARDAR UNA COPIA DEL PRESENTE DOCUMENTO EN LA HISTORIA CLÍNICA -

IMM-32a  
 DEC 22

## APPENDIX H

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860  
www.njiis.nj.gov

### NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS) REQUEST FOR CHANGE TO NJIIS IMMUNIZATION RECORD

*Please attach documents to identify the person requesting this change to the NJIIS immunization record. Some examples of acceptable forms of identification are: a state-issued photo driver's license with address; a state-issued photo non-driver's identification card with address; a similar form of identification issued by this State, another state, or the Federal government; or a photo identification card issued by a New Jersey county clerk.*

*Also include immunization and/or medical documentation to support the change requested.*

INFORMATION AS IT CURRENTLY APPEARS IN NJIIS			
Name of Registrant (Print)		Date of Birth	
Street Address		NJIIS Registry ID Number (if known)	
City	State	Zip Code	
Name of Parent/Guardian		Telephone Number	
Name of Current Primary Health Care Provider		Telephone Number	
SECTION A – DEMOGRAPHIC INFORMATION CHANGE(S) *			
Name (Print)		Date of Birth	
Street Address			
City	State	Zip Code	
Name of Parent/Guardian		Telephone Number	
SECTION B – MEDICAL INFORMATION CHANGE(S) *			
Lead	Newborn Hearing Screening	TB	
Other			
SECTION C – IMMUNIZATION INFORMATION CHANGE(S) *			
Vaccine Type	Date Dose Administered	Name of Health Care Provider	Other
Name of Requestor (Print)		Relationship to Registrant	
Signature of Requestor		Date of Request	

\* Attach a written statement explaining the reason(s) for this change to the NJIIS immunization record  
Mail completed form with copies of official supporting documents to the address above.

IMM-45  
DEC 22

# APPENDIX I

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369, Trenton, NJ 08625-0369  
609-826-4860  
www.njiis.nj.gov

## NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIIS) REQUEST FOR COPY OF NJIIS IMMUNIZATION RECORD

Please attach documents to identify the person requesting this NJIIS immunization record. Some examples of acceptable forms of identification are: a state-issued photo driver's license with address; a state-issued photo non-driver's identification card with address; a similar form of identification issued by this State, another state, or the Federal government; or a photo identification card issued by a New Jersey County Clerk.

INFORMATION ON REQUESTED RECORD	
Name of Registrant (as it currently appears in NJIIS) (Print)	Date of Birth
Street Address	NJIIS Registry ID Number (if known)
City State Zip Code	Daytime Telephone Number
Name of Parent/Guardian	Relationship
Name of Current Primary Health Care Provider	Telephone Number
INDIVIDUAL OR ENTITY TO RECEIVE COPY OF NJIIS IMMUNIZATION RECORD	
Name (Print)	
Street Address	
City State Zip Code	
AUTHORIZATION FOR RELEASE OF INFORMATION	
<p>I am requesting a copy of the NJIIS Immunization Record for the above-named person. I hereby authorize the New Jersey Department of Health to release a copy of the NJIIS Immunization Record for the above-named person to the individual or entity indicated.</p>	
Name of Requestor (Print)	Telephone Number
Street Address	Relationship to person named on the requested NJIIS Immunization Record
City State Zip Code	
Signature of Requestor	Date

Mail completed form with copies of official supporting documents to the address above.

IMM-46  
DEC 22

## APPENDIX J

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369  
Trenton, NJ 08625-0369  
609-826-4860  
www.njiis.nj.gov

### NEW JERSEY IMMUNIZATION INFORMATION SYSTEM (NJIS) REGISTRANT WITHDRAWAL FROM NJIS

*Please attach documents to identify the person requesting this withdrawal from the NJIS immunization record. Some examples of acceptable forms of identification are: a state-issued photo driver's license with address; a state-issued photo non-driver's identification card with address; a similar form of identification issued by this State, another state, or the Federal government; or a photo identification card issued by a New Jersey County Clerk.*

REGISTRANT INFORMATION	PARENT/GUARDIAN INFORMATION (IF REGISTRANT UNDER 18 YEARS OF AGE)
Name of Registrant (Print)	Name (Print)
Date of Birth	Address
Medical Record Number	City, State, Zip Code
Name of Primary Health Care Provider	Relationship to Registrant
<p>I have received information about the New Jersey Immunization Information System (NJIS) and understand that the purpose of this program is to remind health care providers when immunizations are due and to serve as a repository for a person's immunization history.</p> <p>I wish to disenroll my child/myself as a registrant in the New Jersey Immunization Information System (NJIS) at this time.</p> <p>I have been provided with information on how to reactivate my child/myself in the NJIS should I decide to participate in the future.</p>	
Signature of Registrant (or Parent/Guardian, if Registrant under 18 years of age)	Date
Signature of Witness	Date

***Mail completed form with copies of official supporting documents to the above address. The Vaccine Preventable Disease Program will retain a copy of the Registrant Withdrawal form on file.***

IMM-47  
DEC 22

# APPENDIX K

New Jersey Department of Health STANDARD SCHOOL / CHILD CARE CENTER IMMUNIZATION RECORD									
NAME OF CHILD (Last, First, MI)					DATE OF BIRTH (MM/DD/YYYY)		<input type="checkbox"/> M <input type="checkbox"/> F		
NAME OF PARENT/GUARDIAN					TELEPHONE NUMBER(S)				
ADDRESS					IMMUNIZATION REGISTRY NUMBER				
ADDRESS									
VACCINE TYPE	1ST DOSE MO/DAY/YR	2ND DOSE MO/DAY/YR	3RD DOSE MO/DAY/YR	4TH DOSE MO/DAY/YR	5TH DOSE MO/DAY/YR	EXEMPTIONS			
DIPHTHERIA, TETANUS, PERTUSSIS (DTaP) or any combination (Tdap or DTaP) indicate in comments						<input type="checkbox"/> Medical Exemption Attached <input type="checkbox"/> Religious Exemption Attached			
POLIO INACTIVATED POLIO VACCINE (IPV) (If oral vaccine, indicate (OPV in space below)									
MEASLES, MUMPS, RUBELLA (MMR)						<input type="checkbox"/> Document below single antigen vaccine receipt, serology tests, or varicella disease history			
HABERMANN'S II (HII)									
HEPATITIS B (HepB)						Hepatitis B	DATE	TITER	
VARICELLA						Varicella	DATE	TITER	
PNEUMOCOCCAL CONJUGATE (PCV13)						Measles	DATE	TITER	
INFLUENZA						Mumps	DATE	TITER	
OTHER, SPECIFY:						Rubella	DATE	TITER	
OTHER, SPECIFY:						Comments			
OTHER, SPECIFY:									
<input type="checkbox"/> Previous Medical Exemption Data Deleted									

☐ RECUSES MEDICAL EXEMPTION

A complete list of New Jersey's Immunization requirements is accessible at: <http://nj.gov/health/immunization>

IMM-8  
 01/01/00

1041

## APPENDIX L

New Jersey Department of Health  
Vaccine Preventable Disease Program

**REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION**

**INSTRUCTIONS FOR COMPLETION**

It is easiest to use the latest version of Adobe Reader DC. If you do not have the latest version, download and install the free software by visiting this webpage: <https://get.adobe.com/reader/>

1. Fill out the form completely. ALL form fields are required except where noted as being optional.
  - a. Enter the name of the Student and other identifying information.
  - b. Check off each vaccine for which an exemption is requested.
    - i. For each vaccine for which an exemption is requested, check to indicate whether the exemption is Temporary (indicate the date through which the exemption is valid) or Permanent.
    - ii. Check the ACIP contraindication/precaution applicable for each vaccine for which an exemption is requested.
  - c. If the contraindication/precaution is not included in Table 1, please put an "X" next to "Other" and fully explain. Please be sure that the contraindication/precaution does not appear in Table 2, that there is a valid contraindication/precaution noted for each vaccine for which an exemption is requested, and that the contraindication/precaution is consistent with ACIP/AAP guidelines and established national standards for vaccination practices.
2. Sign and date the Attestation Statement
3. Provide a copy to the person requesting the medical exemption or directly to the school, preschool or child care center.
4. Keep a copy of the form for your records.

Name of Student ( <i>first, middle, last</i> )		Date of Birth
Name of Parent/Guardian (if under 18) ( <i>first, middle, last</i> )		Primary Phone
Patient/Parent Home Address		Address Line 2
City	State	Zip Code
Patient/Parent Email Address		
<small>Medical contraindications and precautions for immunizations are based on the most recent General Recommendations of the Advisory Committee on Immunization Practices (ACIP), available at <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</a> or <a href="https://redbook.solutions.aap.org/redbook.aspx">https://redbook.solutions.aap.org/redbook.aspx</a></small>		
<small>Please check the website to ensure that you are reviewing the most recent ACIP information. Please note that the presence of a moderate to severe acute illness with or without fever is a precaution to administration of all vaccines. However, as acute illnesses are short-lived, medical exemptions should not be submitted for this indication.</small>		

# REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION

Table 1. ACIP Contraindications and Precautions to Vaccination for Mandatory Vaccines		
Vaccine	Exemption Length	ACIP Contraindications and Precautions (CHECK ALL THAT APPLY)
DTaP, Tdap	Temporary through:	<p><b>Contraindications</b></p> <p>Severe Allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component.</p> <p>Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of DTP, DTaP, or Tdap</p> <p><b>Precautions</b></p> <p>Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, progressive encephalopathy; defer DTaP or Tdap until neurologic status clarified and stabilized</p> <p>Guillain-Barré syndrome &lt; 6 weeks after previous dose of tetanus-toxoid-containing vaccine</p> <p>History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine</p>
	Permanent	
DT, Td	Temporary through:	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p><b>Precautions</b></p> <p>Guillain-Barré syndrome &lt; 6 weeks after a previous dose of tetanus- toxoid-containing vaccine.</p> <p>History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria- or tetanus toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine</p>
	Permanent	
Haemophilus influenzae type b (Hib)	Temporary through:	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p>
	Permanent	



# REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION

Vaccine	Exemption Length	ACIP Contraindications and Precautions (CHECK ALL THAT APPLY)
Hepatitis B (HepB)	Temporary through:  Permanent	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p>Hypersensitivity to yeast</p>
Inactivated poliovirus vaccine (IPV)	Temporary through:  Permanent	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p><b>Precautions</b></p> <p>Pregnancy</p>
Influenza, inactivated injectable (IIV)	Temporary through:  Permanent	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p><b>Precautions</b></p> <p>Guillain-Barré syndrome &lt; 6 weeks after a previous dose of tetanus- toxoid-containing vaccine.</p> <p>Egg allergy other than hives, e.g., angioedema, respiratory distress, lightheadedness, or recurrent emesis; or required epinephrine or another emergency medical intervention (IIV may be administered in an inpatient or outpatient medical setting, under the supervision of a healthcare provider who is able to recognize and manage severe allergic conditions)</p>
Influenza recombinant (RIV)	Temporary through:  Permanent	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p><b>Precautions</b></p> <p>Guillain-Barré syndrome &lt; 6 weeks after a previous dose of influenza vaccine</p>

# REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION

Vaccine	Exemption Length	ACIP Contraindications and Precautions (CHECK ALL THAT APPLY)
<b>MMR</b>	<p>Temporary through:</p> <p>Permanent</p>	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p>Pregnancy</p> <p>Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with human immunodeficiency virus [HIV] infection who are severely immunocompromised)</p> <p>Family history of congenital or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings), unless the immune competence of the potential vaccine recipient has been substantiated clinically or verified by a laboratory test</p> <p><b>Precautions</b></p> <p>Recent (<math>\leq 11</math> months) receipt of antibody-containing blood product (specific interval depends on product)</p> <p>History of thrombocytopenia or thrombocytopenic purpura</p> <p>Need for tuberculin skin testing or interferon gamma release assay (IGRA) testing</p>
<b>Meningococcal (MenACWY)</b>	<p>Temporary through:</p> <p>Permanent</p>	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p>
<b>Meningococcal (MenB)</b>	<p>Temporary through:</p> <p>Permanent</p>	<p><b>Contraindications</b></p> <p>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</p> <p><b>Precautions</b></p> <p>Pregnancy</p>

# REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION

Vaccine	Exemption Length	ACIP Contraindications and Precautions (CHECK ALL THAT APPLY)
<b>Pneumococcal (PCV13)</b>	Temporary through:  Permanent	<b>Contraindications</b>  Severe allergic reaction (e.g., anaphylaxis) after a previous dose of PCV13 or any diphtheria-toxoid-containing vaccine or to a component of a vaccine (PCV13 or any diphtheria-toxoid-containing vaccine), including yeast
<b>Varicella</b>	Temporary through:  Permanent	<b>Contraindications</b>  Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component  Known severe immunodeficiency (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or persons with HIV infection who are severely immunocompromised)  Pregnancy  Family history of congenital or hereditary immunodeficiency in first-degree relatives (e.g., parents and siblings), unless the immune competence of the potential vaccine recipient has been substantiated clinically or verified by a laboratory test  <b>Precautions</b>  Recent ( $\leq$ 11 months) receipt of antibody-containing blood product (specific interval depends on product)  Receipt of specific antivirals (i.e., acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination)  Use of aspirin or aspirin-containing products
Other: Please explain fully and attach additional sheets as necessary. Please be sure to check Table 2 below to ensure that the condition is not one incorrectly perceived as a contraindication or precaution.		

# **REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION**

<b>Attestation</b>			
<p>I am a physician (M.D. or D.O.) licenses to practice medicine in a jurisdiction of the United States or an advanced practice nurse licensed in a jurisdiction of the United States.</p> <p>By signing below, I affirm that I have reviewed the current ACIP Contraindications and Precautions and affirm that the stated contraindication(s)/precaution(s) is enumerated by the ACIP and consistent with established national standards for vaccination practices. I understand that I might be required to submit supporting medical documentation. I also understand that any misrepresentation might result in referral to the New Jersey State Board of Medical Examiners and/or appropriate licensing/regulatory agency.</p>			
Healthcare Provider Name (please print)			Specialty
NPI Number	License Number		State of Licensure
Phone	Fax	Email	
Address			
City	State		Zip Code
Signature			Date

## REQUEST FOR MEDICAL EXEMPTION FROM MANDATORY IMMUNIZATION

Table 2. Examples of Conditions incorrectly perceived as contraindications or precautions to vaccination* (i.e., vaccines may be given under these conditions)	
Vaccine	Conditions incorrectly perceived as contraindications and precautions to vaccines (i.e., vaccines may be given under these conditions)
General for MMR, Hib, HepB, Varicella, PCV13, MenACWY	<ul style="list-style-type: none"> <li>History of Guillain-Barré syndrome</li> <li>Recent exposure to an infectious disease</li> <li>History of penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy</li> </ul>
DTaP	<ul style="list-style-type: none"> <li>Fever within 48 hours after vaccination with a previous dose of DTP or DTaP</li> <li>Collapse or shock like state (i.e., hypotonic hyporesponsive episode) within 48 hours after receiving a previous dose of DTP/DTaP</li> <li>Seizure <math>\leq</math> 3 days after receiving a previous dose of DTP/DTaP</li> <li>Persistent, inconsolable crying lasting <math>\geq</math> 3 hours within 48 hours after receiving a previous dose of DTP/DTaP</li> <li>Family history of seizures</li> <li>Family history of sudden infant death syndrome</li> <li>Family history of an adverse event after DTP/DTaP</li> <li>Stable neurologic conditions (e.g., cerebral palsy, well-controlled seizures, or developmental delay)</li> </ul>
Hepatitis B (HepB)	<ul style="list-style-type: none"> <li>Pregnancy</li> <li>Autoimmune disease (e.g., systemic lupus erythematosus or rheumatoid arthritis)</li> </ul>
Influenza, inactivated injectable (IIV)	<ul style="list-style-type: none"> <li>Nonsevere (e.g., contact) allergy to latex, thimerosal, or egg</li> </ul>
MMR	<ul style="list-style-type: none"> <li>Breastfeeding</li> <li>Pregnancy of recipient's mother or other close or household contact</li> <li>Recipient is female of child-bearing age</li> <li>Immunodeficient family member or household contact</li> <li>Asymptomatic or mildly symptomatic HIV infection</li> <li>Allergy to eggs</li> </ul>
Tdap	<ul style="list-style-type: none"> <li>History of fever of <math>\geq 40.5^{\circ}\text{C}</math> (<math>\geq 105^{\circ}\text{F}</math>) for <math>&lt; 48</math> hours after vaccination with previous dose of DTP/DTaP</li> <li>History of collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours after receiving a previous dose of DTP/DTaP</li> <li>History of persistent, inconsolable crying lasting <math>&gt; 3</math> hours within 48 hours of receiving a previous dose of DTP/DTaP</li> <li>History of extensive limb swelling after DTP/DTaP/Td that is not an Arthus-type reaction</li> <li>History of stable neurologic disorder</li> <li>Immunosuppression</li> </ul>
Varicella	<ul style="list-style-type: none"> <li>Pregnancy of recipient's mother or other close or household contact</li> <li>Immunodeficient family member or household contact</li> <li>Asymptomatic or mildly symptomatic HIV infection</li> <li>Humoral immunodeficiency (e.g., agammaglobulinemia)</li> </ul>

\* For a complete list of conditions, please review the ACIP Guide to Contraindications and Precautions accessible at <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html>

## APPENDIX M

## NJIS Annual Immunization Status Report

### Current Medical Facility

### School Information

Academic Year                      Facility Name                      Facility ID

Facility Type                      Facility Sub-Type

### Physical Address

Address Line 1                      Address Line 2                      City

State                      Zip                      County                      Municipality

### Mailing Address

Address Line 1                      Address Line 2                      City

State                      Zip                      County                      Municipality

### Contact Information

\*Primary School Contact                      \*Backup School Contact  
Select                      Select

\*Denotes mandatory fields

### Annual Immunization Report

#### Required Immunization Survey

Instructions: In the survey below, please select the grade levels at your facility and then indicate the immunization status of all pupils at those levels:

#### Special Instructions:

- For Child Care Facilities: On the Pre-K row of the table below, enter the immunization status of all enrolled children over 2 months of age.
- For Grade 1: Do not include data in the Grade 1 boxes unless the child is beginning school for the very first time in your school district in Grade 1. Include children in this row if they either attended Kindergarten outside of your school district or you are unsure where they attended Kindergarten.
- For Special Education Students: Ungraded special education children should be included with the appropriate age cohort class.
- For Transfer Students: Includes all children newly transferred into grades 2-5 and 7-12 from out-of-state/country since the submission of last year's report. High schools are only required to report out-of-state or out-of-country transfers.
- Children who are Out-of-Compliance, should not be placed in any of the other categories.
- If an antigen column does not contain white boxes, please ignore. The antigens in those columns are not relevant to children at that grade level.

School not audited due to no applicable grades/no transfer students  
Select

What grade levels are housed in your facility?  
 There will be a separate table for each grade level where you should enter the status of all pupils.

Child Care/Preschool  
 Kindergarten  
 Grade 1  
 Grade 7  
 Transfer Students

---

Example of Grade Table

Grade 7

Annual Immunization Status Report

Overall Coverage

\*Audit Date:                      Number of Children Enrolled in Grade:

Total Children Meeting All Immunization Requirements (Includes Flu Requirements)

Total Children with Provisional Status                      Total Children who are Out of Compliance

Total Children with Exemptions (Medical or Religious)      Total Children with Religious Exemptions

Total Children with Medical Exemptions

Total Children (Total Meeting All Immunization Requirements + Total Provisional Status + Total Exemptions + Total Out of Compliance)

Antigen-Level Coverage

	DTaP, DT, Td, Tdap	Polio	MMR	Hib	HepB	Varicella	PCV	MCV4
Provisional Status								
Out of Compliance								
Total Exemptions								
Religious Exemptions								
Medical Exemptions								
Previous Comments								



APPENDIX N-O  
(RESERVED)

## APPENDIX P

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369  
Trenton, NJ 08625-0369

### INSTITUTIONAL LIAISON DESIGNATION FORM

N.J.A.C. 8:57-6.2 requires each institution of higher education (IHE) to designate an institutional liaison to serve as the institution's representative and the primary point of contact to the Department of Health, specifically the Vaccine Preventable Disease Program (VPDP), with respect to the Department's oversight of the IHE's compliance with N.J.A.C. 8:57-6 and other applicable laws governing immunization of collegians.

The highest-ranking official shall identify the institutional liaison by completing the below information and emailing it to the VPDP at [higheredvax@doh.nj.gov](mailto:higheredvax@doh.nj.gov) by no later than October 1st of the respective academic year. Any changes to the identity or contact information below will require a submission of a new form within 30 days of a change.

If you have any questions, please contact the VPDP at 609-826-4861.

<b><u>Institutional Liaison:</u></b>	
Name:	
Title:	
Phone Number:	Email:
Signature of Highest-Ranking Official:	Date of Signature:
Title of Highest-Ranking Official:	

IMM-54  
JUL 25

## APPENDIX Q

New Jersey Department of Health  
Vaccine Preventable Disease Program  
P.O. Box 369 Trenton, NJ 08625-0369

### ANNUAL COLLEGE IMMUNIZATION STATUS REPORT

Complete electronically using ADOBE READER ([desktop application only](#)). Only electronic submissions will be accepted. Submit one IMM-3 form for each campus location by no later than December 1 to reflect Fall enrollment of the current academic year. For assistance completing the form, contact [HigherEdVax@doh.nj.gov](mailto:HigherEdVax@doh.nj.gov).

Name of Higher Education Institution		Institution Type		Report Year
Street Address	Town/Municipality	State	County	Zip Code
Institutional Liaison or Designee (for implementing immunization requirements and maintaining records)				
(First)	(Last)	(Title)	(Email)	(Phone)

#### A. ENROLLMENT

Total Fall Enrollment (headcount)	total	
Total Incoming College students:	total	

#### B. MEASLES, MUMPS, AND RUBELLA VACCINE REQUIREMENT

a. Number of incoming students in non-degree status not subject to the MMR rules:	a. minus	
b. Number of incoming students born before 1957 not subject to the MMR rules:	b. minus	
c. For 2-year colleges ONLY: Number of incoming students with fewer than 12 credit hours not subject to the MMR rules:	c. minus	
d. Number of students subject to the MMR rules [incoming - (a + b + c) = d]:	d. balance	

Counting each student only once, enter the number of students who:

Meet MMR* Requirement	Have Provisional Status	Have Medical Exemptions	Have Religious Exemptions	Do Not Meet MMR* Requirement
				out of

\* For Incoming students, two doses of a measles-containing vaccine are required, preferably MMR given on or after the first birthday separated by at least one month or laboratory evidence of immunity.

#### C. MENINGOCOCCAL VACCINE REQUIREMENT (MenACWY)

Number of newly enrolled students subject to the meningococcal vaccine requirement: \_\_\_\_\_

Counting each student only once, enter the number of new students who:

Meet Meningococcal Requirement	Have Medical Exemptions	Have Religious Exemptions	Do Not Meet Meningococcal Requirement
			out of

Of those students who meet the meningococcal vaccine requirement, how many students:

Received Two Doses (MenACWY)	Received Meningococcal B Vaccine*

\* Optional vaccine.

#### D. HEPATITIS B VACCINE REQUIREMENT (New Students With 12 Or More Credit Hours)

How many new student with 12 or more credit hours are subject to the Hepatitis B requirement?

Counting each student only once, enter the number of new students with 12 or more credit hours who:

Meet Hepatitis B Requirement*	Have Provisional Status	Have Medical Exemptions	Have Religious Exemptions	Do Not Meet Hepatitis B Requirement
				out of

\* For Incoming students, documentation of three doses of a hepatitis B containing vaccine, or any two doses of a hepatitis B vaccine approved for a two dose regimen administered to the student between 11 through 15 years of age is required or laboratory evidence of immunity.

<b>E. OVERALL VACCINE COMPLIANCE</b>	
a. How many students are subject to all three vaccine requirements?	
b. Of those subject to all three vaccine requirements, how many are meeting all three?	

How does your institution offer the following vaccination services?

VACCINE	SERVICE DELIVERY METHOD	SERVICE DELIVERY ENTITY NAME
MMR		
MENINGOCOCCAL MENINGITIS		
HEPATITIS B		

Other Recommended Vaccinations (hold down Ctrl key and select all that apply in each category)

In House	Contracted	By Referral

**Sign & Submit Electronically:** Click signature field, follow on-screen prompts to e-sign. Then, click "SUBMIT" (Instructions below). Or, save and send the completed and signed form as a file attachment to [HigherEdVax@njdoeh.nj.gov](mailto:HigherEdVax@njdoeh.nj.gov).

Person Signing & Submitting Form				
(First)	(Last)	(Title)	(Email)	(Phone) .
		Form fields will lock upon successful e-signature. To make changes, right-click the signature and select "Clear Signature" from the menu and fields will unlock.		

Electronic Signature

**FORMS MUST BE SIGNED BEFORE SUBMISSION.** Unsigned and/or hard copies of forms are not valid and will not be accepted. Having trouble signing or submitting this form? For technical assistance, please click here to contact the [NJDOH Forms Office](#).

**INSTRUCTIONS:** It is easiest to use the latest version of Adobe Reader DC. If you do not have the latest version, download and install the free software by visiting this webpage: <https://get.adobe.com/reader/>

- Fill out the form completely. ALL form fields are required except where noted as being optional.
- E-sign form by clicking on signature field. The Adobe ID / signature process should be automatic. You might have to click on and select the ID you want to use (if you have multiple) or select the option to create one (if you do not have one). Follow the on screen instructions after clicking on the signature field. Once the form is signed, fields will lock and the "SUBMIT" button will appear. (Be sure the form is correct / complete before signing.)
- Click the "SUBMIT" button. A window will pop up. Select either A) Default Email (application) or B) Webmail (accessed through a web-browser).
  - "Default" - Your email application should launch and a new email should be automatically drafted with the form attached! This may take a few moments to happen, or you may have to look for the email in your "Drafts" folder. Click "SEND" to submit the form via email.
  - "Webmail" - If you have Gmail or Yahoo, select the that option. Otherwise, select "Other" from the dropdown menu and continue.  
Enter your email address and password.  
Enter the IMAP and SMTP server name information for your webmail client. You may want to ask your IT department for this information. You only need to set this up once. After it is set up, your information will be saved for future use.  
If you have your web browser open to your email inbox, you may be directed automatically to your "Drafts" folder. In which you should see the email drafted by Adobe with your form attached. Or, you may have to open your email in a web browser and click on the drafts folder to find this email with your form attached. Open the drafted email (subject should include the form number IMM-3) and click "SEND" to send the email.
- Check your "SENT" folder to ensure the email was sent.

## APPENDIX R

## MODEL ORDINANCE FOR QUARANTINE AND ISOLATION

### 1.1 Authority and scope

(Insert enacting body's statement of authority to promulgate ordinance and identify affected jurisdiction and the applicability of the ordinance.)

### 1.2 Definitions

The following words and terms, as used in this ordinance, have the following meanings, unless the context clearly indicates otherwise:

"Board" means (insert the name of the county, municipal, or regional board of health).

"Department" means the New Jersey Department of Health.

"Isolation" means "isolation" as N.J.A.C. 8:57 defines that term.

"Quarantinable disease" means a disease, infection, or condition that:

1. Presents a risk of serious harm to public health; and
2. Requires the isolation or quarantine of persons to prevent its spread.

"Quarantine" means "quarantine" as N.J.A.C. 8:57 defines that term.

### 1.3 General provisions

(a) Prior to instituting mandatory isolation or quarantine pursuant to this ordinance, the board may request that an individual or group of individuals voluntarily confine themselves to a private home or other facility.

(b) The board is authorized to impose and enforce quarantine and isolation restrictions and shall exercise that authority in accordance with the conditions and principals at section 1.4 below.

1. If a quarantinable disease occurs in New Jersey, the board may isolate or quarantine individuals with a confirmed or suspected quarantinable disease and their contacts as the situation requires.

2. The board shall conduct isolation or quarantine in accordance with this ordinance and N.J.A.C. 8:57-2.10.

3. Upon the declaration of a public health emergency, the board shall comply with the isolation and quarantine procedures established in the Emergency Health Powers Act, N.J.S.A. 26:13-1 et seq.

(c) The board shall notify, consult, and work cooperatively with:

1. The New Jersey Department of Agriculture on issues relating to isolation and quarantine of livestock under that Department's jurisdiction pursuant to applicable law, including Title 4 of the Revised Statutes, if the livestock are, or are suspected of being, infected with a disease that could potentially have an impact on human health; and

2. The New Jersey Department of Environmental Protection on issues relating to isolation and quarantine of wildlife under that Department's jurisdiction pursuant to applicable law, including Title 23 of the Revised Statutes, if the wildlife are, or are suspected of being, infected with a disease that could potentially have an impact on human health.

### 1.4 Conditions and principles

(a) The board shall adhere to the following conditions and principles when isolating or quarantining one or more persons:

1. The isolation or quarantine shall be by the least restrictive means necessary to prevent the spread of a suspected or confirmed quarantinable disease to others and may include, but is not limited to, confinement to a private home, other private premises, or public premises.

2. An isolated person shall be confined separately from a quarantined person.

3. The health authority regularly shall monitor the status of an isolated or quarantined person to determine whether continued isolation or quarantine is necessary.

4. If a quarantined person's infection with a quarantinable disease is suspected or confirmed, the health authority shall promptly remove the person to isolation.

5. A health authority immediately shall release an isolated or a quarantined person upon the board determining that the person is not capable of transmitting a quarantinable disease.

6. The board shall address the needs of isolated or quarantined individuals in a systemic and competent fashion including, but not limited to, providing adequate food, clothing, shelter, means of communicating with those in and outside of isolation or quarantine, medication, and competent medical care.

7. The health authority shall maintain premises used for isolation or quarantine in a safe and hygienic manner and the premises shall be designed to minimize the likelihood of further transmission of infection or other harm to isolated or quarantined persons.

8. To the extent possible, the board shall consider cultural and religious beliefs in addressing the needs of persons in isolation and quarantine.

#### 1.5 Isolation or quarantine premises

(a) The board shall prominently identify sites of isolation or quarantine with isolation or quarantine signs posted on all sides of the premises wherever access is possible.

(b) A person who is subject to isolation or quarantine shall:

1. Comply with the rules and orders of the board; and

2. Remain within the isolation or quarantine premises, subject to the board's authorization and direction and the use of appropriate infection control precautions to protect unexposed people.

(c) The Department or the board may grant physicians, healthcare personnel, or others, access to a person who is in isolation or quarantine as necessary to meet the needs of the isolated or quarantined person.

(d) No person, other than one whom the Department or the board authorizes, shall enter isolation or quarantine premises.

1. If the Department or the board requests the assistance of law enforcement in enforcing the isolation or quarantine, the Department or the board shall provide law enforcement personnel a list of persons whom the Department or the board authorizes to enter the isolation or quarantine premises.

(e) Any person entering an isolation or quarantine premises, with or without Department or board authorization, may be isolated or quarantined pursuant to this ordinance and N.J.A.C. 8:57-2.10.

#### 1.6 Isolation and quarantine

(a) The board may:

1. Isolate a person whom the board suspects or confirms as being infected with a quarantinable disease;

2. Quarantine a person who is exposed to a quarantinable disease;

3. Establish and maintain places of isolation and quarantine; and

4. Adopt emergency rules and issue orders as necessary to establish, maintain, and enforce isolation or quarantine.

(b) The board may issue a spoken order for the temporary isolation or quarantine of one or more persons for no longer than 24 hours, without notice, only if delay in imposing the isolation or quarantine would significantly jeopardize the board's ability to prevent or limit the transmission of a suspected or confirmed quarantinable disease to others.

1. If the board issues a spoken order for the temporary isolation or quarantine of one or more persons, the board shall issue a written order as soon as is reasonably possible and in all cases within 24 hours of issuance of the spoken order if continued isolation or quarantine is necessary to prevent or limit the transmission of a suspected or confirmed quarantinable disease.



(c) The board may isolate or quarantine one or more persons through a written order issued pursuant to this ordinance.

(d) A written order for isolation or quarantine shall contain:

1. The identity of the persons subject to the order for isolation or quarantine;

2. The premises subject to isolation or quarantine;

3. The date and time at which isolation or quarantine is to commence;

4. The quarantinable disease with which the isolated or quarantined person is suspected of being, or confirmed to be, infected;

5. A description of the less restrictive alternative measures to prevent or control disease transmission that the board, if applicable, attempted without success, or the less restrictive alternatives] and/or considered and rejected, and the reasons for which the alternative measures were unsuccessful and/or rejected;

6. A statement of compliance with the conditions and principles for isolation and quarantine specified in section 1.4;

7. The legal authority pursuant to which the board issues the order;

8. The medical basis upon which the board relies to justify the need for isolation or quarantine; and

9. A statement advising the isolated or quarantined person of the right to appeal the written order pursuant to section 1.7 and the rights listed in section 1.8.

(e) A copy of this ordinance shall be appended to the order.

(f) The board shall provide a copy of the written order to the person who is to be isolated or quarantined in accordance with any applicable process authorized by New Jersey law, provided that a written order shall be served upon a person who is in isolation or quarantine pursuant to a spoken order for temporary isolation or quarantine within 24 hours of the board's issuance of the spoken order.

1. If the order applies to more than one person and it is impractical to provide individual copies, the board may post the order in a conspicuous place at the isolation or quarantine premises.

#### **1.7 Appeal from order imposing isolation or quarantine**

(a) The subject of a board order imposing isolation or quarantine may appeal a written order by submitting a written appeal within 10 days of receipt of the written order to (insert name of board and board address).

(b) Unless the board or a court of competent jurisdiction stays, reverses, or modifies the written order, or otherwise directs, the written order for isolation or quarantine shall remain in force and effect until the board issues a final order adjudicating the appeal.

(c) The board shall conduct the appeal proceeding in accordance with this ordinance (or insert specific ordinance or board rule governing appeal proceedings).

1. The board shall convene a hearing on the appeal as soon as is practicable, and in no case later than 10 days from the date of receipt of the appeal.

2. The board may hold the hearing by telephonic or other electronic means if necessary to prevent exposure to the isolated or quarantined person or persons.

3. In extraordinary circumstances and for good cause shown, the board may continue the date of an appeal hearing for up to ten days, giving due regard to the rights of the affected individuals, the protection of public health, and the availability of necessary witnesses and evidence.

4. At the appeal hearing, the subject of the appeal shall have the right to introduce evidence on all issues relevant to the order.

5. The board, by majority vote, shall decide the appeal and may modify, withdraw, or order compliance with the written order that is the subject of the appeal, and shall memorialize its decision on the appeal in a written order, which

it shall issue within three business days of the appeal hearing.

(d) A party that is aggrieved by the board's final order adjudicating the appeal may petition for judicial review of that action by filing an action in a court of competent jurisdiction.

1. A petition for judicial review shall be filed within 30 days of the board's issuance of a written order pursuant to (c)5, above.

(e) The board acknowledges that in certain circumstances the subject or subjects of a board order may desire immediate judicial review of a board order in lieu of proceeding with the board's appeal process.

1. The board may consent to immediate jurisdiction of a court with jurisdiction when requested by the subject or subjects of a board order and justice so requires.

2. Unless the board or a court of competent jurisdiction stays, reverses, or modifies the board's written order for quarantine or isolation, the order shall remain in force and effect until the court issues a final judgment on the appeal.

#### **1.8 Rights of individuals and groups of individuals subject to isolation or quarantine**

(a) A person who is subject to isolation or quarantine shall have the following rights:

1. The right to be represented by legal counsel;

2. The right to receive prior notice of the date, time, and location of any hearing;

3. The right to participate in any hearing, which could be by telephonic or electronic means;

4. The right to respond, present evidence, and submit argument on the person's own behalf in any hearing;

5. The right to cross-examine witnesses who testify against the person; and

6. The right to view and copy all records in the possession of the board that relate to the subject of the written order.

#### **1.9 Consolidation of claims**

(a) In any proceeding brought pursuant to this ordinance, to promote the fair and efficient operation of justice and giving due regard to the rights of affected persons, the protection of public health, and the availability of necessary witnesses and evidence, the board or court with jurisdiction may order the consolidation of individual claims into one or more group claims, if all of the following conditions exist:

1. The number of involved or affected persons is large enough that consolidation would be best use of resources;

2. There are questions of law or fact common to the individual claims or rights to be determined;

3. The group claims or rights to be determined are typical of the affected individuals' claims or rights; and

4. The interests of each member of the group will be adequately addressed by the consolidation.

#### **1.10 Implementation and enforcement of isolation and quarantine**

(a) When a quarantinable disease affects more than one county or has multicounty, Statewide, interstate, or public health emergency implications, the Department may assume primary jurisdiction to issue orders for the isolation or quarantine of one or more persons.

1. The board shall neither have jurisdiction, nor attempt, to alter, amend, modify, or rescind a Department-issued isolation or quarantine order.

(b) The board and the health officer, within the board's jurisdiction shall comply with, and assist in the implementation of, a Department-issued isolation or quarantine order.

(c) A person who violates a lawful board or Department order for isolation or quarantine, whether written or spoken, shall be subject to a penalty pursuant to N.J.S.A. 26:4-129.

(d) The board may file a civil action in accordance with New Jersey law in a court of competent jurisdiction to enforce a board order for isolation or quarantine.

## APPENDIX S

**Electronic Laboratory Reporting**

On-Boarding Manual

Version 1.5

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

## Revision History

Date	Version	Description	Author
17-OCT-2012	.01	First Draft	Eric Bauer
18-SEP-2013	.02	Added additional requirements to LOINC/SNOMED section	Eric Bauer
27-SEP-2013	.03	Added health system reference within list of laboratories section. Removed specific reference to online enrollment form. Updated Test Phase 1 summary Updated Establish electronic transmission mechanism section structure Removed CDS reference from Introduction Updated Scope language	Eric Bauer
1-NOV-2013	.04	Updated language, ERP acronym	Simi Octania-Pole
1-NOV-2013	1.00	Final	Eric Bauer
7-MAR-2014	1.1	Updated subject to match "ELR Main" site Updated section 1.6.3 List of Laboratories to described health system info use in FHS/BHS	Eric Bauer
4-APR-2014	1.2	Updated verbiage relating to acceptance of textual results to relax restrictions to only LOINC's which require SNOMEDs	Eric Bauer
29-APR-2014	1.3	Corrected typo Removed references to PHINMOF Updated verbiage in 1.6.4 relating to approval to contact Data Connect group Changed reference to data connect's process manual to processes Removed mention of ELRP being asked to submit SFTP batches for manual review after external validation	Eric Bauer
26-JUN-2014	1.4	Updated phase 1 to require NIST testing for those seeking MU	Eric Bauer

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

		compliance. Added ISO OID request within lab list Added guidance on what should be tested in phase 1 Added case IDs may be provided in place of hard copies in phase 2	
6-May-2019	1.5	Updated link for NJDOH Validation Service	

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

## Table of Contents

1. Introduction	5
1.1 Purpose	5
1.2 Scope	5
1.3 Definitions, Acronyms and Abbreviations	6
1.4 References	7
1.5 Overview	8
1.6 Enrollment	8
1.6.1 Responsible parties /contact list	9
1.6.2 LOINC, SNOMED lists	9
1.6.3 List of laboratories	9
1.6.4 Establish electronic transmission mechanism	10
1.7 Test Phase 1:	12
1.8 Test Phase 2:	13
1.9 Production phase:	14

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

## NJDOH Electronic Laboratory Reporting

### 1. Introduction

In an effort toward improving disease surveillance and timely notification of communicable disease reports for public health intervention, the New Jersey Department of Health (NJDOH) mandated electronic reporting of laboratory test results from all licensed state, commercial and hospital laboratories. Electronic laboratory reports (ELR) are critical for an effective public health response both for routinely reportable diseases as well as potential bioterrorism (BT) agents.

Currently the NJDOH Electronic Laboratory Reporting System (ELRS) acts as the data repository of all laboratory results and is designed to accept ELR in the CDC-recommended, PHIN-compliant and meaningful use ready format of Health Level 7 (HL7). The ELRS facilitates conveyance of these results to program areas via several downstream systems such as the Communicable Disease Reporting and Surveillance System (CDRSS), Enhanced HIV/AIDS Reporting System (eHARS), LeadTrax, as well as other government agencies.

#### 1.1 Purpose

This document serves to guide an interface implementer through the steps involved in producing, validating, and delivering HL7 messages to the NJDOH ELRS and its associated downstream systems. The intent of this document is to provide a succinct ELR implementation guide to facilitate a rewarding partnership with the NJDOH.

#### 1.2 Scope

Detailed within are processes to obtain authorization for communicating ELR to the NJDOH, producing acceptable HL7 messages and validating these messages for structure and vocabulary constraints. In order to meet the NJDOH requirements, the messages may be in HL7 2.3z, 2.3.1 or 2.5.1 ELR to Public Health format. This document will not serve to re-iterate fundamental HL7 standards and specifications unless such items have been further constrained by this implementation guide. In addition, adherence to an implementation guide(s) contained here-in grant nor imply certification by Meaningful Use standards. This document serves to facilitate the communication of data in a standard format for the consumption of NJDOH and its associated downstream systems only. It is assumed that the reader has background knowledge of, and access to the version of HL7 specifications, on which they wish to build a message. NJDOH may provide some guidance with regard to base HL7 specifications, but cannot be relied upon as the sole



On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

authority for which all decisions are based.

### 1.3 Definitions, Acronyms and Abbreviations

**CDRSS** - <http://www.state.nj.us/health/cd/cdrss.shtml> : (Communicable Disease Reporting and Surveillance System) An electronic, web-enabled system where public health partners statewide can instantly report and track incidences of communicable diseases. The CDRSS facilitates timely reporting and immediate sharing of pertinent data, thus supporting appropriate public health responses, be they isolated incidences or multi-state outbreaks. Direct line feeds from commercial laboratories and acute care hospitals electronically load laboratory results into the system overnight, while the manual keying in of information takes place on a daily basis as hundreds of trained users enter data. The CDRSS is available 24 hours a day, 7 days a week and weekly transmissions to the Centers for Disease Control and Prevention (CDC) support national as well as statewide surveillance.

**ELRP** : (Electronic laboratory reporting partner) An entity conveying data directly or indirectly to the public health department.

**ELRS** : (Electronic Laboratory Reporting System) A system of applications and databases designed to extract, validate, transform, and load laboratory data, facilitating its warehousing and propagation to program areas and government entities.

**HL7** - <http://hl7.org> : Health Level Seven International is one of several American National Standards Institute-accredited Standards Developing Organizations operating in the healthcare arena and the global authority on standards for interoperability of health information technology with members in over 55 countries.

**LOINC** - <http://loinc.org> : Logical Observation Identifiers Names and Codes identify the laboratory observation. LOINC applies universal code names and identifiers to medical terminology related to the electronic health record. The purpose is to assist in the electronic exchange and gathering of clinical results (e.g. laboratory tests, clinical observations, outcomes management, research). The LOINC database is developed and maintained by the Regenstrief Institute.

**NIST ELR Validation Suite** - <http://hl7v2-elr-testing.nist.gov> : The NIST Electronic Lab Reporting (ELR) Validation Suite is intended for certifying 2014 Edition Meaningful Use EHR technology. The validation suite provides functionality to test EHR senders. The ELR test tool covers the *§170.314(f)(4) Inpatient setting only – transmission of reportable laboratory tests and values/results* Test Procedure.

**NJDOH validation service** - [https://cdrs.doh.state.nj.us/cdrss/main/file\\_test](https://cdrs.doh.state.nj.us/cdrss/main/file_test) : This service provides a partner the ability to test their messages directly against NJ's HL7 validation engine.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

**PHIN VADS** - <https://phinvads.cdc.gov/vads> : The Public Health Information Network Vocabulary Access and Distribution is a vocabulary repository and server which allows CDC's public health partners to browse, search and download vocabulary concepts required for PHIN messaging and applications.

**SNOMED** : A system of standardized medical terminology developed by the College of American Pathologists. It can be described as comprehensive clinical terminology covering diseases, clinical findings, and procedures that allow for a consistent way of indexing, storing, retrieving and aggregating clinical data across specialties and sites of care. SNOMED helps provide structure and computerize the medical record, reducing the variability in the way data is captured, encoded and used for clinical care of patients and research.

The following link provided points to a maintained subset of SNOMED codes identified for their applicability to reportable conditions, also known as the Reportable Condition Mapping Table (RCMT).

<https://phinvads.cdc.gov/vads/ViewCodeSystemConcept.action?oid=2.16.840.1.114222.4.5.274&code=RCMT>

#### 1.4 References

- NJAC 8:57 Communicable Diseases Regulations
  - <http://www.lexisnexis.com/hottopics/nicode/>
- HL7 Specifications and implementation guides
  - **HL7 2.3z** : Health Level Seven Specifications for Electronic Laboratory-Based Reporting of Public Health Information (CDC, 1997)
  - **HL7 2.3.1** : Implementation Guide for Transmission of Laboratory-Based Reporting of Public Health Information using Version 2.3.1 of the Health Level Seven (HL7) (CDC, 2005)
  - **HL7 2.5.1** Implementation Guide: Electronic Laboratory Reporting to Public Health, Release 1 (US Realm) (electronic version in PDF) with errata (HL7, 2010)

**NOTE:** The aforementioned guides, and standards upon which they are based, are available free of charge through the CDC or HL7.org.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

## 1.5 Overview

Initiating contact with the NJDOH is the first step in being able to craft an HL7 message for the purpose of communicating electronic laboratory reports. Once the request to establish an HL7 2.x feed with the department is filed and approved, the ELRP will be directed to the NJDOH Data Connect group to facilitate a connection over which data will be conveyed.

A partner will pass through two test phases, during which they will build their messages, test them externally until error free, followed by transmission to the NJDOH for further structural and content review. Once all issues are resolved, the partner will be given permission to report within the production system.

## 1.6 Enrollment

To begin the process of becoming an ELRP, entities will first need to complete an online enrollment form. This form serves to kick-off the interface process by collecting pertinent information such as the type of feed, initial contact information, entities involved, as well a statement of authorization to act on behalf of reporting entities. Upon approval, NJDOH staff will begin communication with the primary contact to facilitate the process as well as provide further NJDOH technical staff contact information.

1. **Complete online enrollment form**
2. **Supply comprehensive contact list**
3. **Compile LOINC & SNOMED list**
4. **Supply list of laboratories** (vendors, health systems, reference laboratories only)
5. **Establish electronic communication mechanism**

Following these preliminary steps, an ELRP may begin test phases 1 and 2, concluding with production approval and migration.

**NOTE:** All lists are required within 45 days of enrollment, prior to proceeding with the establishment of an electronic communication mechanism. Applicants unable to fulfill these requirements within this time frame will be disenrolled.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

#### **1.6.1 Responsible parties /contact list**

All partners will need to provide a contact list containing the name, title, email, phone and contact type (content, IT, vendor) to facilitate communication when issues arise. An email distribution list may also accompany this information to facilitate communication with larger teams. It is recommended that the ELRP indicate primary and secondary contacts.

#### **1.6.2 LOINC, SNOMED lists**

As per CDC-recommended industry standards, all HL7 messages will include Logical Observation Identifiers Names and Codes (LOINC) and Systematized Nomenclature of Medicine (SNOMED) codes, where applicable, to describe the tests and organisms found. A complete compilation of tests, in terms of LOINC's and SNOMED's, which they intend to communicate, must be submitted.

**NOTE:** In order to standardize results, free text may not be used to describe tests, LOINC's must be used. In addition, free text cannot be used for results of a SNOMED dependent LOINC, as in the case of cultures and its organisms.

In terms of HL7, the OBX-2 (Value type) field's data type used to describe OBX-5 (Observation value) must not be of a text data type if the OBX-3 (Observation identifier) contains a test which would describe an organism. OBX-3 (Observation identifier) requires a LOINC. OBX-5 (Observation result) data types shall be dictated by the LOINC's type of scale, which describes the result as quantitative, ordinal, etc.

In addition, for more specific information which cannot be listed in HL7 fields, please use the associated observation group's NTE segments to report such items.

#### **1.6.3 List of laboratories**

*This section applies only to vendors, health systems, and reference laboratories, handling transmissions for multiple entities.*

A list of referring entities whose data will be transmitted must be submitted prior to the receipt of any messages into the NJDOH test environment. These lists help systems downstream of NJDOH's ELRS to easily identify new feed additions, facilitating data review and reporting.

Vendors and health systems may convey data for multiple sites within a single batch utilizing FHS, BHS and MSH fields as described within the NJDOH implementation guide. In summary, the FHS and BHS 4 (Sending facility) fields would reflect the health system name and ISO OID, with MSH-4

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

listing the laboratory name and CLIA/ISO OID.

The list must include:

- **Vendors / Health Systems:**
  1. The exact spelling of the health system name as it will be sent in FHS/BHS-4.1 (Sending Facility Namespace ID).
  2. The ISO OID as it will be sent in FHS/BHS -4.2
  3. The exact spelling of the name as it will be sent in MSH-4.1 (Sending Facility Namespace ID).
  4. The CLIA or ISO OID as it will be sent in MSH-4.2
- **Reference Laboratories**
  1. The exact spelling of the name as it will be sent in ZLR-2.1/ORC 21.1 (Ordering Facility Namespace ID).

**NOTE:** All name, CLIA, and OID changes **must** be communicated to the NJDOH prior to implementation.

#### **1.6.4 Establish electronic transmission mechanism**

*After enrolling to instantiate an interface with the NJDOH, the ELRP will receive the Data Connect group's contact information and processes for establishing electronic communication. Any communication with the Data Connect group must reference "ELR" within the subject to facilitate any request.*

The primary method of file transmission is SFTP. Alternate methods must be negotiated with the NJDOH Data Connect group on a case by case basis.

##### **SFTP Directories:**

When transmitting via SFTP, an account is created for the partner within which two folders, "TEST" and "PROD" will reside. Files deposited within either of these directories will be propagated to the testing or production environments automatically; during which time a notification email may be sent to the sending partner should they elect to receive one.

##### **Transmission frequency:**

Files may be transmitted as often as the partner deems necessary.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

File names:

File names must be unique, no duplicates may be sent. All transmitted HL7 files must be denoted using the ".hl7" file extension, unless otherwise permitted.

**NOTE:** Files placed within the SFTP account's root directory will not be processed automatically unless alternate rules have been agreed upon. Partners unable to differentiate between folders in test and production environments may be permitted to denote test files with the ".test" file extension.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

### 1.7 Test Phase 1:

The ELRP may begin building their HL7 messages as per the guidelines set within this document, HL7 implementation guide and associated specifications. Once the HL7 structural build is complete, the ELRP must use the NJDOH's validation service for all accepted message types. If MU compliance is sought, the ELRP must also validate their messages against NIST's ELR Validation Suite. Validating messages against NIST's ELR Validation Suite, then NJDOH's validation service will help facilitate a successful interface implementation. A comprehensive test bank encompassing a large variety of reports the ELRP intends submit to the NJDOH, if not all, should be verified. **All validation issues should be resolved prior to the submission of message batches via the connection provided by the Data Connect group.**

Once all external validation issues have been addressed, the ELRP will notify the NJDOH and may begin sending message batches of test data via the established connection. Received batches will undergo further review for issues such as, but not withstanding, invalid vocabulary and conditional rules. Given the resolution of all issues, the ELRP will send at least three additional batches, depending on batch volume. Should no new issues arise, the ELRP will be moved on to the second test phase.

#### Step summary:

1. Build messages
2. Validate messages online
3. Submit messages for manual review
4. Receive feedback

**NOTE:** The NJDOH reserves the right to require additional changes to an interface in order to comply with revised state statutes, regulations, and/or HL7 specifications. All validations performed against the NJDOH validation service are based on the absolute minimum NJDOH requirements to assimilate a message successfully, and are not designed to imply HL7 or Meaningful Use compliance. Partners' messages will be validated against the [NIST ELR Validation Suite](#) for purposes of HL7 specification adherence, and asked to continue to update their interface to comply with its standards should errors be identified.

On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

### 1.8 Test Phase 2:

This phase includes placing production data into a test environment as well as providing hard copies of all test results (as they appear at the physicians' office) to public health staff. Partners already submitting data electronically may provide references to production case IDs to facilitate reconciliation. During this phase, intense quality testing and assurance will be conducted to verify that all information on the hard copy result is captured accurately in the electronic transmission. Once all issues are resolved, the ELRP shall continue to send batches until approximately 10 (volume dependent) successive batches are conveyed without error.

Upon completion of the test phase, an ELRP will be notified when public health staff has cleared the interface for migration to the production environment.

#### Step summary:

1. Schedule message submissions via communication mechanism
2. Submit result hard copies
3. Data reviewed by public health staff
4. Receive feedback



On-boarding Manual	Version: 1.5
Electronic Laboratory Reporting	Date: 6-May-19

### 1.9 Production phase:

Once authorization to move to production with a vetted interface is established, public health and ELRP staff will determine a go-live date from which future batches will be sent to the production environment. In addition, the ELRP must designate an individual(s) who will own the process of entering tests into downstream systems (as per NJ regulations) which fail to be electronically reported, or are void of required demographic and/or contact information. Hard copies of results may still be requested by public health staff, but may be discontinued upon agreement by both parties. Any changes to the production interface must be communicated to public health staff and vetted in the test environment before any changes are committed.

With SFTP serving as the communication mechanism, sending to the production environment will mean a partner shall begin placing files within the "PROD" directory on their SFTP account's root. The continued submission of test files to the "TEST" folder may continue only in the case that further testing is being performed and a future change to the production interface is forthcoming.

#### Step summary:

1. Determine go-live date
2. Designate report administrator (as per by NJ regulations)
3. Begin submission of files to production environment
4. Cessation of test files submissions

## APPENDIX T



## Guidance for Prioritizing Communicable Disease Investigations

*THIS GUIDANCE DOCUMENT IS FOR LOCAL HEALTH DEPARTMENT USE ONLY*

Per rule (N.J.A.C. 8:57), local health departments (LHD) are responsible for reporting and investigating designated communicable diseases. N.J.A.C. 8:57-2.8 provides reporting requirements and N.J.A.C. 8:57-2.9 provides requirements for investigation. NJDOH recognizes that not all reportable conditions have the same level of public health response and staffing resources at the LHD are often limited. This guidance document is meant as a guide to help LHDs further prioritize public health investigation and response should case volume exceed local resources<sup>1</sup>. It outlines best practices, but situations may occur that will alter these timeframes. Additionally, LHDs should consider these guidelines to be the maximum timeframe to conduct investigations/follow up, but that more timely investigation should be conducted whenever possible (Table 1: Priority Level Response Actions and Timeframes).

NJDOH has assigned each reportable condition<sup>2</sup> an investigation priority level (Table 2: Communicable Disease Investigation & Response Levels). Each priority level and timeframe for action is defined below. This is NOT the timeframe of when a disease is *reported* to LHDs/NJDOH as this is defined in N.J.A.C. 8:57, but rather the timeframe by which LHDs should initiate and complete communicable disease investigations.

### Priority Level Response Actions and Timeframes

**\*\* LHDs ARE EXPECTED TO RESPOND AS SOON AS POSSIBLE \*\***

Priority Level	Acknowledge notification in CDRSS	Enter initial case information	Respond after acknowledgment	Enter critical details <sup>3</sup> after acknowledgment
1	≤ 2 hours	≤ 2 hours	Immediately	≤ 6 hours
2	≤ 12 hours	≤ 12 hours	Immediately	≤ 12 hours
3	≤ 2 business days	≤ 2 business days	As appropriate	≤ 5 days
4	N/A	≤ 7 business days	As appropriate	≤ 2 weeks
5	N/A	≤ 2 weeks	As appropriate	≤ 3 months

*Note: LHDs should respond as soon as possible, but within these maximum timeframes*

<sup>1</sup> LHD should contact their CDS Regional Epidemiologist and/or the CDS Rapid Response Team for assistance with case investigations.

<sup>2</sup> Lyme disease is reportable, but surveillance is based on laboratory testing only and does not require LHD investigation. Sexually transmitted diseases and tuberculosis are excluded from this document. LHDs should contact the Division of HIV, STDs, and TB for investigation guidance.

<sup>3</sup> Critical details include the following variables: demographics, signs/symptoms, clinical status, laboratory information, patient location, and risk factors appropriate for disease investigation. If critical details cannot be obtained, the LHD should document the reason for the delay in CDRSS and the anticipated time when critical details will be available.

Updated 07/12/2025



#### General considerations

- Case investigation should not be limited to critical details. Collection of additional information as described in NJDOH guidance/investigation documents should also be considered. NJDOH may contact the LHD for additional information, depending on the disease and situation.
- Special circumstances may change a disease priority level unexpectedly (i.e., if associated with an outbreak or bioterrorism event). NJDOH will notify LHD and provide additional guidance when this occurs.
- For priority levels 3, 4, and 5, LHDs do not need to investigate over a weekend/holiday, but timely initiation of the investigation should begin on the next business day as defined by the priority level.
- N.J.A.C. 8:57-2.2-2.4 contains reporting requirements for healthcare professionals and administrators and N.J.A.C. 8:57-2.5-2.6 contains reporting requirements for clinical laboratories. Reporting entities must report certain communicable diseases and suspected outbreaks immediately, by telephone, to the health department where the patient resides. N.J.A.C. 8:57-2.8 provides health officer reporting requirements for notifying NJDOH.
- In cases where a LHD is notified of an immediately reportable disease electronically instead of by telephone, per NJ regulation, if that electronic notification is received after hours (e.g., overnight), LHDs are expected to initiate an investigation at 9 AM the next morning on weekends/holidays or with the start of regular business hours on weekdays.

#### Case Closure

- After completing an investigation, the LHD should review the case definition for that disease and assign the correct case status in CDRSS. The LHD should then select "LHD CLOSED" as the report status, indicating the investigation is complete and ready for review by NJDOH.
- NJDOH will re-open the case and contact the LHD for additional information if needed.
- If the case investigation is not completed by the LHD, NJDOH may designate the case as "NO FOLLOW-UP/INVESTIGATION" as part of the permanent CDRSS record.

Updated 07/12/2025



### Communicable Disease Investigation & Response Levels

Disease	Priority Level	Disease	Priority Level	Disease	Priority Level
Alpha-gal syndrome	5	Giardiasis	4	Q fever	3
Anaplasmosis	4	<i>Haemophilus influenzae</i>	3	<b>Rabies (human)</b>	<b>1</b>
<b>Anthrax</b>	<b>1</b>	Hansen's (leprosy)	5	RSV-associated pediatric mortality	3
Arboviral diseases	3	<b>Hantavirus</b>	<b>1</b>	<b>Rubella</b>	<b>2</b>
Babesiosis	3	<b>Hepatitis A</b>	<b>2</b>	Salmonellosis	4
Bacterial tickborne disease, incl <i>Borrelia</i> spp	5	Hepatitis B	5	Shigellosis	4
<b>Biological intoxications</b>	<b>1</b>	Hepatitis C	5	<b>Smallpox</b>	<b>1</b>
<b>Botulism</b>	<b>1</b>	<b>Influenza A virus, novel/unsubtypable</b>	<b>1</b>	Spotted fever group rickettsiosis	4
Brucellosis	3	Influenza pediatric mortality	3	Streptococcal disease, invasive group A	4
Campylobacteriosis	4	Jamestown Canyon	3	Streptococcal disease, invasive group B	5
<i>Candida auris</i>	3	Legionellosis	3	<i>Streptococcus pneumoniae</i>	5
Carbapenemase-producing organism	3	Leptospirosis	3	Tetanus	5
Chikungunya	3	Listeriosis	3	Toxic shock syndrome	5
<b>Coronavirus, novel (e.g., MERS)</b>	<b>1</b>	Malaria	3	Trichinellosis	4
COVID-19 (identified priority cases)	3	<b>Measles</b>	<b>1</b>	Tularemia	3
<i>Cronobacter</i> infection	3	<b>Melioidosis (<i>B. pseudomallei</i>)</b>	<b>1</b>	Typhoid fever	3
Cryptosporidiosis	4	<b>Meningococcal disease</b>	<b>1</b>	<i>Varicella-zoster</i> (chickenpox)	3
Cyclosporiasis	3	<b>Mpox</b>	<b>2</b>	Vibriosis (including cholera)	3
Dengue	3	Mumps	3	<b>Viral hemorrhagic fevers (Ebola, Lassa)</b>	<b>1</b>
<b>Diphtheria</b>	<b>1</b>	<b>Outbreaks (ALL)</b>	<b>1</b>	VRSA	3
Eastern equine encephalitis	3	Pertussis	3	West Nile virus	3
Ehrlichiosis	4	<b>Plague</b>	<b>1</b>	Yersiniosis	4
<i>Escherichia coli</i> , (STEC)	3	<b>Poliomyelitis</b>	<b>1</b>	Zika virus	3
<b>Foodborne intoxications</b>	<b>1</b>	Powassan	4		
<b>Free-living amebic infections</b>	<b>1</b>	Psittacosis	3		

Updated 07/12/2025

## APPENDIX U



STATE OF NEW JERSEY

IMMUNIZATION INFORMATION SYSTEM



### Interface Enrollment Request Form

Before you complete the form below, please click to review guidance on establishing an HL7 interface with NJIIS.  
If you are establishing Excel interface with NJIIS for COVID-19 Vaccines, please click to review guidance.

#### Practice Information

Practice Name \*

PRACTICE NAME

Are you enrolled in NJIIS? \*

Select

NJIIS Facility Id

NJIIS Facility Id

Practice VFC Pin (if applicable)

Alphanumeric

Tax ID \*

---

Practice Physical Address Line 1 \*

STREET ADDRESS

Practice Physical Address Line 2

P.O.BOX/APT/SUITE NUMBER

City \*

CITY

State \*

Select

Zip \*

County \*

Select

Municipality \*

Select

#### Primary Contact

Contact Last Name \*

LAST NAME

Contact First Name \*

FIRST NAME

Middle Name

MIDDLE NAME

Title

TITLE

Phone *	<input type="text"/>
Extn	<input type="text"/>
Email *	<input type="text"/>
Fax	<input type="text"/>
<a href="#">Backup Contact</a>	
Contact Last Name	<input type="text"/>
Contact First Name	<input type="text"/>
Middle Name	<input type="text"/>
Title	<input type="text"/>
Phone	<input type="text"/>
Extn	<input type="text"/>
Email	<input type="text"/>
Fax	<input type="text"/>
<a href="#">Enrollment Information</a>	
Practice Type *	<input type="text"/>
Specialization *	<input type="text"/>
Reason For Enrollment *	<input type="text"/>
<p>Note: If your reason for enrollment is "Meaningful Use Objective (Stage 1 Attestation Only)," NJIIS will not implement a production interface for your practice.</p>	



Approximate number of vaccines administered in your practice per year (Please provide accurate numbers as these will be used as a baseline to evaluate your transmissions.) \*

Select

Note: If you selected "None", please apply for the exclusion for MU attestation. You do not need to submit this request form for NJIIS interface. NJIIS does not process interface enrollment forms for practices that do not administer vaccines.

Number of patients under 7 years of age seen at the practice \*

Select

#### Vendor Information

- ☒ Existing Vendor  
☐ New Vendor

Vendor Name

Select

Software

ALPHANUMERIC

Primary Contact

Contact Last Name

LAST NAME

Contact First Name

FIRST NAME

Middle Name

MIDDLE NAME

Phone

Extn

Email

Email

Fax

Backup Contact

Contact Last Name

LAST NAME

Contact First Name

FIRST NAME

Middle Name

MIDDLE NAME

Phone

Extn	<input type="text"/>
Email	<input type="text"/>
Fax	<input type="text"/>
<b>▼ Interface Information</b>	
Interface Access Type *	<input type="text" value="Select"/> ▼
To read more about bi-directional messaging.	
Interface Type *	<input type="text" value="Select"/> ▼
Message Type *	<input type="text" value="Select"/> ▼
HL7 Version *	<input type="text" value="Select"/> ▼
Entity	<input type="text" value="Select"/> ▼
<b>▼ Other Information</b>	
Submitted By *	<input type="text"/>
Comments	<div><div></div></div>
*denotes mandatory fields	

## CHAPTER 111

### STANDARDS FOR LICENSURE OF RESIDENTIAL SUBSTANCE USE DISORDERS

#### TREATMENT FACILITIES

##### SUBCHAPTER 9. CLIENT ASSESSMENTS AND TREATMENT PLAN

###### 8:111-9.1 Client assessment

(a) (No change.)

(b) In performing a bio-psychosocial assessment, the facility shall assess the following:

1. (No change.)

2. The results of the client's physical examination, which shall include a certification by the examining physician that the level of medical care needed by the client is available through the facility and the following laboratory tests and evaluations, subject to client's written consent:

i.-iii. (No change.)

iv. Human immunodeficiency virus antibody testing, as medically indicated, for which the facility shall obtain a separate written consent. All clients shall receive HIV pre-test counseling and post-test counseling if the client elects to be tested. If HIV testing is performed onsite, the facility is required to report positive results according to N.J.A.C. [8:57-2] **8:65** and maintain client confidentiality according to N.J.S.A. 26:5C-7 et seq.;

v. All pregnant women shall be provided information on HIV and AIDS and offered testing for HIV infection. This information may be provided by the administrator or delegated to another healthcare professional, but such delegation of duties shall not

relieve the administrator from the ultimate responsibility to see that this information is provided in accordance with N.J.A.C. 8:61-[3.1]**4**;

vi.-vii. (No change.)

3.-10. (No change.)